
<html lang="en"     class="pb-page"  data-request-id="096b61e9-af6e-4806-bfbb-03408d26fecd"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.9b01034;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-5"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of AM-6494: A Potent and Orally Efficacious β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2" /></meta><meta name="dc.Creator" content="Liping H.  Pettus" /></meta><meta name="dc.Creator" content="Matthew P.  Bourbeau" /></meta><meta name="dc.Creator" content="Jodi  Bradley" /></meta><meta name="dc.Creator" content="Michael D.  Bartberger" /></meta><meta name="dc.Creator" content="Kui  Chen" /></meta><meta name="dc.Creator" content="Dean  Hickman" /></meta><meta name="dc.Creator" content="Michael  Johnson" /></meta><meta name="dc.Creator" content="Qingyian  Liu" /></meta><meta name="dc.Creator" content="James R.  Manning" /></meta><meta name="dc.Creator" content="Adrian  Nanez" /></meta><meta name="dc.Creator" content="Aaron C.  Siegmund" /></meta><meta name="dc.Creator" content="Paul H.  Wen" /></meta><meta name="dc.Creator" content="Douglas A.  Whittington" /></meta><meta name="dc.Creator" content="Jennifer R.  Allen" /></meta><meta name="dc.Creator" content="Stephen  Wood" /></meta><meta name="dc.Description" content="β-Site amyloid precursor protein cleaving enzyme 1 (BACE1) is an aspartyl protease that plays a key role in the production of amyloid β (Aβ) in the brain and has been extensively pursued as a targe..." /></meta><meta name="Description" content="β-Site amyloid precursor protein cleaving enzyme 1 (BACE1) is an aspartyl protease that plays a key role in the production of amyloid β (Aβ) in the brain and has been extensively pursued as a targe..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 7, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01034" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01034" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01034" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01034" /></link>
        
    
    

<title>Discovery of AM-6494: A Potent and Orally Efficacious β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2 | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01034" /></meta><meta property="og:title" content="Discovery of AM-6494: A Potent and Orally Efficacious β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0016.jpeg" /></meta><meta property="og:description" content="β-Site amyloid precursor protein cleaving enzyme 1 (BACE1) is an aspartyl protease that plays a key role in the production of amyloid β (Aβ) in the brain and has been extensively pursued as a target for the treatment of Alzheimer’s disease (AD). BACE2, an aspartyl protease that is structurally related to BACE1, has been recently reported to be involved in melanosome maturation and pigmentation. Herein, we describe the development of a series of cyclopropylthiazines as potent and orally efficacious BACE1 inhibitors. Lead optimization led to the identification of 20, a molecule with biochemical IC50 BACE2/BACE1 ratio of 47. Administration of 20 resulted in no skin/fur color change in a 13-day mouse hypopigmentation study and demonstrated robust and sustained reduction of CSF and brain Aβ40 levels in rat and monkey pharmacodynamic models. On the basis of a compelling data package, 20 (AM-6494) was advanced to preclinical development." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01034"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01034">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01034&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01034&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01034&amp;href=/doi/10.1021/acs.jmedchem.9b01034" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2263-2281</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00898" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b01044" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of AM-6494: A Potent and Orally Efficacious β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Liping H. Pettus</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Liping H. Pettus</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Amgen Discovery Research, Thousand Oaks, California 91320, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#177b67726363626457767a7072793974787a"><span class="__cf_email__" data-cfemail="670b17021313121427060a0002094904080a">[email protected]</span></a>. Phone: 805-447-6964.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Liping+H.++Pettus">Liping H. Pettus</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4427-6602" title="Orcid link">http://orcid.org/0000-0002-4427-6602</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Matthew P. Bourbeau</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthew P. Bourbeau</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Amgen Discovery Research, Thousand Oaks, California 91320, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+P.++Bourbeau">Matthew P. Bourbeau</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jodi Bradley</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jodi Bradley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Neuroscience Research, Amgen Discovery Research, Thousand Oaks, California 91320, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jodi++Bradley">Jodi Bradley</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael D. Bartberger</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael D. Bartberger</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Engineering, Amgen Discovery Research, Thousand Oaks, California 91320, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+D.++Bartberger">Michael D. Bartberger</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5167-3139" title="Orcid link">http://orcid.org/0000-0002-5167-3139</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kui Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kui Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Discovery Technologies, Amgen Discovery Research, Thousand Oaks, California 91320, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kui++Chen">Kui Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dean Hickman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dean Hickman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmacokinetics and Drug Metabolism, Amgen Discovery Research, Thousand Oaks, California 91320, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dean++Hickman">Dean Hickman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael Johnson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Johnson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research Automation and Technologies, Amgen Discovery Research, Thousand Oaks, California 91320, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Johnson">Michael Johnson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qingyian Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qingyian Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Amgen Discovery Research, Thousand Oaks, California 91320, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qingyian++Liu">Qingyian Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">James R. Manning</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James R. Manning</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Amgen Discovery Research, Thousand Oaks, California 91320, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James+R.++Manning">James R. Manning</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Adrian Nanez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Adrian Nanez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Comparative Biology and Safety Studies, Amgen Discovery Research, Thousand Oaks, California 91320, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Adrian++Nanez">Adrian Nanez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Aaron C. Siegmund</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Aaron C. Siegmund</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Amgen Discovery Research, Thousand Oaks, California 91320, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Aaron+C.++Siegmund">Aaron C. Siegmund</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul H. Wen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul H. Wen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Neuroscience Research, Amgen Discovery Research, Thousand Oaks, California 91320, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul+H.++Wen">Paul H. Wen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Douglas A. Whittington</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Douglas A. Whittington</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Engineering, Amgen Discovery Research, Thousand Oaks, California 91320, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Douglas+A.++Whittington">Douglas A. Whittington</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jennifer R. Allen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jennifer R. Allen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Amgen Discovery Research, Thousand Oaks, California 91320, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jennifer+R.++Allen">Jennifer R. Allen</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Stephen Wood</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stephen Wood</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Neuroscience Research, Amgen Discovery Research, Thousand Oaks, California 91320, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stephen++Wood">Stephen Wood</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01034&amp;href=/doi/10.1021%2Facs.jmedchem.9b01034" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2263–2281</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 7, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>29 June 2019</li><li><span class="item_label"><b>Published</b> online</span>7 October 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 March 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01034" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01034</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2263%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DLiping%2BH.%2BPettus%252C%2BMatthew%2BP.%2BBourbeau%252C%2BJodi%2BBradley%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D5%26contentID%3Dacs.jmedchem.9b01034%26title%3DDiscovery%2Bof%2BAM-6494%253A%2BA%2BPotent%2Band%2BOrally%2BEfficacious%2B%25CE%25B2-Site%2BAmyloid%2BPrecursor%2BProtein%2BCleaving%2BEnzyme%2B1%2B%2528BACE1%2529%2BInhibitor%2Bwith%2Bin%2BVivo%2BSelectivity%2Bover%2BBACE2%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2281%26publicationDate%3DMarch%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01034"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2155</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">10</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01034" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of AM-6494: A Potent and Orally Efficacious β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor with in Vivo Selectivity over BACE2&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Liping&quot;,&quot;last_name&quot;:&quot;H. Pettus&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;P. Bourbeau&quot;},{&quot;first_name&quot;:&quot;Jodi&quot;,&quot;last_name&quot;:&quot;Bradley&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;D. Bartberger&quot;},{&quot;first_name&quot;:&quot;Kui&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Dean&quot;,&quot;last_name&quot;:&quot;Hickman&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Johnson&quot;},{&quot;first_name&quot;:&quot;Qingyian&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;R. Manning&quot;},{&quot;first_name&quot;:&quot;Adrian&quot;,&quot;last_name&quot;:&quot;Nanez&quot;},{&quot;first_name&quot;:&quot;Aaron&quot;,&quot;last_name&quot;:&quot;C. Siegmund&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;H. Wen&quot;},{&quot;first_name&quot;:&quot;Douglas&quot;,&quot;last_name&quot;:&quot;A. Whittington&quot;},{&quot;first_name&quot;:&quot;Jennifer&quot;,&quot;last_name&quot;:&quot;R. Allen&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;Wood&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;2263-2281&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01034&quot;},&quot;abstract&quot;:&quot;β-Site amyloid precursor protein cleaving enzyme 1 (BACE1) is an aspartyl protease that plays a key role in the production of amyloid β (Aβ) in the brain and has been extensively pursued as a target for the treatment of Alzheimer’s disease (AD). BACE2, an aspartyl protease that is structurally related to BACE1, has been recently reported to be involved in melanosome maturation and pigmentation. Herein, we describe the development of a series of cyclopropylthiazines as potent and orally efficacious BACE1 inhibitors. Lead optimization led to the identification of 20, a molecule with biochemical IC50 BACE2/BACE1 ratio of 47. Administration of 20 resulted in no skin/fur color change in a 13-day mouse hypopigmentation study and demonstrated robust and sustained reduction of CSF and brain Aβ40 levels in rat and monkey pharmacodynamic models. On the basis of a compelling data package, 20 (AM-6494) was advanced to preclinical development.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01034&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01034" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01034&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01034" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01034&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01034" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01034&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01034&amp;href=/doi/10.1021/acs.jmedchem.9b01034" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01034" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01034" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01034%26sid%3Dliteratum%253Aachs%26pmid%3D31589043%26genre%3Darticle%26aulast%3DPettus%26date%3D2020%26atitle%3DDiscovery%2Bof%2BAM-6494%253A%2BA%2BPotent%2Band%2BOrally%2BEfficacious%2B%25CE%25B2-Site%2BAmyloid%2BPrecursor%2BProtein%2BCleaving%2BEnzyme%2B1%2B%2528BACE1%2529%2BInhibitor%2Bwith%2Bin%2BVivo%2BSelectivity%2Bover%2BBACE2%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D5%26spage%3D2263%26epage%3D2281%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292462" title="Central nervous system">Central nervous system</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/jmcmar.2020.63.issue-5/20200312/jmcmar.2020.63.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01034&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">β-Site amyloid precursor protein cleaving enzyme 1 (BACE1) is an aspartyl protease that plays a key role in the production of amyloid β (Aβ) in the brain and has been extensively pursued as a target for the treatment of Alzheimer’s disease (AD). BACE2, an aspartyl protease that is structurally related to BACE1, has been recently reported to be involved in melanosome maturation and pigmentation. Herein, we describe the development of a series of cyclopropylthiazines as potent and orally efficacious BACE1 inhibitors. Lead optimization led to the identification of <b>20</b>, a molecule with biochemical IC<sub>50</sub> BACE2/BACE1 ratio of 47. Administration of <b>20</b> resulted in no skin/fur color change in a 13-day mouse hypopigmentation study and demonstrated robust and sustained reduction of CSF and brain Aβ<sub>40</sub> levels in rat and monkey pharmacodynamic models. On the basis of a compelling data package, <b>20</b> (AM-6494) was advanced to preclinical development.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar/63/5"><issue-title>Women in Medicinal Chemistry</issue-title></a> special issue.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67656" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67656" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Alzheimer’s disease (AD) is a devastating, progressive neurodegenerative disease. It accounts for up to 80% of dementia cases identified each year. The clinical symptoms of AD include progressive loss of memory and impairment of cognitive functions interfering with daily life activities. Current available therapies provide temporary symptomatic relief but do not address the underlying neurophathology.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Therefore, therapeutic treatment that can either delay or halt disease progression remains an urgent unmet medical need.</div><div class="NLM_p">The two histopathological hallmarks observed in the brains of AD patients are extracellular amyloid plaques made mostly of β-amyloid (Aβ) peptides and intraneuronal neurofibrillary tangles composed mostly of aggregates of abnormally phosphorylated tau protein. Aβ peptides are formed in the brain by sequential endoproteolytic cleavage of amyloid precursor protein (APP) by the aspartyl protease β-site APP cleaving enzyme-1 (BACE1) and γ-secretase.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Among this family of Aβ peptides, Aβ<sub>40</sub> is the most abundant isoform and Aβ<sub>42</sub> is believed to be the most prone to aggregate into oligomeric neurotoxic species.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The amyloid hypothesis suggests that inhibiting the formation and accumulation of Aβ in the brain could result in a disease-modifying effect in AD patients.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Recently published genetic evidence has provided further support for this approach, suggesting that even modest decreases in the formation of Aβ (as a result of several mutations near the BACE1 cleavage site in APP) may confer significant protection against the development of AD.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> Therefore, reducing Aβ levels through inhibition of BACE1 remains an attractive approach for the treatment of AD and has been intensely pursued by the pharmaceutical industry over the past 2 decades.<a onclick="showRef(event, 'ref7 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9 ref10">(7−10)</a></div><div class="NLM_p">Despite multiple efforts, BACE inhibitors have not met with success thus far in clinical testing.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> While some molecules have suffered attrition due to adverse events, others have failed based on the lack of a cognitive or functional clinical benefit, despite showing a robust and sustained lowering of Aβ in patients. Given these failures, it is possible to hypothesize that the amyloid cascade hypothesis might be invalid or incomplete. However, an alternative explanation is that amyloid targeting agents need to be given at a much earlier stage in the disease continuum, perhaps even presymptomatically. Evidence from biomarker studies in dominantly inherited AD and in sporadic, late-onset AD shows that accumulation of amyloid burden occurs as early as 3 decades before individuals become symptomatic.<a onclick="showRef(event, 'ref12 ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15">(12−15)</a> These studies have also shown that downstream of amyloid accumulation, a number of other pathological processes become engaged (accumulation of neurofibrillary tangles comprised of tau, inflammation, hypometabolism, synaptic loss, cortical atrophy, etc.) prior to disease onset. It is possible that at some point in the progression of AD, these processes become amyloid-independent and are therefore intractable to BACE inhibition. In an effort to test the amyloid hypothesis at an earlier stage than has been previously attempted, Amgen and Novartis in collaboration with Banner Alzheimer’s Institute conducted the Generation Program. Generation Study 1 and Generation Study 2 were rationally designed, long-term phase 2/3 studies evaluating CNP520 in cognitively unimpaired individuals at risk of developing AD symptoms.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> The studies enrolled cognitively unimpaired individuals, using an enrichment strategy, based on individuals’ age, <i>APOE</i> e4 carrier status, and central Aβ load, to increase the likelihood that participants would develop substantial cognitive decline within the time frame of the studies. During preparation of this manuscript, Novartis, Amgen, and Banner Alzheimer’s Institute announced (on July 11, 2019) the decision to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in two pivotal phase II/III studies in the Alzheimer’s Prevention Initiative Generation Program. An assessment of unblinded data during a regular preplanned review identified worsening in some measures of cognitive function. Given these findings, the sponsors concluded that the potential benefit for participants in the studies did not outweigh the risk. These and similar findings from other companies underscore our need to better understand the effects of BACE inhibition beyond APP processing. If we believe that unimpaired individuals at risk of developing AD symptoms could require the administration of a BACE inhibitor for many years, analogous to the use of statins in individuals with hypercholesterolemia, then a commercially successful BACE inhibitor would need to have a very clean safety profile. Efforts to minimize as many off-target effects as possible seem justified considering the desired safety profile.</div><div class="NLM_p">BACE1 inhibitors have evolved from the substrate inspired peptidomimetics, which in general lack brain–blood barrier penetration, to the more recent non-peptidics with diverse warheads to engage the catalytic aspartic dyad and improved CNS drug-like properties.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Some examples of recently disclosed BACE1 inhibitors are shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>. These inhibitors contain a conserved 2-aminoheterocycle which engages with the catalytic aspartic dyad of BACE1 active site. The catalytic dyad is conserved in the aspartyl protease family which includes cathepsin D (CatD) among others. As inhibition of CatD has been associated with retinal toxicity,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> optimization of BACE1 inhibitors for selectivity against CatD has been a focus of many medicinal chemistry efforts.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> For example, while aminooxazoline <b>1</b> (BACE1 enzymatic IC<sub>50</sub> = 0.3 nM) lacks selectivity against CatD (enzymatic IC<sub>50</sub> = 90 nM),<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> the newer class of amidine-based inhibitors <b>2</b> (MK-8931, verubecestat),<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a><b>3</b> and <b>4</b>,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a><b>5</b> (PF-06751979),<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> and <b>6</b><a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> are devoid of CatD activity (IC<sub>50</sub> > 95 μM).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0001.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures and potency of recently disclosed BACE1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01034&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A further point of differentiation among inhibitors <b>2</b>–<b>6</b> is their selectivity for BACE1 over BACE2. Although BACE2 was discovered simultaneously with its close homologue BACE1,<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> the functional importance of BACE2 has only recently been elucidated.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Unlike BACE1, the expression of BACE2 is low in brain but much greater in peripheral tissue. Recently identified BACE2 substrates include the proproliferative transmembrane protein 27 (TMEM27),<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> islet amyloid polypeptide (IAPP),<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> and premelanosome protein (PMEL17),<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> which is expressed in melanocytes. Since TMEM27 and IAPP are robustly expressed in pancreatic β-cells, it has been proposed that the inhibition of BACE2 may alter glucose homeostasis. In addition, inhibition of BACE2 impacts the processing of the PMEL17 and disrupts melanosome morphology, resulting in a depigmentation phenotype. Consistent with the findings that BACE2 KO mice display a hypopigmented phenotype,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> several nonselective BACE1/2 inhibitors such as AZD3293, NB-360, and SCH1682496 have shown fur and skin pigment loss in mice or dog following chronic dosing regimens.<a onclick="showRef(event, 'ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35">(33−35)</a> In a 78-week clinical trial, MK-8931 was associated with hair-color changes potentially due to its BACE2 inhibitory activity.<a onclick="showRef(event, 'ref22 ref36'); return false;" href="javascript:void(0);" class="ref ref22 ref36">(22,36)</a></div><div class="NLM_p last">The first report of BACE1 inhibitors with selectivity over BACE2 was a series of picolinamides published by researchers from F. Hoffman-La Roche, exemplified by 5-OCH<sub>2</sub>CF<sub>3</sub>-picolinamide <b>4</b> (enzymatic IC<sub>50</sub> BACE2/BACE1 ratio = 69).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The X-ray structures of 5-ethoxypicolinamide <b>3</b> (enzymatic IC<sub>50</sub> BACE2/BACE1 ratio = 5) bound in BACE1 and BACE2 reveal that the S3 pocket in BACE1 is deeper than in BACE2, due to the greater flexibility of the 10s loop (Gly69–Gly74) in BACE1 relative to BACE2. Hence, selectivity for BACE1 over BACE2 (biochemical IC<sub>50</sub> BACE2/BACE1 ratio) increases as the P3 region alkyl substituent R<sup>1</sup> changes from CH<sub>2</sub>CH<sub>3</sub> in picolinamide <b>3</b> to CH<sub>2</sub>CF<sub>3</sub> in <b>4</b>. Subsequently, Pfizer published a BACE1 selective inhibitor, <b>5</b> (PF-06751979, enzymatic IC<sub>50</sub> BACE2/BACE1 ratio = 26), as a result of structure–activity relationship (SAR) work on the inhibitor to engage the S3 and flap regions of BACE1.<a onclick="showRef(event, 'ref25 ref37'); return false;" href="javascript:void(0);" class="ref ref25 ref37">(25,37)</a> We recently disclosed cyclopropylthiazine <b>6</b> as an efficacious BACE1 inhibitor in reducing brain Aβ in a rat pharmacodynamic (PD) model.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> However, compound <b>6</b> inhibited BACE2 (IC<sub>50</sub> = 1.8 nM) with greater potency than BACE1 (IC<sub>50</sub> = 12.3 nM). Herein, we describe our efforts to achieve selectivity for BACE1 over BACE2 and optimize CNS drug-like properties via modification of inhibitor <b>6</b> in the P1′ and P3 regions. To correlate the in vitro BACE2 inhibition with in vivo hypopigmentation, we developed an in vivo mouse model using a camera-based pigmentation detection method to quantify the hypopigmentation risk of advanced analogs. This work led to the nomination of compound <b>20</b> (AM-6494) as a preclinical development candidate.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03210" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03210" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Our previous work on cyclopropylthiazine BACE1 inhibitors exemplified by <b>6</b> had demonstrated that in the P1 region the incorporation of two fluorine atoms at C4 and C5 of the phenyl ring gave a good balance of potency, p<i>K</i><sub>a</sub>, and ADME properties, resulting in higher in vivo efficacy than that of monofluorinated analogs.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Compound <b>6</b> was a potent BACE1 inhibitor with IC<sub>50</sub> values of 12 nM for both enzymatic and cell-based (in HEK cells) assays and selective against CatD (IC<sub>50</sub> = 750 μM). In vivo, <b>6</b> showed a 68% reduction of brain Aβ<sub>40</sub> level following an oral 10 mg/kg dose (estimated unbound plasma EC<sub>50</sub> = 16 nM) in a rat PD model. However, this compound was a more potent inhibitor of BACE2 (enzymatic IC<sub>50</sub> = 1.8 nM) than BACE1. Molecular modeling of <b>6</b> in BACE1 (based on PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6C2I">6C2I</a>)<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> suggests that the S1′ and S3 pockets of BACE1 protein are largely unengaged by compound <b>6</b>, leaving opportunities for better BACE1 potency and selectivity over BACE2 in lead optimization. Our strategies were to keep the P1 region constant with a 4,5-difluorophenyl motif, first explore the P1′ region for better BACE1 potency while maintaining CNS drug-like properties and then explore the deep P3 region for selectivity against BACE2, and finally combine favorable pieces from P1′ and P3 regions.</div><div class="NLM_p"><a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> summarizes the SAR in the P1′ region of compound <b>6</b>. Remarkably, both nonpolar substituents (R = CH<sub>2</sub>OMe, CH<sub>2</sub>F, and CHF<sub>2</sub> in compounds <b>8</b>, <b>9</b>, and <b>10</b>, respectively) and polar substituents (R = CH<sub>2</sub>OH, CONH<sub>2</sub>, CONHMe, CONMe<sub>2</sub>, and CN in compounds <b>7</b>, <b>11</b>, <b>12</b>, <b>13</b>, and <b>14</b>, respectively) improved BACE1 enzyme potency (5- to 30-fold) over R = H. These substituents also generally improved BACE1 cell-based potency (5- to 18-fold) over R = H, with the exception of R = CN, in which the decreased basicity of the warhead (p<i>K</i><sub>a</sub> = 6.2) may have contributed to the increased enzyme-to-cell shift observed in compound <b>14</b>.<a onclick="showRef(event, 'ref25 ref38'); return false;" href="javascript:void(0);" class="ref ref25 ref38">(25,38)</a> In terms of permeability, like <b>6</b> and C1-substituted thiazines <b>7</b>–<b>14</b> all were highly permeable (<i>P</i><sub>app</sub> ≥ 13 × 10<sup>–6</sup> cm/s). However, alcohol <b>7</b>, primary amide <b>11</b>, and secondary amide <b>12</b> had high efflux ratios (≥ 8.4), likely due to the additional H-bond donor(s). Overall, compounds <b>8</b>–<b>10</b> and <b>13</b> stood out as having cellular IC<sub>50</sub> ≤ 10 nM, low efflux ratio (≤ 3.2), and low-to-moderate turnover in liver microsomes. In terms of aspartyl protease selectivity, compounds <b>7</b>–<b>14</b> all were selective against CatD (enzymatic IC<sub>50</sub> ≥ 400 μM) but not against BACE2 (enzymatic IC<sub>50</sub> < 2 nM).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR in P1′ Region</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0013.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">BACE1 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">Pgp efflux</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">enzyme</th><th class="colsep0 rowsep0" align="center">HEK<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">CatD IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center"><i>P</i><sub>app</sub><a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">(h)ER<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">HLM|RLM<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a> (μL min<sup>–1</sup> mg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center">p<i>K</i><sub>a</sub><a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center">cLogP|PSA</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">750</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">2.7</td><td class="colsep0 rowsep0" align="left">21|77</td><td class="colsep0 rowsep0" align="left">8.1</td><td class="colsep0 rowsep0" align="left">4.3|80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">2.0</td><td class="colsep0 rowsep0" align="left">1245</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">8.4</td><td class="colsep0 rowsep0" align="left"><14|<14</td><td class="colsep0 rowsep0" align="left">7.8</td><td class="colsep0 rowsep0" align="left">3.1|101</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OMe</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">281</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">47|161</td><td class="colsep0 rowsep0" align="left">7.5</td><td class="colsep0 rowsep0" align="left">3.9|90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>F</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">425</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">58|67</td><td class="colsep0 rowsep0" align="left">7.3</td><td class="colsep0 rowsep0" align="left">4.3|80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">CHF<sub>2</sub></td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">8.0</td><td class="colsep0 rowsep0" align="left">319</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">2.6</td><td class="colsep0 rowsep0" align="left">21|35</td><td class="colsep0 rowsep0" align="left">7.1</td><td class="colsep0 rowsep0" align="left">4.7|80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">CONH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">0.6</td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" align="left">856</td><td class="colsep0 rowsep0" align="left">38</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left"><14|<14</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t1fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">2.5|123</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">CONHMe</td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">795</td><td class="colsep0 rowsep0" align="left">29</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left"><14|<14</td><td class="colsep0 rowsep0" align="left">6.7</td><td class="colsep0 rowsep0" align="left">2.7|109</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">CONMe<sub>2</sub></td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" align="left">0.7*</td><td class="colsep0 rowsep0" align="left">796</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">3.2</td><td class="colsep0 rowsep0" align="left"><14|82</td><td class="colsep0 rowsep0" align="left">6.9</td><td class="colsep0 rowsep0" align="left">3.1|101</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" align="left">45*</td><td class="colsep0 rowsep0" align="left">400</td><td class="colsep0 rowsep0" align="left">39</td><td class="colsep0 rowsep0" align="left">3.1</td><td class="colsep0 rowsep0" align="left"><14|<14</td><td class="colsep0 rowsep0" align="left">6.2</td><td class="colsep0 rowsep0" align="left">3.0|104</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Average of at least two determinations unless noted by ∗ (<i>n</i> = 1); for full statistical information, see the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01034/suppl_file/jm9b01034_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Human embryonic kidney cells transfected with wild-type human APP in the presence of 10% fetal bovine serum (FBS).</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Apparent permeability values (measured in parental LLC-PK1 cells) are an average of apical to basolateral (A to B) and basolateral to apical (B to A) velocities and are reported as 10<sup>–6</sup> cm/s.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Efflux ratio values (measured in LLC-PK1 cells transfected with human MDR1) are reported as a ratio of (B to A)/(A to B).</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">In vitro microsomal stability (<i>n</i> = 1) measurements were conducted in the presence of NADPH at 37 °C for 30 min at a final compound concentration of 1 μM with microsomal protein concentration of 250 μg/mL.</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">Measured by UV–vis spectrophotometry at 25 °C.</p></div><div class="footnote" id="t1fn7"><sup><sup>g</sup></sup><p class="last">Not tested.</p></div></div></div><div class="NLM_p">To improve selectivity for BACE1 over BACE2, we next examined the SAR of the P3 region expansion while holding the methoxymethyl substituent in the P1′ region of compound <b>8</b> constant (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Compared to 5-Cl-picolinamide <b>8</b>, compound <b>15</b> (5-OCH<sub>2</sub>CF<sub>3</sub>) had reduced BACE1 potency but increased BACE2/BACE1 IC<sub>50</sub> ratio. While picolinamide <b>16</b> (5-OCH<sub>2</sub>CCH) was potent for BACE1 and selective (BACE2/BACE1 IC<sub>50</sub> ratio = 57), it was not stable in rat liver microsomes (RLM). Compared to <b>16</b>, <i>ortho-</i>Me-picolinamide <b>17</b> had weaker cellular potency with no improvement in microsomal stability. The enzyme-to-cell shift appears to be sensitive to the size of P3 group in the pyridinyl analogs. In particular, compounds <b>15</b> and <b>17</b> had ∼9× shift going from BACE1 enzymatic to cell-based IC<sub>50</sub>. Just like the pyridine ring in <b>15</b> and <b>16</b>, the pyrazine ring in <b>18</b>–<b>23</b> at 5-position also provides a vector to fill the S3 pocket of BACE1 enzyme. The BACE2/BACE1 IC<sub>50</sub> ratio increased from 22 to 50 as the size of pyrazinyl 5-position substituent increased from 5-OCH<sub>2</sub>CH<sub>3</sub> in <b>18</b> to 5-OCH<sub>2</sub>CF<sub>3</sub> in <b>19</b>, a selectivity trend similar to that of compounds <b>3</b> and <b>4</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) reported by Roche’s researchers.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Compared to <b>19</b>, the elongated analog <b>21</b> (5-OCH<sub>2</sub>CH<sub>2</sub>CF<sub>3</sub>) had a 21-fold loss in BACE1 potency, while compound <b>22</b> (R<sup>1</sup> = CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>) had comparable BACE1 potency but suffered from high microsomal turnovers. Lastly, 5-OCH<sub>2</sub>-oxazole <b>23</b> had good BACE1 potency (no enzyme-to-cell in part due to the low cLogP, despite having a large P3 group) but modest selectivity over BACE2. Overall, compounds <b>19</b> and <b>20</b> stood out in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> for their BACE1 potency, selectivity over BACE2, and low-to-moderate microsomal turnovers. These two analogs were evaluated in a single-dose rat PD model. Male Sprague-Dawley rats were dosed with an inhibitor (3 or 10 mg/kg) by oral gavage, where after 4 h plasma drug level was determined along with Aβ<sub>40</sub> concentration in the CSF and brain.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> At the 4 h time point, <b>19</b> decreased Aβ40 levels in CSF (50%) and brain (43%) at 10 mg/kg oral dose; in contrast, <b>20</b> robustly decreased Aβ40 levels in CSF (84%) and brain (72%) at 3 mg/kg oral dose. The estimated unbound plasma EC<sub>50</sub> for brain Aβ40 reduction was 0.007 and 0.0003 μM for <b>19</b> and <b>20</b>, respectively.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR in P3 Region</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0014.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">BACE1 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">Pgp efflux</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">enzyme</th><th class="colsep0 rowsep0" align="center">HEK<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">BACE2 enzyme IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (BACE2/BACE1)</th><th class="colsep0 rowsep0" align="center"><i>P</i><sub>app</sub><a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">(h|r)ER<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">HLM|RLM<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a> (μL min<sup>–1</sup> mg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center">cLogP|MW</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">1.1 (<1)</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">2.1|2.3</td><td class="colsep0 rowsep0" align="left">47|161</td><td class="colsep0 rowsep0" align="left">4.3|408.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">6.1</td><td class="colsep0 rowsep0" align="left">52</td><td class="colsep0 rowsep0" align="left">401* (68)</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">3.2|2.9</td><td class="colsep0 rowsep0" align="left">35|79</td><td class="colsep0 rowsep0" align="left">4.3|516.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">0.7</td><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="left">40 (57)</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">2.3|2.5</td><td class="colsep0 rowsep0" align="left">67|144</td><td class="colsep0 rowsep0" align="left">4.1|472.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">1.8</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">31 (17)</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">1.9|2.5</td><td class="colsep0 rowsep0" align="left">20|168</td><td class="colsep0 rowsep0" align="left">4.3|486.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">4.2</td><td class="colsep0 rowsep0" align="left">4.2</td><td class="colsep0 rowsep0" align="left">94* (22)</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">2.8|2.7</td><td class="colsep0 rowsep0" align="left">40|99</td><td class="colsep0 rowsep0" align="left">3.4|463.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">3.4</td><td class="colsep0 rowsep0" align="left">40 (50)</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">3.3|2.9</td><td class="colsep0 rowsep0" align="left">26|<14</td><td class="colsep0 rowsep0" align="left">3.6|517.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">19 (47)</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">2.8|2.8</td><td class="colsep0 rowsep0" align="left">41|84</td><td class="colsep0 rowsep0" align="left">3.5|473.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">66*</td><td class="colsep0 rowsep0" align="left">562* (33)</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">1.3|1.2</td><td class="colsep0 rowsep0" align="left">29|156</td><td class="colsep0 rowsep0" align="left">3.6|531.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">8.4</td><td class="colsep0 rowsep0" align="left">94* (85)</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">2.3|2.7</td><td class="colsep0 rowsep0" align="left">88|306</td><td class="colsep0 rowsep0" align="left">3.9|477.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">34* (8)</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">1.2|1.2</td><td class="colsep0 rowsep0" align="left">42|112</td><td class="colsep0 rowsep0" align="left">2.2|516.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Average of at least two determinations unless noted by ∗ (<i>n</i> = 1); for full statistical information, see the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01034/suppl_file/jm9b01034_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Human embryonic kidney cells transfected with wild-type human APP in the presence of 10% FBS.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Apparent permeability values (measured in parental LLC-PK1 cells) are an average of apical to basolateral (A to B) and basolateral to apical (B to A) velocities and are reported as 10<sup>–6</sup> cm/s.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">Efflux ratio values (measured in LLC-PK1 cells transfected with either human MDR1 or rat MDR1a/1B) are reported as a ratio of (B to A)/(A to B).</p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last">In vitro microsomal stability (<i>n</i> = 1) measurements were conducted in the presence of NADPH at 37 °C for 30 min at a final compound concentration of 1 μM with microsomal protein concentration of 250 μg/mL.</p></div></div></div><div class="NLM_p">To see if we could improve upon compound <b>20</b>, we next prepared a group of analogs keeping the P3 substituent constant as propargyloxy and replacing the P1′ substituent −CH<sub>2</sub>OMe of <b>20</b> with promising R groups from <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. The SAR results are shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. Compounds <b>24</b> (R = CH<sub>2</sub>F) and <b>25</b> (R = CHF<sub>2</sub>) had comparable in vitro and in vivo profile to that of <b>20</b>. Compound <b>24</b> was subsequently deprioritized after glutathione (GSH) conjugation study showed significant alkyl fluoride displacement by GSH. Compound <b>26</b> (R = CONMe<sub>2</sub>) was also deprioritized based on its low selectivity over BACE2.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Replacement of −CH<sub>2</sub>OMe in <b>20</b> with Other P1′ Substituent</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0015.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">BACE1 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">Pgp efflux</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">enzyme</th><th class="colsep0 rowsep0" align="center">HEK<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">BACE2 enzyme IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> (BACE2/BACE1)</th><th class="colsep0 rowsep0" align="center"><i>P</i><sub>app</sub><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">(h|r)ER<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">HLM|RLM (μL min<sup>–1</sup> mg<sup>–1</sup>)<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center">rat brain Aβ<sub>40</sub> reduction|dose<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">19 (47)</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">2.8|2.8</td><td class="colsep0 rowsep0" align="left">41|84</td><td class="colsep0 rowsep0" align="left">72%|3 mg/kg</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">0.2</td><td class="colsep0 rowsep0" align="left">0.6</td><td class="colsep0 rowsep0" align="left">12 (60)</td><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">2.4|2.6</td><td class="colsep0 rowsep0" align="left">76|87</td><td class="colsep0 rowsep0" align="left">74%|3 mg/kg</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">0.2</td><td class="colsep0 rowsep0" align="left">0.6</td><td class="colsep0 rowsep0" align="left">9.7 (49)</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">2.3|2.5</td><td class="colsep0 rowsep0" align="left">40|40</td><td class="colsep0 rowsep0" align="left">66%|3 mg/kg</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">0.8 (3)</td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">5.1|5.2</td><td class="colsep0 rowsep0" align="left">39|100</td><td class="colsep0 rowsep0" align="left">84%|10 mg/kg</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Average of at least two determinations; for full statistical information, see the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01034/suppl_file/jm9b01034_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Human embryonic kidney cells transfected with wild-type human APP in the presence of 10% FBS.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Apparent permeability values (measured in parental LLC-PK1 cells) are an average of apical to basolateral (A to B) and basolateral to apical (B to A) velocities and are reported as 10<sup>–6</sup> cm/s.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Efflux ratio values (measured in LLC-PK1 cells transfected with either human MDR1 or rat MDR1a/1B) are reported as a ratio of (B to A)/(A to B).</p></div><div class="footnote" id="t3fn5"><sup><sup>e</sup></sup><p class="last">In vitro microsomal stability (<i>n</i> = 1) measurements were conducted in the presence of NADPH at 37 °C for 30 min at a final compound concentration of 1 μM with microsomal protein concentration of 250 μg/mL.</p></div><div class="footnote" id="t3fn6"><sup><sup>f</sup></sup><p class="last">Compound given orally, <i>n</i> = 5, 4 h after dose, mean reduction as compared to vehicle control.</p></div></div></div><div class="NLM_p">An X-ray cocrystal structure of compound <b>20</b> with BACE1 at 1.85 Å resolution is shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. The protonated amidine warhead engages BACE1 via tight hydrogen bonds with the catalytic aspartic acid residues Asp289 and Asp93. In the S1′ pocket, there is a hydrogen bond between the O-atom of −OMe group and a water molecule. In the S1 pocket, the cyclopropyl and the 4-F on phenyl ring form van der Waals interactions with Tyr132 in the flap while the 5-F has van der Waals contacts with Phe169. The amide NH in <b>20</b> not only forms a hydrogen bond with the backbone carbonyl oxygen of Gly291 but also forms a favorable electrostatic interaction with the pyrazinyl N1, a conformation similar to what others have observed in picolinamides <b>2</b>, <b>3</b>, and <b>5</b>.<a onclick="showRef(event, 'ref23 ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25">(23−25)</a> The <i>para</i>-propargyloxy projects deep into the S3 pocket where the alkyne forms face to face contacts with Tyr75, resulting in potent and selective BACE1 inhibition. The S3 pocket of BACE1 is deeper than that of BACE2 and other single chain aspartyl proteases, a feature that we and others in the field exploited to achieve selectivity.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Cocrystal structure of <b>20</b> and BACE1 (1.85 Å resolution, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PZ4">6PZ4</a>). Hydrogen bond contacts are shown with dashed lines; the red dot represents water molecule; the segment in orange is part of the flexible hairpin loop commonly referred to as the “flap”.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> (B) Alternative view illustrating that <i>para</i>-propargyloxy projects deep into the S3 pocket. The figures were generated with the PyMOL Molecular Graphics System, version 1.7.0.1, Schrödinger, LLC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01034&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The selectivity data in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a> showcase the evolution of BACE1 inhibitors developed in Amgen in recent years. From aminooxazoline xanthene <b>1</b> to 5-Cl-picolinamide <b>6</b> to 5-propargyloxypyrazinylamides <b>20</b> and <b>25</b>, the selectivity over CatD, BACE2, and other related aspartyl proteases has been steadily improved.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Enzymatic IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> of Related Aspartyl Protease for BACE1 Inhibitors <b>1</b>, <b>6</b>, <b>20</b>, and <b>25</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">BACE1</th><th class="colsep0 rowsep0" align="center">BACE2 (BACE2/BACE1)</th><th class="colsep0 rowsep0" align="center">CatD</th><th class="colsep0 rowsep0" align="center">CatE</th><th class="colsep0 rowsep0" align="center">pepsin</th><th class="colsep0 rowsep0" align="center">renin</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">0.0003</td><td class="colsep0 rowsep0" align="left">0.0008* (2.6)</td><td class="colsep0 rowsep0" align="left">0.093</td><td class="colsep0 rowsep0" align="left">0.075*</td><td class="colsep0 rowsep0" align="left">0.23*</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">0.0120</td><td class="colsep0 rowsep0" align="left">0.0018 (0.1)</td><td class="colsep0 rowsep0" align="left">750</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">0.0004</td><td class="colsep0 rowsep0" align="left">0.0186 (47)</td><td class="colsep0 rowsep0" align="left">137</td><td class="colsep0 rowsep0" align="left">1377*</td><td class="colsep0 rowsep0" align="left">686</td><td class="colsep0 rowsep0" align="left">678</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">0.0002</td><td class="colsep0 rowsep0" align="left">0.0097 (49)</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">453</td><td class="colsep0 rowsep0" align="left">134</td><td class="colsep0 rowsep0" align="left">214</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Average of at least two determinations unless indicated by ∗ (<i>n</i> = 1).</p></div></div></div><div class="NLM_p">To further understand the apparent selectivity for BACE1 over BACE2 of propargyloxy analogs <b>20</b> and <b>25</b> observed in biochemical assays, we set out to develop a cell-based assay for BACE2. Assays that measure inhibitory activities of compounds against natively expressed BACE1 in cells against physiological substrate (amyloid precursor protein (APP)) as used above have been described previously.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> To assess cellular activity of BACE1 inhibitors on BACE2, cellular assay was developed using PMEL17, a known substrate of BACE2.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> PMEL17 is synthesized as a proprotein that is cleaved by a proprotein convertase generating an N-terminal Mα and a membrane-tethered C-terminal Mβ fragment. BACE2 cleaves at a juxtamembrane position within the Mβ domain releasing the PMEL luminal domain for the formation of amyloid fibrils and melanosome maturation. Initially, treatment of mouse melanoma cells with the nonselective inhibitor <b>1</b> resulted in accumulation of the endogenous BACE2 substrate, PMEL17 Mβ (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). This effect was concentration-dependent and could be quantified using densitometric analysis of Western blots (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. In vitro assay for BACE2 activity in mouse melanoma cells. (A) Cleavage of endogenous substrate was assessed by Western blot detection of PMEL17 Mβ. Following a 4-day treatment of mouse melanoma cells with compound <b>1</b> (1 μM), accumulation of intracellular substrate, PMEL17 Mβ, was observed. Such PMEL17 Mβ accumulation was not observed with DMSO control. (B) Intracellular accumulation of PMEL17 Mβ induced by inhibitor <b>1</b> was dose-dependent. EC<sub>50</sub> = 40 nM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01034&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">However, screening of multiple compounds would require a cellular screening assay with improved throughput. To this end, human PMEL17 Mβ construct was generated in which a portion of the extracellular domain, including the BACE2 cleavage site, was fused to the C-terminus of Gaussia luciferase (GLuc) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A) and transiently transfected into HEK293 cells overexpressing the BACE2 enzyme. Cleavage by BACE2 resulted in a release of GLuc into the conditioned media, allowing for a high-throughput, direct read end point, which could be quantified by luminescence to generate IC<sub>50</sub> values for compounds <b>1</b> (55.7 ± 7.5 nM), <b>20</b> (569 ± 123 nM), and <b>25</b> (1290 ± 337 nM). Our hypothesis as to why we observe larger enzyme-to-cell shifts for BACE2 than for BACE1 is related to the pH of the cellular compartment in which each enzyme encounters its substrate and the distribution of compound into those compartments. We propose that BACE2 encounters PMEL17 in melanosome structures that have pH values higher than the early/late endosome compartments in which BACE1 encounters APP. Most BACE1 inhibitors are lipophilic molecules and weakly to moderately basic<a onclick="showRef(event, 'ref20 ref42'); return false;" href="javascript:void(0);" class="ref ref20 ref42">(20,42)</a> and thus will preferentially distribute/accumulate in acidic compartments within the cell, a property described as lysosomotropism.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Expression and cleavage of the substrate in HEK293 cells were further confirmed using PAGE Western blot and luminescence, using nonselective BACE inhibitor <b>1</b> as an example (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B). The Western blot data confirm accumulation of uncleaved substrate consistent with what was observed with results observed above with endogenous PMEL17 in mouse melanoma cells.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Human PMEL17 Mβ expression construct contains gluciferase on the N-terminus, an internal HA tag and a C-terminus Myc tag. (B) Expression confirmation with anti-gluciferase showed reduction of secreted cleavage product and increase in full length intracellular substrate with overnight treatment of nonselective BACE inhibitor <b>1</b> at 1 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01034&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To correlate the in vitro BACE2 inhibition with hypopigmentation, we assessed the pharmacodynamic effects of BACE1 inhibitors, <b>1</b> and <b>20</b> and <b>25</b>, in a mouse model of depilation-induced hair follicle cycling, in which melanogenesis is strictly coupled to the anagen stage of the hair cycle.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> The hair growth cycle consists of three phases: a resting telogen phase, an active hair growth anagen phase, where melanogenesis occurs within the hair follicles and the skin becomes dark gray or black, and finally, a catagen phase where hair growth stops.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> At any given time, hairs are asynchronous with respect to these cycles; however, hair can be resynchronized via mechanical traumatization to the hair follicles (e.g., depilation),<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> allowing for a robust model in which to study effects on pigmentation in which the hair cycle synchronization could be observed as skin pigmentation and hair growth. Following procedures previously described by the Müller-Röver model,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> wax depilation results in pink skin color in the depilated area, which darkens gradually and is visible prior to any hair growth that began around day 11 postdepilation. Synchronization of the hair cycle observed as skin pigmentation and hair growth was validated by measuring mRNA expression of known markers of anagen phase.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Expression of TYR, TYRP1, and TYRP2 all increased following depilation, temporally correlated with the appearance of skin pigmentation and hair growth, while expression of MITF mRNA remained stable over the course of the study (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Additionally, PMEL17 processing increased during melanogenesis as evidenced by decreased levels of PMEL17 Mβ fragment.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Biomarkers correlated with synchronized melanogenesis. mRNA expression of the melanogenesis biomarkers TYR (red square), TYRP1 (green triangle), and TYRP2 (purple triangle) increased following depilation in coordination with hair regrowth and pigmentation. mRNA levels of MITF (blue circles) did not change. PMEL17 Mβ fragment levels decreased during melanogenesis (black diamond). Error bars are standard deviation (<i>n</i> = 9).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01034&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Use of this panel of transcription factors or measures of PMEL17 cleavage would have required terminal sampling of the mice in the study, resulting in a very large burden of animal use and a low screening throughput. As the hair and skin color changes correlated with known markers of anagen phase, developing an assay quantifying the skin and hair color change via a nonterminal measurement would be adequate to establish necessary levels of BACE2 selectivity. To this end, we developed a camera-based hypopigmentation assay to quantitatively monitor the depilation/regrowth process. A camera was used to daily record the color of skin/fur of mice waxed and orally dosed once a day for 13 days with either vehicle or one of the 3 inhibitors: <b>1</b> (3 dosing groups of 10, 30, and 120 mg/kg) or <b>20</b> (100 mg/kg) or <b>25</b> (30 mg/kg). In mice treated with nonselective inhibitor <b>1</b> (120 mg/kg), there was a distinct reduction in pigmentation levels in the depilated skin just at the onset of hair visibility (day 11) and after the hair has completely covered the skin (day 13) when compared to mice treated with vehicle (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). There was a clear dose–response effect with distinct responses in pigmentation levels with three different doses of <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0006.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Hypopigmentation observed in mice treated with nonselective BACE1 inhibitor <b>1</b> but not with selective BACE1 inhibitor <b>20</b> or <b>25</b>. (Top) Depilated mice were dosed orally once a day for 13 days with either vehicle (2% HPMC, 1% Tween 80, pH 2.2) or an inhibitor. Error bars are standard deviation (<i>n</i> = 5). (Bottom) Pictures taken at day 1 and day 13 of mice treated with vehicle, <b>1</b>, <b>20</b>, and <b>25</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01034&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In contrast, in mice treated with selective inhibitors <b>20</b> (100 mg/kg) or <b>25</b> (30 mg/kg), there was no appreciable reduction in pigmentation levels in the depilated skin or newly grown fur when compared to mice treated with vehicle (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). The plasma exposure data (unbound Css, plasma) from day 13 in this pigmentation study are shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. Also listed in the <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> are the unbound EC<sub>50</sub> values for mouse brain Aβ<sub>40</sub> reduction. At multiples of somewhere between 15 (no appreciable reduction in pigmentation levels) and 36 (25% reduction in pigmentation levels), mice treated with nonselective inhibitor <b>1</b> showed hypopigmentation. In contrast, mice treated with selective inhibitor <b>20</b> or <b>25</b>, even at multiples of 86 or 48, respectively, showed no sign of hypopigmentation. This novel methodology for in vivo screening for BACE1-selective inhibitors may be useful for investigations or phenotypic screen for other disease states that are associated with pigmentation effects.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Mouse Plasma Protein Binding (PPB) Unbound Fractions (<i>f</i><sub>u</sub>), Exposure Data from Mouse Hypopigmentation Study, and Mouse Brain Aβ<sub>40</sub> Reduction Unbound EC<sub>50</sub> of Compounds <b>1</b>, <b>20</b>, and <b>25</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center"><b>1</b></th><th class="rowsep1 colsep0" align="center"><b>20</b></th><th class="rowsep1 colsep0" align="center"><b>25</b></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">10 mg/kg dose</th><th class="colsep0 rowsep0" align="center">30 mg/kg dose</th><th class="colsep0 rowsep0" align="center">120 mg/kg dose</th><th class="colsep0 rowsep0" align="center">100 mg/kg dose</th><th class="colsep0 rowsep0" align="center">30 mg/kg dose</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PPB <i>f</i><sub>u</sub> (%)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">1.74</td><td class="colsep0 rowsep0" align="left">1.74</td><td class="colsep0 rowsep0" align="left">1.74</td><td class="colsep0 rowsep0" align="left">1.80</td><td class="colsep0 rowsep0" align="left">1.30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">unbound Css, plasma (μM)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">0.038</td><td class="colsep0 rowsep0" align="left">0.088</td><td class="colsep0 rowsep0" align="left">0.328</td><td class="colsep0 rowsep0" align="left">0.032</td><td class="colsep0 rowsep0" align="left">0.019</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">unbound brain Aβ<sub>40</sub>↓ EC<sub>50</sub> (μM)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">0.0025</td><td class="colsep0 rowsep0" align="left">0.0025</td><td class="colsep0 rowsep0" align="left">0.0025</td><td class="colsep0 rowsep0" align="left">0.00037</td><td class="colsep0 rowsep0" align="left">0.0004</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">multiples (row 3/4)</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">36</td><td class="colsep0 rowsep0" align="left">133</td><td class="colsep0 rowsep0" align="left">86</td><td class="colsep0 rowsep0" align="left">46</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Mouse plasma protein binding unbound fractions measured by ultracentrifugation method (<i>n</i> = 1).</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Unbound Css; plasma is the average plasma concentration over 24 h on day 13 of dosing and is calculated as [blood AUC<sub>0–24,day13</sub> × (ratio<sub>plasma/blood</sub>) × (<i>f</i><sub>u,plasma</sub>)]/24.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Estimated unbound mouse EC<sub>50</sub> in brain Aβ<sub>40</sub> reduction.</p></div></div></div><div class="NLM_p">With good selectivity for BACE1 over BACE2, compounds <b>20</b> and <b>25</b>, along with their respective arylamine metabolites (< 5% in human hepatocytes) <b>8B</b> and <b>10B</b> (for structures, see <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>), were advanced for in vitro genotoxicity screening. All four compounds were negative in the Ames test. In micronucleus assays, inhibitors <b>20</b> and <b>25</b> and arylamine <b>8B</b> were negative but arylamine <b>10B</b> was positive. Subsequently compound <b>20</b> was advanced for additional pharmacokinetic (PK) evaluation in rat, beagle dog, and rhesus monkey (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Consistent with its stability in liver microsomes, <b>20</b> showed moderate to high total clearance across three species. When dosed orally, bioavailability ranged from moderate (28% in monkey) to high (100% in dog).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. In Vitro and in Vivo PK Profiles and Plasma Protein Binding (PPB) Unbound Fractions (<i>f</i><sub>u</sub>) of Compound <b>20</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">iv<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="rowsep1 colsep0" colspan="3" align="center">po<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center">LM (μL min<sup>–1</sup> mg<sup>–1</sup>)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">CL (L h<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">AUC<sub>t</sub> (μM/h)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th><th class="colsep0 rowsep0" align="center">PPB <i>f</i><sub>u</sub> (%)<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">84</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">0.55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">62</td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" align="left">3.2</td><td class="colsep0 rowsep0" align="left">2.0</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">2.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="left">146</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">8.3</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">28</td><td class="colsep0 rowsep0" align="left">6.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">In vitro microsomal stability (<i>n</i> = 1) measurements were conducted in the presence of NADPH at 37 °C for 30 min with microsomal protein concentration of 250 μg/mL and at a final compound concentration of 1 μM for rat and 0.5 μM for dog and monkey.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">1 mg/kg iv dosed as a solution in DMSO (rat); 25% hydroxypropyl β cyclodextrin 75% water/MSA at pH = 4 (beagle dog and rhesus monkey).</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">Orally dosed as a solution in 1% Tween 80 + 2% HPMC + 97% water/MSA at pH = 5 (rat); 1% Tween 80 + 2% HPMC + 97% water pH = 2.2 (beagle dog and cynomolgus monkey).</p></div><div class="footnote" id="t6fn4"><sup><sup>d</sup></sup><p class="last">Plasma protein binding unbound fractions were measured by ultracentrifugation method (<i>n</i> = 1).</p></div></div></div><div class="NLM_p">For cross species activities, compound <b>20</b> was profiled in rat, mouse, dog, and monkey BACE1 biochemical assays which revealed similar IC<sub>50</sub> values to that in human BACE biochemical assay (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01034/suppl_file/jm9b01034_si_001.pdf" class="ext-link">Table SI-1</a>). Compound <b>20</b> was further evaluated in a time-course PD assay in rat following a 3 mg/kg oral dose (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Maximum Aβ<sub>40</sub> reduction in both CSF and brain was observed between 4 and 5 h postdose, with a similar level of Aβ<sub>40</sub> lowering in both tissues. By use of an indirect response PK–PD model,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> the generated in vivo plasma EC<sub>50,unbound</sub> values for CSF and brain Aβ reduction (0.12 nM and 0.36 nM, respectively) were in agreement with the estimated plasma EC<sub>50,unbound</sub> obtained from the single dose PD study (0.25 nM). Subsequently, compound <b>20</b> was evaluated in a rhesus monkey time-course PD assay following a 10 mg/kg oral dose (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). Aβ<sub>40</sub> level in CSF was maximally reduced (80–82%) between 12 and 30 h postdose and returned to near baseline at 72 h. A robust Aβ<sub>40</sub> reduction in CSF was observed at a 10 mg/kg oral dose. The generated in vivo unbound plasma EC<sub>50</sub> value for Aβ<sub>40</sub> reduction in CSF was at 0.18 nM, similar to the potency observed in a rat time-course PD study.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0007.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Time course of brain and CSF Aβ<sub>40</sub> lowering in Sprague-Dawley rat (<i>n</i> = 5) following a 3 mg/kg oral dosing of <b>20</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01034&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0008.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. PK–PD relationship of <b>20</b> in Rhesus monkey (<i>n</i> = 3) following a 10 mg/kg oral dose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01034&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Additional profiling showed that compound <b>20</b> had an IC<sub>50</sub> of 27, 20, and 25 μM for CYP 3A4, 2D6, and 2C9, respectively. Compound <b>20</b> had an IC<sub>50</sub> of 6.9 μM for hERG (binding assay), and in a broader selectivity screen against a variety of G-protein-coupled receptors, <b>20</b> did not exhibit any off-target interactions when tested at 10 μM concentration. When dosed orally once daily, <b>20</b> was well tolerated in 14-day toxicology studies in rats at up to 30 mg/kg and dogs at up to 10 mg/kg.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10615" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10615" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We previously reported the synthesis of arylamine <b>6G</b> and picolinamide <b>6</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a> Thiazine <b>6A</b> was converted to α,β-unsaturated ester <b>6B</b> in a three-step sequence (LDA/CO<sub>2</sub> followed by methylation of the corresponding acid with TMSCHN<sub>2</sub>). Corey–Chaykovsky cyclopropanation of <b>6B</b> afforded fused bicycle <b>6C</b> in >98% de.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Conversion of <b>6C</b> to aldehyde <b>6D</b> was followed by deformylation with Wilkinson’s catalyst to give C1-unsubstituted cyclopropylthiazine <b>6E</b>. Next, the nitration of <b>6E</b> under acidic conditions not only installed the 5-nitro group but also removed N-protecting groups (Boc and SEM) to provide <b>6F</b> which was subjected to Zn/acids reduction to give arylamine <b>6G</b>. Lastly, the amide bond formation between <b>6G</b> and 5-chloropicolinic acid was carried out in the presence of a mild activating agent such as T3P to afford picolinamide <b>6</b>.</div><figure id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Arylamine <b>6G</b> and Inhibitor <b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01034&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (1) LDA, CO<sub>2</sub>; (2) TMSCHN<sub>2</sub>, 92%; (b) NaH, Me<sub>3</sub>SOI, 80%; (c) (1) LiBH<sub>4</sub>, MeOH; (2) SO<sub>3</sub>·pyr, 79%; (d) RhCl(PPh<sub>3</sub>)<sub>3</sub>, DCE, 68%; (e) H<sub>2</sub>SO<sub>4</sub>, NaNO<sub>3</sub>, 56%; (f) Zn, TFA, HOAc, 80%; (g) 5-chloropicolinic acid, T3P, EtOAc, 50%.</p></p></figure><div class="NLM_p">Intermediate <b>6C</b>, having an ester at the C1-position of cyclopropylthiazine, was a versatile starting point for the preparation of arylamines used in the synthesis of the BACE1 inhibitors discussed herein. For example, <b>6C</b> was subjected to nitration followed by nitro reduction to give <b>7A</b> in which the ester was reduced to alcohol thus affording arylamine <b>7B</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). In other routes, <b>6C</b> was first reduced with LiBH<sub>4</sub> to provide alcohol <b>8A</b> which was derivatized to arylamines <b>8B</b> and <b>9B</b>. The deoxyfluorination of <b>6D</b> with Deoxo-Fluor in DCM gave a mixture of cyclobutylthiazine <b>10cBu</b> (24%) and cyclopropylthiazine <b>10A</b> (62%). Nitration of <b>10A</b> and subsequent nitro reduction afforded arylamine <b>10B</b>.</div><figure id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Arylamines <b>7B</b>, <b>8B</b>, <b>9B</b>, and <b>10B</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01034&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (1) H<sub>2</sub>SO<sub>4</sub>, NaNO<sub>3</sub>; (2) Zn, TFA, HOAc, 46–80%; (b) LiBH<sub>4</sub>, MeOH, 88–98%; (c) NaHMDS, MeI, 76%; (d) MsCl, Et<sub>3</sub>N, DCM, 100%; (e) CsF, <i>t</i>BuOH, 88%; (f) Deoxo-Fluor, DCM.</p></p></figure><div class="NLM_p">To further highlight the utility of ester <b>6C</b>, saponification with LiOH provided acid <b>6H</b> which was then converted to amides <b>11B</b>, <b>12B</b>, and <b>13B</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Dehydration of primary amide in <b>11B</b> with trifluoroacetic anhydride (TFAA) afforded cyano <b>14A</b> which was treated with NH<sub>3</sub>/MeOH to give arylamine <b>14B</b>.</div><figure id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Arylamines <b>11B</b>, <b>12B</b>, <b>13B</b>, and <b>14B</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01034&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (1) LiOH; (2) HCl, 100%; (b) CDI or HATU, R<sup>1</sup>R<sup>2</sup>NH, 83–95%; (c) (1) H<sub>2</sub>SO<sub>4</sub>, NaNO<sub>3</sub>; (2) Zn, TFA, HOAc, 46–80%; (d) TFAA, DIPEA, THF, 100%; (e) 2 M NH<sub>3</sub> in MeOH, 44%.</p></p></figure><div class="NLM_p">BACE1 inhibitors <b>7</b>–<b>26</b> discussed in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>–<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> were prepared in a fashion similar to that described for picolinamide <b>6</b>, via T3P mediated amide coupling reactions of an acid (5-chloropicolinic acid or <b>28</b>) with a respective arylamine (<b>7B</b>–<b>14B</b>) (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). An alternative synthetic route for 5-alkoxypyrazinyl analogs was developed, exemplified by <b>18</b>, <b>21</b>–<b>23</b>. Arylamine <b>8B</b> was coupled with 5-chloropyrazine-2-carboxylic acid to give amide <b>30</b> in which the 5-Cl was displaced with an alkoxide generated from R<sup>1</sup>OH/Cs<sub>2</sub>CO<sub>3</sub>.</div><figure id="sch4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0012.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Generic Synthesis of BACE1 Inhibitors <b>7</b>–<b>26</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01034&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) T3P, DCM, 43–83%; (b) R<sup>1</sup>OH, Cs<sub>2</sub>CO<sub>3</sub>, THF, 50 °C, 58–86%.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87241" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87241" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Application of structure-based design with simultaneous balance of physicochemical parameters led to the discovery of a series of highly potent BACE1 selective and BACE2 sparing inhibitors that were orally efficacious at lowering brain Aβ<sub>40</sub> level in rodents. A cell-based assay for BACE2 monitoring the cleavage of PMEL17 Mβ in HEK293 cells was developed to further profile the lead compounds. In particular, compound <b>20</b> with a P3 propargyloxy group exhibited an enzyme BACE2/BACE1 ratio of 47, showed no skin/fur color change in a 13-day mouse hypopigmentation study, and demonstrated robust CSF Aβ<sub>40</sub> reduction in monkey following a single 10 mg/kg oral dose. Furthermore, this compound was well tolerated in 14-day toxicology studies in rats (up to 30 mg/kg, po, QD) and dogs (up to 10 mg/kg, po, QD). Compound <b>20</b> (AM-6494) was ultimately selected as a preclinical development candidate.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51067" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51067" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> A. Biology. BACE1 and BACE2 Enzymatic Assays</h3><div class="NLM_p last">The enzymatic activity of both BACE1 and BACE2 was determined by the enhancement of fluorescence intensity upon enzymatic cleavage of the fluorescence resonance energy transfer (FRET) substrate. The cleavage sequence of the substrate was derived from the literature,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> and a fluorophor and a quencher dye were attached to the lysine side chain at the termini of the substrate. The human recombinant BACE1 and BACE2 FRET assays were performed in 50 mM acetate, pH 4.5/8% DMSO/100 μM Genapol/0.002% Brij-35 using the same FRET substrate in a Costar 96-well black polypropylene plate. In dose–response IC<sub>50</sub> assays, 10 various concentrations of each compound that are made at 1:3 serial dilutions in DMSO were preincubated with the enzyme for 60 min at RT. Subsequently, the FRET substrate was added to initiate the reaction. After 60 min at RT, the reaction was stopped by the addition of untitrated 0.1 M Tris base to raise the pH above the enzyme active range. The fluorescence intensity of each well was measured on Safire II microplate reader (Tecan, Männedorf, Switzerland), and the IC<sub>50</sub> values were calculated by fitting normalized activity data with a four-parameter nonlinear regression equation via Screener software (Genedata AG, Basel, Switzerland).</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> BACE1 Cell-Based Assay</h3><div class="NLM_p last">BACE 1 cellular activity was determined in human embryonic kidney cells (HEK293) stably expressing APP Swedish mutant. After incubation overnight with the test compounds, the conditioned medium was collected and the Aβ<sub>40</sub> levels were determined using a sandwich ELISA as described previously.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a></div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> BACE2 Cell-Based Assays</h3><div class="NLM_p">BACE2 activity was assessed by measuring secretion of PMEL17 Mβ fragment in B16-F1 mouse melanoma cells (B16-F1 ATCC no. CRL-6323). Cells were cultured at 37 °C, 5% CO<sub>2</sub> in ATCC-formulated Dulbecco’s modified Eagle’s medium (ATCC no. 30-2002), 10% fetal bovine serum (Gibco no. 10099-141), 1× pen–strep–glutamine (Gibco no. 10378-016) and split at a ratio of 1:4 every 3 days.</div><div class="NLM_p last">To assess endogenous substrate cleavage, mouse melanoma cells were seeded into 12-well plates (Costar no. 3904) at a density of 500 000 cells per well in a total volume of 1 mL. The nonselective compound <b>1</b> was immediately added at concentrations ranging from 0.15 to 1000 nM, and cells were cultured for 4 days. Cells were rinsed with 500 μL of 1× DPBS (DPBS 1× without Ca/Mg Gibco no. 14190-136) per well and lysed with 300 μL of cytobuster protein extraction reagent (Novagen no. 71009) containing 1 protease inhibitor tablet (Pierce protease inhibitor tablets, EDTA-free no. 88266). Lysates were centrifuged at 14 000 rpm for 10 min at 4 °C to remove cellular debris and stored at −80 °C until PMEL17 measurement by Western blot. Briefly, an amount of 14 μL of whole cell lysates representing 60 μg of total protein (Thermo Scientific Pierce Micro BCA protein assay kit no. 23235) in 2× LDS sample buffer (Invitrogen Life Technologies no. NP0007) was loaded per lane on a NuPAGE 4–12% Bis-Tris gradient gel (Invitrogen Life Technologies no. NP0321) and electrophoresed 55 min at 200 V in 1× NuPAG MES SDS running buffer (Invitrogen Life Technologies no. NP0002) with SeeBlue Plus2 prestained standard (Invitrogen Life Technologies no. LC5925) included to monitor molecular weight. Proteins were transferred to nitrocellulose (Invitrogen Life Technologies iblot transfer system no. IB301001) for 7 min and blocked with Licor blocking buffer (no. 927-40000 Odyssey blocking buffer) for 1 h at RT with gentle shaking. Western blots were probed with silver homologue anti-PMEL17 goat polyclonal antibody (Pierce no. PA5-18538) 4 °C overnight with gentle shaking in Licor blocking buffer with 1% Tween 20. Following 4× wash with TBST buffer (Tris buffered saline + 0.05% Tween 20) for 15 min each, Western blots were probed with secondary antibody (Licor no. 926-32214 IRDye 800CW donkey anti-goat IgG H + L) at a 1:20 000 dilution in Licor blocking buffer with 0.1% SDS for 1 h at RT with gentle shaking protected from light. Following 4× wash in TBST and 1 h drying at RT, Western blots were scanned on the 800 channel using the Licor Odyssey infrared fluorescence imager and the PMEL17 Mβ fragment was quantitated and plotted as relative intensity units.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> BACE2 Human PMEL17 Mβ Luciferase Reporter Assay</h3><div class="NLM_p last">Human PMEL17 (pigment cell-specific melanocyte protein) is a single-pass type I membrane protein involved in melanogenesis. The Mβ chain of human PMEL17, containing the BACE2 cleavage site, was cloned as a CT fusion to Gaussia luciferase (GLuc) under control of the CMV promoter (NEB pCMV-GLuc 2 no. N8081). PMEL17 Mβ GLuc is constitutively cleaved by BACE2, enabling a high throughput, direct readout method to detect and quantify cleavage products in the cell culture medium. To monitor BACE2 activity in cells, a human embryonic kidney (HEK293T) stable cell line overexpressing human BACE2 (Paul Denis, Amgen) was cultured to 100% confluency in a T225 flask (Costar no. 3001). Cells were detached using 0.05% trypsin–EDTA (Gibco no. 25300-054) and split 1:6 into two flasks at 0.5 × 10<sup>6</sup> cells per mL in 50 mL of DMEM complete media (DMEM Gibco no. 11965, 1× penicillin–streptomycin–glutamine (100×) Gibco no. 10378-016, 10% fetal bovine serum Gibco no. 10099-141, puromycin 5 μg/mL Gibco no. A11138-03). Cells were incubated overnight in 5% CO<sub>2</sub> at 37 °C. The following day, transient transfection, using 50 μg of human PMEL17 GLuc Mβ DNA per T225 flask, was performed using Gene Juice (Novagen no. 70967-4) transfection reagent, according to the manufacturer’s protocol. The transfection mix (4 mL) was added to each flask containing 40 mL of fresh transfection media (DMEM Gibco no. 11965, 10% fetal bovine serum Gibco no. 10099-141, puromycin 5 μg/mL Gibco no. A11138-03), mixed gently and placed into incubator overnight in 5% CO<sub>2</sub> at 37 °C. The next day, transiently transfected cells were harvested and seeded at 0.1 × 10<sup>6</sup> cells per well into cell assay plates (96-well black tissue culture plates with clear bottom, poly-<span class="smallcaps smallerCapital">d</span>-lysine coated Corning (96WL PLTEPDLBLK CLR 100/CS, no. 08757465) in 180 μL total volume of transfection media (no cells were added to column 12). Compound plates (Corning no. 3365 polypropylene) containing 10 point dose responses in 100% DMSO were diluted 1:10 into transfection media by adding 10–90 μL of media mixed well, followed by another 1:10 dilution (20 μL) directly into cell assay plate containing 180 μL, mixed gently and incubated overnight in 5% CO<sub>2</sub> at 37 °C. The following day, 20 μL of the conditioned media was removed and transferred into luciferase assay plate (Corning no. 3600 white polystyrene) and combined with 50 μL of luciferase assay solution (New England BioLabs BioLux Gaussia luciferase assay kit no. E3300L), incubated at RT for 30 s, and read on an ENVISION (PerkinElmer) luminescence setting. BACE2 inhibition curves were calculated using luminescence units.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> CatD, CatE, Pepsin, and Resin Enzymatic Assay</h3><div class="NLM_p last">Enzyme activity was determined according to the protocols described in patent <patent country="WO">WO 2016022724</patent>, Feb 11, <span class="NLM_year">2016</span>.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Animals</h3><div class="NLM_p last">All studies were approved by an Institutional Animal Care and Use Committee (IACUC) in compliance with the Federal Animal Welfare Act and conducted in an AAALAC accredited facility.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Biomarker Analysis</h3><div class="NLM_p last">mRNA expression of tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), tyrosinase-related protein 2 (TYRP2), and melanogenesis associated transcription factor (MITF) were measured by real-time RT-PCR. Mice were euthanized by CO<sub>2</sub>, and dorsal skins were collected and immediately frozen at −80 °C. An amount of 30 mg of frozen mouse skin tissue was placed into a 50 mL round-bottom tube and combined with 600 μL RLT buffer. The tissue was homogenized for 20–40 s until it was uniformly homogeneous. The freshly homogenized lysate was transferred directly into a QIAshredder spin column (Qiagen, Germantown, MD, no. 79654) and centrifuged for 3 min at 14 000 rpm at 4 °C. The supernatant was transferred to a new microcentrifuge tube, combined with 600 μL of 70% ethanol, and mixed immediately by pipetting. The sample (700 μL) was transferred to an RNeasy spin column (Qiagen, Germantown, MD, no. 74104) and centrifuged for 15 s at 8000<i>g</i> at RT. Buffer RW1 (350 μL) was added to the RNeasy spin column and centrifuged for 15 s at 8000<i>g</i> to wash. The DNase I (10 μL) was added to 70 μL of RDD buffer and mixed gently. The DNase I mix (80 ul) was applied directly to the RNeasy spin column membrane and incubated at RT for 15 min. RW1 buffer (350 μL) was added to the RNeasy spin column and centrifuged for 15 s at 8000<i>g</i>. RPE buffer (500 μL) was added to the RNeasy spin column and centrifuged for 15 s at 8000<i>g</i> to wash the spin column membrane. The wash was repeated with another 500 μL of RPE buffer and centrifuged for 2 min at 8000<i>g</i>. An additional spin was performed to dry the column by centrifuging at full speed for 1 min. Using a fresh collection tube, RNA was eluted by adding 50 μL of RNase-free water directly to the spin column membrane and centrifuged for 1 min, 8000<i>g</i> at RT to elute the RNA. The concentration of RNA was determined by OD<sub>260</sub> and will be used as templates for qpcr with the SuperScript III Platinum one-step quantitative RT-PCR system with ROX (Invitrogen Thermo Fisher Scientific, USA no. 11745-500) to calculate the relative level of mRNA expression for tyrosine related protein 2/dopachrome tautomerase (DCT), tyrosinase (TYR), and tyrosine related protein 1 (TYRP1). The RNA samples were adjusted to 20 ng/μL in water. Sample reactions for one-step qRT-PCR were prepared in triplicate using a 384-well QPCR plate by combining reaction mix (1× with ROX), SuperScript III RT/Platinum Taq mix (1×), primer sets (250 nM), probe (100 nM), and 20 ng of RNA per 10 μL of reaction mixture in water per well. PCR conditions were as follows: 1 cycle for 30 min at 50 °C, 1 cycle for 10 min at 95 °C, and 40 cycles for 15 s at 95 °C, 60 s at 60 °C. QPCR counts were normalized to GAPDH, averaged, and plotted as relative mRNA expression, using GraphPad Prism.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Depilation-Induced Pigmentation and Hypopigmentation Assessment</h3><div class="NLM_p">Mice were anesthetized with isoflurane in a warmed induction chamber. Rectangular patches (2 in. × 1 in.) of dorsal hair in their back at the level of thoracic to lumber spine were completely removed with mechanical depilatory Nad’s wax strips.</div><div class="NLM_p last">Digital photographs of each mouse against a black and white reference plate were taken under standardized lighting using a Nikon D200 camera using a 60 mm lens set to an f stop of 1/32, shutter speed f 1/400 s, ISO of 1600, and an internal white balance of A4. Images were saved as uncompressed jpg files. Camera settings were set such that the average pixel value of the white and black references was at least 1 standard deviation away from saturated pixel values, 255 and 0, respectively. Photoshop CS6 was used to measure pixel values in each image. No less than 4000 pixels and as many as 500 000 pixels were used for assessment. Mean values were used as indicators of pigment levels for the depilated skin patch and three reference areas (black and white reference plate and head reference).</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Pharmacodynamic Assay</h3><div class="NLM_p last">Male Sprague-Dawley rats (175–200 g) were purchased from Harlan and were maintained on a 12 h light/dark cycle with unrestricted access to food and water until use. Rats were administered compound by oral gavage at the appropriate dose. Rats were euthanized with CO<sub>2</sub> inhalation for 2 min, and cisterna magna was quickly exposed by removing the skin and muscle above it. CSF (50–100 μL) was collected with a 30-gauge needle through the dura membrane covering the cisterna magna. Blood was withdrawn by cardiac puncture and plasma obtained by centrifugation for drug exposures. Brains were removed and, along with the CSF, immediately frozen on dry ice and stored at −80 °C until use. The frozen brains were subsequently homogenized in 10 volumes of (w/v) of 0.5% Triton X-100 in TBS with protease inhibitors. The homogenates were centrifuged at 100 000 rpm for 30 min at 4 °C. The supernatants were analyzed for Aβ40 levels by immunoassay as follows: Meso Scale 96-well avidin plates were coated with biotin-4G8 (Covance) and detected with ruthenium-labeled Fab specific for Aβ40. Plates were read in MSD Sector6000 imager according to the manufacturer’s recommended protocol (Meso Scale Discovery, Inc.). Aβ<sub>40</sub> concentrations were plotted using GraphPad Prism and analyzed by one-way ANOVA followed by Dunnett’s multiple comparison analysis to compare drug-treated animals to vehicle-treated controls.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> B. Chemistry</h3><div class="NLM_p last">Unless otherwise noted, all reagents were commercially available and used as received. All final compounds possessed purity of ≥ 95% as determined by high performance liquid chromatography (HPLC). The HPLC methods used the following conditions: Zorbax SB-C18 column (50 mm × 3.0 mm, 3.5 μm) at 40 °C with a 1.5 mL/min flow rate; solvent A of 0.1% TFA in water, solvent B of 0.1% TFA in MeCN; 0.0–3.0 min, 5–95% B in A; 3.0–3.5 min, 95% B in A; 3.5–3.51 min, 5% B in A. Flow from the UV detector was split (50:50) to the MS detector which was configured with APIES as ionizable source. <sup>1</sup>H NMR spectra were recorded on a 400 MHz Bruker NMR spectrometer at ambient temperature. Data are reported as follows: chemical shift (ppm, δ units) from an internal standard, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, and br = broad), coupling constant (Hz), and integration. <sup>19</sup>F NMR spectra were recorded on a 376 MHz Bruker NMR spectrometer at ambient temperature with proton decoupling. All microwave-assisted reactions were performed in sealed reaction vials using a Personal Chemistry Emrys Optimizer microwave synthesizer. Silica gel chromatography was performed using either an ISCO Companion or Biotage medium pressure liquid chromatography system. RT is used for room temperature, h for hour(s), min for minutes, and sat. for saturated.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> General Synthetic Methods for Biological Testing Compounds</h3><div class="NLM_p"><i>Method A</i> is exemplified by the T3P mediated amide formation of compound <b>13</b> from 5-chloropicolinic and arylaime <b>13B</b>. Compounds <b>7</b>, <b>8</b>, <b>9</b>, <b>10</b>, <b>11</b>, <b>12, 13</b>, and <b>14</b> were prepared according to method A starting from 5-chloropicolinic acid and arylamine <b>7B</b>, <b>8B</b>, <b>9B</b>, <b>10B</b>, <b>11B</b>, <b>12B</b>, <b>13B</b>, and <b>14B</b>, respectively.</div><div class="NLM_p"><i>Method B</i> is exemplified by the T3P mediated amide formation of compound <b>20</b> from 5-(prop-2-yn-1-yloxy)pyrazine-2-carboxylic acid and arylaime <b>8B</b>. Compounds <b>15</b>, <b>16</b>, <b>17</b>, <b>19</b>, and <b>20</b> were prepared according to method B starting from (1<i>S</i>,5<i>S</i>,6<i>S</i>)-5-(5-amino-2,3-difluorophenyl)-1-(methoxymethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-amine (<b>8B</b>) and 5-(2,2,2-trifluoroethoxy)picolinic acid, 5-(prop-2-yn-1-yloxy)picolinic acid, 3-methyl-5-(prop-2-yn-1-yloxy)picolinic acid, 5-(2,2,2-trifluoroethoxy)pyrazine-2-carboxylic acid, and 5-(prop-2-yn-1-yloxy)pyrazine-2-carboxylic acid, respectively. Compounds <b>24</b>, <b>25</b>, and <b>26</b> were prepared according to method B starting from 5-(prop-2-yn-1-yloxy)pyrazine-2-carboxylic acid and aniline <b>9B</b>, <b>10B</b>, and <b>13B</b>, respectively.</div><div class="NLM_p last"><i>Method C</i> is exemplified by the preparation of compound <b>18</b> from the displacement of 5-Cl of compound <b>30</b> with EtOH/Cs<sub>2</sub>CO<sub>3</sub>. Compounds <b>18</b>, <b>21</b>, <b>22</b>, and <b>23</b> were prepared according to method C: displacement of 5-Cl of compound <b>30</b> with an alcohol/Cs<sub>2</sub>CO<sub>3</sub>. Method C is exemplified by the preparation of compound <b>18</b> from the displacement of 5-Cl of compound <b>30</b> with EtOH/Cs<sub>2</sub>CO<sub>3</sub>.</div></div><div id="sec5_3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-((<i>tert</i>-Butoxycarbonyl)((2-(trimethylsilyl)ethoxy)methyl)amino)-5-(2,3-difluorophenyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxylic Acid (<b>6H</b>)</h3><div class="NLM_p last">To a stirring solution of (1<i>S</i>,5<i>S</i>,6<i>S</i>)-methyl 3-((<i>tert</i>-butoxycarbonyl)((2-(trimethylsilyl)ethoxy)methyl)amino)-5-(2,3-difluorophenyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxylate (<b>6C</b>, 13.4 g, 24.7 mmol) in THF (100 mL) and MeOH (50 mL) was added a solution of lithium hydroxide monohydrate (3.1 g, 74.1 mmol) in water (50 mL). The reaction was rapidly stirred at 35 °C for 1 h. The reaction mixture was then partitioned between EtOAc (400 mL) and 1 M HCl (200 mL). The organic layer was washed with brine (2 × 50 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure to afford the title compound (<b>6H</b>, 12.8 g, 24.2 mmol, 98% yield) as a colorless oil. <i>m</i>/<i>z</i> (ESI): 529.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> ((1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-Amino-5-(5-amino-2,3-difluorophenyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-1-yl)methanol (<b>7B</b>)</h3><div class="NLM_p"><i>Step 1.</i> At RT, (1<i>S</i>,5<i>S</i>,6<i>S</i>)-methyl 3-((<i>tert</i>-butoxycarbonyl)((2-(trimethylsilyl)ethoxy)methyl)amino)-5-(2,3-difluorophenyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxylate (<b>6C</b>, 2.00 g, 3.69 mmol) was treated with 4 mL of sulfuric acid and stirred for 10 min, then chilled to 0 °C. Sodium nitrate (0.41 g, 4.79 mmol) was added to the mixture. The mixture was stirred for 1 h at 0 °C. Additional sodium nitrate (0.41 g, 4.79 mmol) was added, and the mixture was warmed to RT. After 1 h, additional 3 mL of sulfuric acid was added (to dissolve the starting material). The reaction was cooled to 0 °C to suppress an exotherm. After 30 min, the reaction mixture was poured onto ∼100 mL of wet ice. 50 mL of DCM was added. Potassium phosphate tribasic (29.70 g, 140 mmol) was added to the mixture over ∼20 min. Aqueous 10 N NaOH was then added until the pH reached ∼8. The mixture was extracted three times with 100 mL of 9:1 mixture of chloroform/IPA. The combined organic extracts were dried over MgSO<sub>4</sub>. Filtration and concentration under reduced pressure afforded (1<i>S</i>,5<i>S</i>,6<i>S</i>)-methyl 3-amino-5-(2,3-difluoro-5-nitrophenyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxylate (<i>m</i>/<i>z</i> (ESI): 358.1 (M + H)<sup>+</sup>) as a sticky brown solid. The solid was taken up in 4 mL of acetic acid and 2 mL of TFA. Zinc (nanopowder, 1.20 g, 18.43 mmol) was added to the mixture. The mixture was stirred for 30 min and then concentrated under reduced pressure. The residue was taken up in 50 mL of 9:1 mixture of chloroform/IPA and basified to pH of ∼8.0 with 1.0 N aqueous NaOH. ∼10 mL of NH<sub>4</sub>OH (28–30%) was then added. The mixture was partitioned, and the aqueous portion was extracted three times with 100 mL of 9:1 mixture of chloroform/IPA. The combined organic extracts were dried over MgSO<sub>4</sub>. Filtration, concentration under reduced pressure, and flash chromatography on silica gel (40–90% EtOAc in DCM) afforded (1<i>S</i>,5<i>S</i>,6<i>S</i>)-methyl 3-amino-5-(2,3-difluoro-5-nitrophenyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxylate (<b>7A</b>, 0.63 g, 52% yield) as a yellow solid. <i>m</i>/<i>z</i> (ESI): 328.1 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 6.74 (d, <i>J</i> = 5.35 Hz, 1H), 6.39 (m, 1H), 3.78 (s, 3H), 3.59 (br s, 2H), 2.52 (m, 1H), 1.69 (s, 3H), 1.56 (br, 2 H), 1.54 (m, 1H), 1.11 (dd, <i>J</i> = 5.18, 7.53 Hz, 1H).</div><div class="NLM_p last"><i>Step 2.</i> At RT, (1<i>S</i>,5<i>S</i>,6<i>S</i>)-methyl 3-amino-5-(5-amino-2,3-difluorophenyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxylate (<b>7A</b>, 0.63 g, 1.92 mmol) was taken up in 10 mL of THF and treated with lithium borohydride (2.0 M solution in THF, 4.81 mL, 9.62 mmol) followed by methanol (1.56 mL, 38.5 mmol). The mixture was stirred for 15 h, then cooled to 0 °C and treated with 30 mL of sat. aqueous NH<sub>4</sub>Cl. The mixture was extracted twice with 50 mL of EtOAc, and the combined organic extracts were washed with 20 mL of brine and dried over MgSO<sub>4</sub>. Filtration and concentration under reduced pressure afforded (1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-amino-5-(5-amino-2,3-difluorophenyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-1-yl)methanol (<b>7B</b>, 0.54 g, 94% yield) as an off-white amorphous solid. <i>m</i>/<i>z</i> (ESI): 300.0 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.68 (br, 1H), 6.33 (m, 1H), 5.85 (br, 2H), 5.09 (br, 2H), 5.00 (t, <i>J</i> = 5.87 Hz, 1H), 3.52 (dd, <i>J</i> = 6.36, 11.64 Hz, 1H), 3.41 (dd, <i>J</i> = 5.58, 11.64 Hz, 1H), 1.58 (m, 1H), 1.53 (s, 3H), 0.79 (m, 1H), 0.46 (t, <i>J</i> = 5.58 Hz, 1H). <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>) δ −140.52 (d, <i>J</i> = 23.35 Hz, 1F), −155.98 (d, <i>J</i> = 23.35 Hz, 1F).</div></div><div id="sec5_3_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> <i>N</i>-(3-((1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-Amino-1-(hydroxymethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4,5-difluorophenyl)-5-chloropicolinamide (<b>7</b>)</h3><div class="NLM_p last"><i>m</i>/<i>z</i> (ESI): 439.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.74 (br, 1H), 8.79 (d, <i>J</i> = 1.96 Hz, 1H), 8.14–8.23 (m, 2H), 7.87–7.98 (m, 2H), 5.95 (br, 2H), 5.05 (br, 1H), 3.55 (m, 1H), 3.44 (m, 1H), 1.70 (m, 1H), 1.61 (s, 3H), 0.86 (br, 1H), 0.58 (br, 1H). <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>) δ −138.50 (d, <i>J</i> = 20.18 Hz, 1F), −143.58 (d, <i>J</i> = 20.18 Hz, 1F).</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (1<i>S</i>,5<i>S</i>,6<i>S</i>)-5-(5-Amino-2,3-difluorophenyl)-1-(methoxymethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-amine (<b>8B</b>)</h3><div class="NLM_p"><i>Step 1.</i> To a solution of (1<i>S</i>,5<i>S</i>,6<i>S</i>)-methyl 3-((<i>tert</i>-butoxycarbonyl)((2-(trimethylsilyl)ethoxy)methyl)amino)-5-(2,3-difluorophenyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxylate (<b>6C</b>, 2.70 g, 4.98 mmol) in THF (20 mL) at RT under nitrogen was added lithium borohydride (2.0 M in THF, 4.98 mL, 9.95 mmol) followed by methanol (2.01 mL, 49.8 mmol). Gas evolution was noticed after addition of methanol. After 15 min, the reaction mixture was cooled to 0 °C and carefully quenched with sat. aqueous NH<sub>4</sub>Cl (20 mL). The mixture was partitioned between 0.5 M K<sub>2</sub>HPO<sub>4</sub> (40 mL) and 1:1 EtOAc/heptane (75 mL). The aqueous layer was further extracted with 1:1 EtOAc/heptane (25 mL). The combined organic extracts were washed with brine (2 × 20 mL), dried over MgSO<sub>4</sub>, and then concentrated under reduced pressure to afford alcohol <b>8A</b> (2.70 g) as a sticky oil. <i>m</i>/<i>z</i> (ESI): 515.2 (M + 1)<sup>+</sup>.</div><div class="NLM_p last"><i>Step 2.</i> To a solution of crude alcohol <b>8A</b> (2.70 g) in THF (6 mL) at 0 °C under nitrogen was added sodium bis(trimethylsilyl)amide (1.0 M in THF, 6.47 mL, 6.47 mmol) at a rate such that the internal temperature did not exceed 5 °C. The solution was stirred for 5 min at 0 °C, and then iodomethane (0.43 mL, 6.97 mmol) was added at a rate that internal temperature did not exceed 7 °C. The cooling bath was removed. The reaction mixture was stirred for 2 h at RT and then quenched with sat. aqueous NH<sub>4</sub>Cl (10 mL). The mixture was extracted with EtOAc (2 × 50 mL). The combined organic extracts were washed with brine (10 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0–15% EtOAc in heptane) to afford <i>tert</i>-butyl ((1<i>S</i>,5<i>S</i>,6<i>S</i>)-5-(2,3-difluorophenyl)-1-(methoxymethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-yl)((2-(trimethylsilyl)ethoxy)methyl)carbamate (2.00 g, 76% yield) as a colorless oil. <i>m</i>/<i>z</i> (ESI): 529.3 (M + 1)<sup>+</sup>. To the resulting oil (2.00 g, 3.78 mmol) in a 250 mL round-bottom flask equipped with a magnetic stir bar at 0 °C was added sulfuric acid (15 mL) in a dropwise manner. The internal temperature reached 5 °C, gas evolution was evident, and a red color developed. After 15 min of stirring, the reaction mixture was treated with sodium nitrate (0.35 g, 4.16 mmol) in small portions. After 10 min of stirring, the reaction mixture was poured onto wet ice (100 mL) in an Erylmeyer flask that was cooled with an ice bath. To the mixture was added DCM (50 mL) followed by NaOH (4 M, 150 mL) slowly in 30 min duration, at a rate such that internal temperature did not exceed 5 °C. The mixture had pH > 12. To the flask was added a 9:1 mixture of CHCl<sub>3</sub>/IPA (50 mL). The mixture was transferred to a separatory funnel, and the layers were separated. The aqueous portion was further extracted with CHCl<sub>3</sub>/IPA (2 × 50 mL). The combined organic extracts were dried over MgSO<sub>4</sub>, filtered, and concentrated. The residue was purified by silica gel chromatography (2% of 2 M NH<sub>3</sub> in MeOH in DCM) to afford (1<i>S</i>,5<i>S</i>,6<i>S</i>)-5-(2,3-difluoro-5-nitrophenyl)-1-(methoxymethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-amine (0.63 g, 48% yield) as an amber oil. <i>m</i>/<i>z</i> (ESI): 344.0 (M + 1)<sup>+</sup>. At RT, the amber oil was treated with glacial AcOH (5 mL) and TFA (5 mL) followed by zinc (0.67 g, 10.29 mmol). After 90 min, the reaction mixture was concentrated under reduced pressure to a thick oil/suspension. The residue was partitioned between 9:1 mixture of CHCl<sub>3</sub>/IPA (50 mL) and 10% NH<sub>4</sub>OH (50 mL). The separated aqueous layer was further extracted with 9:1 mixture of CHCl<sub>3</sub>/IPA (20 mL). The combined organic solution was washed with brine (20 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (2–6% of 2 M NH<sub>3</sub> in MeOH in DCM) to afford (1<i>S</i>,5<i>S</i>,6<i>S</i>)-5-(5-amino-2,3-difluorophenyl)-1-(methoxymethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-amine (<b>8B</b>, 0.53 g, 92% yield) as a tan foam. <i>m</i>/<i>z</i> (ESI): 314.1 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.67 (br, 1H), 6.36 (m, 1H), 5.92 (br, 2H), 5.12 (br s, 2H), 3.55 (d, <i>J</i> = 10.95 Hz, 1H), 3.36 (d, <i>J</i> = 10.95 Hz, 1H), 3.32 (s, 3H), 1.61 (br, 1H), 1.56 (s, 3H), 0.87 (br, 1H), 0.57 (br, 1H).</div></div><div id="sec5_3_3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>N</i>-(3-((1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-Amino-1-(methoxymethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4,5-difluorophenyl)-5-chloropicolinamide (<b>8</b>)</h3><div class="NLM_p last"><i>m</i>/<i>z</i> (ESI): 453.0 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.74 (br, 1H), 8.79 (d, <i>J</i> = 1.96 Hz, 1H), 8.14–8.23 (m, 2H), 7.87–7.97 (m, 2H), 6.00 (br, 2H), 3.57 (d, <i>J</i> = 10.95 Hz, 1H), 3.34 (m, 1H), 3.33 (s, 3H), 1.58 (m, 1H), 1.66 (s, 3H), 0.90 (m, 1H), 0.65 (m, 1H).</div></div><div id="sec5_3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> (1<i>S</i>,5<i>S</i>,6<i>S</i>)-5-(5-Amino-2,3-difluorophenyl)-1-(fluoromethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-amine (<b>9B</b>)</h3><div class="NLM_p"><i>Step 1.</i> At 0 °C, <i>tert</i>-butyl ((1<i>S</i>,5<i>S</i>,6<i>S</i>)-5-(2,3-difluorophenyl)-1-(hydroxymethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-yl)((2-(trimethylsilyl)ethoxy)methyl)carbamate (<b>8A</b>, 4.90 g, 9.52 mmol) in 50 mL of DCM was treated with triethylamine (1.72 mL, 12.38 mmol) followed by methanesulfonyl chloride (0.85 mL, 10.95 mmol). The mixture was stirred for 30 min and then quenched with 30 mL of sat. aqueous NaHCO<sub>3</sub> and 30 mL of water. The layers were separated, and the aqueous portion was extracted with 25 mL of DCM. The combined organic extracts were dried over MgSO<sub>4</sub>. Filtration and concentration under reduced pressure afforded mesylate <b>9A</b> as an oil that was used as crude. <i>m</i>/<i>z</i> (ESI): 593.5 (M + 1)<sup>+</sup>.</div><div class="NLM_p last"><i>Step 2.</i> A mixture of mesylate <b>9A</b> and cesium fluoride (4.34 g, 28.6 mmol) in 20 mL of <i>t</i>BuOH was heated at 75 °C for 10 h. The mixture was cooled to RT and partitioned between 100 mL of EtOAc and 20 mL of water. The organic portion was washed with 20 mL of brine and dried over MgSO<sub>4</sub>. Filtration and concentration under reduced pressure followed by purification via silica gel chromatography (5–25% EtOAc in heptane) afforded <i>tert</i>-butyl ((1<i>S</i>,5<i>S</i>,6<i>S</i>)-5-(2,3-difluorophenyl)-1-(fluoromethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-yl)((2-(trimethylsilyl)ethoxy)methyl)carbamate (4.34 g, 88% yield) as a clear oil. <i>m</i>/<i>z</i> (ESI): 517.3 (M + 1)<sup>+</sup>. <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>) δ −139.35 (d, <i>J</i> = 20.80 Hz, 1F), −139.82 (d, <i>J</i> = 20.81 Hz, 1F), −212.18 (s, 1F). At 0 °C, <i>tert</i>-butyl ((1<i>S</i>,5<i>S</i>,6<i>S</i>)-5-(2,3-difluorophenyl)-1-(fluoromethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-yl)((2-(trimethylsilyl)ethoxy)methyl)carbamate (4.30 g, 8.32 mmol) was treated with sulfuric acid (15.97 mL, 300 mmol) dropwise. The mixture was stirred for 5 min, then warmed to RT and stirred for 15 min. The mixture was chilled to 0 °C and treated with sodium nitrate (0.70 g, 8.32 mmol). The mixture was stirred at RT for 40 min. LC/MS indicated the presence of starting material. The mixture was then chilled to 0 °C and treated with sodium nitrate (0.70 g, 8.32 mmol). The mixture was stirred at RT for 40 min, then chilled to 0 °C and treated with 200 mL of wet ice. Potassium phosphate tribasic monohydrate (72.8 g, 316 mmol) was then added slowly over 15 min period. Aqueous NaOH (10 N) was then added until the mixture had pH > 9.0. The mixture was diluted with 100 mL of water and 200 mL of chloroform/IPA (9:1), stirred for 5 min, then filtered to remove all solid material. The filtrate was transferred to a separatory funnel, and the layers were separated. The aqueous portion was extracted with 100 mL of DCM. The combined organic extracts were then dried over MgSO<sub>4</sub>. Filtration and concentration under reduced pressure followed by flash chromatography on silica gel (5–50% EtOAc in heptane) afforded (1<i>S</i>,5<i>S</i>,6<i>S</i>)-5-(2,3-difluoro-5-nitrophenyl)-1-(fluoromethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-amine (1.44 g, 52% yield) as a sticky yellow solid. <i>mz</i> (ESI): 332.1 (M + 1)<sup>+</sup>. The resulting yellow solid that contained (1<i>S</i>,5<i>S</i>,6<i>S</i>)-5-(2,3-difluoro-5-nitrophenyl)-1-(fluoromethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-amine (1.44 g, 4.35 mmol) was taken up in acetic acid (6 mL, 104 mmol) and trifluoroacetic acid (3 mL, 40.4 mmol). The mixture was cooled to 0 °C, and zinc (nanopowder, 0.85 g, 13.04 mmol) was added in four portions over 20 min. The mixture was warmed to RT and stirred for 1 h. The solvents were removed under reduced pressure, and the residue was treated with 67.5 mL of sat. aqueous NH<sub>4</sub>Cl, 7.5 mL of sat. aqueous NH<sub>4</sub>OH and 75 mL of DCM. The aqueous portion was extracted with 50 mL of DCM, and the combined organic extracts were dried over MgSO<sub>4</sub>. Filtration and concentration under reduced pressure followed by flash chromatography on silica gel (1–5% MeOH in DCM) afforded (1<i>S</i>,5<i>S</i>,6<i>S</i>)-5-(5-amino-2,3-difluorophenyl)-1-(fluoromethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-amine (<b>9B</b>, 0.85 g, 65% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.67 (m, 1H), 6.36 (m, 1H), 6.04 (br, 2H), 5.13 (br, 2H), 4.53 (m, 1H), 4.41 (m, 1H), 1.74 (m, 1H), 1.56 (s, 3H) 1.01 (m, 1H), 0.63 (m, 1H). <sup>19</sup>F NMR (377 MHz, DMSO-<i>d</i><sub>6</sub>) δ −140.38 (d, <i>J</i> = 23.41 Hz, 1F), −155.86 (d, <i>J</i> = 23.41 Hz, 1F), −211.45 (s, 1F). MS (ESI, positive ion) <i>m</i>/<i>z</i>: 302.0 (M + 1) <sup>+</sup>.</div></div><div id="sec5_3_4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>N</i>-(3-((1S,5S,6S)-3-Amino-1-(fluoromethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4,5-difluorophenyl)-5-chloropicolinamide (<b>9</b>)</h3><div class="NLM_p last"><i>m</i>/<i>z</i> (ESI): 441.0 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.75 (s, 1H), 8.79 (d, <i>J</i> = 1.96 Hz, 1H), 8.14–8.23 (m, 2H), 7.87–7.98 (m, 2H), 6.12 (br, 2H), 4.56 (m, 1H), 4.44 (m, 1H), 1.79 (m, 1H), 1.62 (s, 3H), 1.04 (dd, <i>J</i> = 5.48, 9.19 Hz, 1H), 0.71 (m, 1H). <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>) δ −138.40 (d, <i>J</i> = 20.22 Hz, 1F), −143.48 (d, <i>J</i> = 20.22 Hz, 1F), −211.58 (s, 1F).</div></div><div id="sec5_3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> (1<i>S</i>,5<i>S</i>,6<i>S</i>)-5-(5-Amino-2,3-difluorophenyl)-1-(difluoromethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-amine (<b>10B</b>)</h3><div class="NLM_p"><i>Step 1.</i> To a stirred solution of <i>tert</i>-butyl ((1<i>S</i>,5<i>S</i>,6<i>S</i>)-5-(2,3-difluorophenyl)-1-formyl-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-yl)((2-(trimethylsilyl)ethoxy)methyl)carbamate (<b>6D</b>, 380 mg, 0.74 mmol) in 5 mL of DCM at −10 °C (ice/salt bath) was added Deoxo-Fluor (0.48 mL, 2.59 mmol). The mixture was stirred at 0 °C for 1 h and then RT for 2 h. It was diluted with 30 mL of DCM, washed with 20 mL of sat. NaHCO<sub>3</sub> followed by 5 mL of brine. The organic solution was dried over sodium sulfate and concentrated. The residue was purified on a silica gel column (5–10% EtOAc in heptane) to give 2 compounds. The first eluent was <i>tert</i>-butyl ((1<i>R</i>,5<i>S</i>,6<i>S</i>,8<i>S</i>)-5-(2,3-difluorophenyl)-1,8-difluoro-5-methyl-2-thia-4-azabicyclo[4.2.0]oct-3-en-3-yl)((2-(trimethylsilyl)ethoxy)methyl) carbamate (<b>10cBu</b>, 95 mg, 24% yield) as a brown oil. <i>m</i>/<i>z</i> (ESI): 535.1 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.43 (t, <i>J</i> = 7.40 Hz, 1H), 7.10 (m, 2H), 5.30 (d, <i>J</i> = 10.76 Hz, 1H), 5.07–5.16 (m, 0.5H), 5.03 (d, <i>J</i> = 8.61 Hz, 1H), 5.00 (m, 0.5H), 3.69 (m, 2H), 2.97 (m, 1H), 1.76 (m, 1H), 1.67 (s, 3H), 1.52 (s, 9H), 1.20 (m, 1H), 0.94 (m, 2H), 0.02 (s, 9H). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ −112.71 (s, 1F), −138.50 (d, <i>J</i> = 19.94 Hz, 1F), −139.76 (d, <i>J</i> = 19.94 Hz, 1F), −173.68 (s, 1F). The second eluent was <i>tert</i>-butyl ((1<i>S</i>,5<i>S</i>,6<i>S</i>)-1-(difluoromethyl)-5-(2,3-difluorophenyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-yl)((2-(trimethylsilyl)ethoxy)methyl)carbamate (<b>10A</b>, 249 mg, 0.46 mmol, 62% yield) as a brown oil. <i>m</i>/<i>z</i> (ESI): 535.1 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.34 (m, 1H), 7.07 (m, 2H), 5.55–5.88 (m, 1H), 5.29 (d, <i>J</i> = 10.37 Hz, 1H), 5.05 (d, <i>J</i> = 10.56 Hz, 1H), 3.65 (m, 2H), 2.11 (dd, <i>J</i> = 7.73, 9.29 Hz, 1H), 1.78 (s, 3H), 1.52 (s, 9H), 1.23 (m, 1H), 0.95 (m, 3H), 0.00 (s, 9H). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ −118.00 (d, <sup>1</sup><i>J</i> = 280 Hz, 1F), −120.01 (d, <sup>1</sup><i>J</i> = 280 Hz, 1F), −138.73 (d, <sup>2</sup><i>J</i> = 19.94 Hz, 1F), −139.18 (d, <sup>2</sup><i>J</i> = 19.94 Hz, 1F).</div><div class="NLM_p last"><i>Step 2.</i> At RT, sulfuric acid (1 mL, 18.76 mmol) was added to <i>tert</i>-butyl ((1<i>S</i>,5<i>S</i>,6<i>S</i>)-1-(difluoromethyl)-5-(2,3-difluorophenyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-yl)((2-(trimethylsilyl)ethoxy)methyl)carbamate (<b>10A</b>, 120 mg, 0.22 mmol). The mixture was stirred at RT for 10 min. It was cooled with an ice bath and treated with sodium nitrate (24.80 mg, 0.29 mmol). The ice bath was removed. The mixture was stirred at RT for 2 h. It was cooled with an ice bath, treated with ice cube followed by 15 mL of DCM and then potassium phosphate tribasic monohydrate (4.60 g, 20 mmol) in small portions. The mixture was treated with 2 mL of 2 N NaOH dropwise, and pH was about 10. It was extracted with 2 × 20 mL of (9:1 = CHCl<sub>3</sub>/<i>i</i>PrOH). The organic extracts were washed with 5 mL of brine and concentrated. The resulting brown residue containing (1<i>S</i>,5<i>S</i>,6<i>S</i>)-5-(2,3-difluoro-5-nitrophenyl)-1-(difluoromethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-amine was dissolved in 0.8 mL of glacial acetic acid and 0.4 mL of TFA and treated with zinc (nanopowder, 88 mg, 1.34 mmol) at RT. It was stirred at RT for 3 h and then concentrated under reduced pressure. The residue was basified with 2 N NaOH until pH was about 10. The mixture was extracted with 2 × 20 mL of (9:1 = CHCl<sub>3</sub>/<i>i</i>PrOH). The organic extracts were washed with 5 mL of brine and concentrated. The residue was purified on a silica gel column (5% MeOH in DCM followed by 5% 2 M NH<sub>3</sub> in MeOH in DCM) to provide (1<i>S</i>,5<i>S</i>,6<i>S</i>)-5-(5-amino-2,3-difluorophenyl)-1-(difluoromethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-amine (<b>10B</b>, 47 mg, 65% yield) as a brown amorphous solid. <i>m</i>/<i>z</i> (ESI): 320.0 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.52 (br, 1H), 6.38 (m, 2H), 6.23 (br, 1H), 5.77–6.04 (m, 1H), 5.14 (br, 2H), 1.84 (m, 1H), 1.59 (s, 3H), 1.30 (m, 1H), 0.67 (m, 1H). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ −118.06 (d, <sup>1</sup><i>J</i> = 273 Hz, 1F), −115.47 (d, <sup>1</sup><i>J</i> = 273 Hz, 1F), −140.28 (d, <sup>2</sup><i>J</i> = 22.54 Hz, 1F), −155.35 (d, <sup>2</sup><i>J</i> = 22.64 Hz, 1F).</div></div><div id="sec5_3_5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> <i>N</i>-(3-((1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-Amino-1-(difluoromethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4,5-difluorophenyl)-5-chloropicolinamide (<b>10</b>)</h3><div class="NLM_p last"><i>m</i>/<i>z</i> (ESI): 459.2 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.78 (br, 1H), 8.80 (s, 1H), 8.22 (m, 1H), 8.17 (m, 1H), 7.96 (m, 1H), 7.83 (m, 1H), 6.30 (s, 2H), 5.81–6.09 (m, 1H), 1.91 (m, 1H), 1.66 (s, 3H), 1.34 (m, 1H), 0.78 (m, 1H). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ −115.56 (d, <sup>1</sup><i>J</i> = 273.96 Hz, 1F), −118.27 (d, <sup>1</sup><i>J</i> = 273.77 Hz, 1F), −140.28 (d, <sup>2</sup><i>J</i> = 22.54 Hz, 1F), −155.35 (d, <sup>2</sup><i>J</i> = 22.64 Hz, 1F).</div></div><div id="sec5_3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> (1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-Amino-5-(5-amino-2,3-difluorophenyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxamide (<b>11B</b>)</h3><div class="NLM_p"><i>Step 1.</i> To a solution of (1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-((<i>tert</i>-butoxycarbonyl)((2-(trimethylsilyl)ethoxy)methyl)amino)-5-(2,3-difluorophenyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxylic acid (<b>6H</b>, 4.00 g, 7.57 mmol) in THF (40 mL) at RT was added 1,1′-carbonyldiimidazole (1.84 g, 11.35 mmol). The suspension was stirred for 1 h at RT. The solution was chilled to 0 °C, and ammonia was introduced from a lecture bottle. After 30 min, the reaction was partitioned between EtOAc (30 mL) and 1 M HCl (30 mL). The organic extracts were washed with brine (25 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure to afford <i>tert</i>-butyl ((1<i>S</i>,5<i>S</i>,6<i>S</i>)-1-carbamoyl-5-(2,3-difluorophenyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-yl)((2-(trimethylsilyl)ethoxy)methyl)carbamate (<b>11A</b>, 4.0 g, 100% yield) as a colorless oil. <i>m</i>/<i>z</i> (ESI): 528.2 (M + H)<sup>+</sup>.</div><div class="NLM_p last"><i>Step 2.</i><b>11A</b> (4.0 g, 7.58 mmol) was converted to (1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-amino-5-(5-amino-2,3-difluorophenyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxamide (<b>11B</b>, 1.4 g, 54% yield) as a tan foam according to the 2-step procedures (nitration/reduction) described for synthesis the of arylamine <b>12B</b>. <i>m</i>/<i>z</i> (ESI): 313.1 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz) δ 7.15–7.35 (br, 2H), 6.65 (m, 1H), 6.36 (m, 1H), 6.02 (br s, 2H), 5.13 (br s, 2H), 2.11 (m, 1H), 1.56 (s, 3H), 1.38 (m, 1H), 0.78 (m, 1H).</div></div><div id="sec5_3_6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-Amino-5-(5-(5-chloropicolinamido)-2,3-difluorophenyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxamide (<b>11</b>)</h3><div class="NLM_p last"><i>m</i>/<i>z</i> (ESI): 452.0 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.77 (br s, 1H), 8.79 (d, <i>J</i> = 1.76 Hz, 1H), 8.11–8.25 (m, 2H), 7.95 (br s, 1H), 7.88 (t, <i>J</i> = 4.62 Hz, 1H), 7.28 (br s, 1H), 7.21 (br s, 1H), 6.10 (br s, 2H), 2.17 (br s, 1H), 1.57–1.69 (m, 3H), 1.45 (dd, <i>J</i> = 7.43, 15.06 Hz, 1H), 0.79–0.92 (m, 1H).</div></div><div id="sec5_3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> (1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-Amino-5-(5-amino-2,3-difluorophenyl)-<i>N</i>,5-dimethyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxamide (<b>12B</b>)</h3><div class="NLM_p"><i>Step 1.</i> To a stirring solution of (1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-((<i>tert</i>-butoxycarbonyl)((2-(trimethylsilyl)ethoxy)methyl)amino)-5-(2,3-difluorophenyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxylic acid <b>(6H</b>, 13.00 g, 24.59 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (5.35 mL, 30.70 mmol) in CHCl<sub>3</sub> (50 mL) and MeCN (50 mL) at RT was added HATU (10.75 g, 28.30 mmol). The solution was stirred for 45 min at RT. To the reaction mixture was added methylamine (2.0 M in THF, 36.9 mL, 73.8 mmol). After 30 min the reaction mixture was partitioned between EtOAc (300 mL) and sat. aqueous NaHCO<sub>3</sub> (200 mL). The organic layer was washed sequentially with 1 M NaOH (150 mL), 1 M HCl (150 mL), and brine (50 mL). The organic extracts were dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure to afford a light oil. The crude material was purified by silica gel chromatography (0–25% EtOAc in heptane) to afford <i>tert</i>-butyl ((1<i>S</i>,5<i>S</i>,6<i>S</i>)-5-(2,3-difluorophenyl)-5-methyl-1-(methylcarbamoyl)-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-yl)((2-(trimethylsilyl)ethoxy)methyl)carbamate (<b>12A</b>, 11.10 g, 83% yield) as a colorless tar. <i>m</i>/<i>z</i> (ESI): 542.2 (M + H)<sup>+</sup>.</div><div class="NLM_p last"><i>Step 2.</i> To a 500 mL flask containing <i>tert</i>-butyl ((1<i>S</i>,5<i>S</i>,6<i>S</i>)-5-(2,3-difluorophenyl)-5-methyl-1-(methylcarbamoyl)-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-yl)((2-(trimethylsilyl)ethoxy)methyl)carbamate (<b>12A</b>, 5.50 g, 10.15 mmol) at 0 °C was added sulfuric acid (16.24 mL, 305.00 mmol). Gas evolution was evident. The reaction mixture was stirred at 0 °C for 15 min followed by RT for 30 min. The mixture was chilled to 0 °C, and sodium nitrate (0.86 g, 10.15 mmol) was added. The reaction mixture was stirred for 15 min at 0 °C, and then more sodium nitrate (0.86 g, 10.15 mmol) added. The reaction mixture was stirred at RT for 45 min and then poured onto wet ice (700 mL) and along with DCM (150 mL). The mixture was cooled with an ice bath and treated with potassium phosphate tribasic monohydrate (105 g, 457 mmol) over 40 min (pH ∼ 8). The suspension was filtered, and the filtrate was transferred to a separatory funnel. The organic layer was separated, and the aqueous layer was extracted with DCM (100 mL). The combined organic extracts were dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified via silica gel chromatography (0% to 50% EtOAc in DCM) to afford (1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-amino-5-(2,3-difluoro-5-nitrophenyl)-<i>N</i>,5-dimethyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxamide (2.20 g, 61% yield) as an off-white solid. <i>m</i>/<i>z</i> (ESI): 357.0 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.45–8.50 (m, 1H), 8.36 (ddd, <i>J</i> = 2.93, 6.36, 9.49 Hz, 1H), 7.73 (t, <i>J</i> = 5.63 Hz, 1H), 6.41 (s, 2H), 2.64 (d, <i>J</i> = 4.50 Hz, 3H), 2.25 (t, <i>J</i> = 8.22 Hz, 1H), 1.64 (s, 3H), 1.39 (dd, <i>J</i> = 5.28, 9.59 Hz, 1H), 0.84 (dd, <i>J</i> = 5.48, 7.04 Hz, 1H). <sup>19</sup>F NMR (377 MHz, DMSO-<i>d</i><sub>6</sub>) δ −126.77 (d, <i>J</i> = 21.16 Hz, 1F), −134.13 (d, <i>J</i> = 21.16 Hz, 1F). To a stirring solution of (1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-amino-5-(2,3-difluoro-5-nitrophenyl)-<i>N</i>,5-dimethyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxamide (2.20 g, 6.17 mmol) in AcOH (20 mL) and TFA (5 mL) at RT was added zinc dust (1.61 g, 24.69 mmol) in 4 portions over a 15 min period. After 1 h, the suspension was filtered through a pad of Celite and the metallic residue was extensively washed with DCM (100 mL). The filtrate was then chilled to 0 °C, and 30% NH<sub>4</sub>OH (50 mL) was added dropwise via addition funnel over a 10 min period. The mixture was partitioned, and the aqueous portion was further extracted with DCM (50 mL). The combined organic extracts were dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure to afford (1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-amino-5-(5-amino-2,3-difluorophenyl)-<i>N</i>,5-dimethyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxamide (<b>12B</b>, 1.91 g, 5.85 mmol, 95% yield) as a yellow foam. <i>m</i>/<i>z</i> (ESI): 327.1 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.65 (d, <i>J</i> = 4.11 Hz, 1H), 6.61 (br s, 1H), 6.21–6.46 (m, 1H), 6.07 (br s, 2H), 5.14 (br s, 2H), 2.57–2.66 (m, 3H), 2.01–2.18 (m, 1H), 1.56 (s, 3H), 1.42 (br s, 1H), 0.78 (br s, 1H).</div></div><div id="sec5_3_7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> (1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-Amino-5-(5-(5-chloropicolinamido)-2,3-difluorophenyl)-<i>N</i>,5-dimethyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxamide (<b>12</b>)</h3><div class="NLM_p last"><i>m</i>/<i>z</i> (ESI): 466.0 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.07 (s, 1H), 10.82 (s, 1H), 9.81 (br s, 1H), 8.82 (s, 1H), 8.68 (br s, 1H), 8.22–8.26 (m, 1H), 8.15–8.22 (m, 1H), 7.97 (d, <i>J</i> = 4.50 Hz, 1H), 7.85 (d, <i>J</i> = 5.87 Hz, 1H), 2.64 (d, <i>J</i> = 4.30 Hz, 3H), 2.58–2.63 (m, 1H), 1.95–1.99 (m, 1H), 1.93 (s, 3H), 1.42 (t, <i>J</i> = 6.46 Hz, 1H).</div></div><div id="sec5_3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-Amino-5-(5-amino-2,3-difluorophenyl)-<i>N</i>,<i>N</i>,5-trimethyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxamide (<b>13B</b>)</h3><div class="NLM_p"><i>Step 1.</i> To a stirring solution of (1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-((<i>tert</i>-butoxycarbonyl)((2-(trimethylsilyl)ethoxy)methyl)amino)-5-(2,3-difluorophenyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxylic acid (<b>6H</b>, 2.0 g, 3.8 mmol) in THF (20 mL) at RT under nitrogen was added 1,1′-carbonyldiimidazole (0.9 g, 5.6 mmol). The cloudy solution was stirred for 90 min at RT followed by addition of dimethylamine (2.0 M in THF, 9.46 mL, 18.91 mmol). After 2 h the reaction mixture was partitioned between EtOAc (60 mL) and 1 M HCl (60 mL). The organic layer was washed with brine (25 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure to afford <i>tert</i>-butyl((1<i>S</i>,5<i>S</i>,6<i>S</i>)-5-(2,3-difluorophenyl)-1-(dimethylcarbamoyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-yl)((2-(trimethylsilyl)ethoxy)methyl)carbamate (<b>13A</b>, 2.1 g, 3.78 mmol) as a colorless oil. <i>m</i>/<i>z</i> (ESI): 556.3 (M + H)<sup>+</sup>.</div><div class="NLM_p last"><i>Step 2.</i> To <i>tert</i>-butyl ((1<i>S</i>,5<i>S</i>,6<i>S</i>)-5-(2,3-difluorophenyl)-1-(dimethylcarbamoyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-yl)((2-(trimethylsilyl)ethoxy)methyl)carbamate (<b>13A</b>, 2.0 g, 3.60 mmol) at 0 °C was added sulfuric acid (14.39 mL, 270 mmol). The reaction flask was periodically removed from cooling bath, swirled by hand, and then allowed to stir at RT for 1 h. The material was chilled to 0 °C, and sodium nitrate (0.31 g, 3.60 mmol) was added. The reaction was stirred for 15 min at 0 °C and then more sodium nitrate (0.31 g, 3.60 mmol) added. The reaction was stirred at RT for 45 min, then poured onto wet ice (700 mL) and along with DCM (150 mL). To a rapidly stirred mixture was added potassium phosphate tribasic monohydrate (83 g, 360 mmol) over 20 min. The suspension was filtered and the filtrate transferred to a separatory funnel. The organic layer was separated, and the aqueous layer was extracted with 9:1 CHCl<sub>3</sub>/IPA (2 × 50 mL). The combined organic layers were dried over MgSO<sub>4</sub>, filtered, concentrated under reduced pressure, and purified via silica gel flash column chromatography (0–50% EtOAc in DCM) to afford (1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-amino-5-(2,3-difluoro-5-nitrophenyl)-<i>N</i>,<i>N</i>,5-trimethyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxamide (0.89 g, 67% yield) as an off-white solid. <i>m</i>/<i>z</i> (ESI): 371.0 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.32 (br s, 1H), 8.01 (ddd, <i>J</i> = 2.74, 6.26, 9.00 Hz, 1H), 3.05 (br s, 6H), 2.43 (t, <i>J</i> = 8.31 Hz, 1H), 1.90 (s, 3H), 1.40 (br s, 1H), 0.99 (t, <i>J</i> = 6.65 Hz, 1H). To a stirring solution of (1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-amino-5-(2,3-difluoro-5-nitrophenyl)-<i>N</i>,<i>N</i>,5-trimethyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxamide (200 mg, 0.540 mmol) in glacial AcOH (2 mL) and TFA (0.5 mL) was added zinc nano powder (177 mg, 2.70 mmol) in five portions. The reaction mixture was stirred for 2 h at RT and then partitioned between 9:1 CHCl<sub>3</sub>/IPA (30 mL) and 30% NH<sub>4</sub>OH (20 mL). The aqueous portion was further extracted with 9:1 CHCl<sub>3</sub>/IPA (2 × 15 mL). The organic extracts were washed with brine (10 mL), dried over MgSO<sub>4</sub>, filtered, then concentrated under reduced pressure to afford (1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-amino-5-(5-amino-2,3-difluorophenyl)-<i>N</i>,<i>N</i>,5-trimethyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxamide (<b>13B</b>, 170 mg, 92% yield) as a colorless film. <i>m</i>/<i>z</i> (ESI): 341.0 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.50–6.56 (m, 1H), 6.35 (ddd, <i>J</i> = 2.84, 6.31, 12.57 Hz, 1H), 6.18 (s, 2H), 5.12 (s, 2H), 2.98–3.20 (m, 3H), 2.95 (br s, 3H), 2.00 (t, <i>J</i> = 8.80 Hz, 1H), 1.64 (s, 3H), 1.29 (dd, <i>J</i> = 5.48, 9.59 Hz, 1H), 0.68–0.74 (m, 1H).</div></div><div id="sec5_4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> General Procedure for T3P Mediated Amide Formation (Method A). (1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-Amino-5-(5-(5-chloropicolinamido)-2,3-difluorophenyl)-<i>N</i>,<i>N</i>,5-trimethyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxamide (<b>13</b>)</h3><div class="NLM_p last">To a stirring suspension of (1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-amino-5-(5-amino-2,3-difluorophenyl)-<i>N</i>,<i>N</i>,5-trimethyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxamide (<b>13B</b>, 50 mg, 0.15 mmol) and 5-chloropicolinic acid (35 mg, 0.22 mmol) in DCM (1.5 mL) at 0 °C under nitrogen was added 1-propanephosphonic acid cyclic anhydride (50% wt in ethyl acetate, 187 mg, 0.29 mmol). The reaction mixture was slowly warmed to RT and stirred at RT for 18 h. It was treated with sat. NaHCO<sub>3</sub> (5 mL) and extracted with DCM (2 × 15 mL). The organic solution was dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The residue was purified by silica gel chromatography (1–3% MeOH in DCM) to afford (1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-amino-5-(5-(5-chloropicolinamido)-2,3-difluorophenyl)-<i>N,</i>N,5-trimethyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxamide (<b>13</b>, 30 mg, 43% yield) as an off-white solid. <i>m</i>/<i>z</i> (ESI): 480.0 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.76 (s, 1H), 8.80 (s, 1H), 8.15–8.24 (m, 2H), 7.94 (ddd, <i>J</i> = 2.54, 6.80, 12.37 Hz, 1H), 7.83 (d, <i>J</i> = 5.58 Hz, 1H), 6.26 (br, 2H), 3.09 (s, 3H), 2.93 (s, 3H), 2.06 (t, <i>J</i> = 8.41 Hz, 1H), 1.71 (s, 3H), 1.34 (dd, <i>J</i> = 5.48, 9.59 Hz, 1H), 0.81 (t, <i>J</i> = 6.26 Hz, 1H).</div></div><div id="sec5_4_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-Amino-5-(5-amino-2,3-difluorophenyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carbonitrile (<b>14B</b>)</h3><div class="NLM_p"><i>Step 1.</i> To a stirring solution of (1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-amino-5-(5-amino-2,3-difluorophenyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxamide (<b>11B</b>, 0.25 g, 0.80 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (2.08 mL, 12.01 mmol) in THF (10 mL) at −70 °C under nitrogen was added trifluoroacetic anhydride (1.33 mL, 9.60 mmol). After 1 h, the reaction was quenched with sat. NH<sub>4</sub>Cl (1 mL). The mixture was partitioned between EtOAc (10 mL) and 5% NaHCO<sub>3</sub> (10 mL). The organic layer was dried over MgSO<sub>4</sub>, filtered, then concentrated under reduced pressure to afford <i>N</i>-((1<i>S</i>,5<i>S</i>,6<i>S</i>)-1-cyano-5-(2,3-difluoro-5-(2,2,2-trifluoroacetamido)phenyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-yl)-2,2,2-trifluoroacetamide (<b>14A</b>, 450 mg) as a tan oil. <i>m</i>/<i>z</i> (ESI): 487.0 (M + H) <sup>+</sup>.</div><div class="NLM_p last"><i>Step 2.</i> A solution of <i>N</i>-((1<i>S</i>,5<i>S</i>,6<i>S</i>)-1-cyano-5-(2,3-difluoro-5-(2,2,2-trifluoroacetamido)phenyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-yl)-2,2,2-trifluoroacetamide (<b>14A</b>, 375 mg, 0.77 mmol) in 2 M NH<sub>3</sub> in MeOH (10 mL) was stirred for 18 h at 42 °C in a sealed vial. The solvent was removed under reduced pressure and the residue was purified by silica gel chromatography (1–5% 2 M NH<sub>3</sub> in MeOH in DCM) to afford (1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-amino-5-(5-amino-2,3-difluorophenyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carbonitrile (<b>14B</b>, 100 mg, 44% yield) as a yellow film. <i>m</i>/<i>z</i> (ESI): 295.1 (M + H) <sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.49 (br s, 2H), 6.34–6.44 (m, 2H), 5.11–5.21 (m, 2H), 2.29 (dd, <i>J</i> = 8.02, 9.59 Hz, 1H), 1.87 (dd, <i>J</i> = 5.87, 9.78 Hz, 1H), 1.68 (s, 3H), 0.96 (t, <i>J</i> = 6.65 Hz, 1H).</div></div><div id="sec5_4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> <i>N</i>-(3-((1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-Amino-1-cyano-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4,5-difluorophenyl)-5-chloropicolinamide (<b>14</b>)</h3><div class="NLM_p last"><i>m</i>/<i>z</i> (ESI): 434.2 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.81 (s, 1H), 8.80 (s, 1H), 8.19–8.24 (m, 1H), 8.14–8.19 (m, 1H), 7.97 (ddd, <i>J</i> = 2.54, 6.80, 12.37 Hz, 1H), 7.74–7.79 (m, 1H), 6.56 (s, 2H), 2.40 (dd, <i>J</i> = 7.82, 9.78 Hz, 1H), 1.90 (dd, <i>J</i> = 6.06, 9.78 Hz, 1H), 1.77 (s, 3H), 1.09 (t, <i>J</i> = 6.75 Hz, 1H). <sup>19</sup>F NMR (377 MHz, DMSO-<i>d</i><sub>6</sub>) δ −137.87 (d, <i>J</i> = 22.65 Hz, 1F), −142.36 (d, <i>J</i> = 22.65 Hz, 1F).</div></div><div id="sec5_4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> <i>N</i>-(3-((1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-Amino-1-(methoxymethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4,5-difluorophenyl)-5-(2,2,2-trifluoroethoxy)picolinamide (<b>15</b>)</h3><div class="NLM_p last"><i>m</i>/<i>z</i> (ESI): 517.1 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.82 (s, 1H), 8.34 (s, 1H), 8.28 (d, <i>J</i> = 8.73 Hz, 1H), 8.07 (ddd, <i>J</i> = 2.74, 6.85, 11.93 Hz, 1H), 7.39–7.43 (m, 2H), 4.49 (q, <i>J</i> = 7.82 Hz, 3H), 3.67 (d, <i>J</i> = 10.76 Hz, 1H), 3.41 (s, 3H), 3.35 (d, <i>J</i> = 10.56 Hz, 1H), 1.75–1.88 (m, 1H), 1.69–1.74 (m, 3H), 1.25 (s, 1H), 0.90 (dd, <i>J</i> = 5.87, 9.39 Hz, 1H), 0.78–0.83 (m, 1H). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ −73.70 (s, 3F), −136.39 (d, <i>J</i> = 21.67 Hz, 1F), −143.21 (d, <i>J</i> = 21.67 Hz, 1F).</div></div><div id="sec5_4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> <i>N</i>-(3-((1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-Amino-1-(methoxymethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4,5-difluorophenyl)-5-(prop-2-yn-1-yloxy)picolinamide (<b>16</b>)</h3><div class="NLM_p last"><i>m</i>/<i>z</i> (ESI): 473.1 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-d6) δ ppm 10.54 (s, 1H), 8.43 (d, <i>J</i> = 2.74 Hz, 1H), 8.13 (d, <i>J</i> = 8.61 Hz, 1H), 7.89–7.99 (m, 1H), 7.86 (d, <i>J</i> = 5.87 Hz, 1H), 7.67 (dd, <i>J</i> = 8.80, 2.93 Hz, 1H), 6.00 (br s, 2H), 5.04 (d, <i>J</i> = 2.35 Hz, 2H), 3.71 (t, <i>J</i> = 2.35 Hz, 1H), 3.56 (d, <i>J</i> = 10.95 Hz, 1H), 3.36 (d, <i>J</i> = 11.15 Hz, 1H), 3.29–3.32 (m, 3H), 1.56–1.68 (m, 4H), 0.90 (br s, 1H), 0.66 (d, <i>J</i> = 5.28 Hz, 1H).</div></div><div id="sec5_4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> <i>N</i>-(3-((1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-Amino-1-(methoxymethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4,5-difluorophenyl)-3-methyl-5-(prop-2-yn-1-yloxy)picolinamide (<b>17</b>)</h3><div class="NLM_p last"><i>m</i>/<i>z</i> (ESI): 487.2 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.10 (s, 1H), 8.18 (d, <i>J</i> = 2.74 Hz, 1H), 8.09 (ddd, <i>J</i> = 2.93, 6.90, 12.08 Hz, 1H), 7.28–7.34 (m, 1H), 7.18 (s, 1H), 4.80 (d, <i>J</i> = 2.35 Hz, 2H), 3.67 (d, <i>J</i> = 10.76 Hz, 1H), 3.41 (s, 3H), 3.35 (d, <i>J</i> = 10.56 Hz, 1H), 2.81 (s, 3H), 2.60 (t, <i>J</i> = 2.35 Hz, 1H), 1.80 (m, 1H), 1.72 (s, 3H), 0.78–0.96 (m, 2H). -NH<sub>2</sub> peak was not clear. <sup>19</sup>F NMR (377 MHz, CDCl<sub>3</sub>) δ ppm −136.78 (d, <i>J</i> = 20.80 Hz, 1F), −144.00 (d, <i>J</i> = 21.68 Hz, 1F).</div></div><div id="sec5_5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> General Procedure for the Displacement of 5-Cl of Compound <b>30</b> with an Alcohol/Cs<sub>2</sub>CO<sub>3</sub> (Method C). <i>N</i>-(3-((1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-Amino-1-(methoxymethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4,5-difluorophenyl)-5-ethoxypyrazine-2-carboxamide (<b>18</b>)</h3><div class="NLM_p last">To a mixture of <i>N</i>-(3-((1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-amino-1-(methoxymethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4,5-difluorophenyl)-5-chloropyrazine-2-carboxamide (<b>30</b>, 20 mg, 0.044 mmol), ethanol (0.039 mL, 0.661 mmol) in THF (0.5 mL) was added cesium carbonate (57 mg, 0.176 mmol). The reaction mixture was heated at 50 °C for 2 h and then diluted with water and extracted with EtOAc. The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude was purified by flash chromatography on silica gel (10–100% EtOH:EtOAc (1:3) in heptane) to give compound <b>18</b> (86 mg, 58% yield) as an off-white solid. <i>m</i>/<i>z</i> (ESI): 464.0 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ ppm 9.51 (s, 1H), 8.98 (d, <i>J</i> = 1.17 Hz, 1H), 8.11 (d, <i>J</i> = 1.17 Hz, 1H), 8.06 (ddd, <i>J</i> = 11.79, 6.80, 2.74 Hz, 1H), 7.39 (dt, <i>J</i> = 5.38, 2.40 Hz, 1H), 4.50–5.50 (br, 2H), 4.49 (q, <i>J</i> = 7.04 Hz, 2H), 3.66 (d, <i>J</i> = 10.56 Hz, 1H), 3.41 (s, 3H), 3.35 (d, <i>J</i> = 10.76 Hz, 1H), 1.79 (ddd, <i>J</i> = 8.66, 7.38, 0.98 Hz, 1H), 1.72 (d, <i>J</i> = 0.78 Hz, 3H), 1.45 (t, <i>J</i> = 7.04 Hz, 3H), 0.89 (dd, <i>J</i> = 9.39, 5.87 Hz, 1H), 0.75–0.84 (m, 1H). <sup>19</sup>F NMR (376 MHz, chloroform-<i>d</i>) δ ppm −143.07 (d, <i>J</i> = 20.80 Hz, 1F) −136.30 (d, <i>J</i> = 20.81 Hz, 1F).</div></div><div id="sec5_5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> <i>N</i>-(3-((1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-Amino-1-(methoxymethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4,5-difluorophenyl)-5-(2,2,2-trifluoroethoxy)pyrazine-2-carboxamide (<b>19</b>)</h3><div class="NLM_p last"><i>m</i>/<i>z</i> (ESI): 518.2 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.67 (br, 1H), 8.92 (d, <i>J</i> = 0.98 Hz, 1H), 8.62 (m, 1H), 7.95 (m, 2H), 5.99 (s, 2H), 5.17 (q, <i>J</i> = 9.00 Hz, 2H), 3.56 (d, <i>J</i> = 11.15 Hz, 1H), 3.36 (d, <i>J</i> = 11.15 Hz, 1H), 3.31 (s, 3H), 1.61 (m, 1H), 1.59 (s, 3H), 0.90 (m, 1H), 0.64 (m, 1H). <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>) δ −72.13 (s, 3F), −138.52 (d, <i>J</i> = 22.54 Hz, 1F), −143.68 (d, <i>J</i> = 22.55 Hz, 1F).</div></div><div id="sec5_6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> General Procedure for T3P Mediated Amide Formation (Method B). <i>N</i>-(3-((1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-Amino-1-(methoxymethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4,5-difluorophenyl)-5-(prop-2-yn-1-yloxy)pyrazine-2-carboxamide (<b>20</b>)</h3><div class="NLM_p last">To a suspension of (1<i>S</i>,5<i>S</i>,6<i>S</i>)-5-(5-amino-2,3-difluorophenyl)-1-(methoxymethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-amine (<b>8B</b>, 880 mg, 2.81 mmol) and 5-(prop-2-yn-1-yloxy)pyrazine-2-carboxylic acid (750 mg, 4.21 mmol) in DCM (20 mL) at 0 °C under nitrogen was added T3P (3.34 mL of 50% wt solution in ethyl acetate, 5.62 mmol). After 30 min, the cooling bath was removed, and the hazy mixture was stirred for 18 h. The reaction mixture was treated with NaHCO<sub>3</sub> (15 mL) and extracted with DCM (2 × 35 mL). The organic solution was dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The residue was purified by silica gel chromatography (1–3% MeOH in DCM) to afford the title compound (<b>20</b>, 950 mg, 2.01 mmol, 71% yield) as an off-white solid. <i>m</i>/<i>z</i> (ESI): 474.1 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.62 (s, 1H), 8.92 (d, <i>J</i> = 1.37 Hz, 1H), 8.50 (d, <i>J</i> = 1.37 Hz, 1H), 7.89–7.95 (m, 2H), 6.00 (s, 2H), 5.16 (d, <i>J</i> = 2.35 Hz, 2H), 3.66 (t, <i>J</i> = 2.45 Hz, 1H), 3.58 (d, <i>J</i> = 10.95 Hz, 1H), 3.37 (d, <i>J</i> = 10.95 Hz, 1H), 3.30–3.34 (m, 3H), 1.66 (s, 1H), 1.62 (s, 3H), 0.91 (dd, <i>J</i> = 5.18, 9.29 Hz, 1H), 0.66 (t, <i>J</i> = 5.87 Hz, 1H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 161.4, 160.1, 149.5, 148.2, 144.0, 141.3, 138.3, 138.1, 133.7, 133.5, 116.4, 107.4, 78.3, 78.3, 77.4, 58.2, 57.8, 54.4, 27.2, 26.8, 24.8, 14.9. <sup>19</sup>F NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>) δ −138.54 (d, <i>J</i> = 22.54 Hz, 1F), −143.79 (d, <i>J</i> = 22.54 Hz, 1F).</div></div><div id="sec5_6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> <i>N</i>-(3-((1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-Amino-1-(methoxymethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4,5-difluorophenyl)-5-(3,3,3-trifluoropropoxy)pyrazine-2-carboxamide (<b>21</b>)</h3><div class="NLM_p last"><i>m</i>/<i>z</i> (ESI): 532.0 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.60 (s, 1H), 8.89 (d, <i>J</i> = 1.37 Hz, 1H), 8.43 (d, <i>J</i> = 1.37 Hz, 1H), 7.84–7.96 (m, 2H), 5.98 (br s, 2H), 4.65 (t, <i>J</i> = 5.87 Hz, 2H), 3.56 (d, <i>J</i> = 10.95 Hz, 1H), 3.35 (d, <i>J</i> = 10.95 Hz, 1H), 3.30 (s, 3H), 2.89 (tq, <i>J</i> = 5.67, 11.35 Hz, 2H), 1.64 (br s, 1H), 1.61 (s, 3H), 0.89 (d, <i>J</i> = 8.41 Hz, 1H), 0.64 (t, <i>J</i> = 5.67 Hz, 1H).</div></div><div id="sec5_6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> <i>N</i>-(3-((1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-Amino-1-(methoxymethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4,5-difluorophenyl)-5-propoxypyrazine-2-carboxamide (<b>22</b>)</h3><div class="NLM_p last"><i>m</i>/<i>z</i> (ESI): 478.1 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 9.51 (s, 1H), 8.98 (d, <i>J</i> = 1.17 Hz, 1H), 8.12 (d, <i>J</i> = 1.37 Hz, 1H), 8.05 (m, 1H), 7.39 (dt, <i>J</i> = 5.43, 2.47 Hz, 1H), 4.2–4.6 (br, 2H), 4.39 (t, <i>J</i> = 6.75 Hz, 2H), 3.66 (d, <i>J</i> = 10.56 Hz, 1H), 3.41 (s, 3H), 3.35 (d, <i>J</i> = 10.56 Hz, 1H), 1.82 (m, 3H), 1.72 (d, <i>J</i> = 0.98 Hz, 3H), 1.05 (t, <i>J</i> = 7.43 Hz, 3H), 0.90 (dd, <i>J</i> = 9.39, 5.87 Hz, 1H), 0.76–0.84 (m, 1H). <sup>19</sup>F NMR (376 MHz, CDCl<sub>3</sub>) δ ppm −143.07 (d, <i>J</i> = 20.80 Hz, 1 F) −136.29 (d, <i>J</i> = 20.81 Hz, 1 F).</div></div><div id="sec5_6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> <i>N</i>-(3-((1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-Amino-1-(methoxymethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4,5-difluorophenyl)-5-(oxazol-2-ylmethoxy)pyrazine-2-carboxamide (<b>23</b>)</h3><div class="NLM_p last"><i>m</i>/<i>z</i> (ESI): 517.1 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.62 (s, 1H), 8.89 (d, <i>J</i> = 1.17 Hz, 1H), 8.54 (d, <i>J</i> = 1.17 Hz, 1H), 8.20 (s, 1H), 7.88–7.94 (m, 2H), 7.30 (s, 1H), 5.99 (s, 2H), 5.62 (s, 2H), 3.57 (d, <i>J</i> = 10.95 Hz, 1H), 3.36 (d, <i>J</i> = 10.95 Hz, 1H), 3.31 (d, <i>J</i> = 2.54 Hz, 3H), 1.58–1.65 (m, 4H), 0.90 (dd, <i>J</i> = 5.18, 9.10 Hz, 1H), 0.64 (t, <i>J</i> = 5.77 Hz, 1H).</div></div><div id="sec5_6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> <i>N</i>-(3-((1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-Amino-1-(fluoromethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4,5-difluorophenyl)-5-(prop-2-yn-1-yloxy)pyrazine-2-carboxamide (<b>24</b>)</h3><div class="NLM_p last"><i>m</i>/<i>z</i> (ESI): 462.1 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.64 (br, 1H), 8.92 (d, <i>J</i> = 1.37 Hz, 1H), 8.50 (d, <i>J</i> = 1.17 Hz, 1H), 7.89–7.97 (m, 2H), 6.12 (br, 2H), 5.16 (d, <i>J</i> = 2.35 Hz, 2H), 4.44–4.57 (m, 2H), 3.66 (t, <i>J</i> = 2.45 Hz, 1H), 1.80 (m, 1H), 1.63 (s, 3H), 1.05 (m, 1H), 0.72 (m, 1H). <sup>19</sup>F NMR (377 MHz, DMSO-<i>d</i><sub>6</sub>) δ −138.45 (d, <i>J</i> = 22.54 Hz, 1F), −143.62 (d, <i>J</i> = 22.54 Hz, 1F), −211.57 (s, 1F).</div></div><div id="sec5_6_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> <i>N</i>-(3-((1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-Amino-1-(difluoromethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4,5-difluorophenyl)-5-(prop-2-yn-1-yloxy)pyrazine-2-carboxamide (<b>25</b>)</h3><div class="NLM_p last"><i>m</i>/<i>z</i> (ESI): 480.1 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.65 (br, 1H), 8.91 (d, <i>J</i> = 1.17 Hz, 1H), 8.50 (d, <i>J</i> = 1.17 Hz, 1H), 7.93 (m, 1H), 7.83 (d, <i>J</i> = 5.87 Hz, 1H), 6.29 (br, 2H), 5.75–6.09 (m, 1H), 5.16 (d, <i>J</i> = 2.35 Hz, 2H), 3.66 (t, <i>J</i> = 2.35 Hz, 1H), 1.91 (m, 1H), 1.66 (s, 3H), 1.34 (m, 1H), 0.77 (m, 1H). <sup>19</sup>F NMR (377 MHz, DMSO-<i>d</i><sub>6</sub>) δ −115.61 (d, <sup>1</sup><i>J</i> = 273.96 Hz, 1F), −118.23 (d, <sup>1</sup><i>J</i> = 273.90 Hz, 1F), −138.27 (d, <sup>2</sup><i>J</i> = 22.55 Hz, 1F), −143.09 (d, <sup>2</sup><i>J</i> = 22.55 Hz, 1F).</div></div><div id="sec5_6_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> (1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-Amino-5-(2,3-difluoro-5-(5-(prop-2-yn-1-yloxy)pyrazine-2-carboxamido)phenyl)-<i>N</i>,<i>N</i>,5-trimethyl-2-thia-4-azabicyclo[4.1.0]hept-3-ene-1-carboxamide (<b>26</b>)</h3><div class="NLM_p last"><i>m</i>/<i>z</i> (ESI): 501.1 (M + 1)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.62 (s, 1H), 8.90 (d, <i>J</i> = 1.17 Hz, 1H), 8.49 (d, <i>J</i> = 1.17 Hz, 1H), 7.90 (ddd, <i>J</i> = 2.54, 6.85, 12.52 Hz, 1H), 7.82 (d, <i>J</i> = 5.87 Hz, 1H), 6.24 (s, 2H), 5.14 (d, <i>J</i> = 2.35 Hz, 2H), 3.59–3.66 (m, 1H), 3.06 (br s, 6H), 2.04 (t, <i>J</i> = 8.31 Hz, 1H), 1.69 (s, 3H), 1.32 (dd, <i>J</i> = 5.48, 9.59 Hz, 1H), 0.80 (t, <i>J</i> = 6.26 Hz, 1H).</div></div><div id="sec5_6_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> <i>N</i>-(3-((1<i>S</i>,5<i>S</i>,6<i>S</i>)-3-Amino-1-(methoxymethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-5-yl)-4,5-difluorophenyl)-5-chloropyrazine-2-carboxamide (<b>30</b>)</h3><div class="NLM_p last">To a mixture of (1<i>S</i>,5<i>S</i>,6<i>S</i>)-5-(5-amino-2,3-difluorophenyl)-1-(methoxymethyl)-5-methyl-2-thia-4-azabicyclo[4.1.0]hept-3-en-3-amine (<b>8B</b>, 0.40 g, 1.28 mmol), 5-chloropyrazine-2-carboxylic acid (0.30 g, 1.91 mmol) in DCM (10 mL) at RT was added propylphosphonic anhydride solution (50% wt in ethyl acetate, 1.14 mL, 1.91 mmol) dropwise. The reaction mixture was stirred overnight and then diluted with 10 mL of sat. NaHCO<sub>3</sub> and extracted with 20 mL of DCM followed by 20 mL of EtOAc. The organic solution was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The residue was purified by flash chromatography on silica gel (10% to 100% EtOH/EtOAc (1/3) in heptane) to provide compound <b>30</b> (482 mg, 83% yield) as an off-white solid. <i>m</i>/<i>z</i> (ESI): 454.1 (M + H)<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ ppm 9.50 (s, 1H), 9.26 (d, <i>J</i> = 1.37 Hz, 1H), 8.57 (d, <i>J</i> = 1.37 Hz, 1H), 8.04 (m, 1H), 7.40 (m, 1H), 4.20–4.62 (br, 2H), 3.66 (d, <i>J</i> = 10.56 Hz, 1H), 3.41 (s, 3H), 3.35 (d, <i>J</i> = 10.56 Hz, 1H), 1.80 (m, 1H), 1.72 (d, <i>J</i> = 1.17 Hz, 3H), 0.90 (dd, <i>J</i> = 9.39, 5.87 Hz, 1H), 0.80 (m, 1H). <sup>19</sup>F NMR (377 MHz, CDCl<sub>3</sub>) δ ppm −141.93 (d, <i>J</i> = 21.68 Hz, 1 F), −135.78 (d, <i>J</i> = 20.81 Hz, 1 F).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i58"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01034" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76351" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76351" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b01034" class="ext-link">10.1021/acs.jmedchem.9b01034</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Cross species biochemical IC<sub>50</sub> data for compounds <b>20</b> and <b>25</b>; Figure SI-1 for dose–response curves of <b>1</b>, <b>20</b>, and <b>25</b> BACE2 cellular activity; experimental procedure for <b>20</b>/BACE1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PZ4">6PZ4</a>) (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01034/suppl_file/jm9b01034_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and full statistical information (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01034/suppl_file/jm9b01034_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01034/suppl_file/jm9b01034_si_001.pdf">jm9b01034_si_001.pdf (134.08 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01034/suppl_file/jm9b01034_si_002.csv">jm9b01034_si_002.csv (3.38 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates for the X-ray structure of <b>20</b>/BACE1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PZ4">6PZ4</a>) is available from the RCSB Protein Data Bank (<a href="https://www.rcsb.org/" class="extLink">https://www.rcsb.org/</a>). Authors will release the atomic coordinates upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.9b01034" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01164" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01164" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liping H. Pettus</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, , , , , , and , Amgen Discovery Research, Thousand Oaks, California 91320, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4427-6602" title="Orcid link">http://orcid.org/0000-0002-4427-6602</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#cea2beabbababbbd8eafa3a9aba0e0ada1a3"><span class="__cf_email__" data-cfemail="83eff3e6f7f7f6f0c3e2eee4e6edade0ecee">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew P. Bourbeau</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, , , , , , and , Amgen Discovery Research, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jodi Bradley</span> - <span class="hlFld-Affiliation affiliation">Neuroscience Research, , , , , , and , Amgen Discovery Research, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael D. Bartberger</span> - <span class="hlFld-Affiliation affiliation">Molecular Engineering, , , , , , and , Amgen Discovery Research, Thousand Oaks, California 91320, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5167-3139" title="Orcid link">http://orcid.org/0000-0002-5167-3139</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kui Chen</span> - <span class="hlFld-Affiliation affiliation">Discovery Technologies, , , , , , and , Amgen Discovery Research, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dean Hickman</span> - <span class="hlFld-Affiliation affiliation">Pharmacokinetics
and Drug Metabolism, , , , , , and , Amgen Discovery Research, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Johnson</span> - <span class="hlFld-Affiliation affiliation">Research Automation and Technologies, , , , , , and , Amgen Discovery Research, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qingyian Liu</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, , , , , , and , Amgen Discovery Research, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James R. Manning</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, , , , , , and , Amgen Discovery Research, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adrian Nanez</span> - <span class="hlFld-Affiliation affiliation">Comparative Biology and Safety
Studies, , , , , , and , Amgen Discovery Research, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aaron C. Siegmund</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, , , , , , and , Amgen Discovery Research, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul H. Wen</span> - <span class="hlFld-Affiliation affiliation">Neuroscience Research, , , , , , and , Amgen Discovery Research, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Douglas A. Whittington</span> - <span class="hlFld-Affiliation affiliation">Molecular Engineering, , , , , , and , Amgen Discovery Research, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennifer R. Allen</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, , , , , , and , Amgen Discovery Research, Thousand Oaks, California 91320, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen Wood</span> - <span class="hlFld-Affiliation affiliation">Neuroscience Research, , , , , , and , Amgen Discovery Research, Thousand Oaks, California 91320, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e6444-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i61">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45470" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45470" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors express thanks to Jon Nilsen for medical writing assistance and thanks to David Bauer, Jim Brown, Rob Rzasa, and Ted Judd for their efforts in the initial synthetic scale-up of AM-6494 and to Rajiv Kapoor and the Syngene Amgen Research Collaboration (SARC) for their support in supplying key intermediates.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">Aβ</td><td class="NLM_def"><p class="first last">amyloid-β</p></td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer’s disease</p></td></tr><tr><td class="NLM_term">BACE1</td><td class="NLM_def"><p class="first last">β-site amyloid precursor protein (APP) cleaving enzyme 1</p></td></tr><tr><td class="NLM_term">BACE2</td><td class="NLM_def"><p class="first last">β-secretase 2</p></td></tr><tr><td class="NLM_term">CatD</td><td class="NLM_def"><p class="first last">cathepsin D</p></td></tr><tr><td class="NLM_term">CatE</td><td class="NLM_def"><p class="first last">cathepsin E</p></td></tr><tr><td class="NLM_term">CSF</td><td class="NLM_def"><p class="first last">cerebral spinal fluid</p></td></tr><tr><td class="NLM_term">HEK</td><td class="NLM_def"><p class="first last">human embryonic kidney cells</p></td></tr><tr><td class="NLM_term">MITF</td><td class="NLM_def"><p class="first last">melanogenesis associated transcription factor</p></td></tr><tr><td class="NLM_term">H|RLM</td><td class="NLM_def"><p class="first last">human|rat liver microsomes</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamic</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">PMEL17</td><td class="NLM_def"><p class="first last">premelanosome protein</p></td></tr><tr><td class="NLM_term">TYR</td><td class="NLM_def"><p class="first last">tyrosinase</p></td></tr><tr><td class="NLM_term">TYRP1</td><td class="NLM_def"><p class="first last">tyrosinase-related protein 1</p></td></tr><tr><td class="NLM_term">TYRP2</td><td class="NLM_def"><p class="first last">tyrosinase-related protein 2</p></td></tr><tr><td class="NLM_term">TMEM27</td><td class="NLM_def"><p class="first last">transmembrane protein 27</p></td></tr><tr><td class="NLM_term">QD</td><td class="NLM_def"><p class="first last">once a day</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i63">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25075" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25075" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 50 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zemek, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drtinova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepovimova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepsova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korabecny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klimes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuca, K.</span></span> <span> </span><span class="NLM_article-title">Outcomes of Alzheimer’s disease therapy with acetylcholinesterase inhibitors and memantine</span>. <i>Expert Opin. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">759</span>– <span class="NLM_lpage">774</span>, <span class="refDoi"> DOI: 10.1517/14740338.2014.914168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1517%2F14740338.2014.914168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=24845946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVOrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=759-774&author=F.+Zemekauthor=L.+Drtinovaauthor=E.+Nepovimovaauthor=V.+Sepsovaauthor=J.+Korabecnyauthor=J.+Klimesauthor=K.+Kuca&title=Outcomes+of+Alzheimer%E2%80%99s+disease+therapy+with+acetylcholinesterase+inhibitors+and+memantine&doi=10.1517%2F14740338.2014.914168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine</span></div><div class="casAuthors">Zemek, Filip; Drtinova, Lucie; Nepovimova, Eugenie; Sepsova, Vendula; Korabecny, Jan; Klimes, Jiri; Kuca, Kamil</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">759-774</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Alzheimer's disease (AD) is a world-wide health problem with implications for an increasing no. of people and countries.  Populations suffering from AD financially strain the healthcare budgets of rich and poor countries alike.  Moreover, no effective treatment is available and current drugs merely slow the progression of cognitive function deterioration and overall health status toward an inevitable end point.  An increasing no. of novel approaches have been tested in numerous clin. trials, but none of them has proved safe and effective for treating AD.  Areas covered: This review summarizes all currently available compds. (donepezil, rivastigmine, galantamine, memantine) for the management of AD, concg. on clin. aspects such as the mechanisms of action, pharmacokinetics, pharmacodynamics and clin. trials.  This review also considers the mechanisms and side effects to provide perspective on current treatment options.  Expert opinion: Novel approaches in the treatment of AD are being intensively tested, but so far without any major success.  Patients diagnosed with AD still mostly benefit from four compds. to significantly improve cognition functions and overall health and help manage other symptoms or even prolong the symptom-free period.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomCHTA-GByu7Vg90H21EOLACvtfcHk0lj76YbgWqw5-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVOrt70%253D&md5=5dfa0e4ee53453755456895458e49a29</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1517%2F14740338.2014.914168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.2014.914168%26sid%3Dliteratum%253Aachs%26aulast%3DZemek%26aufirst%3DF.%26aulast%3DDrtinova%26aufirst%3DL.%26aulast%3DNepovimova%26aufirst%3DE.%26aulast%3DSepsova%26aufirst%3DV.%26aulast%3DKorabecny%26aufirst%3DJ.%26aulast%3DKlimes%26aufirst%3DJ.%26aulast%3DKuca%26aufirst%3DK.%26atitle%3DOutcomes%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%2520therapy%2520with%2520acetylcholinesterase%2520inhibitors%2520and%2520memantine%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2014%26volume%3D13%26spage%3D759%26epage%3D774%26doi%3D10.1517%2F14740338.2014.914168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vassar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu-Khan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendiaz, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teplow, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amarante, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loeloff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edenson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lile, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarosinski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biere, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treanor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Citron, M.</span></span> <span> </span><span class="NLM_article-title">beta-Secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE1</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">741</span>, <span class="refDoi"> DOI: 10.1126/science.286.5440.735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1126%2Fscience.286.5440.735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10531052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADyaK1MXntFWit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=1999&pages=735-741&author=R.+Vassarauthor=B.+D.+Bennettauthor=S.+Babu-Khanauthor=S.+Kahnauthor=E.+A.+Mendiazauthor=P.+Denisauthor=D.+B.+Teplowauthor=S.+Rossauthor=P.+Amaranteauthor=R.+Loeloffauthor=Y.+Luoauthor=S.+Fisherauthor=J.+Fullerauthor=S.+Edensonauthor=J.+Lileauthor=M.+A.+Jarosinskiauthor=A.+L.+Biereauthor=E.+Curranauthor=T.+Burgessauthor=J.+C.+Louisauthor=F.+Collinsauthor=J.+Treanorauthor=G.+Rogersauthor=M.+Citron&title=beta-Secretase+cleavage+of+Alzheimer%E2%80%99s+amyloid+precursor+protein+by+the+transmembrane+aspartic+protease+BACE1&doi=10.1126%2Fscience.286.5440.735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE</span></div><div class="casAuthors">Vassar, Robert; Bennett, Brian D.; Babu-Khan, Safura; Kahn, Steve; Mendiaz, Elizabeth A.; Denis, Paul; Teplow, David B.; Ross, Sandra; Amarante, Patricia; Loeloff, Richard; Luo, Yi; Fisher, Seth; Fuller, Janis; Edenson, Steven; Lile, Jackson; Jarosinski, Mark A.; Biere, Anja Leona; Curran, Eileen; Burgess, Teresa; Louis, Jean-Claude; Collins, Frank; Treanor, James; Rogers, Gary; Citron, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">5440</span>),
    <span class="NLM_cas:pages">735-741</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Cerebral deposition of amyloid β peptide (Aβ) is an early and crit. feature of Alzheimer's disease.  Aβ generation depends on proteolytic cleavage of the amyloid precursor protein (APP) by two unknown proteases: β-secretase and γ-secretase.  These proteases are prime therapeutic targets.  A transmembrane aspartic protease with all the known characteristics of β-secretase was cloned and characterized.  Overexpression of this protease, termed BACE (for beta-site APP-cleaving enzyme) increased the amt. of β-secretase cleavage products, and these were cleaved exactly and only at known β-secretase positions.  Antisense inhibition of endogenous BACE mRNA decreased the amt. of β-secretase cleavage products, and purified BACE protein cleaved APP-derived substrates with the same sequence specificity as β-secretase.  Finally, the expression pattern and subcellular localization of BACE were consistent with that expected for β-secretase.  Future development of BACE inhibitors may prove beneficial for the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSx3s1NFyByrVg90H21EOLACvtfcHk0lj76YbgWqw5-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFWit74%253D&md5=3f36e8e5b5e9441c7670ccaeb0d2dd4f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.286.5440.735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.286.5440.735%26sid%3Dliteratum%253Aachs%26aulast%3DVassar%26aufirst%3DR.%26aulast%3DBennett%26aufirst%3DB.%2BD.%26aulast%3DBabu-Khan%26aufirst%3DS.%26aulast%3DKahn%26aufirst%3DS.%26aulast%3DMendiaz%26aufirst%3DE.%2BA.%26aulast%3DDenis%26aufirst%3DP.%26aulast%3DTeplow%26aufirst%3DD.%2BB.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DAmarante%26aufirst%3DP.%26aulast%3DLoeloff%26aufirst%3DR.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DFisher%26aufirst%3DS.%26aulast%3DFuller%26aufirst%3DJ.%26aulast%3DEdenson%26aufirst%3DS.%26aulast%3DLile%26aufirst%3DJ.%26aulast%3DJarosinski%26aufirst%3DM.%2BA.%26aulast%3DBiere%26aufirst%3DA.%2BL.%26aulast%3DCurran%26aufirst%3DE.%26aulast%3DBurgess%26aufirst%3DT.%26aulast%3DLouis%26aufirst%3DJ.%2BC.%26aulast%3DCollins%26aufirst%3DF.%26aulast%3DTreanor%26aufirst%3DJ.%26aulast%3DRogers%26aufirst%3DG.%26aulast%3DCitron%26aufirst%3DM.%26atitle%3Dbeta-Secretase%2520cleavage%2520of%2520Alzheimer%25E2%2580%2599s%2520amyloid%2520precursor%2520protein%2520by%2520the%2520transmembrane%2520aspartic%2520protease%2520BACE1%26jtitle%3DScience%26date%3D1999%26volume%3D286%26spage%3D735%26epage%3D741%26doi%3D10.1126%2Fscience.286.5440.735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haass, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selkoe, D. J.</span></span> <span> </span><span class="NLM_article-title">Soluble protein oligomers in neurodegeneration: lesson from the Alzheimer’s amyloid β-peptide</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1038/nrm2101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1038%2Fnrm2101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=17245412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotFKmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=101-112&author=C.+Haassauthor=D.+J.+Selkoe&title=Soluble+protein+oligomers+in+neurodegeneration%3A+lesson+from+the+Alzheimer%E2%80%99s+amyloid+%CE%B2-peptide&doi=10.1038%2Fnrm2101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide</span></div><div class="casAuthors">Haass, Christian; Selkoe, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-112</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The distinct protein aggregates that are found in Alzheimer's, Parkinson's, Huntington's and prion diseases seem to cause these disorders.  Small intermediates - sol. oligomers - in the aggregation process can confer synaptic dysfunction, whereas large, insol. deposits might function as reservoirs of the bioactive oligomers.  These emerging concepts are exemplified by Alzheimer's disease, in which amyloid β-protein oligomers adversely affect synaptic structure and plasticity.  Findings in other neurodegenerative diseases indicate that a broadly similar process of neuronal dysfunction is induced by diffusible oligomers of misfolded proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmPK-IDaBZirVg90H21EOLACvtfcHk0lhR0OWvvOb2vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotFKmtw%253D%253D&md5=e8634ff5c1491580f623c90ded91b4be</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrm2101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2101%26sid%3Dliteratum%253Aachs%26aulast%3DHaass%26aufirst%3DC.%26aulast%3DSelkoe%26aufirst%3DD.%2BJ.%26atitle%3DSoluble%2520protein%2520oligomers%2520in%2520neurodegeneration%253A%2520lesson%2520from%2520the%2520Alzheimer%25E2%2580%2599s%2520amyloid%2520%25CE%25B2-peptide%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2007%26volume%3D8%26spage%3D101%26epage%3D112%26doi%3D10.1038%2Fnrm2101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, R.</span></span> <span> </span><span class="NLM_article-title">Inhibition of BACE1 for therapeutic use in Alzheimer’s disease</span>. <i>Int. J. Clin. Exp. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">618</span>– <span class="NLM_lpage">628</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=20661410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptFagtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=618-628&author=X.+Luoauthor=R.+Yan&title=Inhibition+of+BACE1+for+therapeutic+use+in+Alzheimer%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of BACE1 for therapeutic use in Alzheimer's disease</span></div><div class="casAuthors">Luo, Xiaoyang; Yan, Riqiang</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical and Experimental Pathology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">618-628</span>CODEN:
                <span class="NLM_cas:coden">IJCEC7</span>;
        ISSN:<span class="NLM_cas:issn">1936-2625</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">A review.  Since BACE1 was reported as the β-secretase in Alzheimer's disease (AD) over ten years ago, encouraging progress has been made toward understanding the cellular functions of BACE1.  Genetic studies have further confirmed that BACE1 is essential for processing amyloid precursor protein (APP) at the β-secretase site.  Only after this cleavage can the membrane-bound APP C-terminal fragment be subsequently cleaved by γ-secretase to release so-called AD-causing Aβ peptides.  Hence, in the past decade, a wide variety of BACE1 inhibitors have been developed for AD therapy.  This review will summarize the major historical events during the evolution of BACE1 inhibitors designed through different strategies of drug discovery.  Although BACE1 inhibitors are expected to be safe in general, careful titrn. of drug dosage to avoid undesirable side effects in BACE1-directed AD therapy is also emphasized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUFz1x-AF9XbVg90H21EOLACvtfcHk0lhR0OWvvOb2vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptFagtbo%253D&md5=0cf2745b97b31229b1de6b7db04911e2</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DYan%26aufirst%3DR.%26atitle%3DInhibition%2520of%2520BACE1%2520for%2520therapeutic%2520use%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DInt.%2520J.%2520Clin.%2520Exp.%2520Pathol.%26date%3D2010%26volume%3D3%26spage%3D618%26epage%3D628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Citron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckman, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corcoran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostaszewski, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levesque, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. George Hyslop, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younkin, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selkoe, D. J.</span></span> <span> </span><span class="NLM_article-title">Additive effects of PS1 and APP mutations on secretion of the 42-residue amyloid β-protein</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1006/nbdi.1998.0183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1006%2Fnbdi.1998.0183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=9746908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADyaK1cXmtlenurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1998&pages=107-116&issue=2&author=M.+Citronauthor=C.+B.+Eckmanauthor=T.+S.+Diehlauthor=C.+Corcoranauthor=B.+L.+Ostaszewskiauthor=W.+Xiaauthor=G.+Levesqueauthor=P.+St.+George+Hyslopauthor=S.+G.+Younkinauthor=D.+J.+Selkoe&title=Additive+effects+of+PS1+and+APP+mutations+on+secretion+of+the+42-residue+amyloid+%CE%B2-protein&doi=10.1006%2Fnbdi.1998.0183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Additive effects of PS1 and APP mutations on secretion of the 42-residue amyloid β-protein</span></div><div class="casAuthors">Citron, Martin; Eckman, Christopher B.; Diehl, Thekla S.; Corcoran, Chris; Ostaszewski, Beth L.; Xia, Weiming; Levesque, Georges; St. George Hyslop, Peter; Younkin, Steven G.; Selkoe, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-116</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Humans harboring missense mutations in the presenilin 1 (PS1) gene undergo progressive cerebral deposition of the 42-residue amyloid β-protein (Aβ42) at an early age and develop severe Alzheimer's disease.  Aβ42 is selectively elevated in the conditioned media of cells expressing mutant but not wild-type PS1, indicating that presenilin mutations alter APP processing.  Here we analyze the effects of various PS1 mutant constructs on the cellular prodn. of Aβ42.  A construct expressing only the PS1 N-terminal endoproteolytic fragment with the mutation Y115H causes no significant increase in Aβ42, whereas a full-length PS1 construct with the same mutation does.  This result suggests that the pathogenic effect of mutant presenilins is produced by the full-length mol. even though only a minor proportion of total PS1 occurs as holoprotein in tissues and cell lines.  We demonstrate that the effects of two different PS1 mutations are additive when engineered into the same PS1 mol.  Therefore, two mutations alter γ-secretase processing of APP more than one and the PS1 mutations described to date do not cause the max. possible PS1-mediated rise in Aβ42.  When a PS1 mutation was expressed in cells carrying the APPv7171 mutation, Aβ42 rose dramatically to become the predominant secreted Aβ species, an observation of interest for transgenic modeling of AD.  Our results are consistent with the hypothesis that presenilin is a major regulator of the proteolytic processing of APP by γ-secretases.  (c) 1998 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0ck6RE7yz9LVg90H21EOLACvtfcHk0lhR0OWvvOb2vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtlenurg%253D&md5=afd0de91ae36a1981ce9644f876ee1c1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1006%2Fnbdi.1998.0183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fnbdi.1998.0183%26sid%3Dliteratum%253Aachs%26aulast%3DCitron%26aufirst%3DM.%26aulast%3DEckman%26aufirst%3DC.%2BB.%26aulast%3DDiehl%26aufirst%3DT.%2BS.%26aulast%3DCorcoran%26aufirst%3DC.%26aulast%3DOstaszewski%26aufirst%3DB.%2BL.%26aulast%3DXia%26aufirst%3DW.%26aulast%3DLevesque%26aufirst%3DG.%26aulast%3DSt.%2BGeorge%2BHyslop%26aufirst%3DP.%26aulast%3DYounkin%26aufirst%3DS.%2BG.%26aulast%3DSelkoe%26aufirst%3DD.%2BJ.%26atitle%3DAdditive%2520effects%2520of%2520PS1%2520and%2520APP%2520mutations%2520on%2520secretion%2520of%2520the%252042-residue%2520amyloid%2520%25CE%25B2-protein%26jtitle%3DNeurobiol.%2520Dis.%26date%3D1998%26volume%3D5%26issue%3D2%26spage%3D107%26epage%3D116%26doi%3D10.1006%2Fnbdi.1998.0183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnsson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atwal, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snaedal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefansson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulem, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gudbjartsson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyte, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhangale, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huttenlocher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsdottir, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreassen, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jönsson, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palotie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrens, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, O. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorsteinsdottir, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefansson, K.</span></span> <span> </span><span class="NLM_article-title">A mutation in <i>APP</i> protects against Alzheimer’s disease and age-related cognitive decline</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>488</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1038/nature11283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1038%2Fnature11283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=22801501" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=488&publication_year=2012&pages=96-99&author=T.+Johnssonauthor=J.+K.+Atwalauthor=S.+Steinbergauthor=J.+Snaedalauthor=P.+V.+Jonssonauthor=S.+Bjornssonauthor=H.+Stefanssonauthor=P.+Sulemauthor=D.+Gudbjartssonauthor=J.+Maloneyauthor=K.+Hoyteauthor=A.+Gustafsonauthor=Y.+Liuauthor=Y.+Luauthor=T.+Bhangaleauthor=R.+B.+Grahamauthor=J.+Huttenlocherauthor=G.+Bjornsdottirauthor=O.+A.+Andreassenauthor=E.+G.+J%C3%B6nssonauthor=A.+Palotieauthor=T.+W.+Behrensauthor=O.+T.+Magnussonauthor=A.+Kongauthor=U.+Thorsteinsdottirauthor=R.+J.+Wattsauthor=K.+Stefansson&title=A+mutation+in+APP+protects+against+Alzheimer%E2%80%99s+disease+and+age-related+cognitive+decline&doi=10.1038%2Fnature11283"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature11283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11283%26sid%3Dliteratum%253Aachs%26aulast%3DJohnsson%26aufirst%3DT.%26aulast%3DAtwal%26aufirst%3DJ.%2BK.%26aulast%3DSteinberg%26aufirst%3DS.%26aulast%3DSnaedal%26aufirst%3DJ.%26aulast%3DJonsson%26aufirst%3DP.%2BV.%26aulast%3DBjornsson%26aufirst%3DS.%26aulast%3DStefansson%26aufirst%3DH.%26aulast%3DSulem%26aufirst%3DP.%26aulast%3DGudbjartsson%26aufirst%3DD.%26aulast%3DMaloney%26aufirst%3DJ.%26aulast%3DHoyte%26aufirst%3DK.%26aulast%3DGustafson%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DBhangale%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DR.%2BB.%26aulast%3DHuttenlocher%26aufirst%3DJ.%26aulast%3DBjornsdottir%26aufirst%3DG.%26aulast%3DAndreassen%26aufirst%3DO.%2BA.%26aulast%3DJ%25C3%25B6nsson%26aufirst%3DE.%2BG.%26aulast%3DPalotie%26aufirst%3DA.%26aulast%3DBehrens%26aufirst%3DT.%2BW.%26aulast%3DMagnusson%26aufirst%3DO.%2BT.%26aulast%3DKong%26aufirst%3DA.%26aulast%3DThorsteinsdottir%26aufirst%3DU.%26aulast%3DWatts%26aufirst%3DR.%2BJ.%26aulast%3DStefansson%26aufirst%3DK.%26atitle%3DA%2520mutation%2520in%2520APP%2520protects%2520against%2520Alzheimer%25E2%2580%2599s%2520disease%2520and%2520age-related%2520cognitive%2520decline%26jtitle%3DNature%26date%3D2012%26volume%3D488%26spage%3D96%26epage%3D99%26doi%3D10.1038%2Fnature11283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howlett, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tew, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloger, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southan, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingwall, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, G.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel aspartic protease (Asp 2) as β-Secretase</span>. <i>Mol. Cell. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">427</span>, <span class="refDoi"> DOI: 10.1006/mcne.1999.0811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1006%2Fmcne.1999.0811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10656250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADyaK1MXnt1Chsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1999&pages=419-427&author=I.+Hussainauthor=D.+Powellauthor=D.+R.+Howlettauthor=D.+G.+Tewauthor=T.+D.+Meekauthor=C.+Chapmanauthor=I.+S.+Glogerauthor=K.+E.+Murphyauthor=C.+D.+Southanauthor=D.+M.+Ryanauthor=T.+S.+Smithauthor=D.+L.+Simmonsauthor=F.+S.+Walshauthor=C.+Dingwallauthor=G.+Christie&title=Identification+of+a+novel+aspartic+protease+%28Asp+2%29+as+%CE%B2-Secretase&doi=10.1006%2Fmcne.1999.0811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase</span></div><div class="casAuthors">Hussain, Ishrut; Powell, David; Howlett, David R.; Tew, David G.; Meek, Thomas D.; Chapman, Conrad; Gloger, Israel S.; Murphy, Kay E.; Southan, Christopher D.; Ryan, Dominic M.; Smith, Trudi S.; Simmons, David L.; Walsh, Frank S.; Dingwall, Colin; Christie, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Neuroscience</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">419-427</span>CODEN:
                <span class="NLM_cas:coden">MOCNED</span>;
        ISSN:<span class="NLM_cas:issn">1044-7431</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The Alzheimer's disease β-amyloid peptide (Aβ) is produced by excision from the type 1 integral membrane glycoprotein amyloid precursor protein (APP) by the sequential actions of β- and then γ-secretases.  Here we report that Asp 2, a novel transmembrane aspartic protease, has the key activities expected of β-secretase.  Transient expression of Asp 2 in cells expressing APP causes an increase in the secretion of the N-terminal fragment of APP and an increase in the cell-assocd. C-terminal β-secretase APP fragment.  Mutation of either of the putative catalytic aspartyl residues in Asp 2 abrogates the prodn. of the fragments characteristic of cleavage at the β-secretase site.  The enzyme is present in normal and Alzheimer's disease (AD) brain and is also found in cell lines known to produce Aβ.  Asp 2 localizes to the Golgi/endoplasmic reticulum in transfected cells and shows clear colocalization with APP in cells stably expressing the 751-amino-acid isoform of APP.  (c) 1999 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDUBbUoO6SgLVg90H21EOLACvtfcHk0lhB3zLnYDwe6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXnt1Chsrs%253D&md5=aba834d907c5dae03f060d94729576e9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1006%2Fmcne.1999.0811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fmcne.1999.0811%26sid%3Dliteratum%253Aachs%26aulast%3DHussain%26aufirst%3DI.%26aulast%3DPowell%26aufirst%3DD.%26aulast%3DHowlett%26aufirst%3DD.%2BR.%26aulast%3DTew%26aufirst%3DD.%2BG.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26aulast%3DChapman%26aufirst%3DC.%26aulast%3DGloger%26aufirst%3DI.%2BS.%26aulast%3DMurphy%26aufirst%3DK.%2BE.%26aulast%3DSouthan%26aufirst%3DC.%2BD.%26aulast%3DRyan%26aufirst%3DD.%2BM.%26aulast%3DSmith%26aufirst%3DT.%2BS.%26aulast%3DSimmons%26aufirst%3DD.%2BL.%26aulast%3DWalsh%26aufirst%3DF.%2BS.%26aulast%3DDingwall%26aufirst%3DC.%26aulast%3DChristie%26aufirst%3DG.%26atitle%3DIdentification%2520of%2520a%2520novel%2520aspartic%2520protease%2520%2528Asp%25202%2529%2520as%2520%25CE%25B2-Secretase%26jtitle%3DMol.%2520Cell.%2520Neurosci.%26date%3D1999%26volume%3D14%26spage%3D419%26epage%3D427%26doi%3D10.1006%2Fmcne.1999.0811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Probst, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. Z.</span></span> <span> </span><span class="NLM_article-title">Small-molecule BACE1 inhibitors: a patent literature review (2006 - 2011)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">511</span>– <span class="NLM_lpage">540</span>, <span class="refDoi"> DOI: 10.1517/13543776.2012.681302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1517%2F13543776.2012.681302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=22512789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvFais7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=511-540&author=G.+Probstauthor=Y.+Z.+Xu&title=Small-molecule+BACE1+inhibitors%3A+a+patent+literature+review+%282006+-+2011%29&doi=10.1517%2F13543776.2012.681302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule BACE1 inhibitors: a patent literature review (2006 - 2011)</span></div><div class="casAuthors">Probst, Gary; Xu, Ying-zi</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">511-540</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Alzheimer's disease is a devastating neurodegenerative disorder for which no disease-modifying therapy exists.  The amyloid hypothesis, which implicates Aβ as the toxin initiating a biol. cascade leading to neurodegeneration, is the most prominent theory concerning the underlying cause of the disease.  BACE1 is one of two aspartyl proteinases that generate Aβ, thus inhibition of BACE1 has the potential to ameliorate the progression of Alzheimer's disease by abating the prodn. of Aβ.  Areas covered: This review chronicles small-mol. BACE1 inhibitors as described in the patent literature between 2006 and 2011 and their potential use as disease-modifying treatments for Alzheimer's disease.  Over the past half a dozen years, numerous BACE1 inhibitors have been published in the patent applications, but often these contain a paltry amt. of pertinent biol. data (e.g. potency, selectivity, and efficacy).  Fortunately, numerous relevant publications contg. important data have appeared in the journal literature during this period.  The goal in this effort was to create an amalgam of the two records to add value to this review.  Expert opinion: The pharmaceutical industry has made tremendous progress in the development of small-mol. BACE1 inhibitors that lower Aβ in the central nervous system.  Assuming the amyloid hypothesis is veracious, we anticipate a disease-modifying therapy to combat Alzheimer's disease is near.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp89KaCi3q5Z7Vg90H21EOLACvtfcHk0lhB3zLnYDwe6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvFais7g%253D&md5=174bdc47fbca5aa1f8248dbf03ce402b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1517%2F13543776.2012.681302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2012.681302%26sid%3Dliteratum%253Aachs%26aulast%3DProbst%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DY.%2BZ.%26atitle%3DSmall-molecule%2520BACE1%2520inhibitors%253A%2520a%2520patent%2520literature%2520review%2520%25282006%2520-%25202011%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2012%26volume%3D22%26spage%3D511%26epage%3D540%26doi%3D10.1517%2F13543776.2012.681302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vassar, R.</span></span> <span> </span><span class="NLM_article-title">BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease</span>. <i>Alzheimer’s Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1186/s13195-014-0089-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1186%2Fs13195-014-0089-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1-14&author=R.+Vassar&title=BACE1+inhibitor+drugs+in+clinical+trials+for+Alzheimer%E2%80%99s+disease&doi=10.1186%2Fs13195-014-0089-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1186%2Fs13195-014-0089-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13195-014-0089-7%26sid%3Dliteratum%253Aachs%26aulast%3DVassar%26aufirst%3DR.%26atitle%3DBACE1%2520inhibitor%2520drugs%2520in%2520clinical%2520trials%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DAlzheimer%25E2%2580%2599s%2520Res.%2520Ther.%26date%3D2014%26volume%3D6%26spage%3D1%26epage%3D14%26doi%3D10.1186%2Fs13195-014-0089-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coimbra, J. R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marques, D. F. F</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baptista, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, C. M. F</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinis, T. C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvador, J. A. R.</span></span> <span> </span><span class="NLM_article-title">Highlights in BACE1 inhibitors for Alzheimer’s disease treatment</span>. <i>Front. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">178</span> <span class="refDoi"> DOI: 10.3389/fchem.2018.00178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.3389%2Ffchem.2018.00178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=29881722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisV2mtr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&author=J.+R.+M.+Coimbraauthor=D.+F.+F+Marquesauthor=S.+J.+Baptistaauthor=C.+M.+F+Pereiraauthor=P.+I.+Moreiraauthor=T.+C.+P.+Dinisauthor=A.+E.+Santosauthor=J.+A.+R.+Salvador&title=Highlights+in+BACE1+inhibitors+for+Alzheimer%E2%80%99s+disease+treatment&doi=10.3389%2Ffchem.2018.00178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Highlights in bace1 inhibitors for alzheimer's disease treatment</span></div><div class="casAuthors">Coimbra, Judite R. M.; Marques, Daniela F. F.; Baptista, Salete J.; Pereira, Claudia M. F.; Moreira, Paula I.; Dinis, Teresa C. P.; Santos, Armanda E.; Salvador, Jorge A. R.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Chemistry (Lausanne, Switzerland)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">178/1-178/10</span>CODEN:
                <span class="NLM_cas:coden">FCLSAA</span>;
        ISSN:<span class="NLM_cas:issn">2296-2646</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is a severe neurodegenerative disorder and the most common type of dementia in the elderly.  The clin. symptoms of AD include a progressive loss of memory and impairment of cognitive functions interfering with daily life activities.  The main neuropathol. features consist in extracellular amyloid-β (Aβ) plaque deposition and intracellular Neurofibrillary tangles (NFTs) of hyperphosphorylated Tau.  Understanding the pathophysiol. mechanisms that underlie neurodegeneration in AD is essential for rational design of neuroprotective agents able to prevent disease progression.  According to the "Amyloid Cascade Hypothesis" the crit. mol. event in the pathogenesis of AD is the accumulation of Aβ neurotoxic oligomers.  Since the proteolytic processing of Amyloid Precursor Protein (APP) by β-secretase (beta-site APP cleaving enzyme 1, BACE1) is the rate-limiting step in the prodn. of Aβ, this enzyme is considered a major therapeutic target and BACE1 inhibitors have the potential to be disease-modifying drugs for AD treatment.  Therefore, intensive efforts to discover and develop inhibitors that can reach the brain and effectively inhibit BACE1 have been pursued by several groups worldwide.  The aim of this review is to highlight the progress in the discovery of potent and selective small mol. BACE1 inhibitors over the past decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyV_176RT6cLVg90H21EOLACvtfcHk0lhB3zLnYDwe6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisV2mtr3N&md5=79f20f1bde2dd9993b8b84ba1f188274</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.3389%2Ffchem.2018.00178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffchem.2018.00178%26sid%3Dliteratum%253Aachs%26aulast%3DCoimbra%26aufirst%3DJ.%2BR.%2BM.%26aulast%3DMarques%26aufirst%3DD.%2BF.%2BF%26aulast%3DBaptista%26aufirst%3DS.%2BJ.%26aulast%3DPereira%26aufirst%3DC.%2BM.%2BF%26aulast%3DMoreira%26aufirst%3DP.%2BI.%26aulast%3DDinis%26aufirst%3DT.%2BC.%2BP.%26aulast%3DSantos%26aufirst%3DA.%2BE.%26aulast%3DSalvador%26aufirst%3DJ.%2BA.%2BR.%26atitle%3DHighlights%2520in%2520BACE1%2520inhibitors%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%2520treatment%26jtitle%3DFront.%2520Chem.%26date%3D2018%26volume%3D6%26doi%3D10.3389%2Ffchem.2018.00178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panza, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozupone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logroscino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imbimbo, B. P.</span></span> <span> </span><span class="NLM_article-title">A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease</span>. <i>Nat. Rev. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1038/s41582-018-0116-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1038%2Fs41582-018-0116-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=30610216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A280%3ADC%252BB3cnotFagtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=73-88&author=F.+Panzaauthor=M.+Lozuponeauthor=G.+Logroscinoauthor=B.+P.+Imbimbo&title=A+critical+appraisal+of+amyloid-%CE%B2-targeting+therapies+for+Alzheimer+disease&doi=10.1038%2Fs41582-018-0116-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease</span></div><div class="casAuthors">Panza Francesco; Lozupone Madia; Logroscino Giancarlo; Panza Francesco; Logroscino Giancarlo; Panza Francesco; Imbimbo Bruno P</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Neurology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">73-88</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Brain accumulation of the amyloid-β (Aβ) peptide is believed to be the initial event in the Alzheimer disease (AD) process.  Aβ accumulation begins 15-20 years before clinical symptoms occur, mainly owing to defective brain clearance of the peptide.  Over the past 20 years, we have seen intensive efforts to decrease the levels of Aβ monomers, oligomers, aggregates and plaques using compounds that decrease production, antagonize aggregation or increase brain clearance of Aβ.  Unfortunately, these approaches have failed to show clinical benefit in large clinical trials involving patients with mild to moderate AD.  Clinical trials in patients at earlier stages of the disease are ongoing, but the initial results have not been clinically impressive.  Efforts are now being directed against Aβ oligomers, the most neurotoxic molecular species, and monoclonal antibodies directed against these oligomers are producing encouraging results.  However, Aβ oligomers are in equilibrium with both monomeric and aggregated species; thus, previous drugs that efficiently removed monomeric Aβ or Aβ plaques should have produced clinical benefits.  In patients with sporadic AD, Aβ accumulation could be a reactive compensatory response to neuronal damage of unknown cause, and alternative strategies, including interference with modifiable risk factors, might be needed to defeat this devastating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQwevf7x6znXRjv2lLSLOxFfW6udTcc2eZ0hJrz7bY1Ybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnotFagtA%253D%253D&md5=fa63b5a3ca7e25169dfd6566f56b5152</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fs41582-018-0116-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41582-018-0116-6%26sid%3Dliteratum%253Aachs%26aulast%3DPanza%26aufirst%3DF.%26aulast%3DLozupone%26aufirst%3DM.%26aulast%3DLogroscino%26aufirst%3DG.%26aulast%3DImbimbo%26aufirst%3DB.%2BP.%26atitle%3DA%2520critical%2520appraisal%2520of%2520amyloid-%25CE%25B2-targeting%2520therapies%2520for%2520Alzheimer%2520disease%26jtitle%3DNat.%2520Rev.%2520Neurol.%26date%3D2019%26volume%3D15%26spage%3D73%26epage%3D88%26doi%3D10.1038%2Fs41582-018-0116-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bateman, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benzinger, T. L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcus, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cairns, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blazey, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtzman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santacruz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckles, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisen, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghetti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klunk, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDade, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masters, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayeux, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossor, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schofield, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperling, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salloway, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. C.</span></span> <span> </span><span class="NLM_article-title">Clinical and biomarker changes in dominantly inherited Alzheimer’s disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">795</span>– <span class="NLM_lpage">804</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1202753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1056%2FNEJMoa1202753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=22784036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGktL7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=795-804&author=R.+J.+Batemanauthor=C.+Xiongauthor=T.+L.+S.+Benzingerauthor=A.+M.+Faganauthor=A.+Goateauthor=N.+C.+Foxauthor=D.+S.+Marcusauthor=N.+J.+Cairnsauthor=X.+Xieauthor=T.+M.+Blazeyauthor=D.+M.+Holtzmanauthor=A.+Santacruzauthor=V.+Bucklesauthor=A.+Oliverauthor=K.+Moulderauthor=P.+S.+Aisenauthor=B.+Ghettiauthor=W.+E.+Klunkauthor=E.+McDadeauthor=R.+N.+Martinsauthor=C.+L.+Mastersauthor=R.+Mayeuxauthor=J.+M.+Ringmanauthor=M.+N.+Rossorauthor=P.+R.+Schofieldauthor=R.+A.+Sperlingauthor=S.+Sallowayauthor=J.+C.+Morris&title=Clinical+and+biomarker+changes+in+dominantly+inherited+Alzheimer%E2%80%99s+disease&doi=10.1056%2FNEJMoa1202753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical and biomarker changes in dominantly inherited Alzheimer's disease</span></div><div class="casAuthors">Bateman, Randall J.; Xiong, Chengjie; Benzinger, Tammie L. S.; Fagan, Anne M.; Goate, Alison; Fox, Nick C.; Marcus, Daniel S.; Cairns, Nigel J.; Xie, Xianyun; Blazey, Tyler M.; Holtzman, David M.; Santacruz, Anna; Buckles, Virginia; Oliver, Angela; Moulder, Krista; Aisen, Paul S.; Ghetti, Bernardino; Klunk, William E.; McDade, Eric; Martins, Ralph N.; Masters, Colin L.; Mayeux, Richard; Ringman, John M.; Rossor, Martin N.; Schofield, Peter R.; Sperling, Reisa A.; Salloway, Stephen; Morris, John C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">795-804</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: The order and magnitude of pathol. processes in Alzheimer's disease are not well understood, partly because the disease develops over many years.  Autosomal dominant Alzheimer's disease has a predictable age at onset and provides an opportunity to det. the sequence and magnitude of pathol. changes that culminate in symptomatic disease.  METHODS: In this prospective, longitudinal study, we analyzed data from 128 participants who underwent baseline clin. and cognitive assessments, brain imaging, and cerebrospinal fluid (CSF) and blood tests.  We used the participant's age at baseline assessment and the parent's age at the onset of symptoms of Alzheimer's disease to calc. the estd. years from expected symptom onset (age of the participant minus parent's age at symptom onset).  We conducted cross-sectional analyses of baseline data in relation to estd. years from expected symptom onset in order to det. the relative order and magnitude of pathophysiol. changes.  RESULTS: Concns. of amyloid-beta (Aβ)42 in the CSF appeared to decline 25 years before expected symptom onset.  Aβ deposition, as measured by positron-emission tomog. with the use of Pittsburgh compd. B, was detected 15 years before expected symptom onset.  Increased concns. of tau protein in the CSF and an increase in brain atrophy were detected 15 years before expected symptom onset.  Cerebral hypometabolism and impaired episodic memory were obsd. 10 years before expected symptom onset.  Global cognitive impairment, as measured by the Mini-Mental State Examn. and the Clin. Dementia Rating scale, was detected 5 years before expected symptom onset, and patients met diagnostic criteria for dementia at an av. of 3 years after expected symptom onset.  CONCLUSIONS: We found that autosomal dominant Alzheimer's disease was assocd. with a series of pathophysiol. changes over decades in CSF biochem. markers of Alzheimer's disease, brain amyloid deposition, and brain metab. as well as progressive cognitive impairment.  Our results require confirmation with the use of longitudinal data and may not apply to patients with sporadic Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptJNV9eDXBCLVg90H21EOLACvtfcHk0lgexz2I0DeADA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGktL7J&md5=c4f999ea3401af9651a2770724757bed</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1202753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1202753%26sid%3Dliteratum%253Aachs%26aulast%3DBateman%26aufirst%3DR.%2BJ.%26aulast%3DXiong%26aufirst%3DC.%26aulast%3DBenzinger%26aufirst%3DT.%2BL.%2BS.%26aulast%3DFagan%26aufirst%3DA.%2BM.%26aulast%3DGoate%26aufirst%3DA.%26aulast%3DFox%26aufirst%3DN.%2BC.%26aulast%3DMarcus%26aufirst%3DD.%2BS.%26aulast%3DCairns%26aufirst%3DN.%2BJ.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DBlazey%26aufirst%3DT.%2BM.%26aulast%3DHoltzman%26aufirst%3DD.%2BM.%26aulast%3DSantacruz%26aufirst%3DA.%26aulast%3DBuckles%26aufirst%3DV.%26aulast%3DOliver%26aufirst%3DA.%26aulast%3DMoulder%26aufirst%3DK.%26aulast%3DAisen%26aufirst%3DP.%2BS.%26aulast%3DGhetti%26aufirst%3DB.%26aulast%3DKlunk%26aufirst%3DW.%2BE.%26aulast%3DMcDade%26aufirst%3DE.%26aulast%3DMartins%26aufirst%3DR.%2BN.%26aulast%3DMasters%26aufirst%3DC.%2BL.%26aulast%3DMayeux%26aufirst%3DR.%26aulast%3DRingman%26aufirst%3DJ.%2BM.%26aulast%3DRossor%26aufirst%3DM.%2BN.%26aulast%3DSchofield%26aufirst%3DP.%2BR.%26aulast%3DSperling%26aufirst%3DR.%2BA.%26aulast%3DSalloway%26aufirst%3DS.%26aulast%3DMorris%26aufirst%3DJ.%2BC.%26atitle%3DClinical%2520and%2520biomarker%2520changes%2520in%2520dominantly%2520inherited%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D795%26epage%3D804%26doi%3D10.1056%2FNEJMoa1202753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mormino, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betensky, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedden, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huijbers, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rentz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperling, R. A.</span></span> <span> </span><span class="NLM_article-title">Amyloid and <i>APOE ε4</i> interact to influence short-term decline in preclinical Alzheimer disease</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">1760</span>– <span class="NLM_lpage">1767</span>, <span class="refDoi"> DOI: 10.1212/WNL.0000000000000431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1212%2FWNL.0000000000000431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=24748674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVOnsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2014&pages=1760-1767&author=E.+C.+Morminoauthor=R.+A.+Betenskyauthor=T.+Heddenauthor=A.+P.+Schultzauthor=A.+Wardauthor=W.+Huijbersauthor=D.+M.+Rentzauthor=K.+A.+Johnsonauthor=R.+A.+Sperling&title=Amyloid+and+APOE+%CE%B54+interact+to+influence+short-term+decline+in+preclinical+Alzheimer+disease&doi=10.1212%2FWNL.0000000000000431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease</span></div><div class="casAuthors">Mormino, Elizabeth C.; Betensky, Rebecca A.; Hedden, Trey; Schultz, Aaron P.; Ward, Andrew; Huijbers, Willem; Rentz, Dorene M.; Johnson, Keith A.; Sperling, Reisa A.</div><div class="citationInfo"><span class="NLM_cas:title">Neurology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1760-1767</span>CODEN:
                <span class="NLM_cas:coden">NEURAI</span>;
        ISSN:<span class="NLM_cas:issn">0028-3878</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objective: To examine whether β-amyloid (Aβ) and APOE ε4 status independently contribute or interact to influence longitudinal cognitive decline in clin. normal older individuals (CN).  Methods: Data from 490 CNs were aggregated across 3 observational cohort studies (Harvard Aging Brain Study, Alzheimer's Disease Neuroimaging Initiative, and Australian Imaging Biomarkers and Lifestyle Study of Ageing; median age = 75.0 years, 255 female), and the contributions of APOE ε4 and Aβ on longitudinal change over a median of 1.49 years were examd.  Cognitive decline was assessed with the Mini-Mental State Examn. (MMSE) and Logical Memory (immediate and delayed recall scores).  Results: High Aβ participants were more likely to be APOE ε4+ than low Aβ participants.  CNs who were both high Aβ and APOE ε4+ showed greater decline in Logical Memory immediate recall (p < 0.087), Logical Memory delayed recall (p < 0.024), and MMSE (p < 0.034) compared to all other groups (low Aβ/APOE ε4-, low Aβ/APOE ε4+, and high Aβ/APOE ε4-).  No other pairwise contrast was significant for any cognitive measure.  Conclusions: Clin. normal individuals who are APOE ε4+ and have high Aβ showed the highest cognitive decline.  These results suggest that Aβ and APOE ε4 are not redundant contributors of decline in aging but rather interact to promote decline during the short follow-up period examd. in this study.  Longer follow-up periods will be essential to fully elucidate the influence of Alzheimer disease risk factors on cognitive decline in aging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUJjazGeok1LVg90H21EOLACvtfcHk0lh-2_KSwyYSLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVOnsro%253D&md5=62007857d5f1d384f9e1efe164162847</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1212%2FWNL.0000000000000431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252FWNL.0000000000000431%26sid%3Dliteratum%253Aachs%26aulast%3DMormino%26aufirst%3DE.%2BC.%26aulast%3DBetensky%26aufirst%3DR.%2BA.%26aulast%3DHedden%26aufirst%3DT.%26aulast%3DSchultz%26aufirst%3DA.%2BP.%26aulast%3DWard%26aufirst%3DA.%26aulast%3DHuijbers%26aufirst%3DW.%26aulast%3DRentz%26aufirst%3DD.%2BM.%26aulast%3DJohnson%26aufirst%3DK.%2BA.%26aulast%3DSperling%26aufirst%3DR.%2BA.%26atitle%3DAmyloid%2520and%2520APOE%2520%25CE%25B54%2520interact%2520to%2520influence%2520short-term%2520decline%2520in%2520preclinical%2520Alzheimer%2520disease%26jtitle%3DNeurology%26date%3D2014%26volume%3D82%26spage%3D1760%26epage%3D1767%26doi%3D10.1212%2FWNL.0000000000000431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Villemagne, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourgeat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvado, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szoeke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macaulay, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruff, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ames, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masters, C. L.</span></span> <span> </span><span class="NLM_article-title">Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(13)70044-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1016%2FS1474-4422%2813%2970044-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=23477989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksFejsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=357-367&author=V.+L.+Villemagneauthor=S.+Burnhamauthor=P.+Bourgeatauthor=B.+Brownauthor=K.+A.+Ellisauthor=O.+Salvadoauthor=C.+Szoekeauthor=S.+L.+Macaulayauthor=R.+Martinsauthor=P.+Maruffauthor=D.+Amesauthor=C.+C.+Roweauthor=C.+L.+Masters&title=Amyloid+%CE%B2+deposition%2C+neurodegeneration%2C+and+cognitive+decline+in+sporadic+Alzheimer%E2%80%99s+disease%3A+a+prospective+cohort+study&doi=10.1016%2FS1474-4422%2813%2970044-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study</span></div><div class="casAuthors">Villemagne, Victor L.; Burnham, Samantha; Bourgeat, Pierrick; Brown, Belinda; Ellis, Kathryn A.; Salvado, Olivier; Szoeke, Cassandra; Macaulay, S. Lance; Martins, Ralph; Maruff, Paul; Ames, David; Rowe, Christopher C.; Masters, Colin L.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">357-367</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Similar to most chronic diseases, Alzheimer's disease (AD) develops slowly from a preclin. phase into a fully expressed clin. syndrome.  We aimed to use longitudinal data to calc. the rates of amyloid β (Aβ) deposition, cerebral atrophy, and cognitive decline.  In this prospective cohort study, healthy controls, patients with mild cognitive impairment (MCI), and patients with AD were assessed at enrolment and every 18 mo.  At every visit, participants underwent neuropsychol. examn., MRI, and a carbon-11-labeled Pittsburgh compd. B (11C-PiB) PET scan.  We included participants with three or more 11C-PiB PET follow-up assessments.  Aβ burden was expressed as 11C-PiB standardised uptake value ratio (SUVR) with the cerebellar cortex as ref. region.  An SUVR of 1·5 was used to discriminate high from low Aβ burdens.  The slope of the regression plots over 3-5 years was used to est. rates of change for Aβ deposition, MRI volumetrics, and cognition.  We included those participants with a pos. rate of Aβ deposition to calc. the trajectory of each variable over time.200 participants (145 healthy controls, 36 participants with MCI, and 19 participants with AD) were assessed at enrolment and every 18 mo for a mean follow-up of 3·8 (95% CI CI 3·6-3·9) years.  At baseline, significantly higher Aβ burdens were noted in patients with AD (2·27, SD 0·43) and those with MCI (1·94, 0·64) than in healthy controls (1·38, 0·39).  At follow-up, 163 (82%) of the 200 participants showed pos. rates of Aβ accumulation.  Aβ deposition was estd. to take 19·2 (95% CI 16·8-22·5) years in an almost linear fashion-with a mean increase of 0·043 (95% CI 0·037-0·049) SUVR per yr-to go from the threshold of 11C-PiB positivity (1·5 SUVR) to the levels obsd. in AD.  It was estd. to take 12·0 (95% CI 10·1-14·9) years from the levels obsd. in healthy controls with low Aβ deposition (1·2 [SD 0·1] SUVR) to the threshold of 11C-PiB positivity.  As AD progressed, the rate of Aβ deposition slowed towards a plateau.  Our projections suggest a prolonged preclin. phase of AD in which Aβ deposition reaches our threshold of positivity at 17·0 (95% CI 14·9-19·9) years, hippocampal atrophy at 4·2 (3·6-5·1) years, and memory impairment at 3·3 (2·5-4·5) years before the onset of dementia (clin. dementia rating score 1).  Aβ deposition is slow and protracted, likely to extend for more than two decades.  Such predictions of the rate of preclin. changes and the onset of the clin. phase of AD will facilitate the design and timing of therapeutic interventions aimed at modifying the course of this illness.  Science and Industry Endowment Fund (Australia), The Commonwealth Scientific and Industrial Research Organization (Australia), The National Health and Medical Research Council of Australia Program and Project Grants, the Austin Hospital Medical Research Foundation, Victorian State Government, The Alzheimer's Drug Discovery Foundation, and the Alzheimer's Assocn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH2O2TjFkaAbVg90H21EOLACvtfcHk0lh-2_KSwyYSLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksFejsrw%253D&md5=2e325131e69aea18b4f6a7cc756bcc55</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2813%2970044-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252813%252970044-9%26sid%3Dliteratum%253Aachs%26aulast%3DVillemagne%26aufirst%3DV.%2BL.%26aulast%3DBurnham%26aufirst%3DS.%26aulast%3DBourgeat%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DB.%26aulast%3DEllis%26aufirst%3DK.%2BA.%26aulast%3DSalvado%26aufirst%3DO.%26aulast%3DSzoeke%26aufirst%3DC.%26aulast%3DMacaulay%26aufirst%3DS.%2BL.%26aulast%3DMartins%26aufirst%3DR.%26aulast%3DMaruff%26aufirst%3DP.%26aulast%3DAmes%26aufirst%3DD.%26aulast%3DRowe%26aufirst%3DC.%2BC.%26aulast%3DMasters%26aufirst%3DC.%2BL.%26atitle%3DAmyloid%2520%25CE%25B2%2520deposition%252C%2520neurodegeneration%252C%2520and%2520cognitive%2520decline%2520in%2520sporadic%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520a%2520prospective%2520cohort%2520study%26jtitle%3DLancet%2520Neurol.%26date%3D2013%26volume%3D12%26spage%3D357%26epage%3D367%26doi%3D10.1016%2FS1474-4422%2813%2970044-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jack, C. R.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knopman, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagust, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisen, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiner, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojanowski, J. Q.</span></span> <span> </span><span class="NLM_article-title">Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(09)70299-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1016%2FS1474-4422%2809%2970299-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=20083042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFeru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=119-128&author=C.+R.+Jackauthor=D.+S.+Knopmanauthor=W.+J.+Jagustauthor=L.+M.+Shawauthor=P.+S.+Aisenauthor=M.+W.+Weinerauthor=R.+C.+Petersenauthor=J.+Q.+Trojanowski&title=Hypothetical+model+of+dynamic+biomarkers+of+the+Alzheimer%E2%80%99s+pathological+cascade&doi=10.1016%2FS1474-4422%2809%2970299-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade</span></div><div class="casAuthors">Jack, Clifford R., Jr.; Knopman, David S.; Jagust, William J.; Shaw, Leslie M.; Aisen, Paul S.; Weiner, Michael W.; Petersen, Ronald C.; Trojanowski, John Q.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">119-128</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Currently available evidence strongly supports the position that the initiating event in Alzheimer's disease (AD) is related to abnormal processing of β-amyloid (Aβ) peptide, ultimately leading to formation of Aβ plaques in the brain.  This process occurs while individuals are still cognitively normal.  Biomarkers of brain β-amyloidosis are redns. in CSF Aβ42 and increased amyloid PET tracer retention.  After a lag period, which varies from patient to patient, neuronal dysfunction and neurodegeneration become the dominant pathol. processes.  Biomarkers of neuronal injury and neurodegeneration are increased CSF tau and structural MRI measures of cerebral atrophy.  Neurodegeneration is accompanied by synaptic dysfunction, which is indicated by decreased fluorodeoxyglucose uptake on PET.  We propose a model that relates disease stage to AD biomarkers in which Aβ biomarkers become abnormal first, before neurodegenerative biomarkers and cognitive symptoms, and neurodegenerative biomarkers become abnormal later, and correlate with clin. symptom severity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOnmdY1Eeez7Vg90H21EOLACvtfcHk0lh-2_KSwyYSLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFeru74%253D&md5=5337b3e576ab1e8c58292c2572fb62f6</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2809%2970299-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252809%252970299-6%26sid%3Dliteratum%253Aachs%26aulast%3DJack%26aufirst%3DC.%2BR.%26aulast%3DKnopman%26aufirst%3DD.%2BS.%26aulast%3DJagust%26aufirst%3DW.%2BJ.%26aulast%3DShaw%26aufirst%3DL.%2BM.%26aulast%3DAisen%26aufirst%3DP.%2BS.%26aulast%3DWeiner%26aufirst%3DM.%2BW.%26aulast%3DPetersen%26aufirst%3DR.%2BC.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26atitle%3DHypothetical%2520model%2520of%2520dynamic%2520biomarkers%2520of%2520the%2520Alzheimer%25E2%2580%2599s%2520pathological%2520cascade%26jtitle%3DLancet%2520Neurol.%26date%3D2010%26volume%3D9%26spage%3D119%26epage%3D128%26doi%3D10.1016%2FS1474-4422%2809%2970299-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lopez
Lopez, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caputo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riviere, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouzade-Dominguez, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langbaum, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiman, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tariot, P. N.</span></span> <span> </span><span class="NLM_article-title">The Alzheimer’s prevention initiative generation program: evaluating CNP520 efficacy in the prevention of Alzheimer’s disease</span>. <i>J. Prev. Alzheimer’s  Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">242</span>– <span class="NLM_lpage">246</span>, <span class="refDoi"> DOI: 10.14283/jpad.2017.37</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.14283%2Fjpad.2017.37" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=29181489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A280%3ADC%252BC1M3lsFOrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2017&pages=242-246&author=C.+L.+Lopez%0ALopezauthor=A.+Caputoauthor=F.+Liuauthor=M.+E.+Riviereauthor=M.+L.+Rouzade-Dominguezauthor=R.+G.+Thomasauthor=J.+B.+Langbaumauthor=R.+Lenzauthor=E.+M.+Reimanauthor=A.+Grafauthor=P.+N.+Tariot&title=The+Alzheimer%E2%80%99s+prevention+initiative+generation+program%3A+evaluating+CNP520+efficacy+in+the+prevention+of+Alzheimer%E2%80%99s+disease&doi=10.14283%2Fjpad.2017.37"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The Alzheimer's Prevention Initiative Generation Program: Evaluating CNP520 Efficacy in the Prevention of Alzheimer's Disease</span></div><div class="casAuthors">Lopez Lopez C; Caputo A; Liu F; Riviere M E; Rouzade-Dominguez M-L; Thomas R G; Langbaum J B; Lenz R; Reiman E M; Graf A; Tariot P N</div><div class="citationInfo"><span class="NLM_cas:title">The journal of prevention of Alzheimer's disease</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">242-246</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Alzheimer's disease pathology begins decades before the onset of clinical symptoms.  This provides an opportunity for interventional clinical trials to potentially delay or prevent the onset of cognitive impairment or dementia.  CNP520 (a beta-site-amyloid precursor protein-cleaving enzyme inhibitor) is in clinical development for the treatment of preclinical Alzheimer's disease under the Alzheimer's Prevention Initiative Generation Program.  The Alzheimer's Prevention Initiative is a public-private partnership intended to accelerate the evaluation of Alzheimer's disease prevention therapies.  The Generation Program comprises two pivotal phase II/III studies with similar designs to assess the efficacy and safety of investigational treatments in a cognitively unimpaired population at increased risk for developing Alzheimer's disease based on age and apolipoprotein E (APOE) genotype (i.e., presence of the APOE ε4 allele).  The program has been designed to maximize benefit to Alzheimer's disease research.  Generation Study 1 (NCT02565511) and Generation Study 2 (NCT03131453) are currently enrolling; their key features are presented here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQg8yIA1XjIYRgd2Wuil24tfW6udTcc2eYKYjE__opxYLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3lsFOrtw%253D%253D&md5=bc392bcee85772ecfd57a241f4df30a0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.14283%2Fjpad.2017.37&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14283%252Fjpad.2017.37%26sid%3Dliteratum%253Aachs%26aulast%3DLopez%2BLopez%26aufirst%3DC.%2BL.%26aulast%3DCaputo%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DRiviere%26aufirst%3DM.%2BE.%26aulast%3DRouzade-Dominguez%26aufirst%3DM.%2BL.%26aulast%3DThomas%26aufirst%3DR.%2BG.%26aulast%3DLangbaum%26aufirst%3DJ.%2BB.%26aulast%3DLenz%26aufirst%3DR.%26aulast%3DReiman%26aufirst%3DE.%2BM.%26aulast%3DGraf%26aufirst%3DA.%26aulast%3DTariot%26aufirst%3DP.%2BN.%26atitle%3DThe%2520Alzheimer%25E2%2580%2599s%2520prevention%2520initiative%2520generation%2520program%253A%2520evaluating%2520CNP520%2520efficacy%2520in%2520the%2520prevention%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Prev.%2520Alzheimer%25E2%2580%2599s%2520%2520Dis.%26date%3D2017%26volume%3D4%26spage%3D242%26epage%3D246%26doi%3D10.14283%2Fjpad.2017.37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ufer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouzade-Dominguez, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huledal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lueoend, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machauer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veenstra, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rueeger, Heinrich</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tintelnot-Blomley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staufenbiel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimshek, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrot, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieauff, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubost, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avrameas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kretz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezous, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondeau, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckmann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vormfelde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galli, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez Lopez, C.</span></span> <span> </span><span class="NLM_article-title">The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer’s disease</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e9316</span>, <span class="refDoi"> DOI: 10.15252/emmm.201809316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.15252%2Femmm.201809316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=30224383" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=e9316&author=U.+Neumannauthor=M.+Uferauthor=L.+H.+Jacobsonauthor=M.-L.+Rouzade-Dominguezauthor=G.+Huledalauthor=C.+Kollyauthor=R.+M.+Lueoendauthor=R.+Machauerauthor=S.+J.+Veenstraauthor=K.+Hurthauthor=Heinrich+Rueegerauthor=M.+Tintelnot-Blomleyauthor=M.+Staufenbielauthor=D.+R.+Shimshekauthor=L.+Perrotauthor=W.+Frieauffauthor=V.+Dubostauthor=H.+Schillerauthor=B.+Voggauthor=K.+Beltzauthor=A.+Avrameasauthor=S.+Kretzauthor=N.+Pezousauthor=J.-M.+Rondeauauthor=N.+Beckmannauthor=A.+Hartmannauthor=S.+Vormfeldeauthor=O.+J.+Davidauthor=B.+Galliauthor=R.+Ramosauthor=A.+Grafauthor=C.+Lopez+Lopez&title=The+BACE-1+inhibitor+CNP520+for+prevention+trials+in+Alzheimer%E2%80%99s+disease&doi=10.15252%2Femmm.201809316"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.15252%2Femmm.201809316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Femmm.201809316%26sid%3Dliteratum%253Aachs%26aulast%3DNeumann%26aufirst%3DU.%26aulast%3DUfer%26aufirst%3DM.%26aulast%3DJacobson%26aufirst%3DL.%2BH.%26aulast%3DRouzade-Dominguez%26aufirst%3DM.-L.%26aulast%3DHuledal%26aufirst%3DG.%26aulast%3DKolly%26aufirst%3DC.%26aulast%3DLueoend%26aufirst%3DR.%2BM.%26aulast%3DMachauer%26aufirst%3DR.%26aulast%3DVeenstra%26aufirst%3DS.%2BJ.%26aulast%3DHurth%26aufirst%3DK.%26aulast%3DRueeger%26aufirst%3DHeinrich%26aulast%3DTintelnot-Blomley%26aufirst%3DM.%26aulast%3DStaufenbiel%26aufirst%3DM.%26aulast%3DShimshek%26aufirst%3DD.%2BR.%26aulast%3DPerrot%26aufirst%3DL.%26aulast%3DFrieauff%26aufirst%3DW.%26aulast%3DDubost%26aufirst%3DV.%26aulast%3DSchiller%26aufirst%3DH.%26aulast%3DVogg%26aufirst%3DB.%26aulast%3DBeltz%26aufirst%3DK.%26aulast%3DAvrameas%26aufirst%3DA.%26aulast%3DKretz%26aufirst%3DS.%26aulast%3DPezous%26aufirst%3DN.%26aulast%3DRondeau%26aufirst%3DJ.-M.%26aulast%3DBeckmann%26aufirst%3DN.%26aulast%3DHartmann%26aufirst%3DA.%26aulast%3DVormfelde%26aufirst%3DS.%26aulast%3DDavid%26aufirst%3DO.%2BJ.%26aulast%3DGalli%26aufirst%3DB.%26aulast%3DRamos%26aufirst%3DR.%26aulast%3DGraf%26aufirst%3DA.%26aulast%3DLopez%2BLopez%26aufirst%3DC.%26atitle%3DThe%2520BACE-1%2520inhibitor%2520CNP520%2520for%2520prevention%2520trials%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2018%26volume%3D10%26spage%3De9316%26doi%3D10.15252%2Femmm.201809316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fielden, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamison, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coppi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, R. T.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trueblood, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afshari, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lightfoot-Dunn, R.</span></span> <span> </span><span class="NLM_article-title">Retinal toxicity induced by a novel β-secretase inhibitor in the Sprague-Dawley rat</span>. <i>Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">581</span>– <span class="NLM_lpage">592</span>, <span class="refDoi"> DOI: 10.1177/0192623314553804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1177%2F0192623314553804" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=25361751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVCqu7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=581-592&author=M.+R.+Fieldenauthor=J.+Wernerauthor=J.+A.+Jamisonauthor=A.+Coppiauthor=D.+Hickmanauthor=R.+T.+Dunnauthor=E.+Truebloodauthor=L.+Zhouauthor=C.+A.+Afshariauthor=R.+Lightfoot-Dunn&title=Retinal+toxicity+induced+by+a+novel+%CE%B2-secretase+inhibitor+in+the+Sprague-Dawley+rat&doi=10.1177%2F0192623314553804"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Retinal toxicity induced by a novel β-secretase inhibitor in the sprague-dawley rat</span></div><div class="casAuthors">Fielden, Mark R.; Werner, Jonathan; Jamison, Jeff A.; Coppi, Aldo; Hickman, Dean; Dunn, Robert T., II; Trueblood, Esther; Zhou, Lei; Afshari, Cynthia A.; Lightfoot-Dunn, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">581-592</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">β-Secretase 1 (BACE1) represents an attractive target for the treatment of Alzheimer's disease.  In the course of development of a novel small mol. BACE1 inhibitor (AMG-8718), retinal thinning was obsd. in a 1-mo toxicity study in the rat.  To further understand the lesion, an investigational study was conducted whereby rats were treated daily with AMG-8718 for 1 mo followed by a 2-mo treatment-free phase.  The earliest detectable change in the retina was an increase in autofluorescent granules in the retinal pigment epithelium (RPE) on day 5; however, there were no treatment-related light microscopic changes obsd. in the neuroretina and no changes obsd. by fundus autofluorescence or routine ophthalmoscopic examn. after 28 days of dosing.  Following 2 mo of recovery, there was significant retinal thinning attributed to loss of photoreceptor nuclei from the outer nuclear layer.  Electroretinog. changes were obsd. as early as day 14, before any microscopic evidence of photoreceptor loss.  BACE1 knockout rats were generated and found to have normal retinal morphol. indicating that the retinal toxicity induced by AMG-8718 was likely off-target.  These results suggest that AMG-8718 impairs phagolysosomal function in the rat RPE, which leads to photoreceptor dysfunction and ultimately loss of photoreceptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfyBfTezUdUrVg90H21EOLACvtfcHk0lgx69QJQ7UT1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVCqu7fP&md5=d6f4af801e795995739478385f5e36fd</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1177%2F0192623314553804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0192623314553804%26sid%3Dliteratum%253Aachs%26aulast%3DFielden%26aufirst%3DM.%2BR.%26aulast%3DWerner%26aufirst%3DJ.%26aulast%3DJamison%26aufirst%3DJ.%2BA.%26aulast%3DCoppi%26aufirst%3DA.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DDunn%26aufirst%3DR.%2BT.%26aulast%3DTrueblood%26aufirst%3DE.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DAfshari%26aufirst%3DC.%2BA.%26aulast%3DLightfoot-Dunn%26aufirst%3DR.%26atitle%3DRetinal%2520toxicity%2520induced%2520by%2520a%2520novel%2520%25CE%25B2-secretase%2520inhibitor%2520in%2520the%2520Sprague-Dawley%2520rat%26jtitle%3DToxicol.%2520Pathol.%26date%3D2015%26volume%3D43%26spage%3D581%26epage%3D592%26doi%3D10.1177%2F0192623314553804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zuhl, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodney, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niessen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atchison, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanian, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambroise, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brulet, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">am Ende, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geoghegan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judkins, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span> <span> </span><span class="NLM_article-title">Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">13042</span>– <span class="NLM_lpage">13056</span>, <span class="refDoi"> DOI: 10.1038/ncomms13042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1038%2Fncomms13042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=27727204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1GqtbbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=13042-13056&author=A.+M.+Zuhlauthor=C.+E.+Nolanauthor=M.+A.+Brodneyauthor=S.+Niessenauthor=K.+Atchisonauthor=C.+Houleauthor=D.+A.+Karanianauthor=C.+Ambroiseauthor=J.+W.+Bruletauthor=E.+M.+Beckauthor=S.+D.+Doranauthor=B.+T.+O%E2%80%99Neillauthor=C.+W.+am+Endeauthor=C.+Changauthor=K.+F.+Geogheganauthor=G.+M.+Westauthor=J.+C.+Judkinsauthor=X.+Houauthor=D.+R.+Riddellauthor=D.+S.+Johnson&title=Chemoproteomic+profiling+reveals+that+cathepsin+D+off-target+activity+drives+ocular+toxicity+of+%CE%B2-secretase+inhibitors&doi=10.1038%2Fncomms13042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors</span></div><div class="casAuthors">Zuhl, Andrea M.; Nolan, Charles E.; Brodney, Michael A.; Niessen, Sherry; Atchison, Kevin; Houle, Christopher; Karanian, David A.; Ambroise, Claude; Brulet, Jeffrey W.; Beck, Elizabeth M.; Doran, Shawn D.; O'Neill, Brian T.; am Ende, Christopher W.; Chang, Cheng; Geoghegan, Kieran F.; West, Graham M.; Judkins, Joshua C.; Hou, Xinjun; Riddell, David R.; Johnson, Douglas S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13042</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibition of β-secretase BACE1 is considered one of the most promising approaches for treating Alzheimer's disease.  Several structurally distinct BACE1 inhibitors have been withdrawn from development after inducing ocular toxicity in animal models, but the target mediating this toxicity has not been identified.  Here we use a clickable photoaffinity probe to identify cathepsin D (CatD) as a principal off-target of BACE1 inhibitors in human cells.  We find that several BACE1 inhibitors blocked CatD activity in cells with much greater potency than that displayed in cell-free assays with purified protein.  Through a series of exploratory toxicol. studies, we show that quantifying CatD target engagement in cells with the probe is predictive of ocular toxicity in vivo.  Taken together, our findings designate off-target inhibition of CatD as a principal driver of ocular toxicity for BACE1 inhibitors and more generally underscore the power of chem. proteomics for discerning mechanisms of drug action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0-LulGVRdJLVg90H21EOLACvtfcHk0ljGReXvBpCP9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1GqtbbL&md5=5e2c31195f4f03babec561a5824ccb0d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fncomms13042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms13042%26sid%3Dliteratum%253Aachs%26aulast%3DZuhl%26aufirst%3DA.%2BM.%26aulast%3DNolan%26aufirst%3DC.%2BE.%26aulast%3DBrodney%26aufirst%3DM.%2BA.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DAtchison%26aufirst%3DK.%26aulast%3DHoule%26aufirst%3DC.%26aulast%3DKaranian%26aufirst%3DD.%2BA.%26aulast%3DAmbroise%26aufirst%3DC.%26aulast%3DBrulet%26aufirst%3DJ.%2BW.%26aulast%3DBeck%26aufirst%3DE.%2BM.%26aulast%3DDoran%26aufirst%3DS.%2BD.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DB.%2BT.%26aulast%3Dam%2BEnde%26aufirst%3DC.%2BW.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DGeoghegan%26aufirst%3DK.%2BF.%26aulast%3DWest%26aufirst%3DG.%2BM.%26aulast%3DJudkins%26aufirst%3DJ.%2BC.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DRiddell%26aufirst%3DD.%2BR.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26atitle%3DChemoproteomic%2520profiling%2520reveals%2520that%2520cathepsin%2520D%2520off-target%2520activity%2520drives%2520ocular%2520toxicity%2520of%2520%25CE%25B2-secretase%2520inhibitors%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D13042%26epage%3D13056%26doi%3D10.1038%2Fncomms13042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Low, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fielden, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gore, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sickmier, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minatti, A. E.</span></span> <span> </span><span class="NLM_article-title">Development of 2-aminooxazoline 3-azaxanthene β-amyloid cleaving enzyme (BACE) inhibitors with improved selectivity against Cathepsin D</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1196</span>– <span class="NLM_lpage">1206</span>, <span class="refDoi"> DOI: 10.1039/C7MD00106A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1039%2FC7MD00106A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=30108829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsleiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1196-1206&author=J.+D.+Lowauthor=M.+D.+Bartbergerauthor=K.+Chenauthor=Y.+Chengauthor=M.+R.+Fieldenauthor=V.+Goreauthor=D.+Hickmanauthor=Q.+Liuauthor=E.+A.+Sickmierauthor=H.+M.+Vargasauthor=J.+Wernerauthor=R.+D.+Whiteauthor=D.+A.+Whittingtonauthor=S.+Woodauthor=A.+E.+Minatti&title=Development+of+2-aminooxazoline+3-azaxanthene+%CE%B2-amyloid+cleaving+enzyme+%28BACE%29+inhibitors+with+improved+selectivity+against+Cathepsin+D&doi=10.1039%2FC7MD00106A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Development of 2-aminooxazoline 3-azaxanthene β-amyloid cleaving enzyme (BACE) inhibitors with improved selectivity against Cathepsin D</span></div><div class="casAuthors">Low, Jonathan D.; Bartberger, Michael D.; Chen, Kui; Cheng, Yuan; Fielden, Mark R.; Gore, Vijay; Hickman, Dean; Liu, Qingyian; Allen Sickmier, E.; Vargas, Hugo M.; Werner, Jonathan; White, Ryan D.; Whittington, Douglas A.; Wood, Stephen; Minatti, Ana E.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1196-1206</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">As part of an ongoing effort at Amgen to develop a disease-modifying therapy for Alzheimer's disease, we have previously used the aminooxazoline xanthene (AOX) scaffold to generate potent and orally efficacious BACE1 inhibitors.  While AOX-BACE1 inhibitors demonstrated acceptable cardiovascular safety margins, a retinal pathol. finding in rat toxicol. studies demanded further investigation.  It has been widely postulated that such retinal toxicity might be related to off-target inhibition of Cathepsin D (CatD), a closely related aspartyl protease.  We report the development of AOX-BACE1 inhibitors with improved selectivity against CatD by following a structure- and property-based approach.  Our efforts culminated in the discovery of a picolinamide-substituted 3-aza-AOX-BACE1 inhibitor absent of retinal effects in an early screening rat toxicol. study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW3TmgpxIxfLVg90H21EOLACvtfcHk0ljGReXvBpCP9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsleiurg%253D&md5=52fa3a363cdc6c62e0641b594dbb82c3</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1039%2FC7MD00106A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00106A%26sid%3Dliteratum%253Aachs%26aulast%3DLow%26aufirst%3DJ.%2BD.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DFielden%26aufirst%3DM.%2BR.%26aulast%3DGore%26aufirst%3DV.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DSickmier%26aufirst%3DE.%2BA.%26aulast%3DVargas%26aufirst%3DH.%2BM.%26aulast%3DWerner%26aufirst%3DJ.%26aulast%3DWhite%26aufirst%3DR.%2BD.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWood%26aufirst%3DS.%26aulast%3DMinatti%26aufirst%3DA.%2BE.%26atitle%3DDevelopment%2520of%25202-aminooxazoline%25203-azaxanthene%2520%25CE%25B2-amyloid%2520cleaving%2520enzyme%2520%2528BACE%2529%2520inhibitors%2520with%2520improved%2520selectivity%2520against%2520Cathepsin%2520D%26jtitle%3DMedChemComm%26date%3D2017%26volume%3D8%26spage%3D1196%26epage%3D1206%26doi%3D10.1039%2FC7MD00106A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judd, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, R. T.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fremeau, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harried, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitchcock, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minatti, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S.</span></span> <span> </span><span class="NLM_article-title">An orally available BACE1 inhibitor that affords robust CNS Aβ reduction without cardiovascular liabilities</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">210</span>– <span class="NLM_lpage">215</span>, <span class="refDoi"> DOI: 10.1021/ml500458t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500458t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFyhtLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=210-215&author=Y.+Chengauthor=J.+Brownauthor=T.+C.+Juddauthor=P.+Lopezauthor=W.+Qianauthor=T.+S.+Powersauthor=J.+J.+Chenauthor=M.+D.+Bartbergerauthor=K.+Chenauthor=R.+T.+Dunnauthor=O.+Epsteinauthor=R.+T.+Fremeauauthor=S.+Harriedauthor=D.+Hickmanauthor=S.+A.+Hitchcockauthor=Y.+Luoauthor=A.+E.+Minattiauthor=V.+F.+Patelauthor=H.+M.+Vargasauthor=R.+C.+Wahlauthor=M.+M.+Weissauthor=P.+H.+Wenauthor=R.+D.+Whiteauthor=D.+A.+Whittingtonauthor=X.+M.+Zhengauthor=S.+Wood&title=An+orally+available+BACE1+inhibitor+that+affords+robust+CNS+A%CE%B2+reduction+without+cardiovascular+liabilities&doi=10.1021%2Fml500458t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Available BACE1 Inhibitor That Affords Robust CNS Aβ Reduction without Cardiovascular Liabilities</span></div><div class="casAuthors">Cheng, Yuan; Brown, James; Judd, Ted C.; Lopez, Patricia; Qian, Wenyuan; Powers, Timothy S.; Chen, Jian Jeffrey; Bartberger, Michael D.; Chen, Kui; Dunn, Robert T.; Epstein, Oleg; Fremeau, Robert T.; Harried, Scott; Hickman, Dean; Hitchcock, Stephen A.; Luo, Yi; Minatti, Ana Elena; Patel, Vinod F.; Vargas, Hugo M.; Wahl, Robert C.; Weiss, Matthew M.; Wen, Paul H.; White, Ryan D.; Whittington, Douglas A.; Zheng, Xiao Mei; Wood, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">210-215</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">BACE1 inhibition to prevent Aβ peptide formation is considered to be a potential route to a disease-modifying treatment for Alzheimer's disease.  Previous efforts in our lab. using a combined structure- and property-based approach have resulted in the identification of aminooxazoline xanthenes as potent BACE1 inhibitors.  Herein, we report further optimization leading to the discovery of inhibitor 15 as an orally available and highly efficacious BACE1 inhibitor that robustly reduces CSF and brain Aβ levels in both rats and nonhuman primates.  In addn., compd. 15 exhibited low activity on the hERG ion channel and was well tolerated in an integrated cardiovascular safety model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbH-0fLNUlbrVg90H21EOLACvtfcHk0ljW79RSC5y1Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFyhtLzI&md5=bd8e5a33d06a51646873c4c43d01b003</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fml500458t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500458t%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DJudd%26aufirst%3DT.%2BC.%26aulast%3DLopez%26aufirst%3DP.%26aulast%3DQian%26aufirst%3DW.%26aulast%3DPowers%26aufirst%3DT.%2BS.%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DDunn%26aufirst%3DR.%2BT.%26aulast%3DEpstein%26aufirst%3DO.%26aulast%3DFremeau%26aufirst%3DR.%2BT.%26aulast%3DHarried%26aufirst%3DS.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DHitchcock%26aufirst%3DS.%2BA.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DMinatti%26aufirst%3DA.%2BE.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DVargas%26aufirst%3DH.%2BM.%26aulast%3DWahl%26aufirst%3DR.%2BC.%26aulast%3DWeiss%26aufirst%3DM.%2BM.%26aulast%3DWen%26aufirst%3DP.%2BH.%26aulast%3DWhite%26aufirst%3DR.%2BD.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DZheng%26aufirst%3DX.%2BM.%26aulast%3DWood%26aufirst%3DS.%26atitle%3DAn%2520orally%2520available%2520BACE1%2520inhibitor%2520that%2520affords%2520robust%2520CNS%2520A%25CE%25B2%2520reduction%2520without%2520cardiovascular%2520liabilities%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D210%26epage%3D215%26doi%3D10.1021%2Fml500458t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamford, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dockendorf, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ereshefsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleijn, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuvelkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palcza, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troyer, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, M. S.</span></span> <span> </span><span class="NLM_article-title">The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">363ra150</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aad9704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1126%2Fscitranslmed.aad9704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=27807285" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=363ra150&author=M.+E.+Kennedyauthor=A.+W.+Stamfordauthor=X.+Chenauthor=K.+Coxauthor=J.+N.+Cummingauthor=M.+F.+Dockendorfauthor=M.+Eganauthor=L.+Ereshefskyauthor=R.+A.+Hodgsonauthor=L.+A.+Hydeauthor=S.+Jheeauthor=H.+J.+Kleijnauthor=R.+Kuvelkarauthor=W.+Liauthor=B.+A.+Mattsonauthor=H.+Meiauthor=J.+Palczaauthor=J.+D.+Scottauthor=M.+Tanenauthor=M.+D.+Troyerauthor=J.+L.+Tsengauthor=J.+A.+Stoneauthor=E.+M.+Parkerauthor=M.+S.+Forman&title=The+BACE1+inhibitor+verubecestat+%28MK-8931%29+reduces+CNS+%CE%B2-amyloid+in+animal+models+and+in+Alzheimer%E2%80%99s+disease+patients&doi=10.1126%2Fscitranslmed.aad9704"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aad9704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aad9704%26sid%3Dliteratum%253Aachs%26aulast%3DKennedy%26aufirst%3DM.%2BE.%26aulast%3DStamford%26aufirst%3DA.%2BW.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCox%26aufirst%3DK.%26aulast%3DCumming%26aufirst%3DJ.%2BN.%26aulast%3DDockendorf%26aufirst%3DM.%2BF.%26aulast%3DEgan%26aufirst%3DM.%26aulast%3DEreshefsky%26aufirst%3DL.%26aulast%3DHodgson%26aufirst%3DR.%2BA.%26aulast%3DHyde%26aufirst%3DL.%2BA.%26aulast%3DJhee%26aufirst%3DS.%26aulast%3DKleijn%26aufirst%3DH.%2BJ.%26aulast%3DKuvelkar%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMattson%26aufirst%3DB.%2BA.%26aulast%3DMei%26aufirst%3DH.%26aulast%3DPalcza%26aufirst%3DJ.%26aulast%3DScott%26aufirst%3DJ.%2BD.%26aulast%3DTanen%26aufirst%3DM.%26aulast%3DTroyer%26aufirst%3DM.%2BD.%26aulast%3DTseng%26aufirst%3DJ.%2BL.%26aulast%3DStone%26aufirst%3DJ.%2BA.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DForman%26aufirst%3DM.%2BS.%26atitle%3DThe%2520BACE1%2520inhibitor%2520verubecestat%2520%2528MK-8931%2529%2520reduces%2520CNS%2520%25CE%25B2-amyloid%2520in%2520animal%2520models%2520and%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520patients%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2016%26volume%3D8%26spage%3D363ra150%26doi%3D10.1126%2Fscitranslmed.aad9704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunskill, A. P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iserloh, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazakevich, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuvelkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meredith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misiaszek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossiter, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slater, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickland, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voigt, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenlee, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamford, A. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of the 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative Verubecestat (MK-8931)-a β-site amyloid precursor protein cleaving enzyme 1 inhibitor for the treatment of Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10435</span>– <span class="NLM_lpage">10450</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00307</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00307" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVKnsLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10435-10450&author=J.+D.+Scottauthor=S.+W.+Liauthor=A.+P.+J.+Brunskillauthor=X.+Chenauthor=K.+Coxauthor=J.+N.+Cummingauthor=M.+Formanauthor=E.+J.+Gilbertauthor=R.+A.+Hodgsonauthor=L.+A.+Hydeauthor=Q.+Jiangauthor=U.+Iserlohauthor=I.+Kazakevichauthor=R.+Kuvelkarauthor=H.+Meiauthor=J.+Meredithauthor=J.+Misiaszekauthor=P.+Orthauthor=L.+M.+Rossiterauthor=M.+Slaterauthor=J.+Stoneauthor=C.+O.+Stricklandauthor=J.+H.+Voigtauthor=G.+Wangauthor=H.+Wangauthor=Y.+Wuauthor=W.+J.+Greenleeauthor=E.+M.+Parkerauthor=M.+E.+Kennedyauthor=A.+W.+Stamford&title=Discovery+of+the+3-imino-1%2C2%2C4-thiadiazinane+1%2C1-dioxide+derivative+Verubecestat+%28MK-8931%29-a+%CE%B2-site+amyloid+precursor+protein+cleaving+enzyme+1+inhibitor+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1021%2Facs.jmedchem.6b00307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease</span></div><div class="casAuthors">Scott, Jack D.; Li, Sarah W.; Brunskill, Andrew P. J.; Chen, Xia; Cox, Kathleen; Cumming, Jared N.; Forman, Mark; Gilbert, Eric J.; Hodgson, Robert A.; Hyde, Lynn A.; Jiang, Qin; Iserloh, Ulrich; Kazakevich, Irina; Kuvelkar, Reshma; Mei, Hong; Meredith, John; Misiaszek, Jeffrey; Orth, Peter; Rossiter, Lana M.; Slater, Meagan; Stone, Julie; Strickland, Corey O.; Voigt, Johannes H.; Wang, Ganfeng; Wang, Hongwu; Wu, Yusheng; Greenlee, William J.; Parker, Eric M.; Kennedy, Matthew E.; Stamford, Andrew W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10435-10450</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Verubecestat (MK-8931), a diaryl amide substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide deriv., is a high-affinity β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor currently undergoing Phase 3 clin. evaluation for the treatment of mild to moderate and prodromal Alzheimer's disease.  Although not selective over the closely related aspartyl protease BACE2, verubecesat has high selectivity for BACE1 over other key aspartyl proteases, notably cathepsin D, and profoundly lowers CSF and brain Aβ levels in rats and nonhuman primates, and CSF Aβ levels in humans.  In this annotation, the authors describe the discovery of verubecesat, including design, validation, and selected SAR around the novel iminothiadiazinane dioxide core, as well as aspects of its preclin. and Phase 1 clin. characterization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpN5wdoirs8rVg90H21EOLACvtfcHk0ljW79RSC5y1Qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVKnsLnI&md5=517155e2d4f186261b1451ff4556a621</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00307%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BD.%26aulast%3DLi%26aufirst%3DS.%2BW.%26aulast%3DBrunskill%26aufirst%3DA.%2BP.%2BJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCox%26aufirst%3DK.%26aulast%3DCumming%26aufirst%3DJ.%2BN.%26aulast%3DForman%26aufirst%3DM.%26aulast%3DGilbert%26aufirst%3DE.%2BJ.%26aulast%3DHodgson%26aufirst%3DR.%2BA.%26aulast%3DHyde%26aufirst%3DL.%2BA.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DIserloh%26aufirst%3DU.%26aulast%3DKazakevich%26aufirst%3DI.%26aulast%3DKuvelkar%26aufirst%3DR.%26aulast%3DMei%26aufirst%3DH.%26aulast%3DMeredith%26aufirst%3DJ.%26aulast%3DMisiaszek%26aufirst%3DJ.%26aulast%3DOrth%26aufirst%3DP.%26aulast%3DRossiter%26aufirst%3DL.%2BM.%26aulast%3DSlater%26aufirst%3DM.%26aulast%3DStone%26aufirst%3DJ.%26aulast%3DStrickland%26aufirst%3DC.%2BO.%26aulast%3DVoigt%26aufirst%3DJ.%2BH.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DKennedy%26aufirst%3DM.%2BE.%26aulast%3DStamford%26aufirst%3DA.%2BW.%26atitle%3DDiscovery%2520of%2520the%25203-imino-1%252C2%252C4-thiadiazinane%25201%252C1-dioxide%2520derivative%2520Verubecestat%2520%2528MK-8931%2529-a%2520%25CE%25B2-site%2520amyloid%2520precursor%2520protein%2520cleaving%2520enzyme%25201%2520inhibitor%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10435%26epage%3D10450%26doi%3D10.1021%2Facs.jmedchem.6b00307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hilpert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guba, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woltering, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wostl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayweg, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers-Evans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humm, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krummenacher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnider, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozmen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergadano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banner, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochstrasser, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David-Pierson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narquizian, R.</span></span> <span> </span><span class="NLM_article-title">β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3980</span>– <span class="NLM_lpage">3995</span>, <span class="refDoi"> DOI: 10.1021/jm400225m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400225m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtVymuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3980-3995&author=H.+Hilpertauthor=W.+Gubaauthor=T.+J.+Wolteringauthor=W.+Wostlauthor=E.+Pinardauthor=H.+Mauserauthor=A.+V.+Maywegauthor=M.+Rogers-Evansauthor=R.+Hummauthor=D.+Krummenacherauthor=T.+Muserauthor=C.+Schniderauthor=H.+Jacobsenauthor=L.+Ozmenauthor=A.+Bergadanoauthor=D.+W.+Bannerauthor=R.+Hochstrasserauthor=A.+Kuglstatterauthor=P.+David-Piersonauthor=H.+Fischerauthor=A.+Polaraauthor=R.+Narquizian&title=%CE%B2-Secretase+%28BACE1%29+inhibitors+with+high+in+vivo+efficacy+suitable+for+clinical+evaluation+in+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fjm400225m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">β-Secretase (BACE1) Inhibitors with High in Vivo Efficacy Suitable for Clinical Evaluation in Alzheimer's Disease</span></div><div class="casAuthors">Hilpert, Hans; Guba, Wolfgang; Woltering, Thomas J.; Wostl, Wolfgang; Pinard, Emmanuel; Mauser, Harald; Mayweg, Alexander V.; Rogers-Evans, Mark; Humm, Roland; Krummenacher, Daniela; Muser, Thorsten; Schnider, Christian; Jacobsen, Helmut; Ozmen, Laurence; Bergadano, Alessandra; Banner, David W.; Hochstrasser, Remo; Kuglstatter, Andreas; David-Pierson, Pascale; Fischer, Holger; Polara, Alessandra; Narquizian, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3980-3995</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An extensive fluorine scan of 1,3-oxazines revealed the power of fluorine(s) to lower the pKa and thereby dramatically change the pharmacol. profile of this class of BACE1 inhibitors.  The CF3 substituted oxazine 89, a potent and highly brain penetrant BACE1 inhibitor, was able to reduce significantly CSF Aβ40 and 42 in rats at oral doses as low as 1 mg/kg.  The effect was long lasting, showing a significant redn. of Aβ40 and 42 even after 24 h.  In contrast to 89, compd. 1b lacking the CF3 group was virtually inactive in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmoKRrAxxHErVg90H21EOLACvtfcHk0lgAp8xMXDORCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtVymuro%253D&md5=e5d311d1c8fecfaed043d3a0bf16c168</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm400225m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400225m%26sid%3Dliteratum%253Aachs%26aulast%3DHilpert%26aufirst%3DH.%26aulast%3DGuba%26aufirst%3DW.%26aulast%3DWoltering%26aufirst%3DT.%2BJ.%26aulast%3DWostl%26aufirst%3DW.%26aulast%3DPinard%26aufirst%3DE.%26aulast%3DMauser%26aufirst%3DH.%26aulast%3DMayweg%26aufirst%3DA.%2BV.%26aulast%3DRogers-Evans%26aufirst%3DM.%26aulast%3DHumm%26aufirst%3DR.%26aulast%3DKrummenacher%26aufirst%3DD.%26aulast%3DMuser%26aufirst%3DT.%26aulast%3DSchnider%26aufirst%3DC.%26aulast%3DJacobsen%26aufirst%3DH.%26aulast%3DOzmen%26aufirst%3DL.%26aulast%3DBergadano%26aufirst%3DA.%26aulast%3DBanner%26aufirst%3DD.%2BW.%26aulast%3DHochstrasser%26aufirst%3DR.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DDavid-Pierson%26aufirst%3DP.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DPolara%26aufirst%3DA.%26aulast%3DNarquizian%26aufirst%3DR.%26atitle%3D%25CE%25B2-Secretase%2520%2528BACE1%2529%2520inhibitors%2520with%2520high%2520in%2520vivo%2520efficacy%2520suitable%2520for%2520clinical%2520evaluation%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3980%26epage%3D3995%26doi%3D10.1021%2Fjm400225m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapham, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buzon, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutra, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barreiro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Alsina, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalobos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogilvie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaChapelle, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanyon, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steppan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robshaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hales, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambroise, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bales, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodney, M. A.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of clinical candidate PF-06751979: a potent, brain penetrant, β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor lacking hypopigmentation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4476</span>– <span class="NLM_lpage">4504</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00246</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00246" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVCmtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4476-4504&author=B.+T.+O%E2%80%99Neillauthor=E.+M.+Beckauthor=C.+R.+Butlerauthor=C.+E.+Nolanauthor=C.+Gonzalesauthor=L.+Zhangauthor=S.+D.+Doranauthor=K.+Laphamauthor=L.+M.+Buzonauthor=J.+K.+Dutraauthor=G.+Barreiroauthor=X.+Houauthor=L.+A.+Martinez-Alsinaauthor=B.+N.+Rogersauthor=A.+Villalobosauthor=J.+C.+Murrayauthor=K.+Ogilvieauthor=E.+A.+LaChapelleauthor=C.+Changauthor=L.+F.+Lanyonauthor=C.+M.+Steppanauthor=A.+Robshawauthor=K.+Halesauthor=G.+G.+Boucherauthor=K.+Pandherauthor=C.+Houleauthor=C.+W.+Ambroiseauthor=D.+Karanianauthor=D.+Riddellauthor=K.+R.+Balesauthor=M.+A.+Brodney&title=Design+and+synthesis+of+clinical+candidate+PF-06751979%3A+a+potent%2C+brain+penetrant%2C+%CE%B2-site+amyloid+precursor+protein+cleaving+enzyme+1+%28BACE1%29+inhibitor+lacking+hypopigmentation&doi=10.1021%2Facs.jmedchem.8b00246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation</span></div><div class="casAuthors">O'Neill, Brian T.; Beck, Elizabeth M.; Butler, Christopher R.; Nolan, Charles E.; Gonzales, Cathleen; Zhang, Lei; Doran, Shawn D.; Lapham, Kimberly; Buzon, Leanne M.; Dutra, Jason K.; Barreiro, Gabriela; Hou, Xinjun; Martinez-Alsina, Luis A.; Rogers, Bruce N.; Villalobos, Anabella; Murray, John C.; Ogilvie, Kevin; La Chapelle, Erik A.; Chang, Cheng; Lanyon, Lorraine F.; Steppan, Claire M.; Robshaw, Ashley; Hales, Katherine; Boucher, Germaine G.; Pandher, Karamjeet; Houle, Christopher; Ambroise, Claude W.; Karanian, David; Riddell, David; Bales, Kelly R.; Brodney, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4476-4504</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A major challenge in the development of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease is the alignment of potency, drug-like properties, and selectivity over related aspartyl proteases such as Cathepsin D (CatD) and BACE2.  The potential liabilities of inhibiting BACE2 chronically have only recently begun to emerge as BACE2 impacts the processing of the premelanosome protein (PMEL17) and disrupts melanosome morphol. resulting in a depigmentation phenotype.  Herein, the authors describe the identification of clin. candidate PF-06751979 (I), which displays excellent brain penetration, potent in vivo efficacy, and broad selectivity over related aspartyl proteases including BACE2.  Chronic dosing of I for up to 9 mo in dog did not reveal any observation of hair coat color (pigmentation) changes and suggests a key differentiator over current BACE1 inhibitors that are nonselective against BACE2 in later stage clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs1F61vo0jBbVg90H21EOLACvtfcHk0lgAp8xMXDORCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVCmtrs%253D&md5=3d8cae0bb20298e66f6da1c26cf8d5bc</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00246%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DB.%2BT.%26aulast%3DBeck%26aufirst%3DE.%2BM.%26aulast%3DButler%26aufirst%3DC.%2BR.%26aulast%3DNolan%26aufirst%3DC.%2BE.%26aulast%3DGonzales%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DDoran%26aufirst%3DS.%2BD.%26aulast%3DLapham%26aufirst%3DK.%26aulast%3DBuzon%26aufirst%3DL.%2BM.%26aulast%3DDutra%26aufirst%3DJ.%2BK.%26aulast%3DBarreiro%26aufirst%3DG.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DMartinez-Alsina%26aufirst%3DL.%2BA.%26aulast%3DRogers%26aufirst%3DB.%2BN.%26aulast%3DVillalobos%26aufirst%3DA.%26aulast%3DMurray%26aufirst%3DJ.%2BC.%26aulast%3DOgilvie%26aufirst%3DK.%26aulast%3DLaChapelle%26aufirst%3DE.%2BA.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DLanyon%26aufirst%3DL.%2BF.%26aulast%3DSteppan%26aufirst%3DC.%2BM.%26aulast%3DRobshaw%26aufirst%3DA.%26aulast%3DHales%26aufirst%3DK.%26aulast%3DBoucher%26aufirst%3DG.%2BG.%26aulast%3DPandher%26aufirst%3DK.%26aulast%3DHoule%26aufirst%3DC.%26aulast%3DAmbroise%26aufirst%3DC.%2BW.%26aulast%3DKaranian%26aufirst%3DD.%26aulast%3DRiddell%26aufirst%3DD.%26aulast%3DBales%26aufirst%3DK.%2BR.%26aulast%3DBrodney%26aufirst%3DM.%2BA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520clinical%2520candidate%2520PF-06751979%253A%2520a%2520potent%252C%2520brain%2520penetrant%252C%2520%25CE%25B2-site%2520amyloid%2520precursor%2520protein%2520cleaving%2520enzyme%25201%2520%2528BACE1%2529%2520inhibitor%2520lacking%2520hypopigmentation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4476%26epage%3D4504%26doi%3D10.1021%2Facs.jmedchem.8b00246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegmund, A. C.</span>; <span class="NLM_string-name">Kong, K.</span>; <span class="NLM_string-name">Frohn, M.</span>; <span class="NLM_string-name">Nishimura, N.</span>; <span class="NLM_string-name">Pickrell, A. J.</span>; <span class="NLM_string-name">Stec, M. M.</span>; <span class="NLM_string-name">Chen, J. J.</span>; <span class="NLM_string-name">Qian, W.</span>; <span class="NLM_string-name">Liu, L.</span>; <span class="NLM_string-name">Hong, F.-T.</span>; <span class="NLM_string-name">Yang, K. C.</span>; <span class="NLM_string-name">Wen, P. H.</span>; <span class="NLM_string-name">McCarter, J.</span>; <span class="NLM_string-name">Chen, K.</span>; <span class="NLM_string-name">Whittington, D. A.</span>; <span class="NLM_string-name">Bartberger, M. D.</span>; <span class="NLM_string-name">Hickman, D.</span>; <span class="NLM_string-name">Allen, J. R.</span>; <span class="NLM_string-name">Wood, S.</span>; <span class="NLM_string-name">Bourbeau, M. P.</span></span> <span> </span><span class="NLM_article-title">Cyclopropylthiazines as potent BACE1 inhibitors for Alzheimer’s disease: challenging chemistry and <i>in vivo</i> data of a Nnew pre-clinical series</span>. Presented at the 253rd National Meeting of the American Chemical Society, San Francisco, CA, U.S., April 2–6, <span class="NLM_year">2017</span>; Poster MEDI-127.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=A.+C.+Siegmund&author=K.+Kong&author=M.+Frohn&author=N.+Nishimura&author=A.+J.+Pickrell&author=M.+M.+Stec&author=J.+J.+Chen&author=W.+Qian&author=L.+Liu&author=F.-T.+Hong&author=K.+C.+Yang&author=P.+H.+Wen&author=J.+McCarter&author=K.+Chen&author=D.+A.+Whittington&author=M.+D.+Bartberger&author=D.+Hickman&author=J.+R.+Allen&author=S.+Wood&author=M.+P.+Bourbeau&title=Cyclopropylthiazines+as+potent+BACE1+inhibitors+for+Alzheimer%E2%80%99s+disease%3A+challenging+chemistry+and+in+vivo+data+of+a+Nnew+pre-clinical+series"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DSiegmund%26aufirst%3DA.%2BC.%26atitle%3DCyclopropylthiazines%2520as%2520potent%2520BACE1%2520inhibitors%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520challenging%2520chemistry%2520and%2520in%2520vivo%2520data%2520of%2520a%2520Nnew%2520pre-clinical%2520series%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. R.</span>; <span class="NLM_string-name">Amegadzie, A.</span>; <span class="NLM_string-name">Bourbeau, M. P.</span>; <span class="NLM_string-name">Brown, J. A.</span>; <span class="NLM_string-name">Chen, J. J.</span>; <span class="NLM_string-name">Cheng, Y.</span>; <span class="NLM_string-name">Frohn, M. J.</span>; <span class="NLM_string-name">Guzman-Perez, A.</span>; <span class="NLM_string-name">Harrington, P. E.</span>; <span class="NLM_string-name">Liu, L.</span>; <span class="NLM_string-name">Liu, Q.</span>; <span class="NLM_string-name">Low, J. D.</span>; <span class="NLM_string-name">Ma, V. V.</span>; <span class="NLM_string-name">Manning, J.</span>; <span class="NLM_string-name">Minatti, A. E.</span>; <span class="NLM_string-name">Nguyen, T. T.</span>; <span class="NLM_string-name">Nishmura, N.</span>; <span class="NLM_string-name">Norman, M. H.</span>; <span class="NLM_string-name">Pettus, L. H.</span>; <span class="NLM_string-name">Pickrell, A. J.</span>; <span class="NLM_string-name">Qian, W.</span>; <span class="NLM_string-name">Rumfelt, S.</span>; <span class="NLM_string-name">Rzasa, R. M.</span>; <span class="NLM_string-name">Siegmund, A. C.</span>; <span class="NLM_string-name">Stec, M. M.</span>; <span class="NLM_string-name">White, R.</span>; <span class="NLM_string-name">Xue, Q.</span></span> <span> </span><span class="NLM_article-title">Cyclopropyl fused thiazine-2-amine compounds as beta-secretase inhibitors and methods of use</span>. Patent<span class="NLM_patent">WO2016/022724A1</span>, Feb 11, 2016; Patent <span class="NLM_patent">US2016/0046618A1</span>, Feb 18, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.+R.+Allen&author=A.+Amegadzie&author=M.+P.+Bourbeau&author=J.+A.+Brown&author=J.+J.+Chen&author=Y.+Cheng&author=M.+J.+Frohn&author=A.+Guzman-Perez&author=P.+E.+Harrington&author=L.+Liu&author=Q.+Liu&author=J.+D.+Low&author=V.+V.+Ma&author=J.+Manning&author=A.+E.+Minatti&author=T.+T.+Nguyen&author=N.+Nishmura&author=M.+H.+Norman&author=L.+H.+Pettus&author=A.+J.+Pickrell&author=W.+Qian&author=S.+Rumfelt&author=R.+M.+Rzasa&author=A.+C.+Siegmund&author=M.+M.+Stec&author=R.+White&author=Q.+Xue&title=Cyclopropyl+fused+thiazine-2-amine+compounds+as+beta-secretase+inhibitors+and+methods+of+use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DJ.%2BR.%26atitle%3DCyclopropyl%2520fused%2520thiazine-2-amine%2520compounds%2520as%2520beta-secretase%2520inhibitors%2520and%2520methods%2520of%2520use%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu-Khan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loeloff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Citron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassar, R.</span></span> <span> </span><span class="NLM_article-title">Expression analysis of BACE2 in brain and peripheral tissues</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">20647</span>– <span class="NLM_lpage">20651</span>, <span class="refDoi"> DOI: 10.1074/jbc.M002688200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1074%2Fjbc.M002688200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10749877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkvVyhsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=20647-20651&author=B.+D.+Bennettauthor=S.+Babu-Khanauthor=R.+Loeloffauthor=J.+C.+Louisauthor=E.+Curranauthor=M.+Citronauthor=R.+Vassar&title=Expression+analysis+of+BACE2+in+brain+and+peripheral+tissues&doi=10.1074%2Fjbc.M002688200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Expression analysis of BACE2 in brain and peripheral tissues</span></div><div class="casAuthors">Bennett, Brian D.; Babu-Khan, Safura; Loeloff, Richard; Louis, Jean-Claude; Curran, Eileen; Citron, Martin; Vassar, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">20647-20651</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Beta-site amyloid precursor protein cleaving enzyme (BACE) is a novel transmembrane aspartic protease that possesses all the known characteristics of the β-secretase involved in Alzheimer's disease.  We have analyzed the sequence and expression pattern of a BACE homolog termed BACE2.  BACE and BACE2 are unique among aspartic proteases in that they possess a carboxyl-terminal extension with a predicted transmembrane region and together they define a new family.  Northern anal. reveals that BACE2 mRNA is expressed at low levels in most human peripheral tissues and at higher levels in colon, kidney, pancreas, placenta, prostate, stomach, and trachea.  Human adult and fetal whole brain and most adult brain subregions express very low or undetectable levels of BACE2 mRNA.  In addn., in situ hybridization of adult rat brain shows that BACE2 mRNA is expressed at very low levels in most brain regions.  The very low or undetectable levels of BACE2 mRNA in the brain are not consistent with the expression pattern predicted for β-secretase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodNsksnpZwh7Vg90H21EOLACvtfcHk0lhbwWhPPafonQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkvVyhsbs%253D&md5=3d664572b2a1709c68fffcee3a8880d5</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M002688200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M002688200%26sid%3Dliteratum%253Aachs%26aulast%3DBennett%26aufirst%3DB.%2BD.%26aulast%3DBabu-Khan%26aufirst%3DS.%26aulast%3DLoeloff%26aufirst%3DR.%26aulast%3DLouis%26aufirst%3DJ.%2BC.%26aulast%3DCurran%26aufirst%3DE.%26aulast%3DCitron%26aufirst%3DM.%26aulast%3DVassar%26aufirst%3DR.%26atitle%3DExpression%2520analysis%2520of%2520BACE2%2520in%2520brain%2520and%2520peripheral%2520tissues%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D20647%26epage%3D20651%26doi%3D10.1074%2Fjbc.M002688200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, R.</span></span> <span> </span><span class="NLM_article-title">Physiological functions of the β-site amyloid precursor protein cleaving enzyme 1 and 2</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">97</span> <span class="refDoi"> DOI: 10.3389/fnmol.2017.00097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.3389%2Ffnmol.2017.00097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=28469554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A280%3ADC%252BC1crjvVWksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&author=R.+Yan&title=Physiological+functions+of+the+%CE%B2-site+amyloid+precursor+protein+cleaving+enzyme+1+and+2&doi=10.3389%2Ffnmol.2017.00097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Physiological Functions of the β-Site Amyloid Precursor Protein Cleaving Enzyme 1 and 2</span></div><div class="casAuthors">Yan Riqiang</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in molecular neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">97</span>
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    </div><div class="casAbstract">BACE1 was discovered as the β-secretase for initiating the cleavage of amyloid precursor protein (APP) at the β-secretase site, while its close homology BACE2 cleaves APP within the β-amyloid (Aβ) domain region and shows distinct cleavage preferences in vivo.  Inhibition of BACE1 proteolytic activity has been confirmed to decrease Aβ generation and amyloid deposition, and thus specific inhibition of BACE1 by small molecules is a current focus for Alzheimer's disease therapy.  While BACE1 inhibitors are being tested in advanced clinical trials, knowledge regarding the properties and physiological functions of BACE is highly important and this review summarizes advancements in BACE1 research over the past several years.  We and others have shown that BACE1 is not only a critical enzyme for testing the "Amyloid Hypothesis" associated with Alzheimer's pathogenesis, but also important for various functions such as axon growth and pathfinding, astrogenesis, neurogenesis, hyperexcitation, and synaptic plasticity.  BACE2 appears to play different roles such as glucose homeostasis and pigmentation.  This knowledge regarding BACE1 functions is critical for monitoring the safe use of BACE1 inhibitors in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbYoN5Bm7IDcScOqQTSkOffW6udTcc2eb7lVtd9DeSPLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crjvVWksQ%253D%253D&md5=b8e9ffa2007cebb2ae68c0074b7dea06</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2017.00097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2017.00097%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DR.%26atitle%3DPhysiological%2520functions%2520of%2520the%2520%25CE%25B2-site%2520amyloid%2520precursor%2520protein%2520cleaving%2520enzyme%25201%2520and%25202%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2017%26volume%3D10%26doi%3D10.3389%2Ffnmol.2017.00097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Esterhazy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akpinar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoffel, M.</span></span> <span> </span><span class="NLM_article-title">Tmem27 dimerization, deglycosylation, plasma membrane depletion, and the extracellular Phe-Phe motif are negative regulators of cleavage by BACE2</span>. <i>Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>393</i></span>,  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">484</span>, <span class="refDoi"> DOI: 10.1515/hsz-2012-0104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1515%2Fhsz-2012-0104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=22628310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVSlsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=393&publication_year=2012&pages=473-484&author=D.+Esterhazyauthor=P.+Akpinarauthor=M.+Stoffel&title=Tmem27+dimerization%2C+deglycosylation%2C+plasma+membrane+depletion%2C+and+the+extracellular+Phe-Phe+motif+are+negative+regulators+of+cleavage+by+BACE2&doi=10.1515%2Fhsz-2012-0104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Tmem27 dimerization, deglycosylation, plasma membrane depletion, and the extracellular Phe-Phe motif are negative regulators of cleavage by Bace2</span></div><div class="casAuthors">Esterhazy, Daria; Akpinar, Pinar; Stoffel, Markus</div><div class="citationInfo"><span class="NLM_cas:title">Biological Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">393</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">473-484</span>CODEN:
                <span class="NLM_cas:coden">BICHF3</span>;
        ISSN:<span class="NLM_cas:issn">1431-6730</span>.
    
            (<span class="NLM_cas:orgname">Walter de Gruyter GmbH & Co. KG</span>)
        </div><div class="casAbstract">The pancreatic β-cell surface protein Tmem27 is promotes the preservation of functional β-cell mass.  It is a selective substrate of the protease Bace2, yet the intramol. features of Tmem27 that regulate its processing by this sheddase have not been characterized.  In particular, the importance of homodimerization, glycosylation, trafficking to the plasma membrane (PM), the existence of multiple cleavage sites, and the amino acid residues that govern these features are currently unknown.  Using Tmem27 mutational anal. and multiple biochem. approaches, we here show that Tmem27 dimerization is a dynamic process mediated by its intracellular cysteine residue and that prevents Tmem27 cleavage, that extracellular asparagine glycosylation is essential for Tmem27 trafficking to the PM and its processing by Bace2, that the amt. of Tmem27 at the PM is proportional to its total cell levels upon glucose stimulation and Bace2 inhibition, and that the double phenylalanine motif in the Tmem27 cleavage site is an intramol. Bace2 inhibitor.  These findings define structural properties of Tmem27 that affect the susceptibility to its protease Bace2 and have implications for the efficiency with which Tmem27 and other Bace2 substrates are cleaved in normal and disease states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqc431ObiBZIbVg90H21EOLACvtfcHk0lhnrglnwro9eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVSlsbc%253D&md5=06a566e9a9bdbda2d77a6b36aa9233b3</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1515%2Fhsz-2012-0104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252Fhsz-2012-0104%26sid%3Dliteratum%253Aachs%26aulast%3DEsterhazy%26aufirst%3DD.%26aulast%3DAkpinar%26aufirst%3DP.%26aulast%3DStoffel%26aufirst%3DM.%26atitle%3DTmem27%2520dimerization%252C%2520deglycosylation%252C%2520plasma%2520membrane%2520depletion%252C%2520and%2520the%2520extracellular%2520Phe-Phe%2520motif%2520are%2520negative%2520regulators%2520of%2520cleavage%2520by%2520BACE2%26jtitle%3DBiol.%2520Chem.%26date%3D2012%26volume%3D393%26spage%3D473%26epage%3D484%26doi%3D10.1515%2Fhsz-2012-0104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rulifson, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopecky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samayoa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuruda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homann, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baribault, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiltzius, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">Identification of human islet amyloid polypeptide as a BACE2 substrate</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e0147254</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0147254</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1371%2Fjournal.pone.0147254" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=26840340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC28XnslOqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0147254&author=I.+C.+Rulifsonauthor=P.+Caoauthor=L.+Miaoauthor=D.+Kopeckyauthor=L.+Huangauthor=R.+D.+Whiteauthor=K.+Samayoaauthor=J.+Gardnerauthor=X.+Wuauthor=K.+Chenauthor=T.+Tsurudaauthor=O.+Homannauthor=H.+Baribaultauthor=H.+Yamaneauthor=T.+Carlsonauthor=J.+Wiltziusauthor=Y.+Li&title=Identification+of+human+islet+amyloid+polypeptide+as+a+BACE2+substrate&doi=10.1371%2Fjournal.pone.0147254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of human islet amyloid polypeptide as a BACE2 substrate</span></div><div class="casAuthors">Rulifson, Ingrid C.; Cao, Ping; Miao, Li; Kopecky, David; Huang, Linda; White, Ryan D.; Samayoa, Kim; Gardner, Jonitha; Wu, Xiaosu; Chen, Kui; Tsuruda, Trace; Homann, Oliver; Baribault, Helene; Yamane, Harvey; Carlson, Tim; Wiltzius, Jed; Li, Yang</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e0147254/1-e0147254/23</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Pancreatic amyloid formation by islet amyloid polypeptide (IAPP) is a hallmark pathol. feature of type 2 diabetes.  IAPP is stored in the secretory granules of pancreatic beta-cells and co-secreted with insulin to maintain glucose homeostasis.  IAPP is innocuous under homeostatic conditions but imbalances in prodn. or processing of IAPP may result in homodimer formation leading to the rapid prodn. of cytotoxic oligomers and amyloid fibrils.  The consequence is beta-cell dysfunction and the accumulation of proteinaceous plaques in and around pancreatic islets.  Beta-site APP-cleaving enzyme 2, BACE2, is an aspartyl protease commonly assocd. with BACE1, a related homolog responsible for amyloid processing in the brain and strongly implicated in Alzheimer's disease.  Herein, we identify two distinct sites of the mature human IAPP sequence that are susceptible to BACE2-mediated proteolytic activity.  The result of proteolysis is modulation of human IAPP fibrillation and human IAPP protein degrdn.  These results suggest a potential therapeutic role for BACE2 in type 2 diabetes-assocd. hyperamylinemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXxpM4hmm1pLVg90H21EOLACvtfcHk0lhnrglnwro9eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnslOqtL4%253D&md5=ab081153a95c7462bd208bac8779bd1d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0147254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0147254%26sid%3Dliteratum%253Aachs%26aulast%3DRulifson%26aufirst%3DI.%2BC.%26aulast%3DCao%26aufirst%3DP.%26aulast%3DMiao%26aufirst%3DL.%26aulast%3DKopecky%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DWhite%26aufirst%3DR.%2BD.%26aulast%3DSamayoa%26aufirst%3DK.%26aulast%3DGardner%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DTsuruda%26aufirst%3DT.%26aulast%3DHomann%26aufirst%3DO.%26aulast%3DBaribault%26aufirst%3DH.%26aulast%3DYamane%26aufirst%3DH.%26aulast%3DCarlson%26aufirst%3DT.%26aulast%3DWiltzius%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DIdentification%2520of%2520human%2520islet%2520amyloid%2520polypeptide%2520as%2520a%2520BACE2%2520substrate%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0147254%26doi%3D10.1371%2Fjournal.pone.0147254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rochin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurbain, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serneels, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fort, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblanc, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Strooper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raposo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Niel, G.</span></span> <span> </span><span class="NLM_article-title">BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">10658</span>– <span class="NLM_lpage">10663</span>, <span class="refDoi"> DOI: 10.1073/pnas.1220748110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1073%2Fpnas.1220748110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=23754390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFejs7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=10658-10663&author=L.+Rochinauthor=I.+Hurbainauthor=L.+Serneelsauthor=C.+Fortauthor=B.+Wattauthor=P.+Leblancauthor=M.+S.+Marksauthor=B.+De+Strooperauthor=G.+Raposoauthor=G.+van+Niel&title=BACE2+processes+PMEL+to+form+the+melanosome+amyloid+matrix+in+pigment+cells&doi=10.1073%2Fpnas.1220748110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells</span></div><div class="casAuthors">Rochin, Leila; Hurbain, Ilse; Serneels, Lutgarde; Fort, Cecile; Watt, Brenda; Leblanc, Pascal; Marks, Michael S.; De Strooper, Bart; Raposo, Graca; van Niel, Guillaume</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">10658-10663,S10658/1-S10658/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Amyloids are often assocd. with pathol. processes such as in Alzheimer's disease (AD), but can also underlie physiol. processes such as pigmentation.  Formation of pathol. and functional amyloidogenic substrates can require precursor processing by proteases, as exemplified by the generation of Aβ peptide from amyloid precursor protein (APP) by beta-site APP cleaving enzyme (BACE)1 and γ-secretase.  Proteolytic processing of the pigment cell-specific Melanocyte Protein (PMEL) is also required to form functional amyloid fibrils during melanogenesis, but the enzymes involved are incompletely characterized.  Here we show that the BACE1 homolog BACE2 processes PMEL to generate functional amyloids.  BACE2 is highly expressed in pigment cells and Bace2-/- but not Bace1-/- mice display coat color defects, implying a specific role for BACE2 during melanogenesis.  By using biochem. and morphol. analyses, combined with RNA silencing, pharmacol. inhibition, and BACE2 overexpression in a human melanocytic cell line, we show that BACE2 cleaves the integral membrane form of PMEL within the juxtamembrane domain, releasing the PMEL luminal domain into endosomal precursors for the formation of amyloid fibrils and downstream melanosome morphogenesis.  These studies identify an amyloidogenic substrate of BACE2, reveal an important physiol. role for BACE2 in pigmentation, and highlight analogies in the generation of PMEL-derived functional amyloids and APP-derived pathol. amyloids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLBEney5KFyLVg90H21EOLACvtfcHk0lhnrglnwro9eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFejs7rK&md5=3deb3f80dca6a32748aa6fe2e50c2df1</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1220748110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1220748110%26sid%3Dliteratum%253Aachs%26aulast%3DRochin%26aufirst%3DL.%26aulast%3DHurbain%26aufirst%3DI.%26aulast%3DSerneels%26aufirst%3DL.%26aulast%3DFort%26aufirst%3DC.%26aulast%3DWatt%26aufirst%3DB.%26aulast%3DLeblanc%26aufirst%3DP.%26aulast%3DMarks%26aufirst%3DM.%2BS.%26aulast%3DDe%2BStrooper%26aufirst%3DB.%26aulast%3DRaposo%26aufirst%3DG.%26aulast%3Dvan%2BNiel%26aufirst%3DG.%26atitle%3DBACE2%2520processes%2520PMEL%2520to%2520form%2520the%2520melanosome%2520amyloid%2520matrix%2520in%2520pigment%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D10658%26epage%3D10663%26doi%3D10.1073%2Fpnas.1220748110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cebers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lejeune, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attalla, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soderberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budd Haeberlein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kugler, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingersoll, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, C. W.</span></span> <span> </span><span class="NLM_article-title">Reversible and species-specific depigmentation effects of AZD3293, a BACE inhibitor for the treatment of Alzheimer’s disease, are related to BACE2 inhibition and confined to epidermis and hair</span>. <i>J. Prev. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">202</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.14283/jpad.2016.119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.14283%2Fjpad.2016.119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=29199322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A280%3ADC%252BC1M3ntlKisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&pages=202-218&author=G.+Cebersauthor=T.+Lejeuneauthor=B.+Attallaauthor=M.+Soderbergauthor=R.+C.+Alexanderauthor=S.+Budd+Haeberleinauthor=A.+R.+Kuglerauthor=E.+W.+Ingersollauthor=S.+Platzauthor=C.+W.+Scott&title=Reversible+and+species-specific+depigmentation+effects+of+AZD3293%2C+a+BACE+inhibitor+for+the+treatment+of+Alzheimer%E2%80%99s+disease%2C+are+related+to+BACE2+inhibition+and+confined+to+epidermis+and+hair&doi=10.14283%2Fjpad.2016.119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible and Species-Specific Depigmentation Effects of AZD3293, a BACE Inhibitor for the Treatment of Alzheimer's Disease, Are Related to BACE2 Inhibition and Confined to Epidermis and Hair</span></div><div class="casAuthors">Cebers G; Lejeune T; Attalla B; Soderberg M; Alexander R C; Budd Haeberlein S; Kugler A R; Ingersoll E W; Platz S; Scott C W</div><div class="citationInfo"><span class="NLM_cas:title">The journal of prevention of Alzheimer's disease</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">202-218</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  AZD3293 (also known as LY3314814) is a novel, potent, non-selective BACE1/BACE2 inhibitor currently in Phase 3 clinical development for the treatment of Alzheimer's disease.  OBJECTIVES:  The purpose of these studies was to characterize the effects, putative mechanism, and reversibility of hypopigmentation following treatment with AZD3293 in pigmented Long-Evans rats, Beagle dogs, human cell cultures, and humans.  DESIGN:  Nonclinical studies were conducted in Long-Evans pigmented rats, and both young and older Beagle dogs using a variety of oral dose levels of AZD3293 or AZD3839 (BACE inhibition reference compound; used in older dogs only) for dosing durations of 13 to 26 weeks.  In vitro studies of normal human epidermal melanocytes and reconstituted human epidermis were also conducted.  Skin biopsy data from a multiple-dose Phase 1 clinical study of AZD3293 (NCT01795339) are also reported.  SETTING:  Nonclinical in vivo and in vitro studies were conducted in laboratory settings in the US, Canada, and France; the multiple dose clinical study was conducted in a specialized inpatient setting in the US.  PARTICIPANTS:  Beagle dogs: 13-week study N=36 young (8-10 mo) animals; 39-week study N=64 young animals; and a second 13-week study N=32 older (30-32 mo) animals.  Long-Evans rats: N=68 animals.  Multiple-dose clinical study: only data for subjects enrolled in Part 2 of this study are included in this report (N=16).  INTERVENTIONS:  AZD3293 was the primary intervention used in these studies.  AZD3839, a relatively BACE1-selective reference inhibitor compound was used in one group in the 13 week study in older Beagle dogs and one in vitro assessment.  Finally, AZ1340, another relatively BACE1-selective reference inhibitor compound was used only in one in vitro assessment.  MEASUREMENTS:  Measurements for the nonclinical studies in dogs and rats included macroscopic observation and assessment of skin biopsies via histopathology, immunochemistry, and electron microscopy.  Measurements for the in vitro studies included melanocyte premelanosome protein (PMEL) processing, cytotoxicity, melanin synthesis, Pmel17 labeling, and melanocyte dendricity.  Measurements in the clinical study included scoring of melanin content in skin biopsies taken before and after dosing with AZD3293 over 14 days at dose levels up to 150 mg.  RESULTS:  Depigmentation in rats and dogs was limited to skin, hair, and mucosa with no effects on other pigmented tissues.  At a cellular level depigmentation was observed within a week of treatment, whereas the appearance of depigmentation in skin and hair did not become apparent until, at earliest, 4 weeks of treatment.  The depigmentation effects were reversible, not associated with degenerative or inflammatory changes, and were dose- and species-dependent in severity.  Full recovery of melanization was observed at the microscopic (cellular) level and at least partial recovery was seen in the macroscopic appearance of animals by the end of the 12-week recovery period in both rats and dogs.  Interestingly, no changes in melanin production or melanocyte morphology were seen in human primary melanocytes or reconstituted human epidermis in vitro.  Finally, there were no changes in melanization level in skin biopsies following 12 days of daily AZD3293 treatment at doses of AZD3293 up to 150 mg/day in human subjects.  CONCLUSIONS:  AZD3293, a novel, potent, non-selective BACE1/BACE2 inhibitor is in development as a potentially disease-modifying treatment for Alzheimer's disease.  Chronic nonclinical studies in Beagle dogs and pigmented rats showed macroscopic and microscopic hypopigmentation effects of AZD3293 that were limited to skin, hair, and mucosa.  These effects were shown to be reversible in both species.  Analysis of data from nonclinical and in vitro studies suggests that hypopigmentation is caused by BACE2 inhibition resulting in accumulation of a premelanosome protein fragment, which interrupts the normal production of melanin.  No macroscopic or microscopic reports of hypopigmentation were observed in a Phase 1 clinical study following 13 doses of AZD3293 over 14 days at dose levels up to 150 mg/day.  These data suggest that hypopigmentation is species-specific and humans appear to be least sensitive to the depigmentation effect caused by BACE2 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSnMZvqjWSFT7t7lRqEFUJVfW6udTcc2eb-GzdYd7M5wbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3ntlKisw%253D%253D&md5=8eaa57d7d8e3bb8bfad9244ffb5ae16a</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.14283%2Fjpad.2016.119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14283%252Fjpad.2016.119%26sid%3Dliteratum%253Aachs%26aulast%3DCebers%26aufirst%3DG.%26aulast%3DLejeune%26aufirst%3DT.%26aulast%3DAttalla%26aufirst%3DB.%26aulast%3DSoderberg%26aufirst%3DM.%26aulast%3DAlexander%26aufirst%3DR.%2BC.%26aulast%3DBudd%2BHaeberlein%26aufirst%3DS.%26aulast%3DKugler%26aufirst%3DA.%2BR.%26aulast%3DIngersoll%26aufirst%3DE.%2BW.%26aulast%3DPlatz%26aufirst%3DS.%26aulast%3DScott%26aufirst%3DC.%2BW.%26atitle%3DReversible%2520and%2520species-specific%2520depigmentation%2520effects%2520of%2520AZD3293%252C%2520a%2520BACE%2520inhibitor%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%252C%2520are%2520related%2520to%2520BACE2%2520inhibition%2520and%2520confined%2520to%2520epidermis%2520and%2520hair%26jtitle%3DJ.%2520Prev.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2016%26volume%3D3%26spage%3D202%26epage%3D218%26doi%3D10.14283%2Fjpad.2016.119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rueeger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machauer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veenstra, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lueoend, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tintelnot-Blomley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laue, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieauff, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimshek, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staufenbiel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, L. H.</span></span> <span> </span><span class="NLM_article-title">A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-beta and neuroinflammation in APP transgenic mice</span>. <i>Mol. Neurodegener.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">44</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1186/s13024-015-0033-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1186%2Fs13024-015-0033-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=26336937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC28Xls1Sls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=44-59&author=U.+Neumannauthor=H.+Rueegerauthor=R.+Machauerauthor=S.+J.+Veenstraauthor=R.+M.+Lueoendauthor=M.+Tintelnot-Blomleyauthor=G.+Laueauthor=K.+Beltzauthor=B.+Voggauthor=P.+Schmidauthor=W.+Frieauffauthor=D.+R.+Shimshekauthor=M.+Staufenbielauthor=L.+H.+Jacobson&title=A+novel+BACE+inhibitor+NB-360+shows+a+superior+pharmacological+profile+and+robust+reduction+of+amyloid-beta+and+neuroinflammation+in+APP+transgenic+mice&doi=10.1186%2Fs13024-015-0033-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice</span></div><div class="casAuthors">Neumann, Ulf; Rueeger, Heinrich; Machauer, Rainer; Veenstra, Siem Jacob; Lueoend, Rainer M.; Tintelnot-Blomley, Marina; Laue, Grit; Beltz, Karen; Vogg, Barbara; Schmid, Peter; Frieauff, Wilfried; Shimshek, Derya R.; Staufenbiel, Matthias; Jacobson, Laura H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurodegeneration</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">44/1-44/15</span>CODEN:
                <span class="NLM_cas:coden">MNOEAZ</span>;
        ISSN:<span class="NLM_cas:issn">1750-1326</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Alzheimer's disease (AD) is the most common form of dementia, the no. of affected individuals is rising, with significant impacts for healthcare systems.  Current symptomatic treatments delay, but do not halt, disease progression.  Genetic evidence points to aggregation and deposition of amyloid-β (Aβ) in the brain being causal for the neurodegeneration and dementia typical of AD.  Approaches to target Aβ via inhibition of γ-secretase or passive antibody therapy have not yet resulted in substantial clin. benefits.  Inhibition of BACE1 (β-secretase) has proven a challenging concept, but recent BACE1inhibitors can enter the brain sufficiently well to lower Aβ.  However, failures with the first clin. BACE1 inhibitors have highlighted the need to generate compds. with appropriate efficacy and safety profiles, since long treatment periods are expected to be necessary in humans.  Results: Treatment with NB-360, a potent and brain penetrable BACE-1 inhibitor can completely block the progression of Aβ deposition in the brains of APP transgenic mice, a model for amyloid pathol.  We furthermore show that almost complete redn. of Aβ was achieved also in rats and in dogs, suggesting that these findings are translational across species and can be extrapolated to humans.  Amyloid pathol. may be an initial step in a complex pathol. cascade; therefore we investigated the effect of BACE-1 inhibition on neuroinflammation, a prominent downstream feature of the disease.  NB-360 stopped accumulation of activated inflammatory cells in the brains of APP transgenic mice.  Upon chronic treatment of APP transgenic mice, patches of gray hairs appeared.  Conclusions: In a rapidly developing field, the data on NB-360 broaden the chem. space and expand knowledge on the properties that are needed to make a BACE-1 inhibitor potent and safe enough for long-term use in patients.  Due to its excellent brain penetration, reasonable oral doses of NB-360 were sufficient to completely block amyloid-β deposition in an APP transgenic mouse model.  Data across species suggest similar treatment effects can possibly be achieved in humans.  The reduced neuroinflammation upon amyloid redn. by NB-360 treatment supports the notion that targeting amyloid-β pathol. can have beneficial downstream effects on the progression of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquJLgu8zl8_LVg90H21EOLACvtfcHk0lieaxfaZOXGQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xls1Sls7o%253D&md5=728407859709d7de57d68bfdc374fe85</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1186%2Fs13024-015-0033-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13024-015-0033-8%26sid%3Dliteratum%253Aachs%26aulast%3DNeumann%26aufirst%3DU.%26aulast%3DRueeger%26aufirst%3DH.%26aulast%3DMachauer%26aufirst%3DR.%26aulast%3DVeenstra%26aufirst%3DS.%2BJ.%26aulast%3DLueoend%26aufirst%3DR.%2BM.%26aulast%3DTintelnot-Blomley%26aufirst%3DM.%26aulast%3DLaue%26aufirst%3DG.%26aulast%3DBeltz%26aufirst%3DK.%26aulast%3DVogg%26aufirst%3DB.%26aulast%3DSchmid%26aufirst%3DP.%26aulast%3DFrieauff%26aufirst%3DW.%26aulast%3DShimshek%26aufirst%3DD.%2BR.%26aulast%3DStaufenbiel%26aufirst%3DM.%26aulast%3DJacobson%26aufirst%3DL.%2BH.%26atitle%3DA%2520novel%2520BACE%2520inhibitor%2520NB-360%2520shows%2520a%2520superior%2520pharmacological%2520profile%2520and%2520robust%2520reduction%2520of%2520amyloid-beta%2520and%2520neuroinflammation%2520in%2520APP%2520transgenic%2520mice%26jtitle%3DMol.%2520Neurodegener.%26date%3D2015%26volume%3D10%26spage%3D44%26epage%3D59%26doi%3D10.1186%2Fs13024-015-0033-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovsepian, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blazquez-Llorca, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt Elvang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volbracht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, C. K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herms, J.</span></span> <span> </span><span class="NLM_article-title">Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">729</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2014.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1016%2Fj.biopsych.2014.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=25599931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFKntLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2015&pages=729-739&author=S.+Filserauthor=S.+V.+Ovsepianauthor=M.+Masanaauthor=L.+Blazquez-Llorcaauthor=A.+Brandt+Elvangauthor=C.+Volbrachtauthor=M.+B.+Muellerauthor=C.+K.+E.+Jungauthor=J.+Herms&title=Pharmacological+inhibition+of+BACE1+impairs+synaptic+plasticity+and+cognitive+functions&doi=10.1016%2Fj.biopsych.2014.10.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological Inhibition of BACE1 Impairs Synaptic Plasticity and Cognitive Functions</span></div><div class="casAuthors">Filser, Severin; Ovsepian, Saak V.; Masana, Merce; Blazquez-Llorca, Lidia; Brandt Elvang, Anders; Volbracht, Christiane; Mueller, Marianne B.; Jung, Christian K. E.; Herms, Jochen</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">729-739</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">BACE1 (beta site amyloid precursor protein cleaving enzyme 1) is the rate limiting protease in amyloid β prodn., hence a promising drug target for the treatment of Alzheimer's disease.  Inhibition of BACE1, as the major β-secretase in vivo with multiple substrates, however is likely to have mechanism-based adverse effects.  We explored the impact of long-term pharmacol. inhibition of BACE1 on dendritic spine dynamics, synaptic functions, and cognitive performance of adult mice.  Sandwich ELISA was used to assess Aβ40 levels in brain and plasma after oral administration of BACE1 inhibitors SCH1682496 or LY2811376.  In vivo two-photon microscopy of the somatosensory cortex was performed to monitor structural dynamics of dendritic spines while synaptic functions and plasticity were measured via electrophysiol. recordings of excitatory postsynaptic currents and hippocampal long-term potentiation in brain slices.  Finally, behavioral tests were performed to analyze the impact of pharmacol. inhibition of BACE1 on cognitive performance.  Dose-dependent decrease of Aβ40 levels in vivo confirmed suppression of BACE1 activity by both inhibitors.  Prolonged treatment caused a redn. in spine formation of layer V pyramidal neurons, which recovered after withdrawal of inhibitors.  Congruently, the rate of spontaneous and miniature excitatory postsynaptic currents in pyramidal neurons and hippocampal long-term potentiation were reduced in animals treated with BACE1 inhibitors.  These effects were not detected in Bace1-/- mice treated with SCH1682496, confirming BACE1 as the pharmacol. target.  Described structural and functional changes were assocd. with cognitive deficits as revealed in behavioral tests.  Our findings indicate important functions to BACE1 in structural and functional synaptic plasticity in the mature brain, with implications for cognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBtdj8QyF3sLVg90H21EOLACvtfcHk0lieaxfaZOXGQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFKntLg%253D&md5=cfeed5a68833142e39074442dc343f42</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2014.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2014.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DFilser%26aufirst%3DS.%26aulast%3DOvsepian%26aufirst%3DS.%2BV.%26aulast%3DMasana%26aufirst%3DM.%26aulast%3DBlazquez-Llorca%26aufirst%3DL.%26aulast%3DBrandt%2BElvang%26aufirst%3DA.%26aulast%3DVolbracht%26aufirst%3DC.%26aulast%3DMueller%26aufirst%3DM.%2BB.%26aulast%3DJung%26aufirst%3DC.%2BK.%2BE.%26aulast%3DHerms%26aufirst%3DJ.%26atitle%3DPharmacological%2520inhibition%2520of%2520BACE1%2520impairs%2520synaptic%2520plasticity%2520and%2520cognitive%2520functions%26jtitle%3DBiol.%2520Psychiatry%26date%3D2015%26volume%3D77%26spage%3D729%26epage%3D739%26doi%3D10.1016%2Fj.biopsych.2014.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Egan, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kost, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tariot, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisen, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sur, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furtek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahoney, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mozley, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenberghe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelson, D.</span></span> <span> </span><span class="NLM_article-title">Randomized trial of Verubecestat for mild-to-moderate Alzheimer’s disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">1691</span>– <span class="NLM_lpage">1703</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1706441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1056%2FNEJMoa1706441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=29719179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsFyqsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=1691-1703&author=M.+F.+Eganauthor=J.+Kostauthor=P.+N.+Tariotauthor=P.+S.+Aisenauthor=J.+L.+Cummingsauthor=B.+Vellasauthor=C.+Surauthor=Y.+Mukaiauthor=T.+Vossauthor=C.+Furtekauthor=E.+Mahoneyauthor=L.+H.+Mozleyauthor=R.+Vandenbergheauthor=Y.+Moauthor=D.+Michelson&title=Randomized+trial+of+Verubecestat+for+mild-to-moderate+Alzheimer%E2%80%99s+disease&doi=10.1056%2FNEJMoa1706441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease</span></div><div class="casAuthors">Egan, Michael F.; Kost, James; Tariot, Pierre N.; Aisen, Paul S.; Cummings, Jeffrey L.; Vellas, Bruno; Sur, Cyrille; Mukai, Yuki; Voss, Tiffini; Furtek, Christine; Mahoney, Erin; Mozley, Lyn Harper; Vandenberghe, Rik; Mo, Yi; Michelson, David</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1691-1703</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Alzheimer's disease is characterized by the deposition of amyloid-beta (Aβ) plaques in the brain.  Aβ is produced from the sequential cleavage of amyloid precursor protein by β-site amyloid precursor protein-cleaving enzyme 1 (BACE-1) followed by γ-secretase.  Verubecestat is an oral BACE-1 inhibitor that reduces the Aβ level in the cerebrospinal fluid of patients with Alzheimer's disease. methods We conducted a randomized, double-blind, placebo-controlled, 78-wk trial to evaluate verubecestat at doses of 12 mg and 40 mg per day, as compared with placebo, in patients who had a clin. diagnosis of mild-to-moderate Alzheimer's disease.  The coprimary outcomes were the change from baseline to week 78 in the score on the cognitive subscale of the Alzheimer's disease Assessment Scale (ADAS-cog; scores range from 0 to 70, with higher scores indicating worse dementia) and in the score on the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory scale (ADCS-ADL; scores range from 0 to 78, with lower scores indicating worse function). results A total of 1958 patients underwent randomization; 653 were randomly assigned to receive verubecestat at a dose of 12 mg per day (the 12-mg group), 652 to receive verubecestat at a dose of 40 mg per day (the 40-mg group), and 653 to receive matching placebo.  The trial was terminated early for futility 50 mo after onset, which was within 5 mo before its scheduled completion, and after enrollment of the planned 1958 patients was complete.  The estd. mean change from baseline to week 78 in the ADAS-cog score was 7.9 in the 12-mg group, 8.0 in the 40-mg group, and 7.7 in the placebo group (P = 0.63 for the comparison between the 12-mg group and the placebo group and P = 0.46 for the comparison between the 40-mg group and the placebo group).  The estd. mean change from baseline to week 78 in the ADCS-ADL score was -8.4 in the 12-mg group, -8.2 in the 40-mg group, and -8.9 in the placebo group (P = 0.49 for the comparison between the 12-mg group and the placebo group and P = 0.32 for the comparison between the 40-mg group and the placebo group).  Adverse events, including rash, falls and injuries, sleep disturbance, suicidal ideation, wt. loss, and hair-color change, were more common in the verubecestat groups than in the placebo group. conclusions Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease and was assocd. with treatment-related adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroW5Tf-VIj2LVg90H21EOLACvtfcHk0liDfFQyvmXnrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsFyqsbs%253D&md5=e6ecfbd2981616b343468ae8bed1db2d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1706441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1706441%26sid%3Dliteratum%253Aachs%26aulast%3DEgan%26aufirst%3DM.%2BF.%26aulast%3DKost%26aufirst%3DJ.%26aulast%3DTariot%26aufirst%3DP.%2BN.%26aulast%3DAisen%26aufirst%3DP.%2BS.%26aulast%3DCummings%26aufirst%3DJ.%2BL.%26aulast%3DVellas%26aufirst%3DB.%26aulast%3DSur%26aufirst%3DC.%26aulast%3DMukai%26aufirst%3DY.%26aulast%3DVoss%26aufirst%3DT.%26aulast%3DFurtek%26aufirst%3DC.%26aulast%3DMahoney%26aufirst%3DE.%26aulast%3DMozley%26aufirst%3DL.%2BH.%26aulast%3DVandenberghe%26aufirst%3DR.%26aulast%3DMo%26aufirst%3DY.%26aulast%3DMichelson%26aufirst%3DD.%26atitle%3DRandomized%2520trial%2520of%2520Verubecestat%2520for%2520mild-to-moderate%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26spage%3D1691%26epage%3D1703%26doi%3D10.1056%2FNEJMoa1706441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuillard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleasby, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yon, J.</span></span> <span> </span><span class="NLM_article-title">Apo and inhibitor complex structures of BACE (β-secretase)</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>343</i></span>,  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2004.08.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1016%2Fj.jmb.2004.08.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=15451669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvVyqt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2004&pages=407-416&author=S.+Patelauthor=L.+Vuillardauthor=A.+Cleasbyauthor=C.+W.+Murrayauthor=J.+Yon&title=Apo+and+inhibitor+complex+structures+of+BACE+%28%CE%B2-secretase%29&doi=10.1016%2Fj.jmb.2004.08.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Apo and Inhibitor Complex Structures of BACE (β-secretase)</span></div><div class="casAuthors">Patel, Sahil; Vuillard, Laurent; Cleasby, Anne; Murray, Christopher W.; Yon, Jeff</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">407-416</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Human BACE, also known as β-secretase, shows promise as a potential therapeutic target for Alzheimer's disease.  The authors detd. the apo structure of BACE to 1.75 Å, and a structure of a hydroxyethylamine inhibitor complex derived by soaking.  These show significant active-site movements compared to previously described BACE structures.  Addnl., the structures reveal two pockets that could be targeted by structure-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH0afg2-ZxjLVg90H21EOLACvtfcHk0liDfFQyvmXnrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvVyqt7w%253D&md5=b14e17f86a4729fb8ee66d84ee6c1fab</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2004.08.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2004.08.018%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DVuillard%26aufirst%3DL.%26aulast%3DCleasby%26aufirst%3DA.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DYon%26aufirst%3DJ.%26atitle%3DApo%2520and%2520inhibitor%2520complex%2520structures%2520of%2520BACE%2520%2528%25CE%25B2-secretase%2529%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2004%26volume%3D343%26spage%3D407%26epage%3D416%26doi%3D10.1016%2Fj.jmb.2004.08.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgenthaler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweizer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann-Roder, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaeschke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diederich, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, K.</span></span> <span> </span><span class="NLM_article-title">Predicting and tuning physicochemical properties in lead optimization: amine basicities</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1100</span>– <span class="NLM_lpage">1115</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200700059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1002%2Fcmdc.200700059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=17530727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=1100-1115&issue=8&author=M.+Morgenthalerauthor=E.+Schweizerauthor=A.+Hoffmann-Roderauthor=F.+Beniniauthor=R.+E.+Martinauthor=G.+Jaeschkeauthor=B.+Wagnerauthor=H.+Fischerauthor=S.+Bendelsauthor=D.+Zimmerliauthor=J.+Schneiderauthor=F.+Diederichauthor=M.+Kansyauthor=K.+Muller&title=Predicting+and+tuning+physicochemical+properties+in+lead+optimization%3A+amine+basicities&doi=10.1002%2Fcmdc.200700059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting and tuning physicochemical properties in lead optimization: amine basicities</span></div><div class="casAuthors">Morgenthaler, Martin; Schweizer, Eliane; Hoffmann-Roder, Anja; Benini, Fausta; Martin, Rainer E.; Jaeschke, Georg; Wagner, Bjorn; Fischer, Holger; Bendels, Stefanie; Zimmerli, Daniel; Schneider, Josef; Diederich, Francois; Kansy, Manfred; Muller, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1100-1115</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  This review describes simple and useful concepts for predicting and tuning the pKa values of basic amine centers, a crucial step in the optimization of phys. and ADME properties of many lead structures in drug-discovery research.  The article starts with a case study of tricyclic thrombin inhibitors featuring a tertiary amine center with pKa values that can be tuned over a wide range, from the usual value of around 10 to below 2 by (remote) neighboring functionalities commonly encountered in medicinal chem.  Next, the changes in pKa of acyclic and cyclic amines upon substitution by fluorine, oxygen, nitrogen, and sulfur functionalities, as well as carbonyl and carboxyl derivs. are systematically analyzed, leading to the derivation of simple rules for pKa prediction.  Electronic and stereoelectronic effects in cyclic amines are discussed, and the emerging computational methods for pKa predictions are briefly surveyed.  The rules for tuning amine basicities should not only be of interest in drug-discovery research, but also to the development of new crop-protection agents, new amine ligands for organometallic complexes, and in particular, to the growing field of amine-based organocatalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodsWRMtrxWPbVg90H21EOLACvtfcHk0liDfFQyvmXnrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D&md5=478b70744312c01d3a43cf435d9598de</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700059%26sid%3Dliteratum%253Aachs%26aulast%3DMorgenthaler%26aufirst%3DM.%26aulast%3DSchweizer%26aufirst%3DE.%26aulast%3DHoffmann-Roder%26aufirst%3DA.%26aulast%3DBenini%26aufirst%3DF.%26aulast%3DMartin%26aufirst%3DR.%2BE.%26aulast%3DJaeschke%26aufirst%3DG.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DZimmerli%26aufirst%3DD.%26aulast%3DSchneider%26aufirst%3DJ.%26aulast%3DDiederich%26aufirst%3DF.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DMuller%26aufirst%3DK.%26atitle%3DPredicting%2520and%2520tuning%2520physicochemical%2520properties%2520in%2520lead%2520optimization%253A%2520amine%2520basicities%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26issue%3D8%26spage%3D1100%26epage%3D1115%26doi%3D10.1002%2Fcmdc.200700059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="note"><p class="first last">In general, aminocyclopropylthiazines displayed similar PK profiles in rats, and maximum effects on Aβ reduction in the CSF and brain were observed between 4 and 5 h following an oral dose in the PD assay. Similar single-dose PD studies have been previously reported in the following:</p></div><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dineen, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derakhchan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esmay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreiman, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fremeau, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V. F.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of β-site amyloid precursor protein cleaving enzyme (BACE1): identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)5′H-spiro[chromeno[2,3-b]pyridine-5,4′-oxazol]-2′-amine (AMG-8718)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9811</span>– <span class="NLM_lpage">9831</span>, <span class="refDoi"> DOI: 10.1021/jm5012676</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5012676" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGjtLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9811-9831&author=T.+A.+Dineenauthor=K.+Chenauthor=A.+C.+Chengauthor=K.+Derakhchanauthor=O.+Epsteinauthor=J.+Esmayauthor=D.+Hickmanauthor=C.+E.+Kreimanauthor=I.+E.+Marxauthor=R.+C.+Wahlauthor=P.+H.+Wenauthor=M.+M.+Weissauthor=D.+A.+Whittingtonauthor=S.+Woodauthor=R.+T.+Fremeauauthor=R.+W.+Whiteauthor=V.+F.+Patel&title=Inhibitors+of+%CE%B2-site+amyloid+precursor+protein+cleaving+enzyme+%28BACE1%29%3A+identification+of+%28S%29-7-%282-fluoropyridin-3-yl%29-3-%28%283-methyloxetan-3-yl%29ethynyl%295%E2%80%B2H-spiro%5Bchromeno%5B2%2C3-b%5Dpyridine-5%2C4%E2%80%B2-oxazol%5D-2%E2%80%B2-amine+%28AMG-8718%29&doi=10.1021%2Fjm5012676"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1): Identification of (S)-7-(2-Fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-2'-amine (AMG-8718)</span></div><div class="casAuthors">Dineen, Thomas A.; Chen, Kui; Cheng, Alan C.; Derakhchan, Katayoun; Epstein, Oleg; Esmay, Joel; Hickman, Dean; Kreiman, Chuck E.; Marx, Isaac E.; Wahl, Robert C.; Wen, Paul H.; Weiss, Matthew M.; Whittington, Douglas A.; Wood, Stephen; Fremeau, Robert T.; White, Ryan D.; Patel, Vinod F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9811-9831</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have previously shown that the aminooxazoline xanthene scaffold can generate potent and orally efficacious BACE1 inhibitors although certain of these compds. exhibited potential hERG liabilities.  In this article, we describe 4-aza substitution on the xanthene core as a means to increase BACE1 potency while reducing hERG binding affinity.  Further optimization of the P3 and P2' side chains resulted in the identification of 42 (AMG-8718), a compd. with a balanced profile of BACE1 potency, hERG binding affinity, and Pgp recognition.  This compd. produced robust and sustained redns. of CSF and brain Aβ levels in a rat pharmacodynamic model and exhibited significantly reduced potential for QTc elongation in a cardiovascular safety model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDPCl7cW3IyLVg90H21EOLACvtfcHk0lhzbk0fkWWyrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGjtLrP&md5=4c586d61f5ba555948eed2c27b728fbb</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm5012676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5012676%26sid%3Dliteratum%253Aachs%26aulast%3DDineen%26aufirst%3DT.%2BA.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DCheng%26aufirst%3DA.%2BC.%26aulast%3DDerakhchan%26aufirst%3DK.%26aulast%3DEpstein%26aufirst%3DO.%26aulast%3DEsmay%26aufirst%3DJ.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DKreiman%26aufirst%3DC.%2BE.%26aulast%3DMarx%26aufirst%3DI.%2BE.%26aulast%3DWahl%26aufirst%3DR.%2BC.%26aulast%3DWen%26aufirst%3DP.%2BH.%26aulast%3DWeiss%26aufirst%3DM.%2BM.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWood%26aufirst%3DS.%26aulast%3DFremeau%26aufirst%3DR.%2BT.%26aulast%3DWhite%26aufirst%3DR.%2BW.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26atitle%3DInhibitors%2520of%2520%25CE%25B2-site%2520amyloid%2520precursor%2520protein%2520cleaving%2520enzyme%2520%2528BACE1%2529%253A%2520identification%2520of%2520%2528S%2529-7-%25282-fluoropyridin-3-yl%2529-3-%2528%25283-methyloxetan-3-yl%2529ethynyl%25295%25E2%2580%25B2H-spiro%255Bchromeno%255B2%252C3-b%255Dpyridine-5%252C4%25E2%2580%25B2-oxazol%255D-2%25E2%2580%25B2-amine%2520%2528AMG-8718%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9811%26epage%3D9831%26doi%3D10.1021%2Fjm5012676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="note"><p class="first last">An estimate of unbound plasma EC<sub>50</sub> for Aβ<sub>40</sub> lowering was calculated from a single dose, single time point (4 h) experiment assuming a standard sigmoid dose response (Hill slope of 1). This approach was initially validated by comparing EC<sub>50</sub> values from a dose–response experiment to the single dose, single time point estimate of unbound EC<sub>50</sub>. Subsequently, estimated EC<sub>50</sub> values have been shown to be a good approximation of the IC<sub>50</sub> determined from a time course experiment using an indirect response PK/PD model. Similar studies have been reported in the following:</p></div><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Low, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minatti, A. E.</span></span> <span> </span><span class="NLM_article-title">Diastereoselective synthesis of fused cyclopropyl-3-amino-2,4-oxazine beta-amyloid cleaving enzyme (BACE) inhibitors and their biological evaluation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1111</span>– <span class="NLM_lpage">1115</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.01.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1016%2Fj.bmcl.2018.01.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=29426770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFemu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=1111-1115&author=J.+D.+Lowauthor=M.+D.+Bartbergerauthor=Y.+Chengauthor=D.+Whittingtonauthor=Q.+Xueauthor=S.+Woodauthor=J.+R.+Allenauthor=A.+E.+Minatti&title=Diastereoselective+synthesis+of+fused+cyclopropyl-3-amino-2%2C4-oxazine+beta-amyloid+cleaving+enzyme+%28BACE%29+inhibitors+and+their+biological+evaluation&doi=10.1016%2Fj.bmcl.2018.01.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Diastereoselective synthesis of fused cyclopropyl-3-amino-2,4-oxazine β-amyloid cleaving enzyme (BACE) inhibitors and their biological evaluation</span></div><div class="casAuthors">Low, Jonathan D.; Bartberger, Michael D.; Cheng, Yuan; Whittington, Doug; Xue, Quifen; Wood, Stephen; Allen, Jennifer R.; Minatti, Ana E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1111-1115</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The diastereoselective synthesis and structure activity relationship (SAR) of a series of fused cyclopropyl-3-amino-2,4-oxazine (2-oxa-4-azabicyclo[4.1.0]hept-3-en-3-amine)-contg. BACE inhibitors is described.  Through these efforts compd. I was identified as a potent (cell IC50 = 15 nM) BACE inhibitor with acceptable ADME properties.  When tested in vivo, I demonstrated a significant redn. of brain and cerebral spinal fluid (CSF) Aβ40 levels (46% and 66%, resp.) in a rat pharmacodynamic study and thus represents a suitable starting point for the further development of in vivo efficacious compds. for the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqc82tCAqs6uLVg90H21EOLACvtfcHk0lhzbk0fkWWyrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFemu70%253D&md5=d14d99b766bd131816b185742572aac7</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.01.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.01.056%26sid%3Dliteratum%253Aachs%26aulast%3DLow%26aufirst%3DJ.%2BD.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DWhittington%26aufirst%3DD.%26aulast%3DXue%26aufirst%3DQ.%26aulast%3DWood%26aufirst%3DS.%26aulast%3DAllen%26aufirst%3DJ.%2BR.%26aulast%3DMinatti%26aufirst%3DA.%2BE.%26atitle%3DDiastereoselective%2520synthesis%2520of%2520fused%2520cyclopropyl-3-amino-2%252C4-oxazine%2520beta-amyloid%2520cleaving%2520enzyme%2520%2528BACE%2529%2520inhibitors%2520and%2520their%2520biological%2520evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D1111%26epage%3D1115%26doi%3D10.1016%2Fj.bmcl.2018.01.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dineen, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu-Khan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Citron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croghan, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esmay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graceffa, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harried, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitchcock, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horne, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imbeah-Ampiah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judd, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaller, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreiman, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monenschein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sickmier, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of potent, orally efficacious hydroxyethylamine derived β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">9025</span>– <span class="NLM_lpage">9044</span>, <span class="refDoi"> DOI: 10.1021/jm300118s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300118s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFOnsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9025-9044&author=T.+A.+Dineenauthor=M.+M.+Weissauthor=T.+Williamsonauthor=P.+Actonauthor=S.+Babu-Khanauthor=M.+D.+Bartbergerauthor=J.+Brownauthor=K.+Chenauthor=Y.+Chengauthor=M.+Citronauthor=M.+D.+Croghanauthor=R.+T.+Dunnauthor=J.+Esmayauthor=R.+F.+Graceffaauthor=S.+S.+Harriedauthor=D.+Hickmanauthor=S.+A.+Hitchcockauthor=D.+B.+Horneauthor=H.+Huangauthor=R.+Imbeah-Ampiahauthor=T.+Juddauthor=M.+R.+Kallerauthor=C.+R.+Kreimanauthor=D.+S.+Laauthor=V.+Liauthor=P.+Lopezauthor=S.+Louieauthor=H.+Monenscheinauthor=T.+T.+Nguyenauthor=L.+D.+Penningtonauthor=T.+San+Miguelauthor=E.+A.+Sickmierauthor=H.+M.+Vargasauthor=R.+C.+Wahlauthor=P.+H.+Wenauthor=D.+A.+Whittingtonauthor=S.+Woodauthor=Q.+Xueauthor=B.+H.+Yangauthor=V.+F.+Patelauthor=W.+Zhong&title=Design+and+synthesis+of+potent%2C+orally+efficacious+hydroxyethylamine+derived+%CE%B2-site+amyloid+precursor+protein+cleaving+enzyme+%28BACE1%29+inhibitors&doi=10.1021%2Fjm300118s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors</span></div><div class="casAuthors">Dineen, Thomas A.; Weiss, Matthew M.; Williamson, Toni; Acton, Paul; Babu-Khan, Safura; Bartberger, Michael D.; Brown, James; Chen, Kui; Cheng, Yuan; Citron, Martin; Croghan, Michael D.; Dunn, Robert T.; Esmay, Joel; Graceffa, Russell F.; Harried, Scott S.; Hickman, Dean; Hitchcock, Stephen A.; Horne, Daniel B.; Huang, Hongbing; Imbeah-Ampiah, Ronke; Judd, Ted; Kaller, Matthew R.; Kreiman, Charles R.; La, Daniel S.; Li, Vivian; Lopez, Patricia; Louie, Steven; Monenschein, Holger; Nguyen, Thomas T.; Pennington, Lewis D.; San Miguel, Tisha; Sickmier, E. Allen; Vargas, Hugo M.; Wahl, Robert C.; Wen, Paul H.; Whittington, Douglas A.; Wood, Stephen; Xue, Qiufen; Yang, Bryant H.; Patel, Vinod F.; Zhong, Wenge</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9025-9044</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have previously shown that hydroxyethylamines can be potent inhibitors of the BACE1 enzyme and that the generation of BACE1 inhibitors with CYP 3A4 inhibitory activities in this scaffold affords compds. (e.g., 1, I) with sufficient bioavailability and pharmacokinetic profiles to reduce central amyloid-β peptide (Aβ) levels in wild-type rats following oral dosing.  In this article, we describe further modifications of the Ph ring of the hydroxyethylamine series to afford potent, dual BACE1/CYP 3A4 inhibitors which demonstrate improved penetration into the CNS.  Several of these compds. caused robust redn. of Aβ levels in rat CSF and brain following oral dosing, and compd. II exhibited an improved cardiovascular safety profile relative to 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqApKWBnTeHErVg90H21EOLACvtfcHk0lhzbk0fkWWyrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFOnsbg%253D&md5=1c6ad4a5aa1583864bd778715e1453ea</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm300118s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300118s%26sid%3Dliteratum%253Aachs%26aulast%3DDineen%26aufirst%3DT.%2BA.%26aulast%3DWeiss%26aufirst%3DM.%2BM.%26aulast%3DWilliamson%26aufirst%3DT.%26aulast%3DActon%26aufirst%3DP.%26aulast%3DBabu-Khan%26aufirst%3DS.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DCitron%26aufirst%3DM.%26aulast%3DCroghan%26aufirst%3DM.%2BD.%26aulast%3DDunn%26aufirst%3DR.%2BT.%26aulast%3DEsmay%26aufirst%3DJ.%26aulast%3DGraceffa%26aufirst%3DR.%2BF.%26aulast%3DHarried%26aufirst%3DS.%2BS.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DHitchcock%26aufirst%3DS.%2BA.%26aulast%3DHorne%26aufirst%3DD.%2BB.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DImbeah-Ampiah%26aufirst%3DR.%26aulast%3DJudd%26aufirst%3DT.%26aulast%3DKaller%26aufirst%3DM.%2BR.%26aulast%3DKreiman%26aufirst%3DC.%2BR.%26aulast%3DLa%26aufirst%3DD.%2BS.%26aulast%3DLi%26aufirst%3DV.%26aulast%3DLopez%26aufirst%3DP.%26aulast%3DLouie%26aufirst%3DS.%26aulast%3DMonenschein%26aufirst%3DH.%26aulast%3DNguyen%26aufirst%3DT.%2BT.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DSickmier%26aufirst%3DE.%2BA.%26aulast%3DVargas%26aufirst%3DH.%2BM.%26aulast%3DWahl%26aufirst%3DR.%2BC.%26aulast%3DWen%26aufirst%3DP.%2BH.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWood%26aufirst%3DS.%26aulast%3DXue%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DB.%2BH.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DZhong%26aufirst%3DW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520potent%252C%2520orally%2520efficacious%2520hydroxyethylamine%2520derived%2520%25CE%25B2-site%2520amyloid%2520precursor%2520protein%2520cleaving%2520enzyme%2520%2528BACE1%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9025%26epage%3D9044%26doi%3D10.1021%2Fjm300118s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajapakse, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nantermet, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selnick, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrow, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGaughey, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katherine Holloway, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espeseth, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colussi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietrak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crouthamel, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tugusheva, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazuda, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J. P.</span></span> <span> </span><span class="NLM_article-title">SAR of tertiary carbinamine derived BACE1 inhibitors: role of aspartate ligand amine pKa in enzyme inhibition</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1885</span>– <span class="NLM_lpage">1889</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.01.137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1016%2Fj.bmcl.2010.01.137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=20176482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivFGltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1885-1889&author=H.+A.+Rajapakseauthor=P.+G.+Nantermetauthor=H.+G.+Selnickauthor=J.+C.+Barrowauthor=G.+B.+McGaugheyauthor=S.+Munshiauthor=S.+R.+Lindsleyauthor=M.+B.+Youngauthor=P.+L.+Ngoauthor=M.+Katherine+Hollowayauthor=M.-T.+Laiauthor=A.+S.+Espesethauthor=X.-P.+Shiauthor=D.+Colussiauthor=B.+Pietrakauthor=M.-C.+Crouthamelauthor=K.+Tugushevaauthor=Q.+Huangauthor=M.+Xuauthor=A.+J.+Simonauthor=L.+Kuoauthor=D.+J.+Hazudaauthor=S.+Grahamauthor=J.+P.+Vacca&title=SAR+of+tertiary+carbinamine+derived+BACE1+inhibitors%3A+role+of+aspartate+ligand+amine+pKa+in+enzyme+inhibition&doi=10.1016%2Fj.bmcl.2010.01.137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">SAR of tertiary carbinamine derived BACE1 inhibitors: Role of aspartate ligand amine pK a in enzyme inhibition</span></div><div class="casAuthors">Rajapakse, Hemaka A.; Nantermet, Philippe G.; Selnick, Harold G.; Barrow, James C.; McGaughey, Georgia B.; Munshi, Sanjeev; Lindsley, Stacey R.; Young, Mary Beth; Ngo, Phung L.; Katherine Holloway, M.; Lai, Ming-Tain; Espeseth, Amy S.; Shi, Xiao-Ping; Colussi, Dennis; Pietrak, Beth; Crouthamel, Ming-Chih; Tugusheva, Katherine; Huang, Qian; Xu, Min; Simon, Adam J.; Kuo, Lawrence; Hazuda, Daria J.; Graham, Samuel; Vacca, Joseph P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1885-1889</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The optimization of tertiary carbinamine derived inhibitors of BACE1 from its discovery as an unstable lead to low nanomolar cell active compds. is described.  Five-membered heterocycles are reported as stable and potency enhancing linkers.  In the course of this work, we have discovered a clear trend where the activity of inhibitors at a given assay pH is dependent on pK a of the amino group that interacts directly with the catalytic aspartates.  The potency of compds. as inhibitors of Αβ prodn. in a cell culture assay correlated much better with BACE1 enzyme potency measured at pH 7.5 than at pH 4.5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHLW0Y129P6rVg90H21EOLACvtfcHk0ljq_ZqzL9qrAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivFGltb8%253D&md5=c3e122882f959982cacad8c45bbfcb92</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.01.137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.01.137%26sid%3Dliteratum%253Aachs%26aulast%3DRajapakse%26aufirst%3DH.%2BA.%26aulast%3DNantermet%26aufirst%3DP.%2BG.%26aulast%3DSelnick%26aufirst%3DH.%2BG.%26aulast%3DBarrow%26aufirst%3DJ.%2BC.%26aulast%3DMcGaughey%26aufirst%3DG.%2BB.%26aulast%3DMunshi%26aufirst%3DS.%26aulast%3DLindsley%26aufirst%3DS.%2BR.%26aulast%3DYoung%26aufirst%3DM.%2BB.%26aulast%3DNgo%26aufirst%3DP.%2BL.%26aulast%3DKatherine%2BHolloway%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DM.-T.%26aulast%3DEspeseth%26aufirst%3DA.%2BS.%26aulast%3DShi%26aufirst%3DX.-P.%26aulast%3DColussi%26aufirst%3DD.%26aulast%3DPietrak%26aufirst%3DB.%26aulast%3DCrouthamel%26aufirst%3DM.-C.%26aulast%3DTugusheva%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DSimon%26aufirst%3DA.%2BJ.%26aulast%3DKuo%26aufirst%3DL.%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26aulast%3DGraham%26aufirst%3DS.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26atitle%3DSAR%2520of%2520tertiary%2520carbinamine%2520derived%2520BACE1%2520inhibitors%253A%2520role%2520of%2520aspartate%2520ligand%2520amine%2520pKa%2520in%2520enzyme%2520inhibition%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1885%26epage%3D1889%26doi%3D10.1016%2Fj.bmcl.2010.01.137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutler, D. J.</span></span> <span> </span><span class="NLM_article-title">The potential role of lysosomes in tissue distribution of weak bases</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">513</span>– <span class="NLM_lpage">526</span>, <span class="refDoi"> DOI: 10.1002/bod.2510090602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1002%2Fbod.2510090602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=3067757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADyaL1MXjtlWlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1988&pages=513-526&author=A.+C.+MacIntyreauthor=D.+J.+Cutler&title=The+potential+role+of+lysosomes+in+tissue+distribution+of+weak+bases&doi=10.1002%2Fbod.2510090602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The potential role of lysosomes in tissue distribution of weak bases</span></div><div class="casAuthors">MacIntyre, Anna C.; Cutler, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">513-26</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    </div><div class="casAbstract">A review with 68 refs.  Lysosomal trapping of weak bases, dependence of weak base accumulation on structural integrity of tissues, in vitro studies of weak base distribution in tissues, and pharmacokinetics of lysosomal trapping are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofMtNLuz5Y2bVg90H21EOLACvtfcHk0ljq_ZqzL9qrAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXjtlWlsQ%253D%253D&md5=fbfdb93211453b424daa22355ef88717</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fbod.2510090602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbod.2510090602%26sid%3Dliteratum%253Aachs%26aulast%3DMacIntyre%26aufirst%3DA.%2BC.%26aulast%3DCutler%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520potential%2520role%2520of%2520lysosomes%2520in%2520tissue%2520distribution%2520of%2520weak%2520bases%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D1988%26volume%3D9%26spage%3D513%26epage%3D526%26doi%3D10.1002%2Fbod.2510090602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tobin, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slominski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botchkarev, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paus, R.</span></span> <span> </span><span class="NLM_article-title">The fate of hair follicle melanocytes during the hair growth cycle</span>. <i>J. Invest. Dermatol. Symp. Proc.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1038/sj.jidsp.5640239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1038%2Fsj.jidsp.5640239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10674391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A280%3ADC%252BD3c7js1ymtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1999&pages=323-332&author=D.+J.+Tobinauthor=A.+Slominskiauthor=V.+Botchkarevauthor=R.+Paus&title=The+fate+of+hair+follicle+melanocytes+during+the+hair+growth+cycle&doi=10.1038%2Fsj.jidsp.5640239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The fate of hair follicle melanocytes during the hair growth cycle</span></div><div class="casAuthors">Tobin D J; Slominski A; Botchkarev V; Paus R</div><div class="citationInfo"><span class="NLM_cas:title">The journal of investigative dermatology. Symposium proceedings</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">323-32</span>
        ISSN:<span class="NLM_cas:issn">1087-0024</span>.
    </div><div class="casAbstract">The fate of the follicular pigmentary unit during the hair growth cycle has long been one of the great enigmas of both hair follicle and pigment cell biology.  Although melanocytes are distributed in several different compartments of the anagen hair follicle, melanogenically active cells are located only in the hair bulb, where they are directly involved in hair shaft pigmentation.  These pigment cells are readily detectable only when they become melanogenically active during anagen III of the hair growth cycle.  Thus, their status during hair follicle regression (catagen), when melanogenesis is switched off, until they re-appear again as pigment-producing cells in the anagen III hair follicle, has remained poorly defined.  Historically, it has been proposed that hair bulb melanocytes adopt a self-perpetuating, catagen-resistant strategy of de-differentiation during hair follicle regression and re-differentiation upon entry into a new anagen phase; however, this explanation remains problematic in the absence of evidence for de-differentiation/re-differentiation plasticity in most nonmalignant cell systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSGKmgTz7EtfZI8NvIb08rbfW6udTcc2eauqz5FuUsxkrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c7js1ymtA%253D%253D&md5=d1e82046e17b4d995c01d7616aadf96f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fsj.jidsp.5640239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.jidsp.5640239%26sid%3Dliteratum%253Aachs%26aulast%3DTobin%26aufirst%3DD.%2BJ.%26aulast%3DSlominski%26aufirst%3DA.%26aulast%3DBotchkarev%26aufirst%3DV.%26aulast%3DPaus%26aufirst%3DR.%26atitle%3DThe%2520fate%2520of%2520hair%2520follicle%2520melanocytes%2520during%2520the%2520hair%2520growth%2520cycle%26jtitle%3DJ.%2520Invest.%2520Dermatol.%2520Symp.%2520Proc.%26date%3D1999%26volume%3D4%26spage%3D323%26epage%3D332%26doi%3D10.1038%2Fsj.jidsp.5640239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Müller-Röver, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foitzik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handjiski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Veen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichmüller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKay, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenn, K. S.</span></span> <span> </span><span class="NLM_article-title">A comprehensive guide for the accurate classification of murine hair follicles in distinct hair cycle stages</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1046/j.0022-202x.2001.01377.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1046%2Fj.0022-202x.2001.01377.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=11442744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlsFagtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2001&pages=3-15&author=S.+M%C3%BCller-R%C3%B6verauthor=K.+Foitzikauthor=R.+Pausauthor=B.+Handjiskiauthor=C.+van+der+Veenauthor=S.+Eichm%C3%BCllerauthor=I.+A.+McKayauthor=K.+S.+Stenn&title=A+comprehensive+guide+for+the+accurate+classification+of+murine+hair+follicles+in+distinct+hair+cycle+stages&doi=10.1046%2Fj.0022-202x.2001.01377.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive guide for the accurate classification of murine hair follicles in distinct hair cycle stages</span></div><div class="casAuthors">Muller-Rover, Sven; Handjiski, Bori; Van der Veen, Carina; Eichmuller, Stefan; Foitzik, Kerstin; McKay, Ian A.; Stenn, Kurt S.; Paus, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-15</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science, Inc.</span>)
        </div><div class="casAbstract">A review with 59 refs.  Numerous strains of mice with defined mutations display pronounced abnormalities of hair follicle cycling, even in the absence of overt alterations of the skin and hair phenotype; however, in order to recognize even subtle, hair cycle-related abnormalities, it is critically important to be able to det. accurately and classify the major stages of the normal murine hair cycle.  In this comprehensive guide, we present pragmatic basic and auxiliary criteria for recognizing key stages of hair follicle growth (anagen), regression (catagen) and quiescence (telogen) in C57BL/6NCr1BR mice, which are largely based on previous work from other authors.  For each stage, a schematic drawing and representative micrographs are provided in order to illustrate these criteria.  The basic criteria can be employed for all mouse strains and require only routine histochem. techniques.  The auxiliary criteria depend on the immunohistochem. anal. of three markers (interleukin-1 receptor type I, transforming growth factor-β receptor type II, and neural cell-adhesion mol.), which allow a refined anal. of anatomical hair follicle compartments during all hair cycle stages.  In contrast to prior staging systems, we suggest dividing anagen III into three distinct substages, based on morphol. differences, onset and progression of melanogenesis, and the position of the dermal papilla in the subcutis.  The computer-generated schematic representations of each stage are presented with the aim of standardizing reports on follicular gene and protein expression patterns.  This guide should become a useful tool when screening new mouse mutants or mice treated with pharmaceuticals for discrete morphol. abnormalities of hair follicle cycling in a highly reproducible, easily applicable, and quantifiable manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJESZ9h5Cqe7Vg90H21EOLACvtfcHk0lgKmbTx0dHQsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlsFagtrk%253D&md5=6a20d0035941a99d3b94874b4303e33e</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1046%2Fj.0022-202x.2001.01377.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.0022-202x.2001.01377.x%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller-R%25C3%25B6ver%26aufirst%3DS.%26aulast%3DFoitzik%26aufirst%3DK.%26aulast%3DPaus%26aufirst%3DR.%26aulast%3DHandjiski%26aufirst%3DB.%26aulast%3Dvan%2Bder%2BVeen%26aufirst%3DC.%26aulast%3DEichm%25C3%25BCller%26aufirst%3DS.%26aulast%3DMcKay%26aufirst%3DI.%2BA.%26aulast%3DStenn%26aufirst%3DK.%2BS.%26atitle%3DA%2520comprehensive%2520guide%2520for%2520the%2520accurate%2520classification%2520of%2520murine%2520hair%2520follicles%2520in%2520distinct%2520hair%2520cycle%2520stages%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2001%26volume%3D117%26spage%3D3%26epage%3D15%26doi%3D10.1046%2Fj.0022-202x.2001.01377.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handjiski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czarnetzki, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichmuller, S.</span></span> <span> </span><span class="NLM_article-title">A murine model for inducing and manipulating hair follicle regression (catagen): effects of dexamethasone and cyclosporin A</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">147</span>, <span class="refDoi"> DOI: 10.1111/1523-1747.ep12392542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1111%2F1523-1747.ep12392542" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=8040602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADyaK2cXmsVKhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=1994&pages=143-147&author=R.+Pausauthor=B.+Handjiskiauthor=B.+M.+Czarnetzkiauthor=S.+Eichmuller&title=A+murine+model+for+inducing+and+manipulating+hair+follicle+regression+%28catagen%29%3A+effects+of+dexamethasone+and+cyclosporin+A&doi=10.1111%2F1523-1747.ep12392542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A murine model for inducing and manipulating hair follicle regression (catagen): effects of dexamethasone and cyclosporin A</span></div><div class="casAuthors">Paus, Ralf; Handjiski, Bori; Czarnetzki, Beate M.; Eichmueller, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">143-7</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    </div><div class="casAbstract">Most cases of hair loss are based on premature induction of follicle regression (catagen).  Deciphering the unknown regulation of catagen is therefore clin. important, but catagen is also an excellent model for organ involution by rapid terminal differentiation and for epithelial cell death (apoptosis).  An assay for the controlled pharmacol. induction and manipulation of catagen follicles is reported.  Dexamethasone-21-acetate (0.1%) was applied once daily to depilation-induced, growing follicles (anagen VI) on the backs of C57 Bl-6 mice.  Characteristic catagen-assocd. changes in skin color were photodocumented and assessed by morphometric histol.  Topical dexamethasone induced catagen-like follicles significantly earlier, more homogeneously, and also more extensively than vehicle.  This process was inhibited by high i.p. doses of cyclosporin A.  In addn. to its clin. relevance as a screening assay for catagen-blocking drugs, this simple murine model is an attractive tool for dissecting the mol., cellular, and developmental biol. of catagen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVaPyDBb7PLLVg90H21EOLACvtfcHk0lgKmbTx0dHQsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmsVKhsL4%253D&md5=62d35d864a88a4c8f103f58477d3cb16</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1111%2F1523-1747.ep12392542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252F1523-1747.ep12392542%26sid%3Dliteratum%253Aachs%26aulast%3DPaus%26aufirst%3DR.%26aulast%3DHandjiski%26aufirst%3DB.%26aulast%3DCzarnetzki%26aufirst%3DB.%2BM.%26aulast%3DEichmuller%26aufirst%3DS.%26atitle%3DA%2520murine%2520model%2520for%2520inducing%2520and%2520manipulating%2520hair%2520follicle%2520regression%2520%2528catagen%2529%253A%2520effects%2520of%2520dexamethasone%2520and%2520cyclosporin%2520A%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D1994%26volume%3D103%26spage%3D143%26epage%3D147%26doi%3D10.1111%2F1523-1747.ep12392542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Makpol, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jam, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahim, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khor, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismail, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yusof, Y. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan Ngah, W. Z.</span></span> <span> </span><span class="NLM_article-title">Comparable down-regulation of TYR, TYRP1 and TYRP2 genes and inhibition of melanogenesis by tyrostat, tocotrienol-rich fraction and tocopherol in human skin melanocytes improves skin pigmentation</span>. <i>Clin. Ter.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">45</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2014&pages=39-45&author=S.+Makpolauthor=F.+A.+Jamauthor=N.+A.+Rahimauthor=S.+C.+Khorauthor=Z.+Ismailauthor=Y.+A.+M.+Yusofauthor=W.+Z.+Wan+Ngah&title=Comparable+down-regulation+of+TYR%2C+TYRP1+and+TYRP2+genes+and+inhibition+of+melanogenesis+by+tyrostat%2C+tocotrienol-rich+fraction+and+tocopherol+in+human+skin+melanocytes+improves+skin+pigmentation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMakpol%26aufirst%3DS.%26aulast%3DJam%26aufirst%3DF.%2BA.%26aulast%3DRahim%26aufirst%3DN.%2BA.%26aulast%3DKhor%26aufirst%3DS.%2BC.%26aulast%3DIsmail%26aufirst%3DZ.%26aulast%3DYusof%26aufirst%3DY.%2BA.%2BM.%26aulast%3DWan%2BNgah%26aufirst%3DW.%2BZ.%26atitle%3DComparable%2520down-regulation%2520of%2520TYR%252C%2520TYRP1%2520and%2520TYRP2%2520genes%2520and%2520inhibition%2520of%2520melanogenesis%2520by%2520tyrostat%252C%2520tocotrienol-rich%2520fraction%2520and%2520tocopherol%2520in%2520human%2520skin%2520melanocytes%2520improves%2520skin%2520pigmentation%26jtitle%3DClin.%2520Ter.%26date%3D2014%26volume%3D165%26spage%3D39%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Felmlee, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mager, D. E.</span></span> <span> </span><span class="NLM_article-title">Mechanism-based pharmacodynamic modeling</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>929</i></span>,  <span class="NLM_fpage">583</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1007/978-1-62703-050-2_21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1007%2F978-1-62703-050-2_21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=23007443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC3sXisF2ht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=929&publication_year=2012&pages=583-600&author=M.+A.+Felmleeauthor=M.+E.+Morrisauthor=D.+E.+Mager&title=Mechanism-based+pharmacodynamic+modeling&doi=10.1007%2F978-1-62703-050-2_21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based pharmacodynamic modeling</span></div><div class="casAuthors">Felmlee, Melanie A.; Morris, Marilyn E.; Mager, Donald E.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">929</span>
        (<span class="NLM_cas:issue">Computational Toxicology, Volume I</span>),
    <span class="NLM_cas:pages">583-600</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Pharmacodynamic modeling is based on a quant. integration of pharmacokinetics, pharmacol. systems, and (patho-) physiol. processes for understanding the intensity and time-course of drug effects on the body.  Application of such models to the anal. of meaningful exptl. data allows for the quantification and prediction of drug-system interactions for both therapeutic and adverse drug responses.  In this chapter, commonly used mechanistic pharmacodynamic models are presented with respect to their important features, operable equations, and signature profiles.  In addn., literature examples showcasing the utility of these models to adverse drug events are highlighted.  Common model types that are covered include simple direct effects, biophase distribution, indirect effects, signal transduction, and irreversible effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotNyzwxREt3LVg90H21EOLACvtfcHk0lgKmbTx0dHQsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXisF2ht70%253D&md5=a459c27b92c14cbc01725c085789fa86</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1007%2F978-1-62703-050-2_21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-62703-050-2_21%26sid%3Dliteratum%253Aachs%26aulast%3DFelmlee%26aufirst%3DM.%2BA.%26aulast%3DMorris%26aufirst%3DM.%2BE.%26aulast%3DMager%26aufirst%3DD.%2BE.%26atitle%3DMechanism-based%2520pharmacodynamic%2520modeling%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2012%26volume%3D929%26spage%3D583%26epage%3D600%26doi%3D10.1007%2F978-1-62703-050-2_21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corey, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaykovsky, M.</span></span> <span> </span><span class="NLM_article-title">Dimethyloxosulfonium methylide ((CH<sub>3</sub>)<sub>2</sub>SOCH<sub>2</sub>) and dimethylsulfonium Methylide ((CH<sub>3</sub>)<sub>2</sub>SCH<sub>2</sub>). Formation and application to organic synthesis</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1965</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">1353</span>– <span class="NLM_lpage">1364</span>, <span class="refDoi"> DOI: 10.1021/ja01084a034</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja01084a034" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADyaF2MXntlGrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1965&pages=1353-1364&author=E.+J.+Coreyauthor=M.+Chaykovsky&title=Dimethyloxosulfonium+methylide+%28%28CH3%292SOCH2%29+and+dimethylsulfonium+Methylide+%28%28CH3%292SCH2%29.+Formation+and+application+to+organic+synthesis&doi=10.1021%2Fja01084a034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Dimethyloxosulfonium methylide and dimethylsulfonium methylide. Formation and application to organic synthesis</span></div><div class="casAuthors">Corey, E. J.; Chaykovsky, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1965</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1353-64</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The generation of dimethyloxosulfonium methylide (Me2SOCH2) and dimethylsulfonium methylide (Me2SCH2) as reactive intermediates is described.  Both ylides are nucleophiles and both function to transfer methylene to certain electrophilic unsatd. linkages, including C:O, C:N, C:S, and in certain cases, C:C.  The less reactive oxosulfonium ylide interacts with the carbonyl function of aromatic and nonconjugated aldehydes and ketones to form oxiranes and with α,β-unsatd. ketones which are Michael receptors to form cyclopropyl ketones.  The sulfonium ylide reacts with the same substrates to give oxiranes exclusively even with the α,β-unsatd. carbonyl systems.  These reactions are quite general and, therefore, of considerable practical value.  The stereochemistry of carbonyl addn. to cyclohexanones varies depending on the ylide; the oxosulfonium ylide reacts by equatorial addn. (i.e., of methylene) and the sulfonium ylide shows a preference for axial addn.  A no. of other reactions of these ylides are described including "over-all methylene insertion," and a differential comparison of their chem. properties is made.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt0xfN-tNfFLVg90H21EOLACvtfcHk0lgiJOP1rpBE1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2MXntlGrtw%253D%253D&md5=ae22573e36db50409c7832e5950df7f1</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fja01084a034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja01084a034%26sid%3Dliteratum%253Aachs%26aulast%3DCorey%26aufirst%3DE.%2BJ.%26aulast%3DChaykovsky%26aufirst%3DM.%26atitle%3DDimethyloxosulfonium%2520methylide%2520%2528%2528CH3%25292SOCH2%2529%2520and%2520dimethylsulfonium%2520Methylide%2520%2528%2528CH3%25292SCH2%2529.%2520Formation%2520and%2520application%2520to%2520organic%2520synthesis%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1965%26volume%3D87%26spage%3D1353%26epage%3D1364%26doi%3D10.1021%2Fja01084a034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turner, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koelsch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanheira, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ermolieff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span> <span> </span><span class="NLM_article-title">Subsite specificity of memapsin 2 (ß-Secretase): implication for inhibitor design</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">10001</span>– <span class="NLM_lpage">10006</span>, <span class="refDoi"> DOI: 10.1021/bi015546s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi015546s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlsFygt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=10001-10006&author=R.+T.+Turnerauthor=G.+Koelschauthor=L.+Hongauthor=P.+Castanheiraauthor=J.+Ermolieffauthor=A.+K.+Ghoshauthor=J.+Tang&title=Subsite+specificity+of+memapsin+2+%28%C3%9F-Secretase%29%3A+implication+for+inhibitor+design&doi=10.1021%2Fbi015546s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Subsite Specificity of Memapsin 2 (β-Secretase): Implications for Inhibitor Design</span></div><div class="casAuthors">Turner, Robert T., III; Koelsch, Gerald; Hong, Lin; Castenheira, Pedro; Ghosh, Arun; Tang, Jordan</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">10001-10006</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Memapsin 2 is the protease known as β-secretase whose action on β-amyloid precursor protein leads to the prodn. of the β-amyloid (Aβ) peptide.  Since the accumulation of Aβ in the brain is a key event in the pathogenesis of Alzheimer's disease, memapsin 2 is an important target for the design of inhibitory drugs.  Here we describe the residue preference for the subsites of memapsin 2.  The relative kcat/KM values of residues in each of the eight subsites were detd. by the relative initial cleavage rates of substrate mixts. as quantified by MALDI-TOF mass spectrometry.  We found that each subsite can accommodate multiple residues.  The S1 subsite is the most stringent, preferring residues in the order of Leu > Phe > Met > Tyr.  The preferences of other subsites are the following: S2, Asp > Asn > Met; S3, Ile > Val > Leu; S4, Glu > Gln > Asp; S1', Met > Glu > Gln > Ala; S2', Val > Ile > Ala; S3', Leu > Trp > Ala; S4', Asp > Glu > Trp.  In general, S subsites are more specific than the S' subsites.  A peptide comprising the eight most favored residues (Glu-Ile-Asp-Leu-Met-Val-Leu-Asp) was found to be hydrolyzed with the highest kcat/KM value so far obsd. for memapsin 2.  Residue preferences at four subsites were also studied by binding of memapsin 2 to a combinatorial inhibitor library.  From 10 tight binding inhibitors, the consensus preferences were as follows: S2, Asp and Glu; S3, Leu and Ile; S2', Val; and S3', Glu and Gln.  An inhibitor, OM00-3, Glu-Leu-Asp-Leu*Ala-Val-Glu-Phe (where the asterisk represents the hydroxyethylene transition-state isostere), designed from the consensus residues, was found to be the most potent inhibitor of memapsin 2 so far reported (Ki of 3.1 × 10-10 M).  A mol. model of OM00-3 binding to memapsin 2 revealed crit. improvement of the interactions between inhibitor side chains with enzyme over a previous inhibitor, OM99-2 [Ghosh, A. K., et al. (2000) J. Am. Chem. Soc. 14, 3522-3523].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-VNvG4dfyYrVg90H21EOLACvtfcHk0lgiJOP1rpBE1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlsFygt78%253D&md5=e0ff4b45ee8e6055f707cb9ea571c943</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fbi015546s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi015546s%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DR.%2BT.%26aulast%3DKoelsch%26aufirst%3DG.%26aulast%3DHong%26aufirst%3DL.%26aulast%3DCastanheira%26aufirst%3DP.%26aulast%3DErmolieff%26aufirst%3DJ.%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DTang%26aufirst%3DJ.%26atitle%3DSubsite%2520specificity%2520of%2520memapsin%25202%2520%2528%25C3%259F-Secretase%2529%253A%2520implication%2520for%2520inhibitor%2520design%26jtitle%3DBiochemistry%26date%3D2001%26volume%3D40%26spage%3D10001%26epage%3D10006%26doi%3D10.1021%2Fbi015546s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 10 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Jianzhong Chen, Shaolong Zhang, Wei Wang, Haibo Sun, Qinggang Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Xinguo Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Binding of Inhibitors to BACE1 Affected by pH-Dependent Protonation: An Exploration from Multiple Replica Gaussian Accelerated Molecular Dynamics and MM-GBSA Calculations. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2021,</strong> <em>12 </em>
                                    (14)
                                     , 2591-2607. <a href="https://doi.org/10.1021/acschemneuro.0c00813" title="DOI URL">https://doi.org/10.1021/acschemneuro.0c00813</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.0c00813&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.0c00813%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DBinding%252Bof%252BInhibitors%252Bto%252BBACE1%252BAffected%252Bby%252BpH-Dependent%252BProtonation%25253A%252BAn%252BExploration%252Bfrom%252BMultiple%252BReplica%252BGaussian%252BAccelerated%252BMolecular%252BDynamics%252Band%252BMM-GBSA%252BCalculations%26aulast%3DChen%26aufirst%3DJianzhong%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D22122020%26date%3D14062021%26date%3D29062021%26volume%3D12%26issue%3D14%26spage%3D2591%26epage%3D2607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kazuki Fujimoto, Shuhei Yoshida, Genta Tadano, Naoya Asada, Kouki Fuchino, Shinji Suzuki, Eriko Matsuoka, Takahiko Yamamoto, Shiho Yamamoto, Shigeru Ando, Naoki Kanegawa, Yutaka Tonomura, Hisanori Ito, Diederik Moechars, Frederik J. R. Rombouts, Harrie J. M. Gijsen, <span class="NLM_string-name hlFld-ContribAuthor">Ken-ichi Kusakabe</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based Approaches to Improving Selectivity through Utilizing Explicit Water Molecules: Discovery of Selective β-Secretase (BACE1) Inhibitors over BACE2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (6)
                                     , 3075-3085. <a href="https://doi.org/10.1021/acs.jmedchem.0c01858" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01858</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01858%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Based%252BApproaches%252Bto%252BImproving%252BSelectivity%252Bthrough%252BUtilizing%252BExplicit%252BWater%252BMolecules%25253A%252BDiscovery%252Bof%252BSelective%252B%2525CE%2525B2-Secretase%252B%252528BACE1%252529%252BInhibitors%252Bover%252BBACE2%26aulast%3DFujimoto%26aufirst%3DKazuki%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D26102020%26date%3D15032021%26volume%3D64%26issue%3D6%26spage%3D3075%26epage%3D3085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Tanaji T. Talele</span>. </span><span class="cited-content_cbyCitation_article-title">Opportunities for Tapping into Three-Dimensional Chemical Space through a Quaternary Carbon. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (22)
                                     , 13291-13315. <a href="https://doi.org/10.1021/acs.jmedchem.0c00829" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00829</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00829%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOpportunities%252Bfor%252BTapping%252Binto%252BThree-Dimensional%252BChemical%252BSpace%252Bthrough%252Ba%252BQuaternary%252BCarbon%26aulast%3DTalele%26aufirst%3DTanaji%2BT.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D15052020%26date%3D31082020%26date%3D17082020%26volume%3D63%26issue%3D22%26spage%3D13291%26epage%3D13315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mihirbaran Mandal, Alexei Buevich, John P. Caldwell, Lynn Hyde, Xianhai Huang, Xiaoxiang Liu, Brian McKittrick, Robert D. Mazzola, Dmitri Pissarnitski, Anandan Palani, Lili Zhang, Eric Parker, Li Xiao, Diane Rindgen, <span class="NLM_string-name hlFld-ContribAuthor">Zhaoning Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Generation of Leads for γ-Secretase Modulation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (15)
                                     , 8216-8230. <a href="https://doi.org/10.1021/acs.jmedchem.0c00446" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00446</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00446%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DGeneration%252Bof%252BLeads%252Bfor%252B%2525CE%2525B3-Secretase%252BModulation%26aulast%3DMandal%26aufirst%3DMihirbaran%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D16032020%26date%3D04082020%26date%3D27072020%26volume%3D63%26issue%3D15%26spage%3D8216%26epage%3D8230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samuel C.  Ugbaja</span>, <span class="hlFld-ContribAuthor ">Zainab K.  Sanusi</span>, <span class="hlFld-ContribAuthor ">Patrick  Appiah-Kubi</span>, <span class="hlFld-ContribAuthor ">Monsurat M.  Lawal</span>, <span class="hlFld-ContribAuthor ">Hezekiel M.  Kumalo</span>. </span><span class="cited-content_cbyCitation_article-title">Computational modelling of potent β-secretase (BACE1) inhibitors towards Alzheimer's disease treatment. </span><span class="cited-content_cbyCitation_journal-name">Biophysical Chemistry</span><span> <strong>2021,</strong> <em>270 </em>, 106536. <a href="https://doi.org/10.1016/j.bpc.2020.106536" title="DOI URL">https://doi.org/10.1016/j.bpc.2020.106536</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bpc.2020.106536&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bpc.2020.106536%26sid%3Dliteratum%253Aachs%26jtitle%3DBiophysical%2520Chemistry%26atitle%3DComputational%252Bmodelling%252Bof%252Bpotent%252B%2525CE%2525B2-secretase%252B%252528BACE1%252529%252Binhibitors%252Btowards%252BAlzheimer%252527s%252Bdisease%252Btreatment%26aulast%3DUgbaja%26aufirst%3DSamuel%2BC.%26date%3D2021%26volume%3D270%26spage%3D106536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haizhou  Zhu</span>, <span class="hlFld-ContribAuthor ">Venkateshwara  Dronamraju</span>, <span class="hlFld-ContribAuthor ">Wei  Xie</span>, <span class="hlFld-ContribAuthor ">Swati S.  More</span>. </span><span class="cited-content_cbyCitation_article-title">Sulfur-containing therapeutics in the treatment of Alzheimer’s disease. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2021,</strong> <em>30 </em>
                                    (2)
                                     , 305-352. <a href="https://doi.org/10.1007/s00044-020-02687-1" title="DOI URL">https://doi.org/10.1007/s00044-020-02687-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-020-02687-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-020-02687-1%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DSulfur-containing%252Btherapeutics%252Bin%252Bthe%252Btreatment%252Bof%252BAlzheimer%2525E2%252580%252599s%252Bdisease%26aulast%3DZhu%26aufirst%3DHaizhou%26date%3D2021%26date%3D2021%26volume%3D30%26issue%3D2%26spage%3D305%26epage%3D352" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samuel C.  Ugbaja</span>, <span class="hlFld-ContribAuthor ">Patrick  Appiah-Kubi</span>, <span class="hlFld-ContribAuthor ">Monsurat M.  Lawal</span>, <span class="hlFld-ContribAuthor ">Nelisiwe S.  Gumede</span>, <span class="hlFld-ContribAuthor ">Hezekiel M.  Kumalo</span>. </span><span class="cited-content_cbyCitation_article-title">Unravelling the molecular basis of AM-6494 high potency at BACE1 in Alzheimer’s disease: an integrated dynamic interaction investigation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2021,</strong> <em>117 </em>, 1-13. <a href="https://doi.org/10.1080/07391102.2020.1869099" title="DOI URL">https://doi.org/10.1080/07391102.2020.1869099</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2020.1869099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2020.1869099%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DUnravelling%252Bthe%252Bmolecular%252Bbasis%252Bof%252BAM-6494%252Bhigh%252Bpotency%252Bat%252BBACE1%252Bin%252BAlzheimer%2525E2%252580%252599s%252Bdisease%25253A%252Ban%252Bintegrated%252Bdynamic%252Binteraction%252Binvestigation%26aulast%3DUgbaja%26aufirst%3DSamuel%2BC.%26date%3D2021%26date%3D2021%26volume%3D117%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Frederik  Rombouts</span>, <span class="hlFld-ContribAuthor ">Ken-ichi  Kusakabe</span>, <span class="hlFld-ContribAuthor ">Chien-Chi  Hsiao</span>, <span class="hlFld-ContribAuthor ">Harrie J. M.  Gijsen</span>. </span><span class="cited-content_cbyCitation_article-title">Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em>31 </em>
                                    (1)
                                     , 25-52. <a href="https://doi.org/10.1080/13543776.2021.1832463" title="DOI URL">https://doi.org/10.1080/13543776.2021.1832463</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1832463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1832463%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DSmall-molecule%252BBACE1%252Binhibitors%25253A%252Ba%252Bpatent%252Bliterature%252Breview%252B%2525282011%252Bto%252B2020%252529%26aulast%3DRombouts%26aufirst%3DFrederik%26date%3D2021%26date%3D2020%26volume%3D31%26issue%3D1%26spage%3D25%26epage%3D52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jessica  Bais</span>, <span class="hlFld-ContribAuthor ">Fabio  Benedetti</span>, <span class="hlFld-ContribAuthor ">Federico  Berti</span>, <span class="hlFld-ContribAuthor ">Iole  Cerminara</span>, <span class="hlFld-ContribAuthor ">Sara  Drioli</span>, <span class="hlFld-ContribAuthor ">Maria  Funicello</span>, <span class="hlFld-ContribAuthor ">Giorgia  Regini</span>, <span class="hlFld-ContribAuthor ">Mattia  Vidali</span>, <span class="hlFld-ContribAuthor ">Fulvia  Felluga</span>. </span><span class="cited-content_cbyCitation_article-title">One Pot Synthesis of Micromolar BACE-1 Inhibitors Based on the Dihydropyrimidinone Scaffold and Their Thia and Imino Analogues. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (18)
                                     , 4152. <a href="https://doi.org/10.3390/molecules25184152" title="DOI URL">https://doi.org/10.3390/molecules25184152</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25184152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25184152%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DOne%252BPot%252BSynthesis%252Bof%252BMicromolar%252BBACE-1%252BInhibitors%252BBased%252Bon%252Bthe%252BDihydropyrimidinone%252BScaffold%252Band%252BTheir%252BThia%252Band%252BImino%252BAnalogues%26aulast%3DBais%26aufirst%3DJessica%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D18%26spage%3D4152" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Frohn</span>, <span class="hlFld-ContribAuthor ">Longbin  Liu</span>, <span class="hlFld-ContribAuthor ">Aaron C.  Siegmund</span>, <span class="hlFld-ContribAuthor ">Wenyuan  Qian</span>, <span class="hlFld-ContribAuthor ">Albert  Amegadzie</span>, <span class="hlFld-ContribAuthor ">Ning  Chen</span>, <span class="hlFld-ContribAuthor ">Helming  Tan</span>, <span class="hlFld-ContribAuthor ">Dean  Hickman</span>, <span class="hlFld-ContribAuthor ">Stephen  Wood</span>, <span class="hlFld-ContribAuthor ">Paul H.  Wen</span>, <span class="hlFld-ContribAuthor ">Michael D.  Bartberger</span>, <span class="hlFld-ContribAuthor ">Douglas A.  Whittington</span>, <span class="hlFld-ContribAuthor ">Jennifer R.  Allen</span>, <span class="hlFld-ContribAuthor ">Matthew P.  Bourbeau</span>. </span><span class="cited-content_cbyCitation_article-title">The development of a structurally distinct series of BACE1 inhibitors via the (Z)-fluoro-olefin amide bioisosteric replacement. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (14)
                                     , 127240. <a href="https://doi.org/10.1016/j.bmcl.2020.127240" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127240</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127240&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127240%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DThe%252Bdevelopment%252Bof%252Ba%252Bstructurally%252Bdistinct%252Bseries%252Bof%252BBACE1%252Binhibitors%252Bvia%252Bthe%252B%252528Z%252529-fluoro-olefin%252Bamide%252Bbioisosteric%252Breplacement%26aulast%3DFrohn%26aufirst%3DMichael%26date%3D2020%26volume%3D30%26issue%3D14%26spage%3D127240" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01034&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0001.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures and potency of recently disclosed BACE1 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01034&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Cocrystal structure of <b>20</b> and BACE1 (1.85 Å resolution, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PZ4">6PZ4</a>). Hydrogen bond contacts are shown with dashed lines; the red dot represents water molecule; the segment in orange is part of the flexible hairpin loop commonly referred to as the “flap”.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> (B) Alternative view illustrating that <i>para</i>-propargyloxy projects deep into the S3 pocket. The figures were generated with the PyMOL Molecular Graphics System, version 1.7.0.1, Schrödinger, LLC.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01034&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. In vitro assay for BACE2 activity in mouse melanoma cells. (A) Cleavage of endogenous substrate was assessed by Western blot detection of PMEL17 Mβ. Following a 4-day treatment of mouse melanoma cells with compound <b>1</b> (1 μM), accumulation of intracellular substrate, PMEL17 Mβ, was observed. Such PMEL17 Mβ accumulation was not observed with DMSO control. (B) Intracellular accumulation of PMEL17 Mβ induced by inhibitor <b>1</b> was dose-dependent. EC<sub>50</sub> = 40 nM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01034&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Human PMEL17 Mβ expression construct contains gluciferase on the N-terminus, an internal HA tag and a C-terminus Myc tag. (B) Expression confirmation with anti-gluciferase showed reduction of secreted cleavage product and increase in full length intracellular substrate with overnight treatment of nonselective BACE inhibitor <b>1</b> at 1 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01034&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Biomarkers correlated with synchronized melanogenesis. mRNA expression of the melanogenesis biomarkers TYR (red square), TYRP1 (green triangle), and TYRP2 (purple triangle) increased following depilation in coordination with hair regrowth and pigmentation. mRNA levels of MITF (blue circles) did not change. PMEL17 Mβ fragment levels decreased during melanogenesis (black diamond). Error bars are standard deviation (<i>n</i> = 9).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01034&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0006.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Hypopigmentation observed in mice treated with nonselective BACE1 inhibitor <b>1</b> but not with selective BACE1 inhibitor <b>20</b> or <b>25</b>. (Top) Depilated mice were dosed orally once a day for 13 days with either vehicle (2% HPMC, 1% Tween 80, pH 2.2) or an inhibitor. Error bars are standard deviation (<i>n</i> = 5). (Bottom) Pictures taken at day 1 and day 13 of mice treated with vehicle, <b>1</b>, <b>20</b>, and <b>25</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01034&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0007.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Time course of brain and CSF Aβ<sub>40</sub> lowering in Sprague-Dawley rat (<i>n</i> = 5) following a 3 mg/kg oral dosing of <b>20</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01034&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0008.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. PK–PD relationship of <b>20</b> in Rhesus monkey (<i>n</i> = 3) following a 10 mg/kg oral dose.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01034&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Arylamine <b>6G</b> and Inhibitor <b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01034&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (1) LDA, CO<sub>2</sub>; (2) TMSCHN<sub>2</sub>, 92%; (b) NaH, Me<sub>3</sub>SOI, 80%; (c) (1) LiBH<sub>4</sub>, MeOH; (2) SO<sub>3</sub>·pyr, 79%; (d) RhCl(PPh<sub>3</sub>)<sub>3</sub>, DCE, 68%; (e) H<sub>2</sub>SO<sub>4</sub>, NaNO<sub>3</sub>, 56%; (f) Zn, TFA, HOAc, 80%; (g) 5-chloropicolinic acid, T3P, EtOAc, 50%.</p></p></figure><figure data-id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Arylamines <b>7B</b>, <b>8B</b>, <b>9B</b>, and <b>10B</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01034&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (1) H<sub>2</sub>SO<sub>4</sub>, NaNO<sub>3</sub>; (2) Zn, TFA, HOAc, 46–80%; (b) LiBH<sub>4</sub>, MeOH, 88–98%; (c) NaHMDS, MeI, 76%; (d) MsCl, Et<sub>3</sub>N, DCM, 100%; (e) CsF, <i>t</i>BuOH, 88%; (f) Deoxo-Fluor, DCM.</p></p></figure><figure data-id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Arylamines <b>11B</b>, <b>12B</b>, <b>13B</b>, and <b>14B</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01034&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (1) LiOH; (2) HCl, 100%; (b) CDI or HATU, R<sup>1</sup>R<sup>2</sup>NH, 83–95%; (c) (1) H<sub>2</sub>SO<sub>4</sub>, NaNO<sub>3</sub>; (2) Zn, TFA, HOAc, 46–80%; (d) TFAA, DIPEA, THF, 100%; (e) 2 M NH<sub>3</sub> in MeOH, 44%.</p></p></figure><figure data-id="sch4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/medium/jm9b01034_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0012.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Generic Synthesis of BACE1 Inhibitors <b>7</b>–<b>26</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-5/acs.jmedchem.9b01034/20200306/images/large/jm9b01034_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01034&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) T3P, DCM, 43–83%; (b) R<sup>1</sup>OH, Cs<sub>2</sub>CO<sub>3</sub>, THF, 50 °C, 58–86%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i63">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54712" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54712" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 50 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zemek, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drtinova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepovimova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepsova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korabecny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klimes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuca, K.</span></span> <span> </span><span class="NLM_article-title">Outcomes of Alzheimer’s disease therapy with acetylcholinesterase inhibitors and memantine</span>. <i>Expert Opin. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">759</span>– <span class="NLM_lpage">774</span>, <span class="refDoi"> DOI: 10.1517/14740338.2014.914168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1517%2F14740338.2014.914168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=24845946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVOrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=759-774&author=F.+Zemekauthor=L.+Drtinovaauthor=E.+Nepovimovaauthor=V.+Sepsovaauthor=J.+Korabecnyauthor=J.+Klimesauthor=K.+Kuca&title=Outcomes+of+Alzheimer%E2%80%99s+disease+therapy+with+acetylcholinesterase+inhibitors+and+memantine&doi=10.1517%2F14740338.2014.914168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine</span></div><div class="casAuthors">Zemek, Filip; Drtinova, Lucie; Nepovimova, Eugenie; Sepsova, Vendula; Korabecny, Jan; Klimes, Jiri; Kuca, Kamil</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">759-774</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Alzheimer's disease (AD) is a world-wide health problem with implications for an increasing no. of people and countries.  Populations suffering from AD financially strain the healthcare budgets of rich and poor countries alike.  Moreover, no effective treatment is available and current drugs merely slow the progression of cognitive function deterioration and overall health status toward an inevitable end point.  An increasing no. of novel approaches have been tested in numerous clin. trials, but none of them has proved safe and effective for treating AD.  Areas covered: This review summarizes all currently available compds. (donepezil, rivastigmine, galantamine, memantine) for the management of AD, concg. on clin. aspects such as the mechanisms of action, pharmacokinetics, pharmacodynamics and clin. trials.  This review also considers the mechanisms and side effects to provide perspective on current treatment options.  Expert opinion: Novel approaches in the treatment of AD are being intensively tested, but so far without any major success.  Patients diagnosed with AD still mostly benefit from four compds. to significantly improve cognition functions and overall health and help manage other symptoms or even prolong the symptom-free period.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomCHTA-GByu7Vg90H21EOLACvtfcHk0ljw80cDkDqqrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVOrt70%253D&md5=5dfa0e4ee53453755456895458e49a29</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1517%2F14740338.2014.914168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.2014.914168%26sid%3Dliteratum%253Aachs%26aulast%3DZemek%26aufirst%3DF.%26aulast%3DDrtinova%26aufirst%3DL.%26aulast%3DNepovimova%26aufirst%3DE.%26aulast%3DSepsova%26aufirst%3DV.%26aulast%3DKorabecny%26aufirst%3DJ.%26aulast%3DKlimes%26aufirst%3DJ.%26aulast%3DKuca%26aufirst%3DK.%26atitle%3DOutcomes%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%2520therapy%2520with%2520acetylcholinesterase%2520inhibitors%2520and%2520memantine%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2014%26volume%3D13%26spage%3D759%26epage%3D774%26doi%3D10.1517%2F14740338.2014.914168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vassar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu-Khan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendiaz, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denis, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teplow, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amarante, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loeloff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edenson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lile, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarosinski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biere, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treanor, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Citron, M.</span></span> <span> </span><span class="NLM_article-title">beta-Secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE1</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">741</span>, <span class="refDoi"> DOI: 10.1126/science.286.5440.735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1126%2Fscience.286.5440.735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10531052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADyaK1MXntFWit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=1999&pages=735-741&author=R.+Vassarauthor=B.+D.+Bennettauthor=S.+Babu-Khanauthor=S.+Kahnauthor=E.+A.+Mendiazauthor=P.+Denisauthor=D.+B.+Teplowauthor=S.+Rossauthor=P.+Amaranteauthor=R.+Loeloffauthor=Y.+Luoauthor=S.+Fisherauthor=J.+Fullerauthor=S.+Edensonauthor=J.+Lileauthor=M.+A.+Jarosinskiauthor=A.+L.+Biereauthor=E.+Curranauthor=T.+Burgessauthor=J.+C.+Louisauthor=F.+Collinsauthor=J.+Treanorauthor=G.+Rogersauthor=M.+Citron&title=beta-Secretase+cleavage+of+Alzheimer%E2%80%99s+amyloid+precursor+protein+by+the+transmembrane+aspartic+protease+BACE1&doi=10.1126%2Fscience.286.5440.735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE</span></div><div class="casAuthors">Vassar, Robert; Bennett, Brian D.; Babu-Khan, Safura; Kahn, Steve; Mendiaz, Elizabeth A.; Denis, Paul; Teplow, David B.; Ross, Sandra; Amarante, Patricia; Loeloff, Richard; Luo, Yi; Fisher, Seth; Fuller, Janis; Edenson, Steven; Lile, Jackson; Jarosinski, Mark A.; Biere, Anja Leona; Curran, Eileen; Burgess, Teresa; Louis, Jean-Claude; Collins, Frank; Treanor, James; Rogers, Gary; Citron, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">5440</span>),
    <span class="NLM_cas:pages">735-741</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Cerebral deposition of amyloid β peptide (Aβ) is an early and crit. feature of Alzheimer's disease.  Aβ generation depends on proteolytic cleavage of the amyloid precursor protein (APP) by two unknown proteases: β-secretase and γ-secretase.  These proteases are prime therapeutic targets.  A transmembrane aspartic protease with all the known characteristics of β-secretase was cloned and characterized.  Overexpression of this protease, termed BACE (for beta-site APP-cleaving enzyme) increased the amt. of β-secretase cleavage products, and these were cleaved exactly and only at known β-secretase positions.  Antisense inhibition of endogenous BACE mRNA decreased the amt. of β-secretase cleavage products, and purified BACE protein cleaved APP-derived substrates with the same sequence specificity as β-secretase.  Finally, the expression pattern and subcellular localization of BACE were consistent with that expected for β-secretase.  Future development of BACE inhibitors may prove beneficial for the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSx3s1NFyByrVg90H21EOLACvtfcHk0lgIu5hMMwKSzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFWit74%253D&md5=3f36e8e5b5e9441c7670ccaeb0d2dd4f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.286.5440.735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.286.5440.735%26sid%3Dliteratum%253Aachs%26aulast%3DVassar%26aufirst%3DR.%26aulast%3DBennett%26aufirst%3DB.%2BD.%26aulast%3DBabu-Khan%26aufirst%3DS.%26aulast%3DKahn%26aufirst%3DS.%26aulast%3DMendiaz%26aufirst%3DE.%2BA.%26aulast%3DDenis%26aufirst%3DP.%26aulast%3DTeplow%26aufirst%3DD.%2BB.%26aulast%3DRoss%26aufirst%3DS.%26aulast%3DAmarante%26aufirst%3DP.%26aulast%3DLoeloff%26aufirst%3DR.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DFisher%26aufirst%3DS.%26aulast%3DFuller%26aufirst%3DJ.%26aulast%3DEdenson%26aufirst%3DS.%26aulast%3DLile%26aufirst%3DJ.%26aulast%3DJarosinski%26aufirst%3DM.%2BA.%26aulast%3DBiere%26aufirst%3DA.%2BL.%26aulast%3DCurran%26aufirst%3DE.%26aulast%3DBurgess%26aufirst%3DT.%26aulast%3DLouis%26aufirst%3DJ.%2BC.%26aulast%3DCollins%26aufirst%3DF.%26aulast%3DTreanor%26aufirst%3DJ.%26aulast%3DRogers%26aufirst%3DG.%26aulast%3DCitron%26aufirst%3DM.%26atitle%3Dbeta-Secretase%2520cleavage%2520of%2520Alzheimer%25E2%2580%2599s%2520amyloid%2520precursor%2520protein%2520by%2520the%2520transmembrane%2520aspartic%2520protease%2520BACE1%26jtitle%3DScience%26date%3D1999%26volume%3D286%26spage%3D735%26epage%3D741%26doi%3D10.1126%2Fscience.286.5440.735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haass, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selkoe, D. J.</span></span> <span> </span><span class="NLM_article-title">Soluble protein oligomers in neurodegeneration: lesson from the Alzheimer’s amyloid β-peptide</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">112</span>, <span class="refDoi"> DOI: 10.1038/nrm2101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1038%2Fnrm2101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=17245412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotFKmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=101-112&author=C.+Haassauthor=D.+J.+Selkoe&title=Soluble+protein+oligomers+in+neurodegeneration%3A+lesson+from+the+Alzheimer%E2%80%99s+amyloid+%CE%B2-peptide&doi=10.1038%2Fnrm2101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide</span></div><div class="casAuthors">Haass, Christian; Selkoe, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-112</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The distinct protein aggregates that are found in Alzheimer's, Parkinson's, Huntington's and prion diseases seem to cause these disorders.  Small intermediates - sol. oligomers - in the aggregation process can confer synaptic dysfunction, whereas large, insol. deposits might function as reservoirs of the bioactive oligomers.  These emerging concepts are exemplified by Alzheimer's disease, in which amyloid β-protein oligomers adversely affect synaptic structure and plasticity.  Findings in other neurodegenerative diseases indicate that a broadly similar process of neuronal dysfunction is induced by diffusible oligomers of misfolded proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmPK-IDaBZirVg90H21EOLACvtfcHk0lgIu5hMMwKSzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotFKmtw%253D%253D&md5=e8634ff5c1491580f623c90ded91b4be</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrm2101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2101%26sid%3Dliteratum%253Aachs%26aulast%3DHaass%26aufirst%3DC.%26aulast%3DSelkoe%26aufirst%3DD.%2BJ.%26atitle%3DSoluble%2520protein%2520oligomers%2520in%2520neurodegeneration%253A%2520lesson%2520from%2520the%2520Alzheimer%25E2%2580%2599s%2520amyloid%2520%25CE%25B2-peptide%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2007%26volume%3D8%26spage%3D101%26epage%3D112%26doi%3D10.1038%2Fnrm2101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, R.</span></span> <span> </span><span class="NLM_article-title">Inhibition of BACE1 for therapeutic use in Alzheimer’s disease</span>. <i>Int. J. Clin. Exp. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">618</span>– <span class="NLM_lpage">628</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=20661410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptFagtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=618-628&author=X.+Luoauthor=R.+Yan&title=Inhibition+of+BACE1+for+therapeutic+use+in+Alzheimer%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of BACE1 for therapeutic use in Alzheimer's disease</span></div><div class="casAuthors">Luo, Xiaoyang; Yan, Riqiang</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical and Experimental Pathology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">618-628</span>CODEN:
                <span class="NLM_cas:coden">IJCEC7</span>;
        ISSN:<span class="NLM_cas:issn">1936-2625</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">A review.  Since BACE1 was reported as the β-secretase in Alzheimer's disease (AD) over ten years ago, encouraging progress has been made toward understanding the cellular functions of BACE1.  Genetic studies have further confirmed that BACE1 is essential for processing amyloid precursor protein (APP) at the β-secretase site.  Only after this cleavage can the membrane-bound APP C-terminal fragment be subsequently cleaved by γ-secretase to release so-called AD-causing Aβ peptides.  Hence, in the past decade, a wide variety of BACE1 inhibitors have been developed for AD therapy.  This review will summarize the major historical events during the evolution of BACE1 inhibitors designed through different strategies of drug discovery.  Although BACE1 inhibitors are expected to be safe in general, careful titrn. of drug dosage to avoid undesirable side effects in BACE1-directed AD therapy is also emphasized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUFz1x-AF9XbVg90H21EOLACvtfcHk0lgM6RYU0jRLjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptFagtbo%253D&md5=0cf2745b97b31229b1de6b7db04911e2</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DYan%26aufirst%3DR.%26atitle%3DInhibition%2520of%2520BACE1%2520for%2520therapeutic%2520use%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DInt.%2520J.%2520Clin.%2520Exp.%2520Pathol.%26date%3D2010%26volume%3D3%26spage%3D618%26epage%3D628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Citron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckman, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corcoran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostaszewski, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levesque, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. George Hyslop, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younkin, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selkoe, D. J.</span></span> <span> </span><span class="NLM_article-title">Additive effects of PS1 and APP mutations on secretion of the 42-residue amyloid β-protein</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1006/nbdi.1998.0183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1006%2Fnbdi.1998.0183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=9746908" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADyaK1cXmtlenurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1998&pages=107-116&issue=2&author=M.+Citronauthor=C.+B.+Eckmanauthor=T.+S.+Diehlauthor=C.+Corcoranauthor=B.+L.+Ostaszewskiauthor=W.+Xiaauthor=G.+Levesqueauthor=P.+St.+George+Hyslopauthor=S.+G.+Younkinauthor=D.+J.+Selkoe&title=Additive+effects+of+PS1+and+APP+mutations+on+secretion+of+the+42-residue+amyloid+%CE%B2-protein&doi=10.1006%2Fnbdi.1998.0183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Additive effects of PS1 and APP mutations on secretion of the 42-residue amyloid β-protein</span></div><div class="casAuthors">Citron, Martin; Eckman, Christopher B.; Diehl, Thekla S.; Corcoran, Chris; Ostaszewski, Beth L.; Xia, Weiming; Levesque, Georges; St. George Hyslop, Peter; Younkin, Steven G.; Selkoe, Dennis J.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">107-116</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Humans harboring missense mutations in the presenilin 1 (PS1) gene undergo progressive cerebral deposition of the 42-residue amyloid β-protein (Aβ42) at an early age and develop severe Alzheimer's disease.  Aβ42 is selectively elevated in the conditioned media of cells expressing mutant but not wild-type PS1, indicating that presenilin mutations alter APP processing.  Here we analyze the effects of various PS1 mutant constructs on the cellular prodn. of Aβ42.  A construct expressing only the PS1 N-terminal endoproteolytic fragment with the mutation Y115H causes no significant increase in Aβ42, whereas a full-length PS1 construct with the same mutation does.  This result suggests that the pathogenic effect of mutant presenilins is produced by the full-length mol. even though only a minor proportion of total PS1 occurs as holoprotein in tissues and cell lines.  We demonstrate that the effects of two different PS1 mutations are additive when engineered into the same PS1 mol.  Therefore, two mutations alter γ-secretase processing of APP more than one and the PS1 mutations described to date do not cause the max. possible PS1-mediated rise in Aβ42.  When a PS1 mutation was expressed in cells carrying the APPv7171 mutation, Aβ42 rose dramatically to become the predominant secreted Aβ species, an observation of interest for transgenic modeling of AD.  Our results are consistent with the hypothesis that presenilin is a major regulator of the proteolytic processing of APP by γ-secretases.  (c) 1998 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0ck6RE7yz9LVg90H21EOLACvtfcHk0lgM6RYU0jRLjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtlenurg%253D&md5=afd0de91ae36a1981ce9644f876ee1c1</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1006%2Fnbdi.1998.0183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fnbdi.1998.0183%26sid%3Dliteratum%253Aachs%26aulast%3DCitron%26aufirst%3DM.%26aulast%3DEckman%26aufirst%3DC.%2BB.%26aulast%3DDiehl%26aufirst%3DT.%2BS.%26aulast%3DCorcoran%26aufirst%3DC.%26aulast%3DOstaszewski%26aufirst%3DB.%2BL.%26aulast%3DXia%26aufirst%3DW.%26aulast%3DLevesque%26aufirst%3DG.%26aulast%3DSt.%2BGeorge%2BHyslop%26aufirst%3DP.%26aulast%3DYounkin%26aufirst%3DS.%2BG.%26aulast%3DSelkoe%26aufirst%3DD.%2BJ.%26atitle%3DAdditive%2520effects%2520of%2520PS1%2520and%2520APP%2520mutations%2520on%2520secretion%2520of%2520the%252042-residue%2520amyloid%2520%25CE%25B2-protein%26jtitle%3DNeurobiol.%2520Dis.%26date%3D1998%26volume%3D5%26issue%3D2%26spage%3D107%26epage%3D116%26doi%3D10.1006%2Fnbdi.1998.0183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnsson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atwal, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snaedal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefansson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulem, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gudbjartsson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoyte, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gustafson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhangale, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huttenlocher, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bjornsdottir, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreassen, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jönsson, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palotie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behrens, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, O. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thorsteinsdottir, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watts, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefansson, K.</span></span> <span> </span><span class="NLM_article-title">A mutation in <i>APP</i> protects against Alzheimer’s disease and age-related cognitive decline</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>488</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1038/nature11283</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1038%2Fnature11283" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=22801501" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=488&publication_year=2012&pages=96-99&author=T.+Johnssonauthor=J.+K.+Atwalauthor=S.+Steinbergauthor=J.+Snaedalauthor=P.+V.+Jonssonauthor=S.+Bjornssonauthor=H.+Stefanssonauthor=P.+Sulemauthor=D.+Gudbjartssonauthor=J.+Maloneyauthor=K.+Hoyteauthor=A.+Gustafsonauthor=Y.+Liuauthor=Y.+Luauthor=T.+Bhangaleauthor=R.+B.+Grahamauthor=J.+Huttenlocherauthor=G.+Bjornsdottirauthor=O.+A.+Andreassenauthor=E.+G.+J%C3%B6nssonauthor=A.+Palotieauthor=T.+W.+Behrensauthor=O.+T.+Magnussonauthor=A.+Kongauthor=U.+Thorsteinsdottirauthor=R.+J.+Wattsauthor=K.+Stefansson&title=A+mutation+in+APP+protects+against+Alzheimer%E2%80%99s+disease+and+age-related+cognitive+decline&doi=10.1038%2Fnature11283"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature11283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11283%26sid%3Dliteratum%253Aachs%26aulast%3DJohnsson%26aufirst%3DT.%26aulast%3DAtwal%26aufirst%3DJ.%2BK.%26aulast%3DSteinberg%26aufirst%3DS.%26aulast%3DSnaedal%26aufirst%3DJ.%26aulast%3DJonsson%26aufirst%3DP.%2BV.%26aulast%3DBjornsson%26aufirst%3DS.%26aulast%3DStefansson%26aufirst%3DH.%26aulast%3DSulem%26aufirst%3DP.%26aulast%3DGudbjartsson%26aufirst%3DD.%26aulast%3DMaloney%26aufirst%3DJ.%26aulast%3DHoyte%26aufirst%3DK.%26aulast%3DGustafson%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DBhangale%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DR.%2BB.%26aulast%3DHuttenlocher%26aufirst%3DJ.%26aulast%3DBjornsdottir%26aufirst%3DG.%26aulast%3DAndreassen%26aufirst%3DO.%2BA.%26aulast%3DJ%25C3%25B6nsson%26aufirst%3DE.%2BG.%26aulast%3DPalotie%26aufirst%3DA.%26aulast%3DBehrens%26aufirst%3DT.%2BW.%26aulast%3DMagnusson%26aufirst%3DO.%2BT.%26aulast%3DKong%26aufirst%3DA.%26aulast%3DThorsteinsdottir%26aufirst%3DU.%26aulast%3DWatts%26aufirst%3DR.%2BJ.%26aulast%3DStefansson%26aufirst%3DK.%26atitle%3DA%2520mutation%2520in%2520APP%2520protects%2520against%2520Alzheimer%25E2%2580%2599s%2520disease%2520and%2520age-related%2520cognitive%2520decline%26jtitle%3DNature%26date%3D2012%26volume%3D488%26spage%3D96%26epage%3D99%26doi%3D10.1038%2Fnature11283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hussain, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howlett, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tew, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gloger, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Southan, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingwall, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christie, G.</span></span> <span> </span><span class="NLM_article-title">Identification of a novel aspartic protease (Asp 2) as β-Secretase</span>. <i>Mol. Cell. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">427</span>, <span class="refDoi"> DOI: 10.1006/mcne.1999.0811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1006%2Fmcne.1999.0811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10656250" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADyaK1MXnt1Chsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1999&pages=419-427&author=I.+Hussainauthor=D.+Powellauthor=D.+R.+Howlettauthor=D.+G.+Tewauthor=T.+D.+Meekauthor=C.+Chapmanauthor=I.+S.+Glogerauthor=K.+E.+Murphyauthor=C.+D.+Southanauthor=D.+M.+Ryanauthor=T.+S.+Smithauthor=D.+L.+Simmonsauthor=F.+S.+Walshauthor=C.+Dingwallauthor=G.+Christie&title=Identification+of+a+novel+aspartic+protease+%28Asp+2%29+as+%CE%B2-Secretase&doi=10.1006%2Fmcne.1999.0811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase</span></div><div class="casAuthors">Hussain, Ishrut; Powell, David; Howlett, David R.; Tew, David G.; Meek, Thomas D.; Chapman, Conrad; Gloger, Israel S.; Murphy, Kay E.; Southan, Christopher D.; Ryan, Dominic M.; Smith, Trudi S.; Simmons, David L.; Walsh, Frank S.; Dingwall, Colin; Christie, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Neuroscience</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">419-427</span>CODEN:
                <span class="NLM_cas:coden">MOCNED</span>;
        ISSN:<span class="NLM_cas:issn">1044-7431</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The Alzheimer's disease β-amyloid peptide (Aβ) is produced by excision from the type 1 integral membrane glycoprotein amyloid precursor protein (APP) by the sequential actions of β- and then γ-secretases.  Here we report that Asp 2, a novel transmembrane aspartic protease, has the key activities expected of β-secretase.  Transient expression of Asp 2 in cells expressing APP causes an increase in the secretion of the N-terminal fragment of APP and an increase in the cell-assocd. C-terminal β-secretase APP fragment.  Mutation of either of the putative catalytic aspartyl residues in Asp 2 abrogates the prodn. of the fragments characteristic of cleavage at the β-secretase site.  The enzyme is present in normal and Alzheimer's disease (AD) brain and is also found in cell lines known to produce Aβ.  Asp 2 localizes to the Golgi/endoplasmic reticulum in transfected cells and shows clear colocalization with APP in cells stably expressing the 751-amino-acid isoform of APP.  (c) 1999 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDUBbUoO6SgLVg90H21EOLACvtfcHk0lgM6RYU0jRLjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXnt1Chsrs%253D&md5=aba834d907c5dae03f060d94729576e9</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1006%2Fmcne.1999.0811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fmcne.1999.0811%26sid%3Dliteratum%253Aachs%26aulast%3DHussain%26aufirst%3DI.%26aulast%3DPowell%26aufirst%3DD.%26aulast%3DHowlett%26aufirst%3DD.%2BR.%26aulast%3DTew%26aufirst%3DD.%2BG.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26aulast%3DChapman%26aufirst%3DC.%26aulast%3DGloger%26aufirst%3DI.%2BS.%26aulast%3DMurphy%26aufirst%3DK.%2BE.%26aulast%3DSouthan%26aufirst%3DC.%2BD.%26aulast%3DRyan%26aufirst%3DD.%2BM.%26aulast%3DSmith%26aufirst%3DT.%2BS.%26aulast%3DSimmons%26aufirst%3DD.%2BL.%26aulast%3DWalsh%26aufirst%3DF.%2BS.%26aulast%3DDingwall%26aufirst%3DC.%26aulast%3DChristie%26aufirst%3DG.%26atitle%3DIdentification%2520of%2520a%2520novel%2520aspartic%2520protease%2520%2528Asp%25202%2529%2520as%2520%25CE%25B2-Secretase%26jtitle%3DMol.%2520Cell.%2520Neurosci.%26date%3D1999%26volume%3D14%26spage%3D419%26epage%3D427%26doi%3D10.1006%2Fmcne.1999.0811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Probst, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. Z.</span></span> <span> </span><span class="NLM_article-title">Small-molecule BACE1 inhibitors: a patent literature review (2006 - 2011)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">511</span>– <span class="NLM_lpage">540</span>, <span class="refDoi"> DOI: 10.1517/13543776.2012.681302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1517%2F13543776.2012.681302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=22512789" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC38XmvFais7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=511-540&author=G.+Probstauthor=Y.+Z.+Xu&title=Small-molecule+BACE1+inhibitors%3A+a+patent+literature+review+%282006+-+2011%29&doi=10.1517%2F13543776.2012.681302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule BACE1 inhibitors: a patent literature review (2006 - 2011)</span></div><div class="casAuthors">Probst, Gary; Xu, Ying-zi</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">511-540</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Alzheimer's disease is a devastating neurodegenerative disorder for which no disease-modifying therapy exists.  The amyloid hypothesis, which implicates Aβ as the toxin initiating a biol. cascade leading to neurodegeneration, is the most prominent theory concerning the underlying cause of the disease.  BACE1 is one of two aspartyl proteinases that generate Aβ, thus inhibition of BACE1 has the potential to ameliorate the progression of Alzheimer's disease by abating the prodn. of Aβ.  Areas covered: This review chronicles small-mol. BACE1 inhibitors as described in the patent literature between 2006 and 2011 and their potential use as disease-modifying treatments for Alzheimer's disease.  Over the past half a dozen years, numerous BACE1 inhibitors have been published in the patent applications, but often these contain a paltry amt. of pertinent biol. data (e.g. potency, selectivity, and efficacy).  Fortunately, numerous relevant publications contg. important data have appeared in the journal literature during this period.  The goal in this effort was to create an amalgam of the two records to add value to this review.  Expert opinion: The pharmaceutical industry has made tremendous progress in the development of small-mol. BACE1 inhibitors that lower Aβ in the central nervous system.  Assuming the amyloid hypothesis is veracious, we anticipate a disease-modifying therapy to combat Alzheimer's disease is near.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp89KaCi3q5Z7Vg90H21EOLACvtfcHk0lhaIZD4ns7Utg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmvFais7g%253D&md5=174bdc47fbca5aa1f8248dbf03ce402b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1517%2F13543776.2012.681302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2012.681302%26sid%3Dliteratum%253Aachs%26aulast%3DProbst%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DY.%2BZ.%26atitle%3DSmall-molecule%2520BACE1%2520inhibitors%253A%2520a%2520patent%2520literature%2520review%2520%25282006%2520-%25202011%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2012%26volume%3D22%26spage%3D511%26epage%3D540%26doi%3D10.1517%2F13543776.2012.681302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vassar, R.</span></span> <span> </span><span class="NLM_article-title">BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease</span>. <i>Alzheimer’s Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1186/s13195-014-0089-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1186%2Fs13195-014-0089-7" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=1-14&author=R.+Vassar&title=BACE1+inhibitor+drugs+in+clinical+trials+for+Alzheimer%E2%80%99s+disease&doi=10.1186%2Fs13195-014-0089-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1186%2Fs13195-014-0089-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13195-014-0089-7%26sid%3Dliteratum%253Aachs%26aulast%3DVassar%26aufirst%3DR.%26atitle%3DBACE1%2520inhibitor%2520drugs%2520in%2520clinical%2520trials%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DAlzheimer%25E2%2580%2599s%2520Res.%2520Ther.%26date%3D2014%26volume%3D6%26spage%3D1%26epage%3D14%26doi%3D10.1186%2Fs13195-014-0089-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coimbra, J. R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marques, D. F. F</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baptista, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, C. M. F</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, P. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinis, T. C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvador, J. A. R.</span></span> <span> </span><span class="NLM_article-title">Highlights in BACE1 inhibitors for Alzheimer’s disease treatment</span>. <i>Front. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">178</span> <span class="refDoi"> DOI: 10.3389/fchem.2018.00178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.3389%2Ffchem.2018.00178" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=29881722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisV2mtr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&author=J.+R.+M.+Coimbraauthor=D.+F.+F+Marquesauthor=S.+J.+Baptistaauthor=C.+M.+F+Pereiraauthor=P.+I.+Moreiraauthor=T.+C.+P.+Dinisauthor=A.+E.+Santosauthor=J.+A.+R.+Salvador&title=Highlights+in+BACE1+inhibitors+for+Alzheimer%E2%80%99s+disease+treatment&doi=10.3389%2Ffchem.2018.00178"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Highlights in bace1 inhibitors for alzheimer's disease treatment</span></div><div class="casAuthors">Coimbra, Judite R. M.; Marques, Daniela F. F.; Baptista, Salete J.; Pereira, Claudia M. F.; Moreira, Paula I.; Dinis, Teresa C. P.; Santos, Armanda E.; Salvador, Jorge A. R.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Chemistry (Lausanne, Switzerland)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">178/1-178/10</span>CODEN:
                <span class="NLM_cas:coden">FCLSAA</span>;
        ISSN:<span class="NLM_cas:issn">2296-2646</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is a severe neurodegenerative disorder and the most common type of dementia in the elderly.  The clin. symptoms of AD include a progressive loss of memory and impairment of cognitive functions interfering with daily life activities.  The main neuropathol. features consist in extracellular amyloid-β (Aβ) plaque deposition and intracellular Neurofibrillary tangles (NFTs) of hyperphosphorylated Tau.  Understanding the pathophysiol. mechanisms that underlie neurodegeneration in AD is essential for rational design of neuroprotective agents able to prevent disease progression.  According to the "Amyloid Cascade Hypothesis" the crit. mol. event in the pathogenesis of AD is the accumulation of Aβ neurotoxic oligomers.  Since the proteolytic processing of Amyloid Precursor Protein (APP) by β-secretase (beta-site APP cleaving enzyme 1, BACE1) is the rate-limiting step in the prodn. of Aβ, this enzyme is considered a major therapeutic target and BACE1 inhibitors have the potential to be disease-modifying drugs for AD treatment.  Therefore, intensive efforts to discover and develop inhibitors that can reach the brain and effectively inhibit BACE1 have been pursued by several groups worldwide.  The aim of this review is to highlight the progress in the discovery of potent and selective small mol. BACE1 inhibitors over the past decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyV_176RT6cLVg90H21EOLACvtfcHk0lhaIZD4ns7Utg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisV2mtr3N&md5=79f20f1bde2dd9993b8b84ba1f188274</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.3389%2Ffchem.2018.00178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffchem.2018.00178%26sid%3Dliteratum%253Aachs%26aulast%3DCoimbra%26aufirst%3DJ.%2BR.%2BM.%26aulast%3DMarques%26aufirst%3DD.%2BF.%2BF%26aulast%3DBaptista%26aufirst%3DS.%2BJ.%26aulast%3DPereira%26aufirst%3DC.%2BM.%2BF%26aulast%3DMoreira%26aufirst%3DP.%2BI.%26aulast%3DDinis%26aufirst%3DT.%2BC.%2BP.%26aulast%3DSantos%26aufirst%3DA.%2BE.%26aulast%3DSalvador%26aufirst%3DJ.%2BA.%2BR.%26atitle%3DHighlights%2520in%2520BACE1%2520inhibitors%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%2520treatment%26jtitle%3DFront.%2520Chem.%26date%3D2018%26volume%3D6%26doi%3D10.3389%2Ffchem.2018.00178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Panza, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lozupone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Logroscino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imbimbo, B. P.</span></span> <span> </span><span class="NLM_article-title">A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease</span>. <i>Nat. Rev. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">73</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1038/s41582-018-0116-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1038%2Fs41582-018-0116-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=30610216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A280%3ADC%252BB3cnotFagtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=73-88&author=F.+Panzaauthor=M.+Lozuponeauthor=G.+Logroscinoauthor=B.+P.+Imbimbo&title=A+critical+appraisal+of+amyloid-%CE%B2-targeting+therapies+for+Alzheimer+disease&doi=10.1038%2Fs41582-018-0116-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease</span></div><div class="casAuthors">Panza Francesco; Lozupone Madia; Logroscino Giancarlo; Panza Francesco; Logroscino Giancarlo; Panza Francesco; Imbimbo Bruno P</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Neurology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">73-88</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Brain accumulation of the amyloid-β (Aβ) peptide is believed to be the initial event in the Alzheimer disease (AD) process.  Aβ accumulation begins 15-20 years before clinical symptoms occur, mainly owing to defective brain clearance of the peptide.  Over the past 20 years, we have seen intensive efforts to decrease the levels of Aβ monomers, oligomers, aggregates and plaques using compounds that decrease production, antagonize aggregation or increase brain clearance of Aβ.  Unfortunately, these approaches have failed to show clinical benefit in large clinical trials involving patients with mild to moderate AD.  Clinical trials in patients at earlier stages of the disease are ongoing, but the initial results have not been clinically impressive.  Efforts are now being directed against Aβ oligomers, the most neurotoxic molecular species, and monoclonal antibodies directed against these oligomers are producing encouraging results.  However, Aβ oligomers are in equilibrium with both monomeric and aggregated species; thus, previous drugs that efficiently removed monomeric Aβ or Aβ plaques should have produced clinical benefits.  In patients with sporadic AD, Aβ accumulation could be a reactive compensatory response to neuronal damage of unknown cause, and alternative strategies, including interference with modifiable risk factors, might be needed to defeat this devastating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQwevf7x6znXRjv2lLSLOxFfW6udTcc2eauaXlzyx2BFLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnotFagtA%253D%253D&md5=fa63b5a3ca7e25169dfd6566f56b5152</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fs41582-018-0116-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41582-018-0116-6%26sid%3Dliteratum%253Aachs%26aulast%3DPanza%26aufirst%3DF.%26aulast%3DLozupone%26aufirst%3DM.%26aulast%3DLogroscino%26aufirst%3DG.%26aulast%3DImbimbo%26aufirst%3DB.%2BP.%26atitle%3DA%2520critical%2520appraisal%2520of%2520amyloid-%25CE%25B2-targeting%2520therapies%2520for%2520Alzheimer%2520disease%26jtitle%3DNat.%2520Rev.%2520Neurol.%26date%3D2019%26volume%3D15%26spage%3D73%26epage%3D88%26doi%3D10.1038%2Fs41582-018-0116-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bateman, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benzinger, T. L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fagan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcus, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cairns, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blazey, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holtzman, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santacruz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckles, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliver, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulder, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisen, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghetti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klunk, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDade, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masters, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayeux, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringman, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossor, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schofield, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperling, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salloway, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, J. C.</span></span> <span> </span><span class="NLM_article-title">Clinical and biomarker changes in dominantly inherited Alzheimer’s disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">795</span>– <span class="NLM_lpage">804</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1202753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1056%2FNEJMoa1202753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=22784036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlGktL7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2012&pages=795-804&author=R.+J.+Batemanauthor=C.+Xiongauthor=T.+L.+S.+Benzingerauthor=A.+M.+Faganauthor=A.+Goateauthor=N.+C.+Foxauthor=D.+S.+Marcusauthor=N.+J.+Cairnsauthor=X.+Xieauthor=T.+M.+Blazeyauthor=D.+M.+Holtzmanauthor=A.+Santacruzauthor=V.+Bucklesauthor=A.+Oliverauthor=K.+Moulderauthor=P.+S.+Aisenauthor=B.+Ghettiauthor=W.+E.+Klunkauthor=E.+McDadeauthor=R.+N.+Martinsauthor=C.+L.+Mastersauthor=R.+Mayeuxauthor=J.+M.+Ringmanauthor=M.+N.+Rossorauthor=P.+R.+Schofieldauthor=R.+A.+Sperlingauthor=S.+Sallowayauthor=J.+C.+Morris&title=Clinical+and+biomarker+changes+in+dominantly+inherited+Alzheimer%E2%80%99s+disease&doi=10.1056%2FNEJMoa1202753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical and biomarker changes in dominantly inherited Alzheimer's disease</span></div><div class="casAuthors">Bateman, Randall J.; Xiong, Chengjie; Benzinger, Tammie L. S.; Fagan, Anne M.; Goate, Alison; Fox, Nick C.; Marcus, Daniel S.; Cairns, Nigel J.; Xie, Xianyun; Blazey, Tyler M.; Holtzman, David M.; Santacruz, Anna; Buckles, Virginia; Oliver, Angela; Moulder, Krista; Aisen, Paul S.; Ghetti, Bernardino; Klunk, William E.; McDade, Eric; Martins, Ralph N.; Masters, Colin L.; Mayeux, Richard; Ringman, John M.; Rossor, Martin N.; Schofield, Peter R.; Sperling, Reisa A.; Salloway, Stephen; Morris, John C.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">795-804</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: The order and magnitude of pathol. processes in Alzheimer's disease are not well understood, partly because the disease develops over many years.  Autosomal dominant Alzheimer's disease has a predictable age at onset and provides an opportunity to det. the sequence and magnitude of pathol. changes that culminate in symptomatic disease.  METHODS: In this prospective, longitudinal study, we analyzed data from 128 participants who underwent baseline clin. and cognitive assessments, brain imaging, and cerebrospinal fluid (CSF) and blood tests.  We used the participant's age at baseline assessment and the parent's age at the onset of symptoms of Alzheimer's disease to calc. the estd. years from expected symptom onset (age of the participant minus parent's age at symptom onset).  We conducted cross-sectional analyses of baseline data in relation to estd. years from expected symptom onset in order to det. the relative order and magnitude of pathophysiol. changes.  RESULTS: Concns. of amyloid-beta (Aβ)42 in the CSF appeared to decline 25 years before expected symptom onset.  Aβ deposition, as measured by positron-emission tomog. with the use of Pittsburgh compd. B, was detected 15 years before expected symptom onset.  Increased concns. of tau protein in the CSF and an increase in brain atrophy were detected 15 years before expected symptom onset.  Cerebral hypometabolism and impaired episodic memory were obsd. 10 years before expected symptom onset.  Global cognitive impairment, as measured by the Mini-Mental State Examn. and the Clin. Dementia Rating scale, was detected 5 years before expected symptom onset, and patients met diagnostic criteria for dementia at an av. of 3 years after expected symptom onset.  CONCLUSIONS: We found that autosomal dominant Alzheimer's disease was assocd. with a series of pathophysiol. changes over decades in CSF biochem. markers of Alzheimer's disease, brain amyloid deposition, and brain metab. as well as progressive cognitive impairment.  Our results require confirmation with the use of longitudinal data and may not apply to patients with sporadic Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptJNV9eDXBCLVg90H21EOLACvtfcHk0ljpxJBbrOMycQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlGktL7J&md5=c4f999ea3401af9651a2770724757bed</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1202753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1202753%26sid%3Dliteratum%253Aachs%26aulast%3DBateman%26aufirst%3DR.%2BJ.%26aulast%3DXiong%26aufirst%3DC.%26aulast%3DBenzinger%26aufirst%3DT.%2BL.%2BS.%26aulast%3DFagan%26aufirst%3DA.%2BM.%26aulast%3DGoate%26aufirst%3DA.%26aulast%3DFox%26aufirst%3DN.%2BC.%26aulast%3DMarcus%26aufirst%3DD.%2BS.%26aulast%3DCairns%26aufirst%3DN.%2BJ.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DBlazey%26aufirst%3DT.%2BM.%26aulast%3DHoltzman%26aufirst%3DD.%2BM.%26aulast%3DSantacruz%26aufirst%3DA.%26aulast%3DBuckles%26aufirst%3DV.%26aulast%3DOliver%26aufirst%3DA.%26aulast%3DMoulder%26aufirst%3DK.%26aulast%3DAisen%26aufirst%3DP.%2BS.%26aulast%3DGhetti%26aufirst%3DB.%26aulast%3DKlunk%26aufirst%3DW.%2BE.%26aulast%3DMcDade%26aufirst%3DE.%26aulast%3DMartins%26aufirst%3DR.%2BN.%26aulast%3DMasters%26aufirst%3DC.%2BL.%26aulast%3DMayeux%26aufirst%3DR.%26aulast%3DRingman%26aufirst%3DJ.%2BM.%26aulast%3DRossor%26aufirst%3DM.%2BN.%26aulast%3DSchofield%26aufirst%3DP.%2BR.%26aulast%3DSperling%26aufirst%3DR.%2BA.%26aulast%3DSalloway%26aufirst%3DS.%26aulast%3DMorris%26aufirst%3DJ.%2BC.%26atitle%3DClinical%2520and%2520biomarker%2520changes%2520in%2520dominantly%2520inherited%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D367%26spage%3D795%26epage%3D804%26doi%3D10.1056%2FNEJMoa1202753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mormino, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betensky, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedden, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huijbers, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rentz, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperling, R. A.</span></span> <span> </span><span class="NLM_article-title">Amyloid and <i>APOE ε4</i> interact to influence short-term decline in preclinical Alzheimer disease</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">1760</span>– <span class="NLM_lpage">1767</span>, <span class="refDoi"> DOI: 10.1212/WNL.0000000000000431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1212%2FWNL.0000000000000431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=24748674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVOnsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2014&pages=1760-1767&author=E.+C.+Morminoauthor=R.+A.+Betenskyauthor=T.+Heddenauthor=A.+P.+Schultzauthor=A.+Wardauthor=W.+Huijbersauthor=D.+M.+Rentzauthor=K.+A.+Johnsonauthor=R.+A.+Sperling&title=Amyloid+and+APOE+%CE%B54+interact+to+influence+short-term+decline+in+preclinical+Alzheimer+disease&doi=10.1212%2FWNL.0000000000000431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease</span></div><div class="casAuthors">Mormino, Elizabeth C.; Betensky, Rebecca A.; Hedden, Trey; Schultz, Aaron P.; Ward, Andrew; Huijbers, Willem; Rentz, Dorene M.; Johnson, Keith A.; Sperling, Reisa A.</div><div class="citationInfo"><span class="NLM_cas:title">Neurology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1760-1767</span>CODEN:
                <span class="NLM_cas:coden">NEURAI</span>;
        ISSN:<span class="NLM_cas:issn">0028-3878</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objective: To examine whether β-amyloid (Aβ) and APOE ε4 status independently contribute or interact to influence longitudinal cognitive decline in clin. normal older individuals (CN).  Methods: Data from 490 CNs were aggregated across 3 observational cohort studies (Harvard Aging Brain Study, Alzheimer's Disease Neuroimaging Initiative, and Australian Imaging Biomarkers and Lifestyle Study of Ageing; median age = 75.0 years, 255 female), and the contributions of APOE ε4 and Aβ on longitudinal change over a median of 1.49 years were examd.  Cognitive decline was assessed with the Mini-Mental State Examn. (MMSE) and Logical Memory (immediate and delayed recall scores).  Results: High Aβ participants were more likely to be APOE ε4+ than low Aβ participants.  CNs who were both high Aβ and APOE ε4+ showed greater decline in Logical Memory immediate recall (p < 0.087), Logical Memory delayed recall (p < 0.024), and MMSE (p < 0.034) compared to all other groups (low Aβ/APOE ε4-, low Aβ/APOE ε4+, and high Aβ/APOE ε4-).  No other pairwise contrast was significant for any cognitive measure.  Conclusions: Clin. normal individuals who are APOE ε4+ and have high Aβ showed the highest cognitive decline.  These results suggest that Aβ and APOE ε4 are not redundant contributors of decline in aging but rather interact to promote decline during the short follow-up period examd. in this study.  Longer follow-up periods will be essential to fully elucidate the influence of Alzheimer disease risk factors on cognitive decline in aging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUJjazGeok1LVg90H21EOLACvtfcHk0ljpxJBbrOMycQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVOnsro%253D&md5=62007857d5f1d384f9e1efe164162847</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1212%2FWNL.0000000000000431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252FWNL.0000000000000431%26sid%3Dliteratum%253Aachs%26aulast%3DMormino%26aufirst%3DE.%2BC.%26aulast%3DBetensky%26aufirst%3DR.%2BA.%26aulast%3DHedden%26aufirst%3DT.%26aulast%3DSchultz%26aufirst%3DA.%2BP.%26aulast%3DWard%26aufirst%3DA.%26aulast%3DHuijbers%26aufirst%3DW.%26aulast%3DRentz%26aufirst%3DD.%2BM.%26aulast%3DJohnson%26aufirst%3DK.%2BA.%26aulast%3DSperling%26aufirst%3DR.%2BA.%26atitle%3DAmyloid%2520and%2520APOE%2520%25CE%25B54%2520interact%2520to%2520influence%2520short-term%2520decline%2520in%2520preclinical%2520Alzheimer%2520disease%26jtitle%3DNeurology%26date%3D2014%26volume%3D82%26spage%3D1760%26epage%3D1767%26doi%3D10.1212%2FWNL.0000000000000431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Villemagne, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burnham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourgeat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvado, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szoeke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macaulay, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruff, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ames, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masters, C. L.</span></span> <span> </span><span class="NLM_article-title">Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(13)70044-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1016%2FS1474-4422%2813%2970044-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=23477989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksFejsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=357-367&author=V.+L.+Villemagneauthor=S.+Burnhamauthor=P.+Bourgeatauthor=B.+Brownauthor=K.+A.+Ellisauthor=O.+Salvadoauthor=C.+Szoekeauthor=S.+L.+Macaulayauthor=R.+Martinsauthor=P.+Maruffauthor=D.+Amesauthor=C.+C.+Roweauthor=C.+L.+Masters&title=Amyloid+%CE%B2+deposition%2C+neurodegeneration%2C+and+cognitive+decline+in+sporadic+Alzheimer%E2%80%99s+disease%3A+a+prospective+cohort+study&doi=10.1016%2FS1474-4422%2813%2970044-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study</span></div><div class="casAuthors">Villemagne, Victor L.; Burnham, Samantha; Bourgeat, Pierrick; Brown, Belinda; Ellis, Kathryn A.; Salvado, Olivier; Szoeke, Cassandra; Macaulay, S. Lance; Martins, Ralph; Maruff, Paul; Ames, David; Rowe, Christopher C.; Masters, Colin L.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">357-367</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Similar to most chronic diseases, Alzheimer's disease (AD) develops slowly from a preclin. phase into a fully expressed clin. syndrome.  We aimed to use longitudinal data to calc. the rates of amyloid β (Aβ) deposition, cerebral atrophy, and cognitive decline.  In this prospective cohort study, healthy controls, patients with mild cognitive impairment (MCI), and patients with AD were assessed at enrolment and every 18 mo.  At every visit, participants underwent neuropsychol. examn., MRI, and a carbon-11-labeled Pittsburgh compd. B (11C-PiB) PET scan.  We included participants with three or more 11C-PiB PET follow-up assessments.  Aβ burden was expressed as 11C-PiB standardised uptake value ratio (SUVR) with the cerebellar cortex as ref. region.  An SUVR of 1·5 was used to discriminate high from low Aβ burdens.  The slope of the regression plots over 3-5 years was used to est. rates of change for Aβ deposition, MRI volumetrics, and cognition.  We included those participants with a pos. rate of Aβ deposition to calc. the trajectory of each variable over time.200 participants (145 healthy controls, 36 participants with MCI, and 19 participants with AD) were assessed at enrolment and every 18 mo for a mean follow-up of 3·8 (95% CI CI 3·6-3·9) years.  At baseline, significantly higher Aβ burdens were noted in patients with AD (2·27, SD 0·43) and those with MCI (1·94, 0·64) than in healthy controls (1·38, 0·39).  At follow-up, 163 (82%) of the 200 participants showed pos. rates of Aβ accumulation.  Aβ deposition was estd. to take 19·2 (95% CI 16·8-22·5) years in an almost linear fashion-with a mean increase of 0·043 (95% CI 0·037-0·049) SUVR per yr-to go from the threshold of 11C-PiB positivity (1·5 SUVR) to the levels obsd. in AD.  It was estd. to take 12·0 (95% CI 10·1-14·9) years from the levels obsd. in healthy controls with low Aβ deposition (1·2 [SD 0·1] SUVR) to the threshold of 11C-PiB positivity.  As AD progressed, the rate of Aβ deposition slowed towards a plateau.  Our projections suggest a prolonged preclin. phase of AD in which Aβ deposition reaches our threshold of positivity at 17·0 (95% CI 14·9-19·9) years, hippocampal atrophy at 4·2 (3·6-5·1) years, and memory impairment at 3·3 (2·5-4·5) years before the onset of dementia (clin. dementia rating score 1).  Aβ deposition is slow and protracted, likely to extend for more than two decades.  Such predictions of the rate of preclin. changes and the onset of the clin. phase of AD will facilitate the design and timing of therapeutic interventions aimed at modifying the course of this illness.  Science and Industry Endowment Fund (Australia), The Commonwealth Scientific and Industrial Research Organization (Australia), The National Health and Medical Research Council of Australia Program and Project Grants, the Austin Hospital Medical Research Foundation, Victorian State Government, The Alzheimer's Drug Discovery Foundation, and the Alzheimer's Assocn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH2O2TjFkaAbVg90H21EOLACvtfcHk0lgjgEkbN2GVCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksFejsrw%253D&md5=2e325131e69aea18b4f6a7cc756bcc55</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2813%2970044-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252813%252970044-9%26sid%3Dliteratum%253Aachs%26aulast%3DVillemagne%26aufirst%3DV.%2BL.%26aulast%3DBurnham%26aufirst%3DS.%26aulast%3DBourgeat%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DB.%26aulast%3DEllis%26aufirst%3DK.%2BA.%26aulast%3DSalvado%26aufirst%3DO.%26aulast%3DSzoeke%26aufirst%3DC.%26aulast%3DMacaulay%26aufirst%3DS.%2BL.%26aulast%3DMartins%26aufirst%3DR.%26aulast%3DMaruff%26aufirst%3DP.%26aulast%3DAmes%26aufirst%3DD.%26aulast%3DRowe%26aufirst%3DC.%2BC.%26aulast%3DMasters%26aufirst%3DC.%2BL.%26atitle%3DAmyloid%2520%25CE%25B2%2520deposition%252C%2520neurodegeneration%252C%2520and%2520cognitive%2520decline%2520in%2520sporadic%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520a%2520prospective%2520cohort%2520study%26jtitle%3DLancet%2520Neurol.%26date%3D2013%26volume%3D12%26spage%3D357%26epage%3D367%26doi%3D10.1016%2FS1474-4422%2813%2970044-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jack, C. R.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knopman, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagust, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisen, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiner, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trojanowski, J. Q.</span></span> <span> </span><span class="NLM_article-title">Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(09)70299-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1016%2FS1474-4422%2809%2970299-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=20083042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFeru74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=119-128&author=C.+R.+Jackauthor=D.+S.+Knopmanauthor=W.+J.+Jagustauthor=L.+M.+Shawauthor=P.+S.+Aisenauthor=M.+W.+Weinerauthor=R.+C.+Petersenauthor=J.+Q.+Trojanowski&title=Hypothetical+model+of+dynamic+biomarkers+of+the+Alzheimer%E2%80%99s+pathological+cascade&doi=10.1016%2FS1474-4422%2809%2970299-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade</span></div><div class="casAuthors">Jack, Clifford R., Jr.; Knopman, David S.; Jagust, William J.; Shaw, Leslie M.; Aisen, Paul S.; Weiner, Michael W.; Petersen, Ronald C.; Trojanowski, John Q.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">119-128</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Currently available evidence strongly supports the position that the initiating event in Alzheimer's disease (AD) is related to abnormal processing of β-amyloid (Aβ) peptide, ultimately leading to formation of Aβ plaques in the brain.  This process occurs while individuals are still cognitively normal.  Biomarkers of brain β-amyloidosis are redns. in CSF Aβ42 and increased amyloid PET tracer retention.  After a lag period, which varies from patient to patient, neuronal dysfunction and neurodegeneration become the dominant pathol. processes.  Biomarkers of neuronal injury and neurodegeneration are increased CSF tau and structural MRI measures of cerebral atrophy.  Neurodegeneration is accompanied by synaptic dysfunction, which is indicated by decreased fluorodeoxyglucose uptake on PET.  We propose a model that relates disease stage to AD biomarkers in which Aβ biomarkers become abnormal first, before neurodegenerative biomarkers and cognitive symptoms, and neurodegenerative biomarkers become abnormal later, and correlate with clin. symptom severity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOnmdY1Eeez7Vg90H21EOLACvtfcHk0lgjgEkbN2GVCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFeru74%253D&md5=5337b3e576ab1e8c58292c2572fb62f6</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2809%2970299-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252809%252970299-6%26sid%3Dliteratum%253Aachs%26aulast%3DJack%26aufirst%3DC.%2BR.%26aulast%3DKnopman%26aufirst%3DD.%2BS.%26aulast%3DJagust%26aufirst%3DW.%2BJ.%26aulast%3DShaw%26aufirst%3DL.%2BM.%26aulast%3DAisen%26aufirst%3DP.%2BS.%26aulast%3DWeiner%26aufirst%3DM.%2BW.%26aulast%3DPetersen%26aufirst%3DR.%2BC.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26atitle%3DHypothetical%2520model%2520of%2520dynamic%2520biomarkers%2520of%2520the%2520Alzheimer%25E2%2580%2599s%2520pathological%2520cascade%26jtitle%3DLancet%2520Neurol.%26date%3D2010%26volume%3D9%26spage%3D119%26epage%3D128%26doi%3D10.1016%2FS1474-4422%2809%2970299-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lopez
Lopez, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caputo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riviere, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouzade-Dominguez, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langbaum, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiman, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tariot, P. N.</span></span> <span> </span><span class="NLM_article-title">The Alzheimer’s prevention initiative generation program: evaluating CNP520 efficacy in the prevention of Alzheimer’s disease</span>. <i>J. Prev. Alzheimer’s  Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">242</span>– <span class="NLM_lpage">246</span>, <span class="refDoi"> DOI: 10.14283/jpad.2017.37</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.14283%2Fjpad.2017.37" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=29181489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A280%3ADC%252BC1M3lsFOrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2017&pages=242-246&author=C.+L.+Lopez%0ALopezauthor=A.+Caputoauthor=F.+Liuauthor=M.+E.+Riviereauthor=M.+L.+Rouzade-Dominguezauthor=R.+G.+Thomasauthor=J.+B.+Langbaumauthor=R.+Lenzauthor=E.+M.+Reimanauthor=A.+Grafauthor=P.+N.+Tariot&title=The+Alzheimer%E2%80%99s+prevention+initiative+generation+program%3A+evaluating+CNP520+efficacy+in+the+prevention+of+Alzheimer%E2%80%99s+disease&doi=10.14283%2Fjpad.2017.37"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">The Alzheimer's Prevention Initiative Generation Program: Evaluating CNP520 Efficacy in the Prevention of Alzheimer's Disease</span></div><div class="casAuthors">Lopez Lopez C; Caputo A; Liu F; Riviere M E; Rouzade-Dominguez M-L; Thomas R G; Langbaum J B; Lenz R; Reiman E M; Graf A; Tariot P N</div><div class="citationInfo"><span class="NLM_cas:title">The journal of prevention of Alzheimer's disease</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">242-246</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Alzheimer's disease pathology begins decades before the onset of clinical symptoms.  This provides an opportunity for interventional clinical trials to potentially delay or prevent the onset of cognitive impairment or dementia.  CNP520 (a beta-site-amyloid precursor protein-cleaving enzyme inhibitor) is in clinical development for the treatment of preclinical Alzheimer's disease under the Alzheimer's Prevention Initiative Generation Program.  The Alzheimer's Prevention Initiative is a public-private partnership intended to accelerate the evaluation of Alzheimer's disease prevention therapies.  The Generation Program comprises two pivotal phase II/III studies with similar designs to assess the efficacy and safety of investigational treatments in a cognitively unimpaired population at increased risk for developing Alzheimer's disease based on age and apolipoprotein E (APOE) genotype (i.e., presence of the APOE ε4 allele).  The program has been designed to maximize benefit to Alzheimer's disease research.  Generation Study 1 (NCT02565511) and Generation Study 2 (NCT03131453) are currently enrolling; their key features are presented here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQg8yIA1XjIYRgd2Wuil24tfW6udTcc2ebdNbZFBmzCRbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3lsFOrtw%253D%253D&md5=bc392bcee85772ecfd57a241f4df30a0</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.14283%2Fjpad.2017.37&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14283%252Fjpad.2017.37%26sid%3Dliteratum%253Aachs%26aulast%3DLopez%2BLopez%26aufirst%3DC.%2BL.%26aulast%3DCaputo%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DRiviere%26aufirst%3DM.%2BE.%26aulast%3DRouzade-Dominguez%26aufirst%3DM.%2BL.%26aulast%3DThomas%26aufirst%3DR.%2BG.%26aulast%3DLangbaum%26aufirst%3DJ.%2BB.%26aulast%3DLenz%26aufirst%3DR.%26aulast%3DReiman%26aufirst%3DE.%2BM.%26aulast%3DGraf%26aufirst%3DA.%26aulast%3DTariot%26aufirst%3DP.%2BN.%26atitle%3DThe%2520Alzheimer%25E2%2580%2599s%2520prevention%2520initiative%2520generation%2520program%253A%2520evaluating%2520CNP520%2520efficacy%2520in%2520the%2520prevention%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Prev.%2520Alzheimer%25E2%2580%2599s%2520%2520Dis.%26date%3D2017%26volume%3D4%26spage%3D242%26epage%3D246%26doi%3D10.14283%2Fjpad.2017.37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ufer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouzade-Dominguez, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huledal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lueoend, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machauer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veenstra, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurth, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rueeger, Heinrich</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tintelnot-Blomley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staufenbiel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimshek, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrot, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieauff, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubost, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiller, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avrameas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kretz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pezous, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondeau, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beckmann, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vormfelde, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galli, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez Lopez, C.</span></span> <span> </span><span class="NLM_article-title">The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer’s disease</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">e9316</span>, <span class="refDoi"> DOI: 10.15252/emmm.201809316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.15252%2Femmm.201809316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=30224383" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=e9316&author=U.+Neumannauthor=M.+Uferauthor=L.+H.+Jacobsonauthor=M.-L.+Rouzade-Dominguezauthor=G.+Huledalauthor=C.+Kollyauthor=R.+M.+Lueoendauthor=R.+Machauerauthor=S.+J.+Veenstraauthor=K.+Hurthauthor=Heinrich+Rueegerauthor=M.+Tintelnot-Blomleyauthor=M.+Staufenbielauthor=D.+R.+Shimshekauthor=L.+Perrotauthor=W.+Frieauffauthor=V.+Dubostauthor=H.+Schillerauthor=B.+Voggauthor=K.+Beltzauthor=A.+Avrameasauthor=S.+Kretzauthor=N.+Pezousauthor=J.-M.+Rondeauauthor=N.+Beckmannauthor=A.+Hartmannauthor=S.+Vormfeldeauthor=O.+J.+Davidauthor=B.+Galliauthor=R.+Ramosauthor=A.+Grafauthor=C.+Lopez+Lopez&title=The+BACE-1+inhibitor+CNP520+for+prevention+trials+in+Alzheimer%E2%80%99s+disease&doi=10.15252%2Femmm.201809316"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.15252%2Femmm.201809316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Femmm.201809316%26sid%3Dliteratum%253Aachs%26aulast%3DNeumann%26aufirst%3DU.%26aulast%3DUfer%26aufirst%3DM.%26aulast%3DJacobson%26aufirst%3DL.%2BH.%26aulast%3DRouzade-Dominguez%26aufirst%3DM.-L.%26aulast%3DHuledal%26aufirst%3DG.%26aulast%3DKolly%26aufirst%3DC.%26aulast%3DLueoend%26aufirst%3DR.%2BM.%26aulast%3DMachauer%26aufirst%3DR.%26aulast%3DVeenstra%26aufirst%3DS.%2BJ.%26aulast%3DHurth%26aufirst%3DK.%26aulast%3DRueeger%26aufirst%3DHeinrich%26aulast%3DTintelnot-Blomley%26aufirst%3DM.%26aulast%3DStaufenbiel%26aufirst%3DM.%26aulast%3DShimshek%26aufirst%3DD.%2BR.%26aulast%3DPerrot%26aufirst%3DL.%26aulast%3DFrieauff%26aufirst%3DW.%26aulast%3DDubost%26aufirst%3DV.%26aulast%3DSchiller%26aufirst%3DH.%26aulast%3DVogg%26aufirst%3DB.%26aulast%3DBeltz%26aufirst%3DK.%26aulast%3DAvrameas%26aufirst%3DA.%26aulast%3DKretz%26aufirst%3DS.%26aulast%3DPezous%26aufirst%3DN.%26aulast%3DRondeau%26aufirst%3DJ.-M.%26aulast%3DBeckmann%26aufirst%3DN.%26aulast%3DHartmann%26aufirst%3DA.%26aulast%3DVormfelde%26aufirst%3DS.%26aulast%3DDavid%26aufirst%3DO.%2BJ.%26aulast%3DGalli%26aufirst%3DB.%26aulast%3DRamos%26aufirst%3DR.%26aulast%3DGraf%26aufirst%3DA.%26aulast%3DLopez%2BLopez%26aufirst%3DC.%26atitle%3DThe%2520BACE-1%2520inhibitor%2520CNP520%2520for%2520prevention%2520trials%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2018%26volume%3D10%26spage%3De9316%26doi%3D10.15252%2Femmm.201809316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fielden, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamison, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coppi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, R. T.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trueblood, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afshari, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lightfoot-Dunn, R.</span></span> <span> </span><span class="NLM_article-title">Retinal toxicity induced by a novel β-secretase inhibitor in the Sprague-Dawley rat</span>. <i>Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">581</span>– <span class="NLM_lpage">592</span>, <span class="refDoi"> DOI: 10.1177/0192623314553804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1177%2F0192623314553804" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=25361751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVCqu7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=581-592&author=M.+R.+Fieldenauthor=J.+Wernerauthor=J.+A.+Jamisonauthor=A.+Coppiauthor=D.+Hickmanauthor=R.+T.+Dunnauthor=E.+Truebloodauthor=L.+Zhouauthor=C.+A.+Afshariauthor=R.+Lightfoot-Dunn&title=Retinal+toxicity+induced+by+a+novel+%CE%B2-secretase+inhibitor+in+the+Sprague-Dawley+rat&doi=10.1177%2F0192623314553804"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Retinal toxicity induced by a novel β-secretase inhibitor in the sprague-dawley rat</span></div><div class="casAuthors">Fielden, Mark R.; Werner, Jonathan; Jamison, Jeff A.; Coppi, Aldo; Hickman, Dean; Dunn, Robert T., II; Trueblood, Esther; Zhou, Lei; Afshari, Cynthia A.; Lightfoot-Dunn, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">581-592</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">β-Secretase 1 (BACE1) represents an attractive target for the treatment of Alzheimer's disease.  In the course of development of a novel small mol. BACE1 inhibitor (AMG-8718), retinal thinning was obsd. in a 1-mo toxicity study in the rat.  To further understand the lesion, an investigational study was conducted whereby rats were treated daily with AMG-8718 for 1 mo followed by a 2-mo treatment-free phase.  The earliest detectable change in the retina was an increase in autofluorescent granules in the retinal pigment epithelium (RPE) on day 5; however, there were no treatment-related light microscopic changes obsd. in the neuroretina and no changes obsd. by fundus autofluorescence or routine ophthalmoscopic examn. after 28 days of dosing.  Following 2 mo of recovery, there was significant retinal thinning attributed to loss of photoreceptor nuclei from the outer nuclear layer.  Electroretinog. changes were obsd. as early as day 14, before any microscopic evidence of photoreceptor loss.  BACE1 knockout rats were generated and found to have normal retinal morphol. indicating that the retinal toxicity induced by AMG-8718 was likely off-target.  These results suggest that AMG-8718 impairs phagolysosomal function in the rat RPE, which leads to photoreceptor dysfunction and ultimately loss of photoreceptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfyBfTezUdUrVg90H21EOLACvtfcHk0li9MA9ATneO6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVCqu7fP&md5=d6f4af801e795995739478385f5e36fd</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1177%2F0192623314553804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0192623314553804%26sid%3Dliteratum%253Aachs%26aulast%3DFielden%26aufirst%3DM.%2BR.%26aulast%3DWerner%26aufirst%3DJ.%26aulast%3DJamison%26aufirst%3DJ.%2BA.%26aulast%3DCoppi%26aufirst%3DA.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DDunn%26aufirst%3DR.%2BT.%26aulast%3DTrueblood%26aufirst%3DE.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DAfshari%26aufirst%3DC.%2BA.%26aulast%3DLightfoot-Dunn%26aufirst%3DR.%26atitle%3DRetinal%2520toxicity%2520induced%2520by%2520a%2520novel%2520%25CE%25B2-secretase%2520inhibitor%2520in%2520the%2520Sprague-Dawley%2520rat%26jtitle%3DToxicol.%2520Pathol.%26date%3D2015%26volume%3D43%26spage%3D581%26epage%3D592%26doi%3D10.1177%2F0192623314553804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zuhl, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodney, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niessen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atchison, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanian, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambroise, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brulet, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">am Ende, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geoghegan, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judkins, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddell, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. S.</span></span> <span> </span><span class="NLM_article-title">Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">13042</span>– <span class="NLM_lpage">13056</span>, <span class="refDoi"> DOI: 10.1038/ncomms13042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1038%2Fncomms13042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=27727204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1GqtbbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=13042-13056&author=A.+M.+Zuhlauthor=C.+E.+Nolanauthor=M.+A.+Brodneyauthor=S.+Niessenauthor=K.+Atchisonauthor=C.+Houleauthor=D.+A.+Karanianauthor=C.+Ambroiseauthor=J.+W.+Bruletauthor=E.+M.+Beckauthor=S.+D.+Doranauthor=B.+T.+O%E2%80%99Neillauthor=C.+W.+am+Endeauthor=C.+Changauthor=K.+F.+Geogheganauthor=G.+M.+Westauthor=J.+C.+Judkinsauthor=X.+Houauthor=D.+R.+Riddellauthor=D.+S.+Johnson&title=Chemoproteomic+profiling+reveals+that+cathepsin+D+off-target+activity+drives+ocular+toxicity+of+%CE%B2-secretase+inhibitors&doi=10.1038%2Fncomms13042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors</span></div><div class="casAuthors">Zuhl, Andrea M.; Nolan, Charles E.; Brodney, Michael A.; Niessen, Sherry; Atchison, Kevin; Houle, Christopher; Karanian, David A.; Ambroise, Claude; Brulet, Jeffrey W.; Beck, Elizabeth M.; Doran, Shawn D.; O'Neill, Brian T.; am Ende, Christopher W.; Chang, Cheng; Geoghegan, Kieran F.; West, Graham M.; Judkins, Joshua C.; Hou, Xinjun; Riddell, David R.; Johnson, Douglas S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13042</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Inhibition of β-secretase BACE1 is considered one of the most promising approaches for treating Alzheimer's disease.  Several structurally distinct BACE1 inhibitors have been withdrawn from development after inducing ocular toxicity in animal models, but the target mediating this toxicity has not been identified.  Here we use a clickable photoaffinity probe to identify cathepsin D (CatD) as a principal off-target of BACE1 inhibitors in human cells.  We find that several BACE1 inhibitors blocked CatD activity in cells with much greater potency than that displayed in cell-free assays with purified protein.  Through a series of exploratory toxicol. studies, we show that quantifying CatD target engagement in cells with the probe is predictive of ocular toxicity in vivo.  Taken together, our findings designate off-target inhibition of CatD as a principal driver of ocular toxicity for BACE1 inhibitors and more generally underscore the power of chem. proteomics for discerning mechanisms of drug action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0-LulGVRdJLVg90H21EOLACvtfcHk0li9MA9ATneO6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1GqtbbL&md5=5e2c31195f4f03babec561a5824ccb0d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fncomms13042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms13042%26sid%3Dliteratum%253Aachs%26aulast%3DZuhl%26aufirst%3DA.%2BM.%26aulast%3DNolan%26aufirst%3DC.%2BE.%26aulast%3DBrodney%26aufirst%3DM.%2BA.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DAtchison%26aufirst%3DK.%26aulast%3DHoule%26aufirst%3DC.%26aulast%3DKaranian%26aufirst%3DD.%2BA.%26aulast%3DAmbroise%26aufirst%3DC.%26aulast%3DBrulet%26aufirst%3DJ.%2BW.%26aulast%3DBeck%26aufirst%3DE.%2BM.%26aulast%3DDoran%26aufirst%3DS.%2BD.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DB.%2BT.%26aulast%3Dam%2BEnde%26aufirst%3DC.%2BW.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DGeoghegan%26aufirst%3DK.%2BF.%26aulast%3DWest%26aufirst%3DG.%2BM.%26aulast%3DJudkins%26aufirst%3DJ.%2BC.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DRiddell%26aufirst%3DD.%2BR.%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26atitle%3DChemoproteomic%2520profiling%2520reveals%2520that%2520cathepsin%2520D%2520off-target%2520activity%2520drives%2520ocular%2520toxicity%2520of%2520%25CE%25B2-secretase%2520inhibitors%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D13042%26epage%3D13056%26doi%3D10.1038%2Fncomms13042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Low, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fielden, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gore, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sickmier, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minatti, A. E.</span></span> <span> </span><span class="NLM_article-title">Development of 2-aminooxazoline 3-azaxanthene β-amyloid cleaving enzyme (BACE) inhibitors with improved selectivity against Cathepsin D</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1196</span>– <span class="NLM_lpage">1206</span>, <span class="refDoi"> DOI: 10.1039/C7MD00106A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1039%2FC7MD00106A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=30108829" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmsleiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1196-1206&author=J.+D.+Lowauthor=M.+D.+Bartbergerauthor=K.+Chenauthor=Y.+Chengauthor=M.+R.+Fieldenauthor=V.+Goreauthor=D.+Hickmanauthor=Q.+Liuauthor=E.+A.+Sickmierauthor=H.+M.+Vargasauthor=J.+Wernerauthor=R.+D.+Whiteauthor=D.+A.+Whittingtonauthor=S.+Woodauthor=A.+E.+Minatti&title=Development+of+2-aminooxazoline+3-azaxanthene+%CE%B2-amyloid+cleaving+enzyme+%28BACE%29+inhibitors+with+improved+selectivity+against+Cathepsin+D&doi=10.1039%2FC7MD00106A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Development of 2-aminooxazoline 3-azaxanthene β-amyloid cleaving enzyme (BACE) inhibitors with improved selectivity against Cathepsin D</span></div><div class="casAuthors">Low, Jonathan D.; Bartberger, Michael D.; Chen, Kui; Cheng, Yuan; Fielden, Mark R.; Gore, Vijay; Hickman, Dean; Liu, Qingyian; Allen Sickmier, E.; Vargas, Hugo M.; Werner, Jonathan; White, Ryan D.; Whittington, Douglas A.; Wood, Stephen; Minatti, Ana E.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1196-1206</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">As part of an ongoing effort at Amgen to develop a disease-modifying therapy for Alzheimer's disease, we have previously used the aminooxazoline xanthene (AOX) scaffold to generate potent and orally efficacious BACE1 inhibitors.  While AOX-BACE1 inhibitors demonstrated acceptable cardiovascular safety margins, a retinal pathol. finding in rat toxicol. studies demanded further investigation.  It has been widely postulated that such retinal toxicity might be related to off-target inhibition of Cathepsin D (CatD), a closely related aspartyl protease.  We report the development of AOX-BACE1 inhibitors with improved selectivity against CatD by following a structure- and property-based approach.  Our efforts culminated in the discovery of a picolinamide-substituted 3-aza-AOX-BACE1 inhibitor absent of retinal effects in an early screening rat toxicol. study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW3TmgpxIxfLVg90H21EOLACvtfcHk0lgHKFfsfQVVzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmsleiurg%253D&md5=52fa3a363cdc6c62e0641b594dbb82c3</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1039%2FC7MD00106A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7MD00106A%26sid%3Dliteratum%253Aachs%26aulast%3DLow%26aufirst%3DJ.%2BD.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DFielden%26aufirst%3DM.%2BR.%26aulast%3DGore%26aufirst%3DV.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DSickmier%26aufirst%3DE.%2BA.%26aulast%3DVargas%26aufirst%3DH.%2BM.%26aulast%3DWerner%26aufirst%3DJ.%26aulast%3DWhite%26aufirst%3DR.%2BD.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWood%26aufirst%3DS.%26aulast%3DMinatti%26aufirst%3DA.%2BE.%26atitle%3DDevelopment%2520of%25202-aminooxazoline%25203-azaxanthene%2520%25CE%25B2-amyloid%2520cleaving%2520enzyme%2520%2528BACE%2529%2520inhibitors%2520with%2520improved%2520selectivity%2520against%2520Cathepsin%2520D%26jtitle%3DMedChemComm%26date%3D2017%26volume%3D8%26spage%3D1196%26epage%3D1206%26doi%3D10.1039%2FC7MD00106A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judd, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, R. T.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fremeau, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harried, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitchcock, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minatti, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S.</span></span> <span> </span><span class="NLM_article-title">An orally available BACE1 inhibitor that affords robust CNS Aβ reduction without cardiovascular liabilities</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">210</span>– <span class="NLM_lpage">215</span>, <span class="refDoi"> DOI: 10.1021/ml500458t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500458t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFyhtLzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=210-215&author=Y.+Chengauthor=J.+Brownauthor=T.+C.+Juddauthor=P.+Lopezauthor=W.+Qianauthor=T.+S.+Powersauthor=J.+J.+Chenauthor=M.+D.+Bartbergerauthor=K.+Chenauthor=R.+T.+Dunnauthor=O.+Epsteinauthor=R.+T.+Fremeauauthor=S.+Harriedauthor=D.+Hickmanauthor=S.+A.+Hitchcockauthor=Y.+Luoauthor=A.+E.+Minattiauthor=V.+F.+Patelauthor=H.+M.+Vargasauthor=R.+C.+Wahlauthor=M.+M.+Weissauthor=P.+H.+Wenauthor=R.+D.+Whiteauthor=D.+A.+Whittingtonauthor=X.+M.+Zhengauthor=S.+Wood&title=An+orally+available+BACE1+inhibitor+that+affords+robust+CNS+A%CE%B2+reduction+without+cardiovascular+liabilities&doi=10.1021%2Fml500458t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Available BACE1 Inhibitor That Affords Robust CNS Aβ Reduction without Cardiovascular Liabilities</span></div><div class="casAuthors">Cheng, Yuan; Brown, James; Judd, Ted C.; Lopez, Patricia; Qian, Wenyuan; Powers, Timothy S.; Chen, Jian Jeffrey; Bartberger, Michael D.; Chen, Kui; Dunn, Robert T.; Epstein, Oleg; Fremeau, Robert T.; Harried, Scott; Hickman, Dean; Hitchcock, Stephen A.; Luo, Yi; Minatti, Ana Elena; Patel, Vinod F.; Vargas, Hugo M.; Wahl, Robert C.; Weiss, Matthew M.; Wen, Paul H.; White, Ryan D.; Whittington, Douglas A.; Zheng, Xiao Mei; Wood, Stephen</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">210-215</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">BACE1 inhibition to prevent Aβ peptide formation is considered to be a potential route to a disease-modifying treatment for Alzheimer's disease.  Previous efforts in our lab. using a combined structure- and property-based approach have resulted in the identification of aminooxazoline xanthenes as potent BACE1 inhibitors.  Herein, we report further optimization leading to the discovery of inhibitor 15 as an orally available and highly efficacious BACE1 inhibitor that robustly reduces CSF and brain Aβ levels in both rats and nonhuman primates.  In addn., compd. 15 exhibited low activity on the hERG ion channel and was well tolerated in an integrated cardiovascular safety model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbH-0fLNUlbrVg90H21EOLACvtfcHk0lgHKFfsfQVVzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFyhtLzI&md5=bd8e5a33d06a51646873c4c43d01b003</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fml500458t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500458t%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DJudd%26aufirst%3DT.%2BC.%26aulast%3DLopez%26aufirst%3DP.%26aulast%3DQian%26aufirst%3DW.%26aulast%3DPowers%26aufirst%3DT.%2BS.%26aulast%3DChen%26aufirst%3DJ.%2BJ.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DDunn%26aufirst%3DR.%2BT.%26aulast%3DEpstein%26aufirst%3DO.%26aulast%3DFremeau%26aufirst%3DR.%2BT.%26aulast%3DHarried%26aufirst%3DS.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DHitchcock%26aufirst%3DS.%2BA.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DMinatti%26aufirst%3DA.%2BE.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DVargas%26aufirst%3DH.%2BM.%26aulast%3DWahl%26aufirst%3DR.%2BC.%26aulast%3DWeiss%26aufirst%3DM.%2BM.%26aulast%3DWen%26aufirst%3DP.%2BH.%26aulast%3DWhite%26aufirst%3DR.%2BD.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DZheng%26aufirst%3DX.%2BM.%26aulast%3DWood%26aufirst%3DS.%26atitle%3DAn%2520orally%2520available%2520BACE1%2520inhibitor%2520that%2520affords%2520robust%2520CNS%2520A%25CE%25B2%2520reduction%2520without%2520cardiovascular%2520liabilities%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D210%26epage%3D215%26doi%3D10.1021%2Fml500458t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamford, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dockendorf, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ereshefsky, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jhee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleijn, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuvelkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattson, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palcza, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troyer, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, M. S.</span></span> <span> </span><span class="NLM_article-title">The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">363ra150</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.aad9704</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1126%2Fscitranslmed.aad9704" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=27807285" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=363ra150&author=M.+E.+Kennedyauthor=A.+W.+Stamfordauthor=X.+Chenauthor=K.+Coxauthor=J.+N.+Cummingauthor=M.+F.+Dockendorfauthor=M.+Eganauthor=L.+Ereshefskyauthor=R.+A.+Hodgsonauthor=L.+A.+Hydeauthor=S.+Jheeauthor=H.+J.+Kleijnauthor=R.+Kuvelkarauthor=W.+Liauthor=B.+A.+Mattsonauthor=H.+Meiauthor=J.+Palczaauthor=J.+D.+Scottauthor=M.+Tanenauthor=M.+D.+Troyerauthor=J.+L.+Tsengauthor=J.+A.+Stoneauthor=E.+M.+Parkerauthor=M.+S.+Forman&title=The+BACE1+inhibitor+verubecestat+%28MK-8931%29+reduces+CNS+%CE%B2-amyloid+in+animal+models+and+in+Alzheimer%E2%80%99s+disease+patients&doi=10.1126%2Fscitranslmed.aad9704"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aad9704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aad9704%26sid%3Dliteratum%253Aachs%26aulast%3DKennedy%26aufirst%3DM.%2BE.%26aulast%3DStamford%26aufirst%3DA.%2BW.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCox%26aufirst%3DK.%26aulast%3DCumming%26aufirst%3DJ.%2BN.%26aulast%3DDockendorf%26aufirst%3DM.%2BF.%26aulast%3DEgan%26aufirst%3DM.%26aulast%3DEreshefsky%26aufirst%3DL.%26aulast%3DHodgson%26aufirst%3DR.%2BA.%26aulast%3DHyde%26aufirst%3DL.%2BA.%26aulast%3DJhee%26aufirst%3DS.%26aulast%3DKleijn%26aufirst%3DH.%2BJ.%26aulast%3DKuvelkar%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DMattson%26aufirst%3DB.%2BA.%26aulast%3DMei%26aufirst%3DH.%26aulast%3DPalcza%26aufirst%3DJ.%26aulast%3DScott%26aufirst%3DJ.%2BD.%26aulast%3DTanen%26aufirst%3DM.%26aulast%3DTroyer%26aufirst%3DM.%2BD.%26aulast%3DTseng%26aufirst%3DJ.%2BL.%26aulast%3DStone%26aufirst%3DJ.%2BA.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DForman%26aufirst%3DM.%2BS.%26atitle%3DThe%2520BACE1%2520inhibitor%2520verubecestat%2520%2528MK-8931%2529%2520reduces%2520CNS%2520%25CE%25B2-amyloid%2520in%2520animal%2520models%2520and%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520patients%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2016%26volume%3D8%26spage%3D363ra150%26doi%3D10.1126%2Fscitranslmed.aad9704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scott, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunskill, A. P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cumming, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyde, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iserloh, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazakevich, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuvelkar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meredith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misiaszek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orth, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossiter, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slater, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickland, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voigt, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenlee, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stamford, A. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of the 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative Verubecestat (MK-8931)-a β-site amyloid precursor protein cleaving enzyme 1 inhibitor for the treatment of Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">10435</span>– <span class="NLM_lpage">10450</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00307</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00307" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVKnsLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=10435-10450&author=J.+D.+Scottauthor=S.+W.+Liauthor=A.+P.+J.+Brunskillauthor=X.+Chenauthor=K.+Coxauthor=J.+N.+Cummingauthor=M.+Formanauthor=E.+J.+Gilbertauthor=R.+A.+Hodgsonauthor=L.+A.+Hydeauthor=Q.+Jiangauthor=U.+Iserlohauthor=I.+Kazakevichauthor=R.+Kuvelkarauthor=H.+Meiauthor=J.+Meredithauthor=J.+Misiaszekauthor=P.+Orthauthor=L.+M.+Rossiterauthor=M.+Slaterauthor=J.+Stoneauthor=C.+O.+Stricklandauthor=J.+H.+Voigtauthor=G.+Wangauthor=H.+Wangauthor=Y.+Wuauthor=W.+J.+Greenleeauthor=E.+M.+Parkerauthor=M.+E.+Kennedyauthor=A.+W.+Stamford&title=Discovery+of+the+3-imino-1%2C2%2C4-thiadiazinane+1%2C1-dioxide+derivative+Verubecestat+%28MK-8931%29-a+%CE%B2-site+amyloid+precursor+protein+cleaving+enzyme+1+inhibitor+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1021%2Facs.jmedchem.6b00307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease</span></div><div class="casAuthors">Scott, Jack D.; Li, Sarah W.; Brunskill, Andrew P. J.; Chen, Xia; Cox, Kathleen; Cumming, Jared N.; Forman, Mark; Gilbert, Eric J.; Hodgson, Robert A.; Hyde, Lynn A.; Jiang, Qin; Iserloh, Ulrich; Kazakevich, Irina; Kuvelkar, Reshma; Mei, Hong; Meredith, John; Misiaszek, Jeffrey; Orth, Peter; Rossiter, Lana M.; Slater, Meagan; Stone, Julie; Strickland, Corey O.; Voigt, Johannes H.; Wang, Ganfeng; Wang, Hongwu; Wu, Yusheng; Greenlee, William J.; Parker, Eric M.; Kennedy, Matthew E.; Stamford, Andrew W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10435-10450</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Verubecestat (MK-8931), a diaryl amide substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide deriv., is a high-affinity β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor currently undergoing Phase 3 clin. evaluation for the treatment of mild to moderate and prodromal Alzheimer's disease.  Although not selective over the closely related aspartyl protease BACE2, verubecesat has high selectivity for BACE1 over other key aspartyl proteases, notably cathepsin D, and profoundly lowers CSF and brain Aβ levels in rats and nonhuman primates, and CSF Aβ levels in humans.  In this annotation, the authors describe the discovery of verubecesat, including design, validation, and selected SAR around the novel iminothiadiazinane dioxide core, as well as aspects of its preclin. and Phase 1 clin. characterization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpN5wdoirs8rVg90H21EOLACvtfcHk0lgc5bZdb0P0GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVKnsLnI&md5=517155e2d4f186261b1451ff4556a621</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00307%26sid%3Dliteratum%253Aachs%26aulast%3DScott%26aufirst%3DJ.%2BD.%26aulast%3DLi%26aufirst%3DS.%2BW.%26aulast%3DBrunskill%26aufirst%3DA.%2BP.%2BJ.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DCox%26aufirst%3DK.%26aulast%3DCumming%26aufirst%3DJ.%2BN.%26aulast%3DForman%26aufirst%3DM.%26aulast%3DGilbert%26aufirst%3DE.%2BJ.%26aulast%3DHodgson%26aufirst%3DR.%2BA.%26aulast%3DHyde%26aufirst%3DL.%2BA.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DIserloh%26aufirst%3DU.%26aulast%3DKazakevich%26aufirst%3DI.%26aulast%3DKuvelkar%26aufirst%3DR.%26aulast%3DMei%26aufirst%3DH.%26aulast%3DMeredith%26aufirst%3DJ.%26aulast%3DMisiaszek%26aufirst%3DJ.%26aulast%3DOrth%26aufirst%3DP.%26aulast%3DRossiter%26aufirst%3DL.%2BM.%26aulast%3DSlater%26aufirst%3DM.%26aulast%3DStone%26aufirst%3DJ.%26aulast%3DStrickland%26aufirst%3DC.%2BO.%26aulast%3DVoigt%26aufirst%3DJ.%2BH.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DGreenlee%26aufirst%3DW.%2BJ.%26aulast%3DParker%26aufirst%3DE.%2BM.%26aulast%3DKennedy%26aufirst%3DM.%2BE.%26aulast%3DStamford%26aufirst%3DA.%2BW.%26atitle%3DDiscovery%2520of%2520the%25203-imino-1%252C2%252C4-thiadiazinane%25201%252C1-dioxide%2520derivative%2520Verubecestat%2520%2528MK-8931%2529-a%2520%25CE%25B2-site%2520amyloid%2520precursor%2520protein%2520cleaving%2520enzyme%25201%2520inhibitor%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D10435%26epage%3D10450%26doi%3D10.1021%2Facs.jmedchem.6b00307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hilpert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guba, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woltering, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wostl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinard, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mauser, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayweg, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers-Evans, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humm, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krummenacher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muser, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnider, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozmen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergadano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banner, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hochstrasser, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David-Pierson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polara, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narquizian, R.</span></span> <span> </span><span class="NLM_article-title">β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer’s disease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">3980</span>– <span class="NLM_lpage">3995</span>, <span class="refDoi"> DOI: 10.1021/jm400225m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400225m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmtVymuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=3980-3995&author=H.+Hilpertauthor=W.+Gubaauthor=T.+J.+Wolteringauthor=W.+Wostlauthor=E.+Pinardauthor=H.+Mauserauthor=A.+V.+Maywegauthor=M.+Rogers-Evansauthor=R.+Hummauthor=D.+Krummenacherauthor=T.+Muserauthor=C.+Schniderauthor=H.+Jacobsenauthor=L.+Ozmenauthor=A.+Bergadanoauthor=D.+W.+Bannerauthor=R.+Hochstrasserauthor=A.+Kuglstatterauthor=P.+David-Piersonauthor=H.+Fischerauthor=A.+Polaraauthor=R.+Narquizian&title=%CE%B2-Secretase+%28BACE1%29+inhibitors+with+high+in+vivo+efficacy+suitable+for+clinical+evaluation+in+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fjm400225m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">β-Secretase (BACE1) Inhibitors with High in Vivo Efficacy Suitable for Clinical Evaluation in Alzheimer's Disease</span></div><div class="casAuthors">Hilpert, Hans; Guba, Wolfgang; Woltering, Thomas J.; Wostl, Wolfgang; Pinard, Emmanuel; Mauser, Harald; Mayweg, Alexander V.; Rogers-Evans, Mark; Humm, Roland; Krummenacher, Daniela; Muser, Thorsten; Schnider, Christian; Jacobsen, Helmut; Ozmen, Laurence; Bergadano, Alessandra; Banner, David W.; Hochstrasser, Remo; Kuglstatter, Andreas; David-Pierson, Pascale; Fischer, Holger; Polara, Alessandra; Narquizian, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3980-3995</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An extensive fluorine scan of 1,3-oxazines revealed the power of fluorine(s) to lower the pKa and thereby dramatically change the pharmacol. profile of this class of BACE1 inhibitors.  The CF3 substituted oxazine 89, a potent and highly brain penetrant BACE1 inhibitor, was able to reduce significantly CSF Aβ40 and 42 in rats at oral doses as low as 1 mg/kg.  The effect was long lasting, showing a significant redn. of Aβ40 and 42 even after 24 h.  In contrast to 89, compd. 1b lacking the CF3 group was virtually inactive in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmoKRrAxxHErVg90H21EOLACvtfcHk0lgc5bZdb0P0GQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmtVymuro%253D&md5=e5d311d1c8fecfaed043d3a0bf16c168</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm400225m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400225m%26sid%3Dliteratum%253Aachs%26aulast%3DHilpert%26aufirst%3DH.%26aulast%3DGuba%26aufirst%3DW.%26aulast%3DWoltering%26aufirst%3DT.%2BJ.%26aulast%3DWostl%26aufirst%3DW.%26aulast%3DPinard%26aufirst%3DE.%26aulast%3DMauser%26aufirst%3DH.%26aulast%3DMayweg%26aufirst%3DA.%2BV.%26aulast%3DRogers-Evans%26aufirst%3DM.%26aulast%3DHumm%26aufirst%3DR.%26aulast%3DKrummenacher%26aufirst%3DD.%26aulast%3DMuser%26aufirst%3DT.%26aulast%3DSchnider%26aufirst%3DC.%26aulast%3DJacobsen%26aufirst%3DH.%26aulast%3DOzmen%26aufirst%3DL.%26aulast%3DBergadano%26aufirst%3DA.%26aulast%3DBanner%26aufirst%3DD.%2BW.%26aulast%3DHochstrasser%26aufirst%3DR.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DDavid-Pierson%26aufirst%3DP.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DPolara%26aufirst%3DA.%26aulast%3DNarquizian%26aufirst%3DR.%26atitle%3D%25CE%25B2-Secretase%2520%2528BACE1%2529%2520inhibitors%2520with%2520high%2520in%2520vivo%2520efficacy%2520suitable%2520for%2520clinical%2520evaluation%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D3980%26epage%3D3995%26doi%3D10.1021%2Fjm400225m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doran, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapham, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buzon, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutra, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barreiro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Alsina, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalobos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogilvie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaChapelle, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanyon, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steppan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robshaw, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hales, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houle, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambroise, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karanian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riddell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bales, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodney, M. A.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of clinical candidate PF-06751979: a potent, brain penetrant, β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor lacking hypopigmentation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4476</span>– <span class="NLM_lpage">4504</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00246</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00246" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntVCmtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4476-4504&author=B.+T.+O%E2%80%99Neillauthor=E.+M.+Beckauthor=C.+R.+Butlerauthor=C.+E.+Nolanauthor=C.+Gonzalesauthor=L.+Zhangauthor=S.+D.+Doranauthor=K.+Laphamauthor=L.+M.+Buzonauthor=J.+K.+Dutraauthor=G.+Barreiroauthor=X.+Houauthor=L.+A.+Martinez-Alsinaauthor=B.+N.+Rogersauthor=A.+Villalobosauthor=J.+C.+Murrayauthor=K.+Ogilvieauthor=E.+A.+LaChapelleauthor=C.+Changauthor=L.+F.+Lanyonauthor=C.+M.+Steppanauthor=A.+Robshawauthor=K.+Halesauthor=G.+G.+Boucherauthor=K.+Pandherauthor=C.+Houleauthor=C.+W.+Ambroiseauthor=D.+Karanianauthor=D.+Riddellauthor=K.+R.+Balesauthor=M.+A.+Brodney&title=Design+and+synthesis+of+clinical+candidate+PF-06751979%3A+a+potent%2C+brain+penetrant%2C+%CE%B2-site+amyloid+precursor+protein+cleaving+enzyme+1+%28BACE1%29+inhibitor+lacking+hypopigmentation&doi=10.1021%2Facs.jmedchem.8b00246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation</span></div><div class="casAuthors">O'Neill, Brian T.; Beck, Elizabeth M.; Butler, Christopher R.; Nolan, Charles E.; Gonzales, Cathleen; Zhang, Lei; Doran, Shawn D.; Lapham, Kimberly; Buzon, Leanne M.; Dutra, Jason K.; Barreiro, Gabriela; Hou, Xinjun; Martinez-Alsina, Luis A.; Rogers, Bruce N.; Villalobos, Anabella; Murray, John C.; Ogilvie, Kevin; La Chapelle, Erik A.; Chang, Cheng; Lanyon, Lorraine F.; Steppan, Claire M.; Robshaw, Ashley; Hales, Katherine; Boucher, Germaine G.; Pandher, Karamjeet; Houle, Christopher; Ambroise, Claude W.; Karanian, David; Riddell, David; Bales, Kelly R.; Brodney, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4476-4504</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A major challenge in the development of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease is the alignment of potency, drug-like properties, and selectivity over related aspartyl proteases such as Cathepsin D (CatD) and BACE2.  The potential liabilities of inhibiting BACE2 chronically have only recently begun to emerge as BACE2 impacts the processing of the premelanosome protein (PMEL17) and disrupts melanosome morphol. resulting in a depigmentation phenotype.  Herein, the authors describe the identification of clin. candidate PF-06751979 (I), which displays excellent brain penetration, potent in vivo efficacy, and broad selectivity over related aspartyl proteases including BACE2.  Chronic dosing of I for up to 9 mo in dog did not reveal any observation of hair coat color (pigmentation) changes and suggests a key differentiator over current BACE1 inhibitors that are nonselective against BACE2 in later stage clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs1F61vo0jBbVg90H21EOLACvtfcHk0lgq_bcapcmU8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntVCmtrs%253D&md5=3d8cae0bb20298e66f6da1c26cf8d5bc</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00246%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DB.%2BT.%26aulast%3DBeck%26aufirst%3DE.%2BM.%26aulast%3DButler%26aufirst%3DC.%2BR.%26aulast%3DNolan%26aufirst%3DC.%2BE.%26aulast%3DGonzales%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DDoran%26aufirst%3DS.%2BD.%26aulast%3DLapham%26aufirst%3DK.%26aulast%3DBuzon%26aufirst%3DL.%2BM.%26aulast%3DDutra%26aufirst%3DJ.%2BK.%26aulast%3DBarreiro%26aufirst%3DG.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DMartinez-Alsina%26aufirst%3DL.%2BA.%26aulast%3DRogers%26aufirst%3DB.%2BN.%26aulast%3DVillalobos%26aufirst%3DA.%26aulast%3DMurray%26aufirst%3DJ.%2BC.%26aulast%3DOgilvie%26aufirst%3DK.%26aulast%3DLaChapelle%26aufirst%3DE.%2BA.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DLanyon%26aufirst%3DL.%2BF.%26aulast%3DSteppan%26aufirst%3DC.%2BM.%26aulast%3DRobshaw%26aufirst%3DA.%26aulast%3DHales%26aufirst%3DK.%26aulast%3DBoucher%26aufirst%3DG.%2BG.%26aulast%3DPandher%26aufirst%3DK.%26aulast%3DHoule%26aufirst%3DC.%26aulast%3DAmbroise%26aufirst%3DC.%2BW.%26aulast%3DKaranian%26aufirst%3DD.%26aulast%3DRiddell%26aufirst%3DD.%26aulast%3DBales%26aufirst%3DK.%2BR.%26aulast%3DBrodney%26aufirst%3DM.%2BA.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520clinical%2520candidate%2520PF-06751979%253A%2520a%2520potent%252C%2520brain%2520penetrant%252C%2520%25CE%25B2-site%2520amyloid%2520precursor%2520protein%2520cleaving%2520enzyme%25201%2520%2528BACE1%2529%2520inhibitor%2520lacking%2520hypopigmentation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4476%26epage%3D4504%26doi%3D10.1021%2Facs.jmedchem.8b00246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegmund, A. C.</span>; <span class="NLM_string-name">Kong, K.</span>; <span class="NLM_string-name">Frohn, M.</span>; <span class="NLM_string-name">Nishimura, N.</span>; <span class="NLM_string-name">Pickrell, A. J.</span>; <span class="NLM_string-name">Stec, M. M.</span>; <span class="NLM_string-name">Chen, J. J.</span>; <span class="NLM_string-name">Qian, W.</span>; <span class="NLM_string-name">Liu, L.</span>; <span class="NLM_string-name">Hong, F.-T.</span>; <span class="NLM_string-name">Yang, K. C.</span>; <span class="NLM_string-name">Wen, P. H.</span>; <span class="NLM_string-name">McCarter, J.</span>; <span class="NLM_string-name">Chen, K.</span>; <span class="NLM_string-name">Whittington, D. A.</span>; <span class="NLM_string-name">Bartberger, M. D.</span>; <span class="NLM_string-name">Hickman, D.</span>; <span class="NLM_string-name">Allen, J. R.</span>; <span class="NLM_string-name">Wood, S.</span>; <span class="NLM_string-name">Bourbeau, M. P.</span></span> <span> </span><span class="NLM_article-title">Cyclopropylthiazines as potent BACE1 inhibitors for Alzheimer’s disease: challenging chemistry and <i>in vivo</i> data of a Nnew pre-clinical series</span>. Presented at the 253rd National Meeting of the American Chemical Society, San Francisco, CA, U.S., April 2–6, <span class="NLM_year">2017</span>; Poster MEDI-127.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=A.+C.+Siegmund&author=K.+Kong&author=M.+Frohn&author=N.+Nishimura&author=A.+J.+Pickrell&author=M.+M.+Stec&author=J.+J.+Chen&author=W.+Qian&author=L.+Liu&author=F.-T.+Hong&author=K.+C.+Yang&author=P.+H.+Wen&author=J.+McCarter&author=K.+Chen&author=D.+A.+Whittington&author=M.+D.+Bartberger&author=D.+Hickman&author=J.+R.+Allen&author=S.+Wood&author=M.+P.+Bourbeau&title=Cyclopropylthiazines+as+potent+BACE1+inhibitors+for+Alzheimer%E2%80%99s+disease%3A+challenging+chemistry+and+in+vivo+data+of+a+Nnew+pre-clinical+series"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DSiegmund%26aufirst%3DA.%2BC.%26atitle%3DCyclopropylthiazines%2520as%2520potent%2520BACE1%2520inhibitors%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520challenging%2520chemistry%2520and%2520in%2520vivo%2520data%2520of%2520a%2520Nnew%2520pre-clinical%2520series%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. R.</span>; <span class="NLM_string-name">Amegadzie, A.</span>; <span class="NLM_string-name">Bourbeau, M. P.</span>; <span class="NLM_string-name">Brown, J. A.</span>; <span class="NLM_string-name">Chen, J. J.</span>; <span class="NLM_string-name">Cheng, Y.</span>; <span class="NLM_string-name">Frohn, M. J.</span>; <span class="NLM_string-name">Guzman-Perez, A.</span>; <span class="NLM_string-name">Harrington, P. E.</span>; <span class="NLM_string-name">Liu, L.</span>; <span class="NLM_string-name">Liu, Q.</span>; <span class="NLM_string-name">Low, J. D.</span>; <span class="NLM_string-name">Ma, V. V.</span>; <span class="NLM_string-name">Manning, J.</span>; <span class="NLM_string-name">Minatti, A. E.</span>; <span class="NLM_string-name">Nguyen, T. T.</span>; <span class="NLM_string-name">Nishmura, N.</span>; <span class="NLM_string-name">Norman, M. H.</span>; <span class="NLM_string-name">Pettus, L. H.</span>; <span class="NLM_string-name">Pickrell, A. J.</span>; <span class="NLM_string-name">Qian, W.</span>; <span class="NLM_string-name">Rumfelt, S.</span>; <span class="NLM_string-name">Rzasa, R. M.</span>; <span class="NLM_string-name">Siegmund, A. C.</span>; <span class="NLM_string-name">Stec, M. M.</span>; <span class="NLM_string-name">White, R.</span>; <span class="NLM_string-name">Xue, Q.</span></span> <span> </span><span class="NLM_article-title">Cyclopropyl fused thiazine-2-amine compounds as beta-secretase inhibitors and methods of use</span>. Patent<span class="NLM_patent">WO2016/022724A1</span>, Feb 11, 2016; Patent <span class="NLM_patent">US2016/0046618A1</span>, Feb 18, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=J.+R.+Allen&author=A.+Amegadzie&author=M.+P.+Bourbeau&author=J.+A.+Brown&author=J.+J.+Chen&author=Y.+Cheng&author=M.+J.+Frohn&author=A.+Guzman-Perez&author=P.+E.+Harrington&author=L.+Liu&author=Q.+Liu&author=J.+D.+Low&author=V.+V.+Ma&author=J.+Manning&author=A.+E.+Minatti&author=T.+T.+Nguyen&author=N.+Nishmura&author=M.+H.+Norman&author=L.+H.+Pettus&author=A.+J.+Pickrell&author=W.+Qian&author=S.+Rumfelt&author=R.+M.+Rzasa&author=A.+C.+Siegmund&author=M.+M.+Stec&author=R.+White&author=Q.+Xue&title=Cyclopropyl+fused+thiazine-2-amine+compounds+as+beta-secretase+inhibitors+and+methods+of+use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DJ.%2BR.%26atitle%3DCyclopropyl%2520fused%2520thiazine-2-amine%2520compounds%2520as%2520beta-secretase%2520inhibitors%2520and%2520methods%2520of%2520use%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu-Khan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loeloff, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Citron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vassar, R.</span></span> <span> </span><span class="NLM_article-title">Expression analysis of BACE2 in brain and peripheral tissues</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>275</i></span>,  <span class="NLM_fpage">20647</span>– <span class="NLM_lpage">20651</span>, <span class="refDoi"> DOI: 10.1074/jbc.M002688200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1074%2Fjbc.M002688200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10749877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkvVyhsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2000&pages=20647-20651&author=B.+D.+Bennettauthor=S.+Babu-Khanauthor=R.+Loeloffauthor=J.+C.+Louisauthor=E.+Curranauthor=M.+Citronauthor=R.+Vassar&title=Expression+analysis+of+BACE2+in+brain+and+peripheral+tissues&doi=10.1074%2Fjbc.M002688200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Expression analysis of BACE2 in brain and peripheral tissues</span></div><div class="casAuthors">Bennett, Brian D.; Babu-Khan, Safura; Loeloff, Richard; Louis, Jean-Claude; Curran, Eileen; Citron, Martin; Vassar, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">20647-20651</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Beta-site amyloid precursor protein cleaving enzyme (BACE) is a novel transmembrane aspartic protease that possesses all the known characteristics of the β-secretase involved in Alzheimer's disease.  We have analyzed the sequence and expression pattern of a BACE homolog termed BACE2.  BACE and BACE2 are unique among aspartic proteases in that they possess a carboxyl-terminal extension with a predicted transmembrane region and together they define a new family.  Northern anal. reveals that BACE2 mRNA is expressed at low levels in most human peripheral tissues and at higher levels in colon, kidney, pancreas, placenta, prostate, stomach, and trachea.  Human adult and fetal whole brain and most adult brain subregions express very low or undetectable levels of BACE2 mRNA.  In addn., in situ hybridization of adult rat brain shows that BACE2 mRNA is expressed at very low levels in most brain regions.  The very low or undetectable levels of BACE2 mRNA in the brain are not consistent with the expression pattern predicted for β-secretase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodNsksnpZwh7Vg90H21EOLACvtfcHk0lgq_bcapcmU8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkvVyhsbs%253D&md5=3d664572b2a1709c68fffcee3a8880d5</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M002688200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M002688200%26sid%3Dliteratum%253Aachs%26aulast%3DBennett%26aufirst%3DB.%2BD.%26aulast%3DBabu-Khan%26aufirst%3DS.%26aulast%3DLoeloff%26aufirst%3DR.%26aulast%3DLouis%26aufirst%3DJ.%2BC.%26aulast%3DCurran%26aufirst%3DE.%26aulast%3DCitron%26aufirst%3DM.%26aulast%3DVassar%26aufirst%3DR.%26atitle%3DExpression%2520analysis%2520of%2520BACE2%2520in%2520brain%2520and%2520peripheral%2520tissues%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2000%26volume%3D275%26spage%3D20647%26epage%3D20651%26doi%3D10.1074%2Fjbc.M002688200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, R.</span></span> <span> </span><span class="NLM_article-title">Physiological functions of the β-site amyloid precursor protein cleaving enzyme 1 and 2</span>. <i>Front. Mol. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">97</span> <span class="refDoi"> DOI: 10.3389/fnmol.2017.00097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.3389%2Ffnmol.2017.00097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=28469554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A280%3ADC%252BC1crjvVWksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2017&author=R.+Yan&title=Physiological+functions+of+the+%CE%B2-site+amyloid+precursor+protein+cleaving+enzyme+1+and+2&doi=10.3389%2Ffnmol.2017.00097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Physiological Functions of the β-Site Amyloid Precursor Protein Cleaving Enzyme 1 and 2</span></div><div class="casAuthors">Yan Riqiang</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in molecular neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">97</span>
        ISSN:<span class="NLM_cas:issn">1662-5099</span>.
    </div><div class="casAbstract">BACE1 was discovered as the β-secretase for initiating the cleavage of amyloid precursor protein (APP) at the β-secretase site, while its close homology BACE2 cleaves APP within the β-amyloid (Aβ) domain region and shows distinct cleavage preferences in vivo.  Inhibition of BACE1 proteolytic activity has been confirmed to decrease Aβ generation and amyloid deposition, and thus specific inhibition of BACE1 by small molecules is a current focus for Alzheimer's disease therapy.  While BACE1 inhibitors are being tested in advanced clinical trials, knowledge regarding the properties and physiological functions of BACE is highly important and this review summarizes advancements in BACE1 research over the past several years.  We and others have shown that BACE1 is not only a critical enzyme for testing the "Amyloid Hypothesis" associated with Alzheimer's pathogenesis, but also important for various functions such as axon growth and pathfinding, astrogenesis, neurogenesis, hyperexcitation, and synaptic plasticity.  BACE2 appears to play different roles such as glucose homeostasis and pigmentation.  This knowledge regarding BACE1 functions is critical for monitoring the safe use of BACE1 inhibitors in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbYoN5Bm7IDcScOqQTSkOffW6udTcc2eZVUKVNPazof7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crjvVWksQ%253D%253D&md5=b8e9ffa2007cebb2ae68c0074b7dea06</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.3389%2Ffnmol.2017.00097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnmol.2017.00097%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DR.%26atitle%3DPhysiological%2520functions%2520of%2520the%2520%25CE%25B2-site%2520amyloid%2520precursor%2520protein%2520cleaving%2520enzyme%25201%2520and%25202%26jtitle%3DFront.%2520Mol.%2520Neurosci.%26date%3D2017%26volume%3D10%26doi%3D10.3389%2Ffnmol.2017.00097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Esterhazy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akpinar, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoffel, M.</span></span> <span> </span><span class="NLM_article-title">Tmem27 dimerization, deglycosylation, plasma membrane depletion, and the extracellular Phe-Phe motif are negative regulators of cleavage by BACE2</span>. <i>Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>393</i></span>,  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">484</span>, <span class="refDoi"> DOI: 10.1515/hsz-2012-0104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1515%2Fhsz-2012-0104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=22628310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVSlsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=393&publication_year=2012&pages=473-484&author=D.+Esterhazyauthor=P.+Akpinarauthor=M.+Stoffel&title=Tmem27+dimerization%2C+deglycosylation%2C+plasma+membrane+depletion%2C+and+the+extracellular+Phe-Phe+motif+are+negative+regulators+of+cleavage+by+BACE2&doi=10.1515%2Fhsz-2012-0104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Tmem27 dimerization, deglycosylation, plasma membrane depletion, and the extracellular Phe-Phe motif are negative regulators of cleavage by Bace2</span></div><div class="casAuthors">Esterhazy, Daria; Akpinar, Pinar; Stoffel, Markus</div><div class="citationInfo"><span class="NLM_cas:title">Biological Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">393</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">473-484</span>CODEN:
                <span class="NLM_cas:coden">BICHF3</span>;
        ISSN:<span class="NLM_cas:issn">1431-6730</span>.
    
            (<span class="NLM_cas:orgname">Walter de Gruyter GmbH & Co. KG</span>)
        </div><div class="casAbstract">The pancreatic β-cell surface protein Tmem27 is promotes the preservation of functional β-cell mass.  It is a selective substrate of the protease Bace2, yet the intramol. features of Tmem27 that regulate its processing by this sheddase have not been characterized.  In particular, the importance of homodimerization, glycosylation, trafficking to the plasma membrane (PM), the existence of multiple cleavage sites, and the amino acid residues that govern these features are currently unknown.  Using Tmem27 mutational anal. and multiple biochem. approaches, we here show that Tmem27 dimerization is a dynamic process mediated by its intracellular cysteine residue and that prevents Tmem27 cleavage, that extracellular asparagine glycosylation is essential for Tmem27 trafficking to the PM and its processing by Bace2, that the amt. of Tmem27 at the PM is proportional to its total cell levels upon glucose stimulation and Bace2 inhibition, and that the double phenylalanine motif in the Tmem27 cleavage site is an intramol. Bace2 inhibitor.  These findings define structural properties of Tmem27 that affect the susceptibility to its protease Bace2 and have implications for the efficiency with which Tmem27 and other Bace2 substrates are cleaved in normal and disease states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqc431ObiBZIbVg90H21EOLACvtfcHk0ljohNnoz-aBsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVSlsbc%253D&md5=06a566e9a9bdbda2d77a6b36aa9233b3</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1515%2Fhsz-2012-0104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252Fhsz-2012-0104%26sid%3Dliteratum%253Aachs%26aulast%3DEsterhazy%26aufirst%3DD.%26aulast%3DAkpinar%26aufirst%3DP.%26aulast%3DStoffel%26aufirst%3DM.%26atitle%3DTmem27%2520dimerization%252C%2520deglycosylation%252C%2520plasma%2520membrane%2520depletion%252C%2520and%2520the%2520extracellular%2520Phe-Phe%2520motif%2520are%2520negative%2520regulators%2520of%2520cleavage%2520by%2520BACE2%26jtitle%3DBiol.%2520Chem.%26date%3D2012%26volume%3D393%26spage%3D473%26epage%3D484%26doi%3D10.1515%2Fhsz-2012-0104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rulifson, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopecky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samayoa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuruda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homann, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baribault, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiltzius, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">Identification of human islet amyloid polypeptide as a BACE2 substrate</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e0147254</span>, <span class="refDoi"> DOI: 10.1371/journal.pone.0147254</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1371%2Fjournal.pone.0147254" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=26840340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC28XnslOqtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e0147254&author=I.+C.+Rulifsonauthor=P.+Caoauthor=L.+Miaoauthor=D.+Kopeckyauthor=L.+Huangauthor=R.+D.+Whiteauthor=K.+Samayoaauthor=J.+Gardnerauthor=X.+Wuauthor=K.+Chenauthor=T.+Tsurudaauthor=O.+Homannauthor=H.+Baribaultauthor=H.+Yamaneauthor=T.+Carlsonauthor=J.+Wiltziusauthor=Y.+Li&title=Identification+of+human+islet+amyloid+polypeptide+as+a+BACE2+substrate&doi=10.1371%2Fjournal.pone.0147254"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of human islet amyloid polypeptide as a BACE2 substrate</span></div><div class="casAuthors">Rulifson, Ingrid C.; Cao, Ping; Miao, Li; Kopecky, David; Huang, Linda; White, Ryan D.; Samayoa, Kim; Gardner, Jonitha; Wu, Xiaosu; Chen, Kui; Tsuruda, Trace; Homann, Oliver; Baribault, Helene; Yamane, Harvey; Carlson, Tim; Wiltzius, Jed; Li, Yang</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e0147254/1-e0147254/23</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Pancreatic amyloid formation by islet amyloid polypeptide (IAPP) is a hallmark pathol. feature of type 2 diabetes.  IAPP is stored in the secretory granules of pancreatic beta-cells and co-secreted with insulin to maintain glucose homeostasis.  IAPP is innocuous under homeostatic conditions but imbalances in prodn. or processing of IAPP may result in homodimer formation leading to the rapid prodn. of cytotoxic oligomers and amyloid fibrils.  The consequence is beta-cell dysfunction and the accumulation of proteinaceous plaques in and around pancreatic islets.  Beta-site APP-cleaving enzyme 2, BACE2, is an aspartyl protease commonly assocd. with BACE1, a related homolog responsible for amyloid processing in the brain and strongly implicated in Alzheimer's disease.  Herein, we identify two distinct sites of the mature human IAPP sequence that are susceptible to BACE2-mediated proteolytic activity.  The result of proteolysis is modulation of human IAPP fibrillation and human IAPP protein degrdn.  These results suggest a potential therapeutic role for BACE2 in type 2 diabetes-assocd. hyperamylinemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXxpM4hmm1pLVg90H21EOLACvtfcHk0ljohNnoz-aBsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnslOqtL4%253D&md5=ab081153a95c7462bd208bac8779bd1d</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0147254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0147254%26sid%3Dliteratum%253Aachs%26aulast%3DRulifson%26aufirst%3DI.%2BC.%26aulast%3DCao%26aufirst%3DP.%26aulast%3DMiao%26aufirst%3DL.%26aulast%3DKopecky%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DWhite%26aufirst%3DR.%2BD.%26aulast%3DSamayoa%26aufirst%3DK.%26aulast%3DGardner%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DTsuruda%26aufirst%3DT.%26aulast%3DHomann%26aufirst%3DO.%26aulast%3DBaribault%26aufirst%3DH.%26aulast%3DYamane%26aufirst%3DH.%26aulast%3DCarlson%26aufirst%3DT.%26aulast%3DWiltzius%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DIdentification%2520of%2520human%2520islet%2520amyloid%2520polypeptide%2520as%2520a%2520BACE2%2520substrate%26jtitle%3DPLoS%2520One%26date%3D2016%26volume%3D11%26spage%3De0147254%26doi%3D10.1371%2Fjournal.pone.0147254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rochin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurbain, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serneels, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fort, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblanc, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Strooper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raposo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Niel, G.</span></span> <span> </span><span class="NLM_article-title">BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">10658</span>– <span class="NLM_lpage">10663</span>, <span class="refDoi"> DOI: 10.1073/pnas.1220748110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1073%2Fpnas.1220748110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=23754390" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFejs7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=10658-10663&author=L.+Rochinauthor=I.+Hurbainauthor=L.+Serneelsauthor=C.+Fortauthor=B.+Wattauthor=P.+Leblancauthor=M.+S.+Marksauthor=B.+De+Strooperauthor=G.+Raposoauthor=G.+van+Niel&title=BACE2+processes+PMEL+to+form+the+melanosome+amyloid+matrix+in+pigment+cells&doi=10.1073%2Fpnas.1220748110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">BACE2 processes PMEL to form the melanosome amyloid matrix in pigment cells</span></div><div class="casAuthors">Rochin, Leila; Hurbain, Ilse; Serneels, Lutgarde; Fort, Cecile; Watt, Brenda; Leblanc, Pascal; Marks, Michael S.; De Strooper, Bart; Raposo, Graca; van Niel, Guillaume</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">10658-10663,S10658/1-S10658/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Amyloids are often assocd. with pathol. processes such as in Alzheimer's disease (AD), but can also underlie physiol. processes such as pigmentation.  Formation of pathol. and functional amyloidogenic substrates can require precursor processing by proteases, as exemplified by the generation of Aβ peptide from amyloid precursor protein (APP) by beta-site APP cleaving enzyme (BACE)1 and γ-secretase.  Proteolytic processing of the pigment cell-specific Melanocyte Protein (PMEL) is also required to form functional amyloid fibrils during melanogenesis, but the enzymes involved are incompletely characterized.  Here we show that the BACE1 homolog BACE2 processes PMEL to generate functional amyloids.  BACE2 is highly expressed in pigment cells and Bace2-/- but not Bace1-/- mice display coat color defects, implying a specific role for BACE2 during melanogenesis.  By using biochem. and morphol. analyses, combined with RNA silencing, pharmacol. inhibition, and BACE2 overexpression in a human melanocytic cell line, we show that BACE2 cleaves the integral membrane form of PMEL within the juxtamembrane domain, releasing the PMEL luminal domain into endosomal precursors for the formation of amyloid fibrils and downstream melanosome morphogenesis.  These studies identify an amyloidogenic substrate of BACE2, reveal an important physiol. role for BACE2 in pigmentation, and highlight analogies in the generation of PMEL-derived functional amyloids and APP-derived pathol. amyloids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLBEney5KFyLVg90H21EOLACvtfcHk0lhWAuWSsZH6Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFejs7rK&md5=3deb3f80dca6a32748aa6fe2e50c2df1</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1220748110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1220748110%26sid%3Dliteratum%253Aachs%26aulast%3DRochin%26aufirst%3DL.%26aulast%3DHurbain%26aufirst%3DI.%26aulast%3DSerneels%26aufirst%3DL.%26aulast%3DFort%26aufirst%3DC.%26aulast%3DWatt%26aufirst%3DB.%26aulast%3DLeblanc%26aufirst%3DP.%26aulast%3DMarks%26aufirst%3DM.%2BS.%26aulast%3DDe%2BStrooper%26aufirst%3DB.%26aulast%3DRaposo%26aufirst%3DG.%26aulast%3Dvan%2BNiel%26aufirst%3DG.%26atitle%3DBACE2%2520processes%2520PMEL%2520to%2520form%2520the%2520melanosome%2520amyloid%2520matrix%2520in%2520pigment%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D10658%26epage%3D10663%26doi%3D10.1073%2Fpnas.1220748110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cebers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lejeune, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attalla, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soderberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Budd Haeberlein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kugler, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingersoll, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, C. W.</span></span> <span> </span><span class="NLM_article-title">Reversible and species-specific depigmentation effects of AZD3293, a BACE inhibitor for the treatment of Alzheimer’s disease, are related to BACE2 inhibition and confined to epidermis and hair</span>. <i>J. Prev. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">202</span>– <span class="NLM_lpage">218</span>, <span class="refDoi"> DOI: 10.14283/jpad.2016.119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.14283%2Fjpad.2016.119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=29199322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A280%3ADC%252BC1M3ntlKisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2016&pages=202-218&author=G.+Cebersauthor=T.+Lejeuneauthor=B.+Attallaauthor=M.+Soderbergauthor=R.+C.+Alexanderauthor=S.+Budd+Haeberleinauthor=A.+R.+Kuglerauthor=E.+W.+Ingersollauthor=S.+Platzauthor=C.+W.+Scott&title=Reversible+and+species-specific+depigmentation+effects+of+AZD3293%2C+a+BACE+inhibitor+for+the+treatment+of+Alzheimer%E2%80%99s+disease%2C+are+related+to+BACE2+inhibition+and+confined+to+epidermis+and+hair&doi=10.14283%2Fjpad.2016.119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible and Species-Specific Depigmentation Effects of AZD3293, a BACE Inhibitor for the Treatment of Alzheimer's Disease, Are Related to BACE2 Inhibition and Confined to Epidermis and Hair</span></div><div class="casAuthors">Cebers G; Lejeune T; Attalla B; Soderberg M; Alexander R C; Budd Haeberlein S; Kugler A R; Ingersoll E W; Platz S; Scott C W</div><div class="citationInfo"><span class="NLM_cas:title">The journal of prevention of Alzheimer's disease</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">202-218</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  AZD3293 (also known as LY3314814) is a novel, potent, non-selective BACE1/BACE2 inhibitor currently in Phase 3 clinical development for the treatment of Alzheimer's disease.  OBJECTIVES:  The purpose of these studies was to characterize the effects, putative mechanism, and reversibility of hypopigmentation following treatment with AZD3293 in pigmented Long-Evans rats, Beagle dogs, human cell cultures, and humans.  DESIGN:  Nonclinical studies were conducted in Long-Evans pigmented rats, and both young and older Beagle dogs using a variety of oral dose levels of AZD3293 or AZD3839 (BACE inhibition reference compound; used in older dogs only) for dosing durations of 13 to 26 weeks.  In vitro studies of normal human epidermal melanocytes and reconstituted human epidermis were also conducted.  Skin biopsy data from a multiple-dose Phase 1 clinical study of AZD3293 (NCT01795339) are also reported.  SETTING:  Nonclinical in vivo and in vitro studies were conducted in laboratory settings in the US, Canada, and France; the multiple dose clinical study was conducted in a specialized inpatient setting in the US.  PARTICIPANTS:  Beagle dogs: 13-week study N=36 young (8-10 mo) animals; 39-week study N=64 young animals; and a second 13-week study N=32 older (30-32 mo) animals.  Long-Evans rats: N=68 animals.  Multiple-dose clinical study: only data for subjects enrolled in Part 2 of this study are included in this report (N=16).  INTERVENTIONS:  AZD3293 was the primary intervention used in these studies.  AZD3839, a relatively BACE1-selective reference inhibitor compound was used in one group in the 13 week study in older Beagle dogs and one in vitro assessment.  Finally, AZ1340, another relatively BACE1-selective reference inhibitor compound was used only in one in vitro assessment.  MEASUREMENTS:  Measurements for the nonclinical studies in dogs and rats included macroscopic observation and assessment of skin biopsies via histopathology, immunochemistry, and electron microscopy.  Measurements for the in vitro studies included melanocyte premelanosome protein (PMEL) processing, cytotoxicity, melanin synthesis, Pmel17 labeling, and melanocyte dendricity.  Measurements in the clinical study included scoring of melanin content in skin biopsies taken before and after dosing with AZD3293 over 14 days at dose levels up to 150 mg.  RESULTS:  Depigmentation in rats and dogs was limited to skin, hair, and mucosa with no effects on other pigmented tissues.  At a cellular level depigmentation was observed within a week of treatment, whereas the appearance of depigmentation in skin and hair did not become apparent until, at earliest, 4 weeks of treatment.  The depigmentation effects were reversible, not associated with degenerative or inflammatory changes, and were dose- and species-dependent in severity.  Full recovery of melanization was observed at the microscopic (cellular) level and at least partial recovery was seen in the macroscopic appearance of animals by the end of the 12-week recovery period in both rats and dogs.  Interestingly, no changes in melanin production or melanocyte morphology were seen in human primary melanocytes or reconstituted human epidermis in vitro.  Finally, there were no changes in melanization level in skin biopsies following 12 days of daily AZD3293 treatment at doses of AZD3293 up to 150 mg/day in human subjects.  CONCLUSIONS:  AZD3293, a novel, potent, non-selective BACE1/BACE2 inhibitor is in development as a potentially disease-modifying treatment for Alzheimer's disease.  Chronic nonclinical studies in Beagle dogs and pigmented rats showed macroscopic and microscopic hypopigmentation effects of AZD3293 that were limited to skin, hair, and mucosa.  These effects were shown to be reversible in both species.  Analysis of data from nonclinical and in vitro studies suggests that hypopigmentation is caused by BACE2 inhibition resulting in accumulation of a premelanosome protein fragment, which interrupts the normal production of melanin.  No macroscopic or microscopic reports of hypopigmentation were observed in a Phase 1 clinical study following 13 doses of AZD3293 over 14 days at dose levels up to 150 mg/day.  These data suggest that hypopigmentation is species-specific and humans appear to be least sensitive to the depigmentation effect caused by BACE2 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSnMZvqjWSFT7t7lRqEFUJVfW6udTcc2ealol010mSPl7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3ntlKisw%253D%253D&md5=8eaa57d7d8e3bb8bfad9244ffb5ae16a</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.14283%2Fjpad.2016.119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14283%252Fjpad.2016.119%26sid%3Dliteratum%253Aachs%26aulast%3DCebers%26aufirst%3DG.%26aulast%3DLejeune%26aufirst%3DT.%26aulast%3DAttalla%26aufirst%3DB.%26aulast%3DSoderberg%26aufirst%3DM.%26aulast%3DAlexander%26aufirst%3DR.%2BC.%26aulast%3DBudd%2BHaeberlein%26aufirst%3DS.%26aulast%3DKugler%26aufirst%3DA.%2BR.%26aulast%3DIngersoll%26aufirst%3DE.%2BW.%26aulast%3DPlatz%26aufirst%3DS.%26aulast%3DScott%26aufirst%3DC.%2BW.%26atitle%3DReversible%2520and%2520species-specific%2520depigmentation%2520effects%2520of%2520AZD3293%252C%2520a%2520BACE%2520inhibitor%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%252C%2520are%2520related%2520to%2520BACE2%2520inhibition%2520and%2520confined%2520to%2520epidermis%2520and%2520hair%26jtitle%3DJ.%2520Prev.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2016%26volume%3D3%26spage%3D202%26epage%3D218%26doi%3D10.14283%2Fjpad.2016.119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rueeger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machauer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veenstra, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lueoend, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tintelnot-Blomley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laue, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frieauff, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimshek, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staufenbiel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, L. H.</span></span> <span> </span><span class="NLM_article-title">A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-beta and neuroinflammation in APP transgenic mice</span>. <i>Mol. Neurodegener.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">44</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1186/s13024-015-0033-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1186%2Fs13024-015-0033-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=26336937" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC28Xls1Sls7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=44-59&author=U.+Neumannauthor=H.+Rueegerauthor=R.+Machauerauthor=S.+J.+Veenstraauthor=R.+M.+Lueoendauthor=M.+Tintelnot-Blomleyauthor=G.+Laueauthor=K.+Beltzauthor=B.+Voggauthor=P.+Schmidauthor=W.+Frieauffauthor=D.+R.+Shimshekauthor=M.+Staufenbielauthor=L.+H.+Jacobson&title=A+novel+BACE+inhibitor+NB-360+shows+a+superior+pharmacological+profile+and+robust+reduction+of+amyloid-beta+and+neuroinflammation+in+APP+transgenic+mice&doi=10.1186%2Fs13024-015-0033-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice</span></div><div class="casAuthors">Neumann, Ulf; Rueeger, Heinrich; Machauer, Rainer; Veenstra, Siem Jacob; Lueoend, Rainer M.; Tintelnot-Blomley, Marina; Laue, Grit; Beltz, Karen; Vogg, Barbara; Schmid, Peter; Frieauff, Wilfried; Shimshek, Derya R.; Staufenbiel, Matthias; Jacobson, Laura H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Neurodegeneration</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">44/1-44/15</span>CODEN:
                <span class="NLM_cas:coden">MNOEAZ</span>;
        ISSN:<span class="NLM_cas:issn">1750-1326</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Alzheimer's disease (AD) is the most common form of dementia, the no. of affected individuals is rising, with significant impacts for healthcare systems.  Current symptomatic treatments delay, but do not halt, disease progression.  Genetic evidence points to aggregation and deposition of amyloid-β (Aβ) in the brain being causal for the neurodegeneration and dementia typical of AD.  Approaches to target Aβ via inhibition of γ-secretase or passive antibody therapy have not yet resulted in substantial clin. benefits.  Inhibition of BACE1 (β-secretase) has proven a challenging concept, but recent BACE1inhibitors can enter the brain sufficiently well to lower Aβ.  However, failures with the first clin. BACE1 inhibitors have highlighted the need to generate compds. with appropriate efficacy and safety profiles, since long treatment periods are expected to be necessary in humans.  Results: Treatment with NB-360, a potent and brain penetrable BACE-1 inhibitor can completely block the progression of Aβ deposition in the brains of APP transgenic mice, a model for amyloid pathol.  We furthermore show that almost complete redn. of Aβ was achieved also in rats and in dogs, suggesting that these findings are translational across species and can be extrapolated to humans.  Amyloid pathol. may be an initial step in a complex pathol. cascade; therefore we investigated the effect of BACE-1 inhibition on neuroinflammation, a prominent downstream feature of the disease.  NB-360 stopped accumulation of activated inflammatory cells in the brains of APP transgenic mice.  Upon chronic treatment of APP transgenic mice, patches of gray hairs appeared.  Conclusions: In a rapidly developing field, the data on NB-360 broaden the chem. space and expand knowledge on the properties that are needed to make a BACE-1 inhibitor potent and safe enough for long-term use in patients.  Due to its excellent brain penetration, reasonable oral doses of NB-360 were sufficient to completely block amyloid-β deposition in an APP transgenic mouse model.  Data across species suggest similar treatment effects can possibly be achieved in humans.  The reduced neuroinflammation upon amyloid redn. by NB-360 treatment supports the notion that targeting amyloid-β pathol. can have beneficial downstream effects on the progression of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquJLgu8zl8_LVg90H21EOLACvtfcHk0lhWAuWSsZH6Wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xls1Sls7o%253D&md5=728407859709d7de57d68bfdc374fe85</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1186%2Fs13024-015-0033-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13024-015-0033-8%26sid%3Dliteratum%253Aachs%26aulast%3DNeumann%26aufirst%3DU.%26aulast%3DRueeger%26aufirst%3DH.%26aulast%3DMachauer%26aufirst%3DR.%26aulast%3DVeenstra%26aufirst%3DS.%2BJ.%26aulast%3DLueoend%26aufirst%3DR.%2BM.%26aulast%3DTintelnot-Blomley%26aufirst%3DM.%26aulast%3DLaue%26aufirst%3DG.%26aulast%3DBeltz%26aufirst%3DK.%26aulast%3DVogg%26aufirst%3DB.%26aulast%3DSchmid%26aufirst%3DP.%26aulast%3DFrieauff%26aufirst%3DW.%26aulast%3DShimshek%26aufirst%3DD.%2BR.%26aulast%3DStaufenbiel%26aufirst%3DM.%26aulast%3DJacobson%26aufirst%3DL.%2BH.%26atitle%3DA%2520novel%2520BACE%2520inhibitor%2520NB-360%2520shows%2520a%2520superior%2520pharmacological%2520profile%2520and%2520robust%2520reduction%2520of%2520amyloid-beta%2520and%2520neuroinflammation%2520in%2520APP%2520transgenic%2520mice%26jtitle%3DMol.%2520Neurodegener.%26date%3D2015%26volume%3D10%26spage%3D44%26epage%3D59%26doi%3D10.1186%2Fs13024-015-0033-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Filser, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ovsepian, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masana, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blazquez-Llorca, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt Elvang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volbracht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, C. K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herms, J.</span></span> <span> </span><span class="NLM_article-title">Pharmacological inhibition of BACE1 impairs synaptic plasticity and cognitive functions</span>. <i>Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">729</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1016/j.biopsych.2014.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1016%2Fj.biopsych.2014.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=25599931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFKntLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2015&pages=729-739&author=S.+Filserauthor=S.+V.+Ovsepianauthor=M.+Masanaauthor=L.+Blazquez-Llorcaauthor=A.+Brandt+Elvangauthor=C.+Volbrachtauthor=M.+B.+Muellerauthor=C.+K.+E.+Jungauthor=J.+Herms&title=Pharmacological+inhibition+of+BACE1+impairs+synaptic+plasticity+and+cognitive+functions&doi=10.1016%2Fj.biopsych.2014.10.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological Inhibition of BACE1 Impairs Synaptic Plasticity and Cognitive Functions</span></div><div class="casAuthors">Filser, Severin; Ovsepian, Saak V.; Masana, Merce; Blazquez-Llorca, Lidia; Brandt Elvang, Anders; Volbracht, Christiane; Mueller, Marianne B.; Jung, Christian K. E.; Herms, Jochen</div><div class="citationInfo"><span class="NLM_cas:title">Biological Psychiatry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">729-739</span>CODEN:
                <span class="NLM_cas:coden">BIPCBF</span>;
        ISSN:<span class="NLM_cas:issn">0006-3223</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">BACE1 (beta site amyloid precursor protein cleaving enzyme 1) is the rate limiting protease in amyloid β prodn., hence a promising drug target for the treatment of Alzheimer's disease.  Inhibition of BACE1, as the major β-secretase in vivo with multiple substrates, however is likely to have mechanism-based adverse effects.  We explored the impact of long-term pharmacol. inhibition of BACE1 on dendritic spine dynamics, synaptic functions, and cognitive performance of adult mice.  Sandwich ELISA was used to assess Aβ40 levels in brain and plasma after oral administration of BACE1 inhibitors SCH1682496 or LY2811376.  In vivo two-photon microscopy of the somatosensory cortex was performed to monitor structural dynamics of dendritic spines while synaptic functions and plasticity were measured via electrophysiol. recordings of excitatory postsynaptic currents and hippocampal long-term potentiation in brain slices.  Finally, behavioral tests were performed to analyze the impact of pharmacol. inhibition of BACE1 on cognitive performance.  Dose-dependent decrease of Aβ40 levels in vivo confirmed suppression of BACE1 activity by both inhibitors.  Prolonged treatment caused a redn. in spine formation of layer V pyramidal neurons, which recovered after withdrawal of inhibitors.  Congruently, the rate of spontaneous and miniature excitatory postsynaptic currents in pyramidal neurons and hippocampal long-term potentiation were reduced in animals treated with BACE1 inhibitors.  These effects were not detected in Bace1-/- mice treated with SCH1682496, confirming BACE1 as the pharmacol. target.  Described structural and functional changes were assocd. with cognitive deficits as revealed in behavioral tests.  Our findings indicate important functions to BACE1 in structural and functional synaptic plasticity in the mature brain, with implications for cognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBtdj8QyF3sLVg90H21EOLACvtfcHk0lhus289pFR5Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFKntLg%253D&md5=cfeed5a68833142e39074442dc343f42</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.biopsych.2014.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopsych.2014.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DFilser%26aufirst%3DS.%26aulast%3DOvsepian%26aufirst%3DS.%2BV.%26aulast%3DMasana%26aufirst%3DM.%26aulast%3DBlazquez-Llorca%26aufirst%3DL.%26aulast%3DBrandt%2BElvang%26aufirst%3DA.%26aulast%3DVolbracht%26aufirst%3DC.%26aulast%3DMueller%26aufirst%3DM.%2BB.%26aulast%3DJung%26aufirst%3DC.%2BK.%2BE.%26aulast%3DHerms%26aufirst%3DJ.%26atitle%3DPharmacological%2520inhibition%2520of%2520BACE1%2520impairs%2520synaptic%2520plasticity%2520and%2520cognitive%2520functions%26jtitle%3DBiol.%2520Psychiatry%26date%3D2015%26volume%3D77%26spage%3D729%26epage%3D739%26doi%3D10.1016%2Fj.biopsych.2014.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Egan, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kost, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tariot, P. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisen, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cummings, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vellas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sur, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voss, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furtek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahoney, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mozley, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenberghe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michelson, D.</span></span> <span> </span><span class="NLM_article-title">Randomized trial of Verubecestat for mild-to-moderate Alzheimer’s disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>378</i></span>,  <span class="NLM_fpage">1691</span>– <span class="NLM_lpage">1703</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1706441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1056%2FNEJMoa1706441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=29719179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpsFyqsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2018&pages=1691-1703&author=M.+F.+Eganauthor=J.+Kostauthor=P.+N.+Tariotauthor=P.+S.+Aisenauthor=J.+L.+Cummingsauthor=B.+Vellasauthor=C.+Surauthor=Y.+Mukaiauthor=T.+Vossauthor=C.+Furtekauthor=E.+Mahoneyauthor=L.+H.+Mozleyauthor=R.+Vandenbergheauthor=Y.+Moauthor=D.+Michelson&title=Randomized+trial+of+Verubecestat+for+mild-to-moderate+Alzheimer%E2%80%99s+disease&doi=10.1056%2FNEJMoa1706441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease</span></div><div class="casAuthors">Egan, Michael F.; Kost, James; Tariot, Pierre N.; Aisen, Paul S.; Cummings, Jeffrey L.; Vellas, Bruno; Sur, Cyrille; Mukai, Yuki; Voss, Tiffini; Furtek, Christine; Mahoney, Erin; Mozley, Lyn Harper; Vandenberghe, Rik; Mo, Yi; Michelson, David</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">378</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1691-1703</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Alzheimer's disease is characterized by the deposition of amyloid-beta (Aβ) plaques in the brain.  Aβ is produced from the sequential cleavage of amyloid precursor protein by β-site amyloid precursor protein-cleaving enzyme 1 (BACE-1) followed by γ-secretase.  Verubecestat is an oral BACE-1 inhibitor that reduces the Aβ level in the cerebrospinal fluid of patients with Alzheimer's disease. methods We conducted a randomized, double-blind, placebo-controlled, 78-wk trial to evaluate verubecestat at doses of 12 mg and 40 mg per day, as compared with placebo, in patients who had a clin. diagnosis of mild-to-moderate Alzheimer's disease.  The coprimary outcomes were the change from baseline to week 78 in the score on the cognitive subscale of the Alzheimer's disease Assessment Scale (ADAS-cog; scores range from 0 to 70, with higher scores indicating worse dementia) and in the score on the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory scale (ADCS-ADL; scores range from 0 to 78, with lower scores indicating worse function). results A total of 1958 patients underwent randomization; 653 were randomly assigned to receive verubecestat at a dose of 12 mg per day (the 12-mg group), 652 to receive verubecestat at a dose of 40 mg per day (the 40-mg group), and 653 to receive matching placebo.  The trial was terminated early for futility 50 mo after onset, which was within 5 mo before its scheduled completion, and after enrollment of the planned 1958 patients was complete.  The estd. mean change from baseline to week 78 in the ADAS-cog score was 7.9 in the 12-mg group, 8.0 in the 40-mg group, and 7.7 in the placebo group (P = 0.63 for the comparison between the 12-mg group and the placebo group and P = 0.46 for the comparison between the 40-mg group and the placebo group).  The estd. mean change from baseline to week 78 in the ADCS-ADL score was -8.4 in the 12-mg group, -8.2 in the 40-mg group, and -8.9 in the placebo group (P = 0.49 for the comparison between the 12-mg group and the placebo group and P = 0.32 for the comparison between the 40-mg group and the placebo group).  Adverse events, including rash, falls and injuries, sleep disturbance, suicidal ideation, wt. loss, and hair-color change, were more common in the verubecestat groups than in the placebo group. conclusions Verubecestat did not reduce cognitive or functional decline in patients with mild-to-moderate Alzheimer's disease and was assocd. with treatment-related adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroW5Tf-VIj2LVg90H21EOLACvtfcHk0lhus289pFR5Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpsFyqsbs%253D&md5=e6ecfbd2981616b343468ae8bed1db2d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1706441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1706441%26sid%3Dliteratum%253Aachs%26aulast%3DEgan%26aufirst%3DM.%2BF.%26aulast%3DKost%26aufirst%3DJ.%26aulast%3DTariot%26aufirst%3DP.%2BN.%26aulast%3DAisen%26aufirst%3DP.%2BS.%26aulast%3DCummings%26aufirst%3DJ.%2BL.%26aulast%3DVellas%26aufirst%3DB.%26aulast%3DSur%26aufirst%3DC.%26aulast%3DMukai%26aufirst%3DY.%26aulast%3DVoss%26aufirst%3DT.%26aulast%3DFurtek%26aufirst%3DC.%26aulast%3DMahoney%26aufirst%3DE.%26aulast%3DMozley%26aufirst%3DL.%2BH.%26aulast%3DVandenberghe%26aufirst%3DR.%26aulast%3DMo%26aufirst%3DY.%26aulast%3DMichelson%26aufirst%3DD.%26atitle%3DRandomized%2520trial%2520of%2520Verubecestat%2520for%2520mild-to-moderate%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2018%26volume%3D378%26spage%3D1691%26epage%3D1703%26doi%3D10.1056%2FNEJMoa1706441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuillard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleasby, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yon, J.</span></span> <span> </span><span class="NLM_article-title">Apo and inhibitor complex structures of BACE (β-secretase)</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>343</i></span>,  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.1016/j.jmb.2004.08.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1016%2Fj.jmb.2004.08.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=15451669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvVyqt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2004&pages=407-416&author=S.+Patelauthor=L.+Vuillardauthor=A.+Cleasbyauthor=C.+W.+Murrayauthor=J.+Yon&title=Apo+and+inhibitor+complex+structures+of+BACE+%28%CE%B2-secretase%29&doi=10.1016%2Fj.jmb.2004.08.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Apo and Inhibitor Complex Structures of BACE (β-secretase)</span></div><div class="casAuthors">Patel, Sahil; Vuillard, Laurent; Cleasby, Anne; Murray, Christopher W.; Yon, Jeff</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">407-416</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Human BACE, also known as β-secretase, shows promise as a potential therapeutic target for Alzheimer's disease.  The authors detd. the apo structure of BACE to 1.75 Å, and a structure of a hydroxyethylamine inhibitor complex derived by soaking.  These show significant active-site movements compared to previously described BACE structures.  Addnl., the structures reveal two pockets that could be targeted by structure-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH0afg2-ZxjLVg90H21EOLACvtfcHk0lhus289pFR5Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvVyqt7w%253D&md5=b14e17f86a4729fb8ee66d84ee6c1fab</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2004.08.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2004.08.018%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DVuillard%26aufirst%3DL.%26aulast%3DCleasby%26aufirst%3DA.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DYon%26aufirst%3DJ.%26atitle%3DApo%2520and%2520inhibitor%2520complex%2520structures%2520of%2520BACE%2520%2528%25CE%25B2-secretase%2529%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2004%26volume%3D343%26spage%3D407%26epage%3D416%26doi%3D10.1016%2Fj.jmb.2004.08.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgenthaler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweizer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann-Roder, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaeschke, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diederich, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, K.</span></span> <span> </span><span class="NLM_article-title">Predicting and tuning physicochemical properties in lead optimization: amine basicities</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1100</span>– <span class="NLM_lpage">1115</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200700059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1002%2Fcmdc.200700059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=17530727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=1100-1115&issue=8&author=M.+Morgenthalerauthor=E.+Schweizerauthor=A.+Hoffmann-Roderauthor=F.+Beniniauthor=R.+E.+Martinauthor=G.+Jaeschkeauthor=B.+Wagnerauthor=H.+Fischerauthor=S.+Bendelsauthor=D.+Zimmerliauthor=J.+Schneiderauthor=F.+Diederichauthor=M.+Kansyauthor=K.+Muller&title=Predicting+and+tuning+physicochemical+properties+in+lead+optimization%3A+amine+basicities&doi=10.1002%2Fcmdc.200700059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Predicting and tuning physicochemical properties in lead optimization: amine basicities</span></div><div class="casAuthors">Morgenthaler, Martin; Schweizer, Eliane; Hoffmann-Roder, Anja; Benini, Fausta; Martin, Rainer E.; Jaeschke, Georg; Wagner, Bjorn; Fischer, Holger; Bendels, Stefanie; Zimmerli, Daniel; Schneider, Josef; Diederich, Francois; Kansy, Manfred; Muller, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1100-1115</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  This review describes simple and useful concepts for predicting and tuning the pKa values of basic amine centers, a crucial step in the optimization of phys. and ADME properties of many lead structures in drug-discovery research.  The article starts with a case study of tricyclic thrombin inhibitors featuring a tertiary amine center with pKa values that can be tuned over a wide range, from the usual value of around 10 to below 2 by (remote) neighboring functionalities commonly encountered in medicinal chem.  Next, the changes in pKa of acyclic and cyclic amines upon substitution by fluorine, oxygen, nitrogen, and sulfur functionalities, as well as carbonyl and carboxyl derivs. are systematically analyzed, leading to the derivation of simple rules for pKa prediction.  Electronic and stereoelectronic effects in cyclic amines are discussed, and the emerging computational methods for pKa predictions are briefly surveyed.  The rules for tuning amine basicities should not only be of interest in drug-discovery research, but also to the development of new crop-protection agents, new amine ligands for organometallic complexes, and in particular, to the growing field of amine-based organocatalysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodsWRMtrxWPbVg90H21EOLACvtfcHk0lhyTd7_oWQV1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpsFemsbY%253D&md5=478b70744312c01d3a43cf435d9598de</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700059%26sid%3Dliteratum%253Aachs%26aulast%3DMorgenthaler%26aufirst%3DM.%26aulast%3DSchweizer%26aufirst%3DE.%26aulast%3DHoffmann-Roder%26aufirst%3DA.%26aulast%3DBenini%26aufirst%3DF.%26aulast%3DMartin%26aufirst%3DR.%2BE.%26aulast%3DJaeschke%26aufirst%3DG.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DZimmerli%26aufirst%3DD.%26aulast%3DSchneider%26aufirst%3DJ.%26aulast%3DDiederich%26aufirst%3DF.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DMuller%26aufirst%3DK.%26atitle%3DPredicting%2520and%2520tuning%2520physicochemical%2520properties%2520in%2520lead%2520optimization%253A%2520amine%2520basicities%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26issue%3D8%26spage%3D1100%26epage%3D1115%26doi%3D10.1002%2Fcmdc.200700059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="note"><p class="first last">In general, aminocyclopropylthiazines displayed similar PK profiles in rats, and maximum effects on Aβ reduction in the CSF and brain were observed between 4 and 5 h following an oral dose in the PD assay. Similar single-dose PD studies have been previously reported in the following:</p></div><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dineen, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derakhchan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esmay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreiman, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fremeau, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V. F.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of β-site amyloid precursor protein cleaving enzyme (BACE1): identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)5′H-spiro[chromeno[2,3-b]pyridine-5,4′-oxazol]-2′-amine (AMG-8718)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9811</span>– <span class="NLM_lpage">9831</span>, <span class="refDoi"> DOI: 10.1021/jm5012676</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5012676" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVGjtLrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9811-9831&author=T.+A.+Dineenauthor=K.+Chenauthor=A.+C.+Chengauthor=K.+Derakhchanauthor=O.+Epsteinauthor=J.+Esmayauthor=D.+Hickmanauthor=C.+E.+Kreimanauthor=I.+E.+Marxauthor=R.+C.+Wahlauthor=P.+H.+Wenauthor=M.+M.+Weissauthor=D.+A.+Whittingtonauthor=S.+Woodauthor=R.+T.+Fremeauauthor=R.+W.+Whiteauthor=V.+F.+Patel&title=Inhibitors+of+%CE%B2-site+amyloid+precursor+protein+cleaving+enzyme+%28BACE1%29%3A+identification+of+%28S%29-7-%282-fluoropyridin-3-yl%29-3-%28%283-methyloxetan-3-yl%29ethynyl%295%E2%80%B2H-spiro%5Bchromeno%5B2%2C3-b%5Dpyridine-5%2C4%E2%80%B2-oxazol%5D-2%E2%80%B2-amine+%28AMG-8718%29&doi=10.1021%2Fjm5012676"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1): Identification of (S)-7-(2-Fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-2'-amine (AMG-8718)</span></div><div class="casAuthors">Dineen, Thomas A.; Chen, Kui; Cheng, Alan C.; Derakhchan, Katayoun; Epstein, Oleg; Esmay, Joel; Hickman, Dean; Kreiman, Chuck E.; Marx, Isaac E.; Wahl, Robert C.; Wen, Paul H.; Weiss, Matthew M.; Whittington, Douglas A.; Wood, Stephen; Fremeau, Robert T.; White, Ryan D.; Patel, Vinod F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9811-9831</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have previously shown that the aminooxazoline xanthene scaffold can generate potent and orally efficacious BACE1 inhibitors although certain of these compds. exhibited potential hERG liabilities.  In this article, we describe 4-aza substitution on the xanthene core as a means to increase BACE1 potency while reducing hERG binding affinity.  Further optimization of the P3 and P2' side chains resulted in the identification of 42 (AMG-8718), a compd. with a balanced profile of BACE1 potency, hERG binding affinity, and Pgp recognition.  This compd. produced robust and sustained redns. of CSF and brain Aβ levels in a rat pharmacodynamic model and exhibited significantly reduced potential for QTc elongation in a cardiovascular safety model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDPCl7cW3IyLVg90H21EOLACvtfcHk0lhyTd7_oWQV1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVGjtLrP&md5=4c586d61f5ba555948eed2c27b728fbb</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm5012676&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5012676%26sid%3Dliteratum%253Aachs%26aulast%3DDineen%26aufirst%3DT.%2BA.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DCheng%26aufirst%3DA.%2BC.%26aulast%3DDerakhchan%26aufirst%3DK.%26aulast%3DEpstein%26aufirst%3DO.%26aulast%3DEsmay%26aufirst%3DJ.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DKreiman%26aufirst%3DC.%2BE.%26aulast%3DMarx%26aufirst%3DI.%2BE.%26aulast%3DWahl%26aufirst%3DR.%2BC.%26aulast%3DWen%26aufirst%3DP.%2BH.%26aulast%3DWeiss%26aufirst%3DM.%2BM.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWood%26aufirst%3DS.%26aulast%3DFremeau%26aufirst%3DR.%2BT.%26aulast%3DWhite%26aufirst%3DR.%2BW.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26atitle%3DInhibitors%2520of%2520%25CE%25B2-site%2520amyloid%2520precursor%2520protein%2520cleaving%2520enzyme%2520%2528BACE1%2529%253A%2520identification%2520of%2520%2528S%2529-7-%25282-fluoropyridin-3-yl%2529-3-%2528%25283-methyloxetan-3-yl%2529ethynyl%25295%25E2%2580%25B2H-spiro%255Bchromeno%255B2%252C3-b%255Dpyridine-5%252C4%25E2%2580%25B2-oxazol%255D-2%25E2%2580%25B2-amine%2520%2528AMG-8718%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9811%26epage%3D9831%26doi%3D10.1021%2Fjm5012676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="note"><p class="first last">An estimate of unbound plasma EC<sub>50</sub> for Aβ<sub>40</sub> lowering was calculated from a single dose, single time point (4 h) experiment assuming a standard sigmoid dose response (Hill slope of 1). This approach was initially validated by comparing EC<sub>50</sub> values from a dose–response experiment to the single dose, single time point estimate of unbound EC<sub>50</sub>. Subsequently, estimated EC<sub>50</sub> values have been shown to be a good approximation of the IC<sub>50</sub> determined from a time course experiment using an indirect response PK/PD model. Similar studies have been reported in the following:</p></div><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Low, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minatti, A. E.</span></span> <span> </span><span class="NLM_article-title">Diastereoselective synthesis of fused cyclopropyl-3-amino-2,4-oxazine beta-amyloid cleaving enzyme (BACE) inhibitors and their biological evaluation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1111</span>– <span class="NLM_lpage">1115</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.01.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1016%2Fj.bmcl.2018.01.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=29426770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFemu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=1111-1115&author=J.+D.+Lowauthor=M.+D.+Bartbergerauthor=Y.+Chengauthor=D.+Whittingtonauthor=Q.+Xueauthor=S.+Woodauthor=J.+R.+Allenauthor=A.+E.+Minatti&title=Diastereoselective+synthesis+of+fused+cyclopropyl-3-amino-2%2C4-oxazine+beta-amyloid+cleaving+enzyme+%28BACE%29+inhibitors+and+their+biological+evaluation&doi=10.1016%2Fj.bmcl.2018.01.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Diastereoselective synthesis of fused cyclopropyl-3-amino-2,4-oxazine β-amyloid cleaving enzyme (BACE) inhibitors and their biological evaluation</span></div><div class="casAuthors">Low, Jonathan D.; Bartberger, Michael D.; Cheng, Yuan; Whittington, Doug; Xue, Quifen; Wood, Stephen; Allen, Jennifer R.; Minatti, Ana E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1111-1115</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The diastereoselective synthesis and structure activity relationship (SAR) of a series of fused cyclopropyl-3-amino-2,4-oxazine (2-oxa-4-azabicyclo[4.1.0]hept-3-en-3-amine)-contg. BACE inhibitors is described.  Through these efforts compd. I was identified as a potent (cell IC50 = 15 nM) BACE inhibitor with acceptable ADME properties.  When tested in vivo, I demonstrated a significant redn. of brain and cerebral spinal fluid (CSF) Aβ40 levels (46% and 66%, resp.) in a rat pharmacodynamic study and thus represents a suitable starting point for the further development of in vivo efficacious compds. for the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqc82tCAqs6uLVg90H21EOLACvtfcHk0lhyTd7_oWQV1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFemu70%253D&md5=d14d99b766bd131816b185742572aac7</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.01.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.01.056%26sid%3Dliteratum%253Aachs%26aulast%3DLow%26aufirst%3DJ.%2BD.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DWhittington%26aufirst%3DD.%26aulast%3DXue%26aufirst%3DQ.%26aulast%3DWood%26aufirst%3DS.%26aulast%3DAllen%26aufirst%3DJ.%2BR.%26aulast%3DMinatti%26aufirst%3DA.%2BE.%26atitle%3DDiastereoselective%2520synthesis%2520of%2520fused%2520cyclopropyl-3-amino-2%252C4-oxazine%2520beta-amyloid%2520cleaving%2520enzyme%2520%2528BACE%2529%2520inhibitors%2520and%2520their%2520biological%2520evaluation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D1111%26epage%3D1115%26doi%3D10.1016%2Fj.bmcl.2018.01.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dineen, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acton, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu-Khan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartberger, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Citron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croghan, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esmay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graceffa, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harried, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hitchcock, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horne, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imbeah-Ampiah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judd, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaller, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreiman, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monenschein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">San Miguel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sickmier, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vargas, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahl, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittington, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, V. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of potent, orally efficacious hydroxyethylamine derived β-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">9025</span>– <span class="NLM_lpage">9044</span>, <span class="refDoi"> DOI: 10.1021/jm300118s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300118s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvFOnsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9025-9044&author=T.+A.+Dineenauthor=M.+M.+Weissauthor=T.+Williamsonauthor=P.+Actonauthor=S.+Babu-Khanauthor=M.+D.+Bartbergerauthor=J.+Brownauthor=K.+Chenauthor=Y.+Chengauthor=M.+Citronauthor=M.+D.+Croghanauthor=R.+T.+Dunnauthor=J.+Esmayauthor=R.+F.+Graceffaauthor=S.+S.+Harriedauthor=D.+Hickmanauthor=S.+A.+Hitchcockauthor=D.+B.+Horneauthor=H.+Huangauthor=R.+Imbeah-Ampiahauthor=T.+Juddauthor=M.+R.+Kallerauthor=C.+R.+Kreimanauthor=D.+S.+Laauthor=V.+Liauthor=P.+Lopezauthor=S.+Louieauthor=H.+Monenscheinauthor=T.+T.+Nguyenauthor=L.+D.+Penningtonauthor=T.+San+Miguelauthor=E.+A.+Sickmierauthor=H.+M.+Vargasauthor=R.+C.+Wahlauthor=P.+H.+Wenauthor=D.+A.+Whittingtonauthor=S.+Woodauthor=Q.+Xueauthor=B.+H.+Yangauthor=V.+F.+Patelauthor=W.+Zhong&title=Design+and+synthesis+of+potent%2C+orally+efficacious+hydroxyethylamine+derived+%CE%B2-site+amyloid+precursor+protein+cleaving+enzyme+%28BACE1%29+inhibitors&doi=10.1021%2Fjm300118s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Potent, Orally Efficacious Hydroxyethylamine Derived β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors</span></div><div class="casAuthors">Dineen, Thomas A.; Weiss, Matthew M.; Williamson, Toni; Acton, Paul; Babu-Khan, Safura; Bartberger, Michael D.; Brown, James; Chen, Kui; Cheng, Yuan; Citron, Martin; Croghan, Michael D.; Dunn, Robert T.; Esmay, Joel; Graceffa, Russell F.; Harried, Scott S.; Hickman, Dean; Hitchcock, Stephen A.; Horne, Daniel B.; Huang, Hongbing; Imbeah-Ampiah, Ronke; Judd, Ted; Kaller, Matthew R.; Kreiman, Charles R.; La, Daniel S.; Li, Vivian; Lopez, Patricia; Louie, Steven; Monenschein, Holger; Nguyen, Thomas T.; Pennington, Lewis D.; San Miguel, Tisha; Sickmier, E. Allen; Vargas, Hugo M.; Wahl, Robert C.; Wen, Paul H.; Whittington, Douglas A.; Wood, Stephen; Xue, Qiufen; Yang, Bryant H.; Patel, Vinod F.; Zhong, Wenge</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9025-9044</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have previously shown that hydroxyethylamines can be potent inhibitors of the BACE1 enzyme and that the generation of BACE1 inhibitors with CYP 3A4 inhibitory activities in this scaffold affords compds. (e.g., 1, I) with sufficient bioavailability and pharmacokinetic profiles to reduce central amyloid-β peptide (Aβ) levels in wild-type rats following oral dosing.  In this article, we describe further modifications of the Ph ring of the hydroxyethylamine series to afford potent, dual BACE1/CYP 3A4 inhibitors which demonstrate improved penetration into the CNS.  Several of these compds. caused robust redn. of Aβ levels in rat CSF and brain following oral dosing, and compd. II exhibited an improved cardiovascular safety profile relative to 1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqApKWBnTeHErVg90H21EOLACvtfcHk0ljUyKmIFg32YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvFOnsbg%253D&md5=1c6ad4a5aa1583864bd778715e1453ea</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Fjm300118s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300118s%26sid%3Dliteratum%253Aachs%26aulast%3DDineen%26aufirst%3DT.%2BA.%26aulast%3DWeiss%26aufirst%3DM.%2BM.%26aulast%3DWilliamson%26aufirst%3DT.%26aulast%3DActon%26aufirst%3DP.%26aulast%3DBabu-Khan%26aufirst%3DS.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DBrown%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DCitron%26aufirst%3DM.%26aulast%3DCroghan%26aufirst%3DM.%2BD.%26aulast%3DDunn%26aufirst%3DR.%2BT.%26aulast%3DEsmay%26aufirst%3DJ.%26aulast%3DGraceffa%26aufirst%3DR.%2BF.%26aulast%3DHarried%26aufirst%3DS.%2BS.%26aulast%3DHickman%26aufirst%3DD.%26aulast%3DHitchcock%26aufirst%3DS.%2BA.%26aulast%3DHorne%26aufirst%3DD.%2BB.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DImbeah-Ampiah%26aufirst%3DR.%26aulast%3DJudd%26aufirst%3DT.%26aulast%3DKaller%26aufirst%3DM.%2BR.%26aulast%3DKreiman%26aufirst%3DC.%2BR.%26aulast%3DLa%26aufirst%3DD.%2BS.%26aulast%3DLi%26aufirst%3DV.%26aulast%3DLopez%26aufirst%3DP.%26aulast%3DLouie%26aufirst%3DS.%26aulast%3DMonenschein%26aufirst%3DH.%26aulast%3DNguyen%26aufirst%3DT.%2BT.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26aulast%3DSan%2BMiguel%26aufirst%3DT.%26aulast%3DSickmier%26aufirst%3DE.%2BA.%26aulast%3DVargas%26aufirst%3DH.%2BM.%26aulast%3DWahl%26aufirst%3DR.%2BC.%26aulast%3DWen%26aufirst%3DP.%2BH.%26aulast%3DWhittington%26aufirst%3DD.%2BA.%26aulast%3DWood%26aufirst%3DS.%26aulast%3DXue%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DB.%2BH.%26aulast%3DPatel%26aufirst%3DV.%2BF.%26aulast%3DZhong%26aufirst%3DW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520potent%252C%2520orally%2520efficacious%2520hydroxyethylamine%2520derived%2520%25CE%25B2-site%2520amyloid%2520precursor%2520protein%2520cleaving%2520enzyme%2520%2528BACE1%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9025%26epage%3D9044%26doi%3D10.1021%2Fjm300118s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajapakse, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nantermet, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selnick, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrow, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGaughey, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munshi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katherine Holloway, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espeseth, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colussi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietrak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crouthamel, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tugusheva, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazuda, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J. P.</span></span> <span> </span><span class="NLM_article-title">SAR of tertiary carbinamine derived BACE1 inhibitors: role of aspartate ligand amine pKa in enzyme inhibition</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1885</span>– <span class="NLM_lpage">1889</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.01.137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1016%2Fj.bmcl.2010.01.137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=20176482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivFGltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1885-1889&author=H.+A.+Rajapakseauthor=P.+G.+Nantermetauthor=H.+G.+Selnickauthor=J.+C.+Barrowauthor=G.+B.+McGaugheyauthor=S.+Munshiauthor=S.+R.+Lindsleyauthor=M.+B.+Youngauthor=P.+L.+Ngoauthor=M.+Katherine+Hollowayauthor=M.-T.+Laiauthor=A.+S.+Espesethauthor=X.-P.+Shiauthor=D.+Colussiauthor=B.+Pietrakauthor=M.-C.+Crouthamelauthor=K.+Tugushevaauthor=Q.+Huangauthor=M.+Xuauthor=A.+J.+Simonauthor=L.+Kuoauthor=D.+J.+Hazudaauthor=S.+Grahamauthor=J.+P.+Vacca&title=SAR+of+tertiary+carbinamine+derived+BACE1+inhibitors%3A+role+of+aspartate+ligand+amine+pKa+in+enzyme+inhibition&doi=10.1016%2Fj.bmcl.2010.01.137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">SAR of tertiary carbinamine derived BACE1 inhibitors: Role of aspartate ligand amine pK a in enzyme inhibition</span></div><div class="casAuthors">Rajapakse, Hemaka A.; Nantermet, Philippe G.; Selnick, Harold G.; Barrow, James C.; McGaughey, Georgia B.; Munshi, Sanjeev; Lindsley, Stacey R.; Young, Mary Beth; Ngo, Phung L.; Katherine Holloway, M.; Lai, Ming-Tain; Espeseth, Amy S.; Shi, Xiao-Ping; Colussi, Dennis; Pietrak, Beth; Crouthamel, Ming-Chih; Tugusheva, Katherine; Huang, Qian; Xu, Min; Simon, Adam J.; Kuo, Lawrence; Hazuda, Daria J.; Graham, Samuel; Vacca, Joseph P.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1885-1889</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The optimization of tertiary carbinamine derived inhibitors of BACE1 from its discovery as an unstable lead to low nanomolar cell active compds. is described.  Five-membered heterocycles are reported as stable and potency enhancing linkers.  In the course of this work, we have discovered a clear trend where the activity of inhibitors at a given assay pH is dependent on pK a of the amino group that interacts directly with the catalytic aspartates.  The potency of compds. as inhibitors of Αβ prodn. in a cell culture assay correlated much better with BACE1 enzyme potency measured at pH 7.5 than at pH 4.5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHLW0Y129P6rVg90H21EOLACvtfcHk0ljUyKmIFg32YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivFGltb8%253D&md5=c3e122882f959982cacad8c45bbfcb92</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.01.137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.01.137%26sid%3Dliteratum%253Aachs%26aulast%3DRajapakse%26aufirst%3DH.%2BA.%26aulast%3DNantermet%26aufirst%3DP.%2BG.%26aulast%3DSelnick%26aufirst%3DH.%2BG.%26aulast%3DBarrow%26aufirst%3DJ.%2BC.%26aulast%3DMcGaughey%26aufirst%3DG.%2BB.%26aulast%3DMunshi%26aufirst%3DS.%26aulast%3DLindsley%26aufirst%3DS.%2BR.%26aulast%3DYoung%26aufirst%3DM.%2BB.%26aulast%3DNgo%26aufirst%3DP.%2BL.%26aulast%3DKatherine%2BHolloway%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DM.-T.%26aulast%3DEspeseth%26aufirst%3DA.%2BS.%26aulast%3DShi%26aufirst%3DX.-P.%26aulast%3DColussi%26aufirst%3DD.%26aulast%3DPietrak%26aufirst%3DB.%26aulast%3DCrouthamel%26aufirst%3DM.-C.%26aulast%3DTugusheva%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DSimon%26aufirst%3DA.%2BJ.%26aulast%3DKuo%26aufirst%3DL.%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26aulast%3DGraham%26aufirst%3DS.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26atitle%3DSAR%2520of%2520tertiary%2520carbinamine%2520derived%2520BACE1%2520inhibitors%253A%2520role%2520of%2520aspartate%2520ligand%2520amine%2520pKa%2520in%2520enzyme%2520inhibition%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1885%26epage%3D1889%26doi%3D10.1016%2Fj.bmcl.2010.01.137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cutler, D. J.</span></span> <span> </span><span class="NLM_article-title">The potential role of lysosomes in tissue distribution of weak bases</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">513</span>– <span class="NLM_lpage">526</span>, <span class="refDoi"> DOI: 10.1002/bod.2510090602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1002%2Fbod.2510090602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=3067757" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADyaL1MXjtlWlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1988&pages=513-526&author=A.+C.+MacIntyreauthor=D.+J.+Cutler&title=The+potential+role+of+lysosomes+in+tissue+distribution+of+weak+bases&doi=10.1002%2Fbod.2510090602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The potential role of lysosomes in tissue distribution of weak bases</span></div><div class="casAuthors">MacIntyre, Anna C.; Cutler, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">513-26</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    </div><div class="casAbstract">A review with 68 refs.  Lysosomal trapping of weak bases, dependence of weak base accumulation on structural integrity of tissues, in vitro studies of weak base distribution in tissues, and pharmacokinetics of lysosomal trapping are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofMtNLuz5Y2bVg90H21EOLACvtfcHk0lhWDi1gyD80IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXjtlWlsQ%253D%253D&md5=fbfdb93211453b424daa22355ef88717</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1002%2Fbod.2510090602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbod.2510090602%26sid%3Dliteratum%253Aachs%26aulast%3DMacIntyre%26aufirst%3DA.%2BC.%26aulast%3DCutler%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520potential%2520role%2520of%2520lysosomes%2520in%2520tissue%2520distribution%2520of%2520weak%2520bases%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D1988%26volume%3D9%26spage%3D513%26epage%3D526%26doi%3D10.1002%2Fbod.2510090602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tobin, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slominski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botchkarev, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paus, R.</span></span> <span> </span><span class="NLM_article-title">The fate of hair follicle melanocytes during the hair growth cycle</span>. <i>J. Invest. Dermatol. Symp. Proc.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1038/sj.jidsp.5640239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1038%2Fsj.jidsp.5640239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10674391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A280%3ADC%252BD3c7js1ymtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1999&pages=323-332&author=D.+J.+Tobinauthor=A.+Slominskiauthor=V.+Botchkarevauthor=R.+Paus&title=The+fate+of+hair+follicle+melanocytes+during+the+hair+growth+cycle&doi=10.1038%2Fsj.jidsp.5640239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">The fate of hair follicle melanocytes during the hair growth cycle</span></div><div class="casAuthors">Tobin D J; Slominski A; Botchkarev V; Paus R</div><div class="citationInfo"><span class="NLM_cas:title">The journal of investigative dermatology. Symposium proceedings</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">323-32</span>
        ISSN:<span class="NLM_cas:issn">1087-0024</span>.
    </div><div class="casAbstract">The fate of the follicular pigmentary unit during the hair growth cycle has long been one of the great enigmas of both hair follicle and pigment cell biology.  Although melanocytes are distributed in several different compartments of the anagen hair follicle, melanogenically active cells are located only in the hair bulb, where they are directly involved in hair shaft pigmentation.  These pigment cells are readily detectable only when they become melanogenically active during anagen III of the hair growth cycle.  Thus, their status during hair follicle regression (catagen), when melanogenesis is switched off, until they re-appear again as pigment-producing cells in the anagen III hair follicle, has remained poorly defined.  Historically, it has been proposed that hair bulb melanocytes adopt a self-perpetuating, catagen-resistant strategy of de-differentiation during hair follicle regression and re-differentiation upon entry into a new anagen phase; however, this explanation remains problematic in the absence of evidence for de-differentiation/re-differentiation plasticity in most nonmalignant cell systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSGKmgTz7EtfZI8NvIb08rbfW6udTcc2ebk3UFq3UYlebntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c7js1ymtA%253D%253D&md5=d1e82046e17b4d995c01d7616aadf96f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fsj.jidsp.5640239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.jidsp.5640239%26sid%3Dliteratum%253Aachs%26aulast%3DTobin%26aufirst%3DD.%2BJ.%26aulast%3DSlominski%26aufirst%3DA.%26aulast%3DBotchkarev%26aufirst%3DV.%26aulast%3DPaus%26aufirst%3DR.%26atitle%3DThe%2520fate%2520of%2520hair%2520follicle%2520melanocytes%2520during%2520the%2520hair%2520growth%2520cycle%26jtitle%3DJ.%2520Invest.%2520Dermatol.%2520Symp.%2520Proc.%26date%3D1999%26volume%3D4%26spage%3D323%26epage%3D332%26doi%3D10.1038%2Fsj.jidsp.5640239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Müller-Röver, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foitzik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handjiski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der Veen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichmüller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKay, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stenn, K. S.</span></span> <span> </span><span class="NLM_article-title">A comprehensive guide for the accurate classification of murine hair follicles in distinct hair cycle stages</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">3</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1046/j.0022-202x.2001.01377.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1046%2Fj.0022-202x.2001.01377.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=11442744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlsFagtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2001&pages=3-15&author=S.+M%C3%BCller-R%C3%B6verauthor=K.+Foitzikauthor=R.+Pausauthor=B.+Handjiskiauthor=C.+van+der+Veenauthor=S.+Eichm%C3%BCllerauthor=I.+A.+McKayauthor=K.+S.+Stenn&title=A+comprehensive+guide+for+the+accurate+classification+of+murine+hair+follicles+in+distinct+hair+cycle+stages&doi=10.1046%2Fj.0022-202x.2001.01377.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive guide for the accurate classification of murine hair follicles in distinct hair cycle stages</span></div><div class="casAuthors">Muller-Rover, Sven; Handjiski, Bori; Van der Veen, Carina; Eichmuller, Stefan; Foitzik, Kerstin; McKay, Ian A.; Stenn, Kurt S.; Paus, Ralf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">117</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-15</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science, Inc.</span>)
        </div><div class="casAbstract">A review with 59 refs.  Numerous strains of mice with defined mutations display pronounced abnormalities of hair follicle cycling, even in the absence of overt alterations of the skin and hair phenotype; however, in order to recognize even subtle, hair cycle-related abnormalities, it is critically important to be able to det. accurately and classify the major stages of the normal murine hair cycle.  In this comprehensive guide, we present pragmatic basic and auxiliary criteria for recognizing key stages of hair follicle growth (anagen), regression (catagen) and quiescence (telogen) in C57BL/6NCr1BR mice, which are largely based on previous work from other authors.  For each stage, a schematic drawing and representative micrographs are provided in order to illustrate these criteria.  The basic criteria can be employed for all mouse strains and require only routine histochem. techniques.  The auxiliary criteria depend on the immunohistochem. anal. of three markers (interleukin-1 receptor type I, transforming growth factor-β receptor type II, and neural cell-adhesion mol.), which allow a refined anal. of anatomical hair follicle compartments during all hair cycle stages.  In contrast to prior staging systems, we suggest dividing anagen III into three distinct substages, based on morphol. differences, onset and progression of melanogenesis, and the position of the dermal papilla in the subcutis.  The computer-generated schematic representations of each stage are presented with the aim of standardizing reports on follicular gene and protein expression patterns.  This guide should become a useful tool when screening new mouse mutants or mice treated with pharmaceuticals for discrete morphol. abnormalities of hair follicle cycling in a highly reproducible, easily applicable, and quantifiable manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJESZ9h5Cqe7Vg90H21EOLACvtfcHk0lhWDi1gyD80IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlsFagtrk%253D&md5=6a20d0035941a99d3b94874b4303e33e</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1046%2Fj.0022-202x.2001.01377.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.0022-202x.2001.01377.x%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25BCller-R%25C3%25B6ver%26aufirst%3DS.%26aulast%3DFoitzik%26aufirst%3DK.%26aulast%3DPaus%26aufirst%3DR.%26aulast%3DHandjiski%26aufirst%3DB.%26aulast%3Dvan%2Bder%2BVeen%26aufirst%3DC.%26aulast%3DEichm%25C3%25BCller%26aufirst%3DS.%26aulast%3DMcKay%26aufirst%3DI.%2BA.%26aulast%3DStenn%26aufirst%3DK.%2BS.%26atitle%3DA%2520comprehensive%2520guide%2520for%2520the%2520accurate%2520classification%2520of%2520murine%2520hair%2520follicles%2520in%2520distinct%2520hair%2520cycle%2520stages%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2001%26volume%3D117%26spage%3D3%26epage%3D15%26doi%3D10.1046%2Fj.0022-202x.2001.01377.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handjiski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czarnetzki, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichmuller, S.</span></span> <span> </span><span class="NLM_article-title">A murine model for inducing and manipulating hair follicle regression (catagen): effects of dexamethasone and cyclosporin A</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">147</span>, <span class="refDoi"> DOI: 10.1111/1523-1747.ep12392542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1111%2F1523-1747.ep12392542" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=8040602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADyaK2cXmsVKhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=1994&pages=143-147&author=R.+Pausauthor=B.+Handjiskiauthor=B.+M.+Czarnetzkiauthor=S.+Eichmuller&title=A+murine+model+for+inducing+and+manipulating+hair+follicle+regression+%28catagen%29%3A+effects+of+dexamethasone+and+cyclosporin+A&doi=10.1111%2F1523-1747.ep12392542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A murine model for inducing and manipulating hair follicle regression (catagen): effects of dexamethasone and cyclosporin A</span></div><div class="casAuthors">Paus, Ralf; Handjiski, Bori; Czarnetzki, Beate M.; Eichmueller, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">143-7</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    </div><div class="casAbstract">Most cases of hair loss are based on premature induction of follicle regression (catagen).  Deciphering the unknown regulation of catagen is therefore clin. important, but catagen is also an excellent model for organ involution by rapid terminal differentiation and for epithelial cell death (apoptosis).  An assay for the controlled pharmacol. induction and manipulation of catagen follicles is reported.  Dexamethasone-21-acetate (0.1%) was applied once daily to depilation-induced, growing follicles (anagen VI) on the backs of C57 Bl-6 mice.  Characteristic catagen-assocd. changes in skin color were photodocumented and assessed by morphometric histol.  Topical dexamethasone induced catagen-like follicles significantly earlier, more homogeneously, and also more extensively than vehicle.  This process was inhibited by high i.p. doses of cyclosporin A.  In addn. to its clin. relevance as a screening assay for catagen-blocking drugs, this simple murine model is an attractive tool for dissecting the mol., cellular, and developmental biol. of catagen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVaPyDBb7PLLVg90H21EOLACvtfcHk0lh3zCu2NRVzyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmsVKhsL4%253D&md5=62d35d864a88a4c8f103f58477d3cb16</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1111%2F1523-1747.ep12392542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252F1523-1747.ep12392542%26sid%3Dliteratum%253Aachs%26aulast%3DPaus%26aufirst%3DR.%26aulast%3DHandjiski%26aufirst%3DB.%26aulast%3DCzarnetzki%26aufirst%3DB.%2BM.%26aulast%3DEichmuller%26aufirst%3DS.%26atitle%3DA%2520murine%2520model%2520for%2520inducing%2520and%2520manipulating%2520hair%2520follicle%2520regression%2520%2528catagen%2529%253A%2520effects%2520of%2520dexamethasone%2520and%2520cyclosporin%2520A%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D1994%26volume%3D103%26spage%3D143%26epage%3D147%26doi%3D10.1111%2F1523-1747.ep12392542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Makpol, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jam, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahim, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khor, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismail, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yusof, Y. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan Ngah, W. Z.</span></span> <span> </span><span class="NLM_article-title">Comparable down-regulation of TYR, TYRP1 and TYRP2 genes and inhibition of melanogenesis by tyrostat, tocotrienol-rich fraction and tocopherol in human skin melanocytes improves skin pigmentation</span>. <i>Clin. Ter.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">39</span>– <span class="NLM_lpage">45</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2014&pages=39-45&author=S.+Makpolauthor=F.+A.+Jamauthor=N.+A.+Rahimauthor=S.+C.+Khorauthor=Z.+Ismailauthor=Y.+A.+M.+Yusofauthor=W.+Z.+Wan+Ngah&title=Comparable+down-regulation+of+TYR%2C+TYRP1+and+TYRP2+genes+and+inhibition+of+melanogenesis+by+tyrostat%2C+tocotrienol-rich+fraction+and+tocopherol+in+human+skin+melanocytes+improves+skin+pigmentation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMakpol%26aufirst%3DS.%26aulast%3DJam%26aufirst%3DF.%2BA.%26aulast%3DRahim%26aufirst%3DN.%2BA.%26aulast%3DKhor%26aufirst%3DS.%2BC.%26aulast%3DIsmail%26aufirst%3DZ.%26aulast%3DYusof%26aufirst%3DY.%2BA.%2BM.%26aulast%3DWan%2BNgah%26aufirst%3DW.%2BZ.%26atitle%3DComparable%2520down-regulation%2520of%2520TYR%252C%2520TYRP1%2520and%2520TYRP2%2520genes%2520and%2520inhibition%2520of%2520melanogenesis%2520by%2520tyrostat%252C%2520tocotrienol-rich%2520fraction%2520and%2520tocopherol%2520in%2520human%2520skin%2520melanocytes%2520improves%2520skin%2520pigmentation%26jtitle%3DClin.%2520Ter.%26date%3D2014%26volume%3D165%26spage%3D39%26epage%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Felmlee, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mager, D. E.</span></span> <span> </span><span class="NLM_article-title">Mechanism-based pharmacodynamic modeling</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>929</i></span>,  <span class="NLM_fpage">583</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.1007/978-1-62703-050-2_21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=10.1007%2F978-1-62703-050-2_21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=23007443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BC3sXisF2ht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=929&publication_year=2012&pages=583-600&author=M.+A.+Felmleeauthor=M.+E.+Morrisauthor=D.+E.+Mager&title=Mechanism-based+pharmacodynamic+modeling&doi=10.1007%2F978-1-62703-050-2_21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism-based pharmacodynamic modeling</span></div><div class="casAuthors">Felmlee, Melanie A.; Morris, Marilyn E.; Mager, Donald E.</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">929</span>
        (<span class="NLM_cas:issue">Computational Toxicology, Volume I</span>),
    <span class="NLM_cas:pages">583-600</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Pharmacodynamic modeling is based on a quant. integration of pharmacokinetics, pharmacol. systems, and (patho-) physiol. processes for understanding the intensity and time-course of drug effects on the body.  Application of such models to the anal. of meaningful exptl. data allows for the quantification and prediction of drug-system interactions for both therapeutic and adverse drug responses.  In this chapter, commonly used mechanistic pharmacodynamic models are presented with respect to their important features, operable equations, and signature profiles.  In addn., literature examples showcasing the utility of these models to adverse drug events are highlighted.  Common model types that are covered include simple direct effects, biophase distribution, indirect effects, signal transduction, and irreversible effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotNyzwxREt3LVg90H21EOLACvtfcHk0lh3zCu2NRVzyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXisF2ht70%253D&md5=a459c27b92c14cbc01725c085789fa86</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1007%2F978-1-62703-050-2_21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-62703-050-2_21%26sid%3Dliteratum%253Aachs%26aulast%3DFelmlee%26aufirst%3DM.%2BA.%26aulast%3DMorris%26aufirst%3DM.%2BE.%26aulast%3DMager%26aufirst%3DD.%2BE.%26atitle%3DMechanism-based%2520pharmacodynamic%2520modeling%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2012%26volume%3D929%26spage%3D583%26epage%3D600%26doi%3D10.1007%2F978-1-62703-050-2_21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corey, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaykovsky, M.</span></span> <span> </span><span class="NLM_article-title">Dimethyloxosulfonium methylide ((CH<sub>3</sub>)<sub>2</sub>SOCH<sub>2</sub>) and dimethylsulfonium Methylide ((CH<sub>3</sub>)<sub>2</sub>SCH<sub>2</sub>). Formation and application to organic synthesis</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">1965</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">1353</span>– <span class="NLM_lpage">1364</span>, <span class="refDoi"> DOI: 10.1021/ja01084a034</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja01084a034" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADyaF2MXntlGrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1965&pages=1353-1364&author=E.+J.+Coreyauthor=M.+Chaykovsky&title=Dimethyloxosulfonium+methylide+%28%28CH3%292SOCH2%29+and+dimethylsulfonium+Methylide+%28%28CH3%292SCH2%29.+Formation+and+application+to+organic+synthesis&doi=10.1021%2Fja01084a034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Dimethyloxosulfonium methylide and dimethylsulfonium methylide. Formation and application to organic synthesis</span></div><div class="casAuthors">Corey, E. J.; Chaykovsky, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1965</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1353-64</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    </div><div class="casAbstract">The generation of dimethyloxosulfonium methylide (Me2SOCH2) and dimethylsulfonium methylide (Me2SCH2) as reactive intermediates is described.  Both ylides are nucleophiles and both function to transfer methylene to certain electrophilic unsatd. linkages, including C:O, C:N, C:S, and in certain cases, C:C.  The less reactive oxosulfonium ylide interacts with the carbonyl function of aromatic and nonconjugated aldehydes and ketones to form oxiranes and with α,β-unsatd. ketones which are Michael receptors to form cyclopropyl ketones.  The sulfonium ylide reacts with the same substrates to give oxiranes exclusively even with the α,β-unsatd. carbonyl systems.  These reactions are quite general and, therefore, of considerable practical value.  The stereochemistry of carbonyl addn. to cyclohexanones varies depending on the ylide; the oxosulfonium ylide reacts by equatorial addn. (i.e., of methylene) and the sulfonium ylide shows a preference for axial addn.  A no. of other reactions of these ylides are described including "over-all methylene insertion," and a differential comparison of their chem. properties is made.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt0xfN-tNfFLVg90H21EOLACvtfcHk0lh3zCu2NRVzyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2MXntlGrtw%253D%253D&md5=ae22573e36db50409c7832e5950df7f1</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fja01084a034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja01084a034%26sid%3Dliteratum%253Aachs%26aulast%3DCorey%26aufirst%3DE.%2BJ.%26aulast%3DChaykovsky%26aufirst%3DM.%26atitle%3DDimethyloxosulfonium%2520methylide%2520%2528%2528CH3%25292SOCH2%2529%2520and%2520dimethylsulfonium%2520Methylide%2520%2528%2528CH3%25292SCH2%2529.%2520Formation%2520and%2520application%2520to%2520organic%2520synthesis%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1965%26volume%3D87%26spage%3D1353%26epage%3D1364%26doi%3D10.1021%2Fja01084a034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turner, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koelsch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanheira, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ermolieff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span> <span> </span><span class="NLM_article-title">Subsite specificity of memapsin 2 (ß-Secretase): implication for inhibitor design</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">10001</span>– <span class="NLM_lpage">10006</span>, <span class="refDoi"> DOI: 10.1021/bi015546s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi015546s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlsFygt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2001&pages=10001-10006&author=R.+T.+Turnerauthor=G.+Koelschauthor=L.+Hongauthor=P.+Castanheiraauthor=J.+Ermolieffauthor=A.+K.+Ghoshauthor=J.+Tang&title=Subsite+specificity+of+memapsin+2+%28%C3%9F-Secretase%29%3A+implication+for+inhibitor+design&doi=10.1021%2Fbi015546s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Subsite Specificity of Memapsin 2 (β-Secretase): Implications for Inhibitor Design</span></div><div class="casAuthors">Turner, Robert T., III; Koelsch, Gerald; Hong, Lin; Castenheira, Pedro; Ghosh, Arun; Tang, Jordan</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">10001-10006</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Memapsin 2 is the protease known as β-secretase whose action on β-amyloid precursor protein leads to the prodn. of the β-amyloid (Aβ) peptide.  Since the accumulation of Aβ in the brain is a key event in the pathogenesis of Alzheimer's disease, memapsin 2 is an important target for the design of inhibitory drugs.  Here we describe the residue preference for the subsites of memapsin 2.  The relative kcat/KM values of residues in each of the eight subsites were detd. by the relative initial cleavage rates of substrate mixts. as quantified by MALDI-TOF mass spectrometry.  We found that each subsite can accommodate multiple residues.  The S1 subsite is the most stringent, preferring residues in the order of Leu > Phe > Met > Tyr.  The preferences of other subsites are the following: S2, Asp > Asn > Met; S3, Ile > Val > Leu; S4, Glu > Gln > Asp; S1', Met > Glu > Gln > Ala; S2', Val > Ile > Ala; S3', Leu > Trp > Ala; S4', Asp > Glu > Trp.  In general, S subsites are more specific than the S' subsites.  A peptide comprising the eight most favored residues (Glu-Ile-Asp-Leu-Met-Val-Leu-Asp) was found to be hydrolyzed with the highest kcat/KM value so far obsd. for memapsin 2.  Residue preferences at four subsites were also studied by binding of memapsin 2 to a combinatorial inhibitor library.  From 10 tight binding inhibitors, the consensus preferences were as follows: S2, Asp and Glu; S3, Leu and Ile; S2', Val; and S3', Glu and Gln.  An inhibitor, OM00-3, Glu-Leu-Asp-Leu*Ala-Val-Glu-Phe (where the asterisk represents the hydroxyethylene transition-state isostere), designed from the consensus residues, was found to be the most potent inhibitor of memapsin 2 so far reported (Ki of 3.1 × 10-10 M).  A mol. model of OM00-3 binding to memapsin 2 revealed crit. improvement of the interactions between inhibitor side chains with enzyme over a previous inhibitor, OM99-2 [Ghosh, A. K., et al. (2000) J. Am. Chem. Soc. 14, 3522-3523].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-VNvG4dfyYrVg90H21EOLACvtfcHk0liWBQvaLPd2AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlsFygt78%253D&md5=e0ff4b45ee8e6055f707cb9ea571c943</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fbi015546s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi015546s%26sid%3Dliteratum%253Aachs%26aulast%3DTurner%26aufirst%3DR.%2BT.%26aulast%3DKoelsch%26aufirst%3DG.%26aulast%3DHong%26aufirst%3DL.%26aulast%3DCastanheira%26aufirst%3DP.%26aulast%3DErmolieff%26aufirst%3DJ.%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DTang%26aufirst%3DJ.%26atitle%3DSubsite%2520specificity%2520of%2520memapsin%25202%2520%2528%25C3%259F-Secretase%2529%253A%2520implication%2520for%2520inhibitor%2520design%26jtitle%3DBiochemistry%26date%3D2001%26volume%3D40%26spage%3D10001%26epage%3D10006%26doi%3D10.1021%2Fbi015546s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6C2I" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6C2I','PDB','6C2I'); return false;">PDB: 6C2I</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PZ4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PZ4','PDB','6PZ4'); return false;">PDB: 6PZ4</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i58"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01034">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_24146"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b01034">10.1021/acs.jmedchem.9b01034</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Cross species biochemical IC<sub>50</sub> data for compounds <b>20</b> and <b>25</b>; Figure SI-1 for dose–response curves of <b>1</b>, <b>20</b>, and <b>25</b> BACE2 cellular activity; experimental procedure for <b>20</b>/BACE1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PZ4">6PZ4</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01034/suppl_file/jm9b01034_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and full statistical information (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01034/suppl_file/jm9b01034_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01034/suppl_file/jm9b01034_si_001.pdf">jm9b01034_si_001.pdf (134.08 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01034/suppl_file/jm9b01034_si_002.csv">jm9b01034_si_002.csv (3.38 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates for the X-ray structure of <b>20</b>/BACE1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PZ4">6PZ4</a>) is available from the RCSB Protein Data Bank (<a href="https://www.rcsb.org/" class="extLink">https://www.rcsb.org/</a>). Authors will release the atomic coordinates upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01034&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01034%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-5" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01034" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679915b568913d6c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
